

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/12, C07K 14/435, C12N 5/10, A01K 67/027, 67/033, A61K 38/17, A01H 5/00, C07K 16/18, C12N 5/26, C12Q 1/02	A2	(11) International Publication Number: WO 96/38555 (43) International Publication Date: 5 December 1996 (05.12.96)
(21) International Application Number: PCT/EP96/02311 (22) International Filing Date: 31 May 1996 (31.05.96) (30) Priority Data: 9510944.3 31 May 1995 (31.05.95) GB (71)(72) Applicants and Inventors: BOGAERT, Thierry [BE/BE]; Voorstraat 36 bus 11, B-8500 Kortrijk (BE). STRINGHAM, Eve [CA/CA]; 9326-133 A Street, Surrey, British Columbia V3V 5R5 (CA). VANDEKERCKHOVE, Joel [BE/BE]; Rode Beukendreef 27, B-Loppem (BE). (74) Agent: BALDOCK, Sharon, Claire; Boulton Wade Tennant, 27 Furnival Street, London EC4A 1PQ (GB).	(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(54) Title: PROCESSES FOR THE IDENTIFICATION OF COMPOUNDS WHICH CONTROL CELL BEHAVIOUR, THE COMPOUNDS IDENTIFIED AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THE CONTROL OF CELL BEHAVIOUR (57) Abstract <p>UNC-53 protein of <i>C. elegans</i> or its functional equivalent is identified as a signal transducer/integrator involved in controlling the rate and directionality of cell migration and/or cell shape. Nucleic acid sequences encoding UNC-53 protein or its functional equivalent, such as genomic or cDNA are used to transfect <i>C. elegans</i> or mammalian cell lines useful for identifying inhibitors or enhancers of the UNC-53 protein. Any of the inhibitors or enhancers identified or the UNC-53 protein itself or sequences encoding UNC-53 protein can be used in the preparation of medicament for treatment of neurological conditions such as Alzheimer's or Huntington's disease, peripheral neuropathies for inhibition of metastasis.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

PROCESSES FOR THE IDENTIFICATION OF COMPOUNDS
WHICH CONTROL CELL BEHAVIOUR, THE COMPOUNDS IDENTIFIED
AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND
THEIR USE IN THE CONTROL OF CELL BEHAVIOUR

5

The present invention relates to processes for the identification of compounds which inhibit or enhance the rate and direction of cell migration or the control of cell shape, the compounds identified and pharmaceutical formulations containing such compounds together with their use in the regulation of cell behaviour. The invention also relates to an UNC-53 protein encoded by nucleic acid in the cells of the nematode worm C. elegans and cDNA sequences encoding an UNC-53 protein or functional equivalents thereof.

15

The control of cell motility, cell shape and the outgrowth of axones or other cell outgrowths is an essential feature in the morphogenesis and function of both unicellular and multicellular organisms. The control of this process is disturbed in a variety of disease states in which for example the Receptor Tyrosine Kinase (RTK) signal transduction pathways or the like or their downstream intra-cellular pathways (which are shared with other extra-cellular receptors, including cell adhesion molecules like N-CAMS and integrins) are overstimulated.

20

25

Some cell surface proteins and extracellular molecules controlling the directionality and potential of cell migration have been identified. However the processes in which these proteins or molecules are involved to effect cell migration, shape or rate of cell differentiation are not understood.

30

It is generally considered that a long-range migration of a cell process (which may also be known as a growth cone spike) is a stepwise event, whereby prior to and after each extension there is the

35

- 2 -

formation of a structure at the leading edge of the cell which senses signals in the environment instructing the cell to either stabilize a cell process extending in a preferred direction, or to cause a cell process lamellipodium to extend a process in a given direction. Localized stabilization of the actin cytoskeleton, is a general cell biological process underlying this choice of directional extension.

10 A gene from the free-living nematode Caenorhabditis elegans, designated "unc-53" has been previously identified and cloned (Abstract, International C. elegans meeting; June 1-5 1991, Madison, Wisconsin, 58, Bogaert and Goh). However, to
15 date no known biological function has been attributed to the unc-53 gene or its corresponding UNC-53 protein.

 The present inventors have surprisingly identified, through biochemical, genetic, phenotypic
20 and transgenic evidence which is presented herewith, UNC-53 as a signal transducer or signal integrator controlling the rate and directionality of cell migration, and/or cell shape. Key experiments leading to this conclusion were the molecular identification
25 of its domain structure, its biochemical interaction with GRB-2, actin cytoskeleton sequence information and the presence of a potential signal integrating domain in the UNC-53 protein.

 An additional key observation is that increased
30 UNC-53 protein activity is proportional to increased cell process extension in the correct direction of cell migration. Reduction of UNC-53 function has previously been shown to lead to a reduction of cell process extension, identifying it as a general
35 component required for cell migration. However, it had not been identified as a component whose level of

- 3 -

activity has a determining role in the specification of the quantum and directionality of migration.

The work of the present inventors suggests that UNC-53 plays a central role in quantitatively transducing extracellular signals to the machinery controlling directional cell migration.

The importance of UNC-53 in a variety of cell types in C. elegans has been demonstrated. The gene encodes a signal transduction molecule that transduces a signal from a Receptor Tyrosine Kinase such as for example via the adaptor protein SEM-5/GRB-2, to the machinery controlling directional growth cone extension or stabilization. The UNC-53 protein does this in a highly dosage-dependent fashion whereby reduction of protein activity such as reduction in expression of protein or in the reduction in its activity leads to proportional reduction of cell process extension (cell migration). This is believed to be either by regulated cross-linking of the actin cytoskeleton or by transferring the received signal downstream within the transduction pathway. Higher than wild type UNC-53 expression leads to higher than wild type growth cone extension in the anterior-posterior axis. Both the observed SEM-5/GRB-2 binding to UNC-53 and the predicted ATP/GTP-ase activity of UNC-53 demonstrate a signal transduction role for UNC-53 involved in cell process or growth cone guidance.

UNC-53 is a protein working at the intracellular level. It is so far believed to be the only intracellular protein identified which is involved in the control of directionality and rate of cell migration in response to a specific signal and which integrates different directional signals in defining direction of migration.

Based on the present inventors accumulated

knowledge of the unc-53 gene function in C. elegans it is understood that inhibitors or enhancers of the unc-53 gene or the UNC-53 protein will affect the cell motility including (metastasis) via an RTK pathway or the like, or may lead to changes in the shape of the cells (which has been demonstrated in C. elegans body muscle). Applications for such inhibitors and/or enhancers are envisaged in a wide variety of pathologies in which the RTK pathways play a central role, including oncogenesis, psoriasis, cell migration (metastasis), neuronal regeneration/degeneration and immunological disorders among others.

The identification of the biochemical function of the unc-53 gene (and UNC-53 pathway) in the RTK signal transduction pathway is novel and unexpected. No biological function has previously been linked to the unc-53 gene or UNC-53 protein, nor has any homology with any other nucleic acid sequence or gene been recognised.

An analysis of the predicted protein sequence of UNC-53 from the gene sequence thereof has revealed the following:

- (a) an N-terminal domain with homology to cortical actin binding proteins of the α -actinin and β -spectrin families (designated ABPII in Figure 11). Alignment of UNC-53 with the α -actinin and β -spectrin family of proteins is shown in Fig. 15.).
- (b) two putative actin binding sites of the LKK class (ABS1 and ABS2).
- (c) two polyproline rich sequences similar to the SH3 binding domains of the SOS family of signal transduction molecules (SH3 binding site) (Fig. 16).
- (d) a putative ATP/GTP nucleotide binding site having some of the additional features of the GTP

- 5 -

binding domain of RAS-like proteins (Dynamin, NBD).

(e) besides the N-terminal region of the protein, which is similar to actin binding proteins, the predicted protein sequence of UNC-53 identified two putative actin binding sites. The first borders on the 3' end of the region of α -actinin/ β -spectrin homology and the second lies in the 3' end of the cDNA sequence.

This suggests that UNC-53 could potentially bind two actin molecules and via actin cross linking, could stabilize a particular cell process to promote directional extension.

In addition, genetic evidence shows that alleles of *unc-53* enhance the sex myoblast migration defect of *sem-5* mutants. *Sem-5* represents the *C. elegans* homologue of GRB2, the function of these proteins being assigned/attributed to their SH2 and SH3 domains (Clark et al., (1992) *Nature* **356**, 340-344; Stern et al., (1993), *Molec. Biol. Cell*, **4**, 1175-1188). The current model regarding *sem-5* function in the migration of sex myoblasts is that *sem-5* transduces a signal received at the cell surface by *egl-15*, a receptor kinase of the fibroblast growth factor family. Together, the genetic and molecular data suggest a role for UNC-53 in both signal transduction and actin binding. We have been able to demonstrate how UNC-53 might act to direct both growth cone rate and directionality. By binding directly to the actin cytoskeleton, UNC-53 may stabilize and cross-link actin molecules (assuming a two actin binding site model) to promote directional growth cone extension. Alternatively, by binding actin, UNC-53 may convey a signal to the cytoskeleton and then via an ATP/GTPase activity transduce the signal to downstream targets. To test these models, biochemical experiments were

conducted to determine if any of the sequence similarities observed represented functional domains (see examples 2 to 5). Transgenic analysis as described in examples 6 to 8 support this proposed model.

As described above, the *unc-53* gene from *C. elegans* has been previously identified. However, cDNA sequences substantially corresponding to *unc-53* genomic exon sequences of *C. elegans* or fragments or derivatives thereof have never been previously disclosed. The present inventors have advantageously identified two *unc-53* cDNA clones which have been designated as the 7A and 8A clones. The two clones differ in the number of Adenosine(A) residues (7 or 8) in a poly A stretch of the 3' coding region. Therefore, the two clones have different reading frames in the carboxyterminal coding region.

Therefore according to one aspect of the present invention there is provided a cDNA encoding an UNC-53 protein of *C. elegans* or a functional equivalent derivative or bioprecursor of said protein which cDNA comprises at least from nucleotide position 431 to nucleotide position 4647 or alternatively to the 3' poly-A region of the sequence shown in Figure 1. More preferably the cDNA comprises at least from nucleotide position 64 to nucleotide position 4647 or to the 3' poly-A region of the sequence as shown in Figure 1. This cDNA is comprised in the 8A clone having 8A residues in a poly A stretch of the 3' coding region as shown in Figure 1.

In an alternative embodiment of this aspect of the invention the cDNA comprises at least from nucleotide position 431 to nucleotide position 4812 or alternatively to the 3' poly-A region of the sequence shown in Figure 2 and more preferably at least from position 64 to nucleotide position 4812 or the 3'

- 7 -

poly-A region of the sequence shown in Figure 2. This cDNA according to the invention comprises the 7A clone, having only 7 Adenine residues in the poly A stretch of the 3' coding region as shown in the nucleotide sequence of Figure 2 page 8. Each of the cDNA clones according to the invention, may be included in an expression vector which vector may itself be used to transform or transfect a host cell which may be bacterial, animal or plant in origin. Thus, advantageously, once the cDNA corresponding to the unc-53 genome is synthesised using for example reverse transcriptase or the like, a range of cells, tissues or organisms may be transfected following incorporation of the selected cDNA clone into an appropriate expression vector.

The present invention therefore, also further comprises a transgenic cell, tissue or organism comprising a transgene capable of expressing UNC-53 protein of C. elegans or a functional equivalent, fragment, derivative or bioprecursor thereof. The term "transgene capable of expressing UNC-53 protein" as used herein means a suitable nucleic acid sequence which leads to the expression of an UNC-53 protein having the same function and/or activity. The transgene may include for example genomic nucleic acid isolated from C. elegans or synthetic nucleic acid or alternatively any of the cDNA clones as described above.

The term "transgenic organism, tissue or cell" as used herein means any suitable organism and/or part of an organism, tissue or cell that contains exogenous nucleic acid either stably integrated in the genome or in an extra chromosomal state.

Preferably, the transgenic cell comprises either a C. elegans cell, an N4 neuroblastoma cell or an MCF-7 breast carcinoma cell. The transgenic organism may

be C. elegans itself, or alternatively may be an insect, a non-human animal or a plant. Preferably the unc-53 transgene comprises the unc-53 gene or a functional fragment thereof. The term "functional fragment" as used herein should be taken to mean a fragment of an UNC-53 gene which encodes an UNC-53 protein or a functional equivalent or bioprecursor of the protein. For example the gene may comprise deletions or mutations but may still encode a functional UNC-53 protein.

Reference to "tissue or tissue culture" for the purpose of the present invention should be taken to mean such a mutant cell which has been grown in such a culture. Further provided by the present invention is a mutant C. elegans organism which comprises an induced mutation, such as a point mutation in the wild-type unc-53 gene and which mutation affects the regulation of cell motility or shape or the direction of cell migration. Such mutations may be introduced using changes in the cDNA corresponding to qualitative, quantitative direct and indirect changes in the genomic make up.

The term "mutant organism" used herein means any suitable organism that contains genetic information which has been induced to mutate and is thus altered from the wild-type. Therefore naturally occurring mutations in the wild-type organism are not within the scope of this term.

The present invention further comprises an UNC-53 protein or a functional equivalent or fragment thereof, which protein may be encoded by a cDNA according to the invention, and which protein has the amino acid sequence shown in Figure 4 from amino acid position 135 to amino acid position 1528; this corresponds to the 8A clone. More preferably the UNC-53 protein, when encoded by a cDNA according to the

invention, comprises the amino acid sequence shown in Figure 4. In another aspect of the invention the protein comprises an UNC-53 protein or a functional equivalent, fragment or bioprecursor of the protein which comprises the sequence of from amino acid position 135 to amino acid position 1583 of the amino acid sequence shown in Figure 6. Preferably, the UNC-53 protein when encoded by a cDNA in accordance with the invention has the amino acid sequence shown in Figure 6.

The UNC-53 protein of C. elegans or a functional equivalent, fragment or bioprecursor of the UNC-53 protein, may advantageously be used as a medicament to promote neuronal regeneration, revascularisation or wound healing or the treatment of chronic neuro-degenerative disorders or acute traumatic injuries. Similarly, the UNC-53 protein produced by the transgenic cells, tissue or organisms according to the invention may also be used in the preparation of a medicament for treatment of the conditions as described above.

Furthermore, in an alternative embodiment of the invention the nucleic acid sequence itself encoding an UNC-53 protein of C. elegans or a functional equivalent, fragment or bioprecursor of the protein may also be used as a medicament or, alternatively in the preparation of a medicament, to promote neuronal regeneration, vascularisation or wound healing or for treatment of chronic neuro-degenerative diseases or acute traumatic injuries. Typically neurological conditions which may be treated by either an UNC-53 protein or a functional equivalent thereof, or a nucleic acid according to the invention, comprise peripheral nerve regeneration after trauma; recovery of function of the spinal cord after spinal cord trauma or peripheral neuropathies. Similarly neuro-

- 10 -

d generation diseases which may be treated include Alzheimers disease or Huntingdons disease. Acute traumatic injuries such as stroke, head trauma or haemorrhages may also advantageously be treated.

5 The nucleic acid sequence according to the invention may comprise a cDNA sequence according to the invention as described above or alternatively may be genomic DNA derived from C. elegans.

10 The UNC-53 protein of C. elegans, or a functional equivalent, fragment or bioprecursor of said protein may be incorporated into a pharmaceutically acceptable composition together with a suitable carrier, diluent or an excipient therefor. The pharmaceutical
15 composition may advantageously comprise, additionally or alternatively to the UNC-53 protein according to the invention, the nucleic acid sequence according to the invention as defined above.

20 The present invention also provides for a method of determining whether a compound is an inhibitor or an enhancer of the regulation of cell shape or motility or the direction of cell migration in a transgenic cell, tissue or organism according to the invention as described herein. The method preferably
25 comprises contacting the compound with a transgenic cell, tissue or organism according to the invention as described above, and screening for a phenotypic change in the cell, tissue or organism. Preferably the compound comprises an inhibitor or enhancer of a protein of the signal transduction pathway of the
30 cell, tissue or organism of which UNC-53 is a component or is an inhibitor or enhancer of a parallel or redundant signal transduction pathway. Such enhancers or inhibitors are defined by particular phenotypic changes in the transgenic cell, tissue or
35 organism, for example changes in cell shape or mobility or the direction of cell migration.

- 11 -

Preferably the compound is an inhibitor or an enhancer of the activity of UNC-53 protein of C. elegans or a functional equivalent, derivative or bioprecursor thereof, which protein is expressed in the transgenic cell, tissue or organism as defined herein.

Preferably the phenotypic change to be screened comprises a change in cell shape or a change in cell motility. Where a transgenic cell is used in accordance with one embodiment of the method of the invention, an N4 neuroblastoma cell may be used and in such an embodiment the phenotypic change to be screened may be the length of neurite growth or changes in filipodia outgrowth or alternatively changes in ruffling behaviour or cell adhesion. In an alternative embodiment of the method of the invention, the transgenic cell may comprise an MCF-7 breast carcinoma cell. Typically in such an embodiment the phenotypic change to be screened comprises the extent of phagokinesis. The method according to the invention, may also utilise a mutant cell or mutant organism according to the invention as described above, where the mutant cell is capable of growing in tissue culture and either of which cell or organism has a mutation in the wild-type unc-53 gene.

In accordance with the present invention, a "phenotypic change", may be any phenotype resulting from changes at any suitable point in the life cycle of the cell, tissue or organism defined above, which change can be attributed to the expression of the transgene such as for example, growth, viability, morphology, behaviour, movement, cell migration or cell process or growth cone extension of cells and includes changes in body shape, locomotion, chemotaxis, mating behaviour or the like. The phenotypic change may preferably be monitored directly by visual inspection or alternatively by for example

- 12 -

measuring indicators of viability including endogenous or transgenically introduced histochemical markers or other reporter genes, such as for example β -galactosidase.

5 A compound which is identifiable by the method according to the invention as described above, as an enhancer of the regulation of cell shape or motility or the direction of cell migration in C. elegans may be used as a medicament, or alternatively in the
10 preparation of a medicament, for promoting neuronal regeneration, revascularisation or wound healing, or for treatment of chronic neuro-degenerative diseases or acute traumatic injuries. Examples of promoting neuronal regeneration include for example peripheral
15 nerve regeneration after trauma and spinal cord trauma.

 Where a compound is identified in accordance with the method described above as being an inhibitor of the regulation of cell shape, the compound may be used
20 as a medicament, or in the preparation of a medicament, for substantially alleviating spread of disease inducing cells, such as in spread of cancers, or the like in metastasis. Advantageously, any of the compounds which may have been identified as an
25 inhibitor or an enhancer in accordance with the method as described above, may also be included in a pharmaceutically acceptable formulation comprising the respective compound and an acceptable carrier, diluent or excipient therefor.

30 The particular mechanism of action of a compound identified as either an inhibitor or an enhancer of the cell motility or direction of cell migration is not limiting preferably the compound acts as an inhibitor or enhancer of a signal transduction pathway
35 downstream. The compound may also act on parallel pathway or on the UNC-53 protein of C. elegans. For

- 13 -

example, the method of action of the compound may include direct interaction with UNC-53 protein, interaction with processes for regulating phosphorylation of UNC-53 or for processes regulating activity of an unc-53 gene or for processes for post-transcriptional or post-translational modification or the like.

Preferably the compound is identified by the method according to the invention as an inhibitor or an enhancer, by utilising differences of phenotype of the cell, tissue or organism, which are visible to the eye. Alternatively indicators of viability including endogenous or transgenically introduced histochemical markers or a reporter gene may be used.

According to a further aspect of the invention there is also provided a transgenic cell or tissue culture which has been constructed to comprise a promoter sequence of an unc-53 gene of C. elegans or a functional fragment thereof, fused to a nucleic acid sequence encoding a reporter molecule. Preferably, the reporter sequence encoding the reporter molecule encodes for a detectable protein, for example one which may be monitored by eye inspection such as antibiotic resistance, β -galactosidase or a molecule detectable by spectrophotometric, spectrofluorometric, luminescent or radioactive assays. Preferably the reporter molecule is green fluorescent protein (GFP), which advantageously allows inhibition or enhancement of the UNC-53 protein according to the invention to be monitored visually.

The present invention also provides a method of determining whether a compound is an inhibitor or an enhancer of transcription of a an unc-53 gene in C. elegans, or a functional fragment thereof, which method comprises the steps of:

(a) contacting said compound with a transgenic

- 14 -

cell according to the further aspect of the invention as described above,

5 (b) monitoring the reporter molecule and comparing results obtained from this monitoring step with a control comprising a transgenic cell having the promoter sequence of an unc-53 gene, or a functional fragment thereof and the reporter molecule, in the absence of the compound.

10 In one embodiment of the method according to the invention the reporter molecule may comprise messenger RNA. Alternatively the reporter molecule may be green fluorescent protein (GFP).

15 A compound identified as an inhibitor or enhancer of transcription of the unc-53 gene or a fragment thereof may also be used as a medicament, or in the preparation of a medicament, for promoting neuronal regeneration, revascularisation or wound healing, or for treatment of chronic neuro-degenerative diseases or acute traumatic injuries. Furthermore, such
20 compounds may be included in a pharmaceutical formulation including a carrier, diluent or excipient therefor.

The present invention also provides a kit for determining whether a compound is an enhancer or an
25 inhibitor of the regulation of cell motility or shape or the direction of cell migration, which kit comprises at least a plurality of transgenic or mutant cells according to the invention as described above and a plurality of wild-type cells of the same cell
30 type or cell line or tissue culture.

Also provided by the present invention is a kit for determining whether a compound is an inhibitor or an enhancer of transcription of an unc-53 gene of C. elegans or a functional fragment thereof, which
35 comprises at least a plurality of transgenic cells as described above and means for monitoring the reporter

- 15 -

molecule.

For the purposes of the present invention, the term "unc-53 gene or a functional fragment thereof" includes the nucleic acid sequence shown in Figure 1 or a fragment thereof, including the differentially spliced isoforms and transcriptional start of the unc-53 gene sequence and which sequence encodes an UNC-53 protein or a functional equivalent, derivative, fragment or bioprecursor of the protein.

The present invention also provides an oligonucleotide probe which comprises the carboxy-terminal 1.5 kb of the coding nucleic acid sequence shown in Figure 1 or a fragment thereof comprising not less than 15 base pairs. In addition, the present invention provides a further oligonucleotide probe comprising a nucleic acid sequence encoding the amino acid sequence as numbered 1 to 10 and 14 to 133, 487 to 495, 537 to 545, 1032 to 1037, 1097 to 1116 or 1300 to 1307, as shown in Figure 3 or a fragment thereof comprising between 18 and 24 base pairs. The oligonucleotide probes described above may also be advantageously be labelled for detection.

The present invention also provides methods of identifying C. elegans genes or fragments thereof, which encode proteins which are active in the signal transduction pathway of which UNC-53 is a component and which are homologues of UNC-53. A preferred method comprises hybridizing to a C. elegans cDNA library an oligonucleotide probe according to the invention as described above, under appropriate conditions or stringency in order to identify genes having statistically significant homology with the cDNA clones of any one of the cDNA sequences according to the invention described above.

Furthermore, there is also provided by the present invention a method of identifying a protein

which is active in the signal transduction pathway of a cell. According to this aspect of the invention, the method comprises;

- 5 (a) contacting an extract of said cell with an antibody to the UNC-53 protein or a functional equivalent, fragment or bioprecursor thereof,
- (b) identifying the antibody/UNC-53 complex, and
- 10 (c) analysing the complex to identify any protein bound to the UNC-53 protein other than the antibody.

The UNC-53 protein, therefore may bind regions of other proteins involved in the signal transduction pathway. It is also possible to sequentially identify a whole range of proteins involved in the signal
15 transduction pathway. This aspect of the invention, further comprises a method of identifying a further protein or proteins which are active in the signal transduction pathway of a cell which method comprises:

- 20 (a) forming an antibody to the identified protein bound to the UNC-53 protein in the method as described above,
- (b) contacting a cell extract of C. elegans with the antibody,
- (c) identifying the antibody/protein complex,
- 25 (d) analysing the complex to identify any further protein bound to the first protein other than the antibody, and
- (e) optionally repeating steps (a) to (d) to identify further proteins in the pathway.

30 According to this aspect of the present invention, the antibody, which is preferably a monoclonal antibody, such as for example monoclonal antibody designated as 16-48-2, starts the process by binding to the UNC-53 protein or a functional
35 equivalent thereof in the signal transduction pathway. Any other proteins found complexed to the bound

- 17 -

antibody or UNC-53 protein can then be used to identify further interacting proteins involved in the pathway.

5 It may also be possible to identify proteins involved in the signal transduction of a cell by using UNC-53 protein of C. elegans. According to this aspect of the invention the method comprises:

- 10 (a) contacting an extract of the cell with the UNC-53 protein of C. elegans or a functional equivalent, fragment or bioprecursor of said UNC-53 protein
- (b) identifying the UNC-53 protein/protein complex and
- 15 (c) analysing the complex to identify any protein bound to the UNC-53 protein other than another UNC-53 protein

20 This method can also advantageously be used to identify further proteins in a signal transduction pathway of a cell by contacting an extract of the cell used as described above, with any protein identified from step (c) above not being an UNC-53 protein and
25 repeating steps (b) and (c).

Other methods which may be used for identifying proteins in a signal transduction pathway of a cell may comprise for example a western blot overlay method
30 which method is well known to those skilled in the art. Cell extracts are run on SDS-gels to separate out protein and subsequently blotted onto a nylon membrane. These membranes may then be incubated, for example in a medium containing UNC-53 with a biotin
35 label thereon and any protein conjugates visualised

with a streptavidin-alkaline phosphatase conjugated antibody.

5 The present invention also advantageously provides a process for the preparation of binding antibodies which recognise proteins or fragments thereof involved in the rate and direction of cell migration or the control of cell shape, for the above methods. Preferably the antibody is monoclonal
10 antibody and more preferably monoclonal antibody 16-48-2.

The monoclonal antibody for binding to UNC-53 (or its functional equivalent) may be prepared by known techniques as described by Kohler R. and Milstein C.,
15 (1975) Nature 256, 495 to 497.

Another method which may be used to identify proteins involved in the signal transduction pathway involves investigating protein-protein interactions using the two-hybrid vector method. This method,
20 which is well known to those skilled in the art, utilises the properties of the GAL4 protein in yeast. GAL4 is a transcriptional activator of galactose metabolism in yeast and has a separate domain for binding to activators upstream of the galactose
25 metabolising genes as well as a protein binding domain. Nucleotide vectors may be constructed, one of which comprises the nucleotide residues encoding the DNA binding domain of GAL4. These binding domain residues may be fused to a known protein encoding
30 sequence, such as for example unc-53. The other vector comprises the residues encoding the protein binding domain of GAL4. These residues are fused to residues encoding a test protein, preferably from the signal transduction pathway of C. elegans. Any
35 interaction between the UNC-53 protein and the protein to be tested leads to transcriptional activation of a

- 19 -

reporter molecule in a GAL-4 transcription deficient yeast cell into which the vectors have been transformed. Preferably, a reporter molecule such as β -galactosidase is activated upon restoration of transcription of the yeast galactose metabolism genes. This method enables any interactions between proteins involved in the signal transduction pathway to be investigated.

Any proteins identified in the signal transduction pathway of the cell, which may be for example a mammalian cell, may also be included in a pharmaceutical composition together with a carrier, diluent or excipient therefor.

The present invention also provides a process for producing an UNC-53 protein of C. elegans or a functional equivalent, fragment, or derivative of the protein, which process comprises culturing the cells transformed or transfected with a cDNA expression vector having any of the cDNA sequences according to the invention as described above, and recovering the expressed UNC-53 protein. The cell may advantageously be a bacterial, animal, insect or plant cell.

A particularly preferred process for producing UNC-53 protein comprises using insect cells. Accordingly, the invention provides a process for producing an UNC-53 protein of C. elegans or a functional equivalent, fragment, derivative or bioprecursor of the UNC-53 protein, which process comprises culturing an insect cell transfected with a recombinant Baculovirus vector, said vector comprising a nucleotide vector encoding the UNC-53 protein or a functional equivalent, fragment or bioprecursor thereof downstream of the Baculovirus polyhedrin promoter and recovering the expressed UNC-53 protein. Advantageously, this method produces large amounts of protein for recovery. The insect cell may be from for

- 20 -

example Spodoptera frugiperda or Drosophila
Melanogaster.

In accordance with the present invention, a defined nucleic acid sequence includes not only the identical nucleic acid but also any minor base variations from the natural nucleic acid sequence including in particular, substitutions in bases which result in a synonymous codon (a different codon specifying the same amino acid), due to the degenerate code in conservative amino acid substitution. The term "nucleic acid sequence" also includes the complimentary sequence to any single stranded sequence given which includes the definition above regarding base variations.

Furthermore, a defined protein, polypeptide or amino acid sequence according to the invention, includes not only the identical amino acid sequence but also minor amino acid variations from the natural amino acid sequence including conservative amino acid replacements (a replacement by an amino acid that is related in its side chains). Also included are amino acid sequences which vary from the natural amino acid but result in a polypeptide which is immunologically identical or similar to the polypeptide encoded by the naturally occurring sequence. Such polypeptides may be encoded by a corresponding nucleic acid sequence.

The invention may be more clearly understood from the following description with reference to the accompanying drawings and photographs, in which

Fig. 1 shows one strand of the C. elegans unc-53 mRNA translated into DNA (U to T) (5073 bases) which corresponds to the 8A clone variant encoding the corresponding 8A protein shown in Figure 3. Designations "TB" are positions onto which SL1 transplacers have been identified at the 5' end of the sequence. Different mRNAs which differ in their 5'

end therefore exist. Potential start methionines are double underlined (M). Restriction endonuclease sites are indicated. A region of 8 sequential A bases at positions 4594 to 4601 is underlined. This region
5 differs from the corresponding region of the known sequence in the database (F45E10.1) by having 8 rather than 7 A'denine (A) bases resulting in a frame shift (see Fig 15) and corresponds to the 7A form of the protein. The nucleic acid sequence from the database
10 is also included in the nucleic acid sequences of the present application for reference only.

Fig. 2 shows a comparison of the sequences of the 7A and 8A clones of Figure 1.

Fig. 3 shows the predicted C. elegans amino acid
15 UNC-53 sequence corresponding to the nucleic acid sequence of the 8A clone shown numbered from 1 to 1528. Again, potential start methionines are double underlined (M). Designations "tb" are regions for PCR clones to identify PCR products. Other regions of
20 interest are identified. The region indicated as S4 is part of a lambda clone - 16.8 kb of the UNC-53 nucleic acid. This sequence, when translated is part only of the UNC-53 protein. Yet, injection of this part gives transformation rescue in organisms, i.e.
25 providing additional evidence for the existence of shorter forms of the protein.

Fig. 4 shows the predicted C. elegans amino acid sequences of Figure 3 in the three letter code for indicating amino acids.

30 Fig. 5 shows the predicted C. elegans amino acid sequence UNC-53 sequence corresponding to the nucleic acid sequence of the 7A clone of Figure 2 shown numbered from 1 to 1583.

35 Fig. 6 shows the amino acid sequence of Figure 5 in the corresponding three letter code format for indicating amino acids.

Fig. 7 shows sequences of low complexity of the amino acid sequence of the corresponding nucleic acid sequence of the 8A clone of Fig. 3 identified with the filter and SEG algorithms of the BLAST sequence
5 homology package. Regions of low complexity are indicated by "X" for the first copy of the sequence and by underlined amino acids for the second copy.

Fig. 8 shows, schematically, the known branches of the highly conserved Receptor Tyrosine Kinase/GRB2
10 signal transduction pathway including UNC-53.

Fig. 9 shows, schematically, the differences in cells with increased and decreased UNC-53 expression from the wild type.

Fig. 10 is a graph of the effect of anterior-posterior signal strength on growth cone extension
15 rate of C. elegans organisms, with increased and decreased UNC-53 expression from the wild type. This graph translates the observation that UNC-53 acts in a dosage-dependent way to direct the rate of extension
20 in the anterior/posterior axis into a model. The signal received e.g. (egl-15) is an RTK mediated signal which is postulated to be received by UNC-53 and which results in extension in the
25 anterior/posterior axis. The graph shows an allelic series of organisms with a graded reduction in extension from increased UNC-53 expression down through wild type to a reduced UNC-53 expression. The prediction is thus: for the same level of RTK mediated
30 signal the increased/decreased growth in the anterior/posterior axis depends on the level of expression of UNC-53 in any organism. The graph also reflects the prediction that for organisms with a particular level of UNC-53 overexpression there is no requirement for a signal before growth cone extension
35 occurs. This extension is likely to be in a random direction or influenced by alternative factors.

Fig. 11 shows constructs of unc-53 nucleic acid including identified functional domains .

Fig. 12 shows 5' amino terminus of the cDNA encoding from the first methionine amino acid through the actin binding protein homology domain (amino acids 1-133 from Fig. 1) and oligonucleotides designated oligo BG01, BG02 and BG03 (amplification strategies of amino terminus of the unc-53 cDNA). Combinations of oligo BG02 with either oligo BG02 or BG03 were used to amplify the 5' terminus of the cDNA from the first methionine through the actin binding protein homology domain (amino acids 1-133). All of the oligonucleotides are underlined and sequences identical to the cDNA are shown in upper-case. In addition to unc-53 sequence, oligo BG02 contains a stop codon and the recognition sequence for BamHI endonuclease. Oligo BG01 has engineered EcoRI and NdeI recognition sites for inclusion in bacterial expression vectors. Both constructs remove the 5' untranslated region of unc-53 and oligo BG03 contains a NotI cleavage site. Oligo BG03 has an improved ribosome binding site similar to mammalian ribosome binding sites. Use of BG03 in PCR thus results in constructs optimised for mammalian expression.

Figure 13 shows, schematically, constructs of the plasmids pTB109, pTB110, pTB111 and pTB112.

Fig. 14(a) shows a summary of transcript starts at the 5' end of the unc-53 gene. Different identified transcript starts and corresponding in-frame ATG-codons are marked. Tab2 is the oligo from within cDNA M5 which was used in RT PCR experiment to identify/isolate the 5' ends of different UNC-53 mRNAs.

Figure 14(b) shows the location of the different transcript starts on the genomic DNA and the position of the S4 Lambda clone with respect to genomic DNA.

Figure 14(c) shows the sequence near the 5' and 3' ends of the lambda S4 clone, identifying its composition corresponding to the 5' and at position 2260 of comid COGH10 and the 3' end of F45R10 at position 3287.

Fig. 15 shows the alignment of UNC-53 protein with the carboxytermini of the α -actinin and β -spectrin family (QY is UNC-53).

Fig. 16 shows the predicted actin binding sites of UNC-53. The comparison shows internal LKK repeats.

Fig. 17 shows the alignment of the candidate SH3 binding sites in UNC-53 with known SH3 sites of other named proteins. Proteins at positions 4 and 7 are critical for binding into SH3 pockets.

Fig. 18 shows the alignment of the predicted amino acid sequences from F45E10.1 (available in public database) with UNC-53. The different identified amino acid is shown at position 1186. The frameshift which results in the different amino acid sequence from position 1513 is a result of the different number of adenine bases in the nucleic acid sequence (see Fig. 1).

Fig. 19 is a series of photographs of C. elegans embryos (strain TB4Ex25 (Table 1) [UNC-53-UNC-54 construct]). The photographs show increased outgrowth in the anterior-posterior axis of body wall cells in the C. elegans embryos which overexpress UNC-53 (immunofluorescence with UNC-53 mab 16-48-2) Individual photographs are as follows:

- A: early embryo comma stage
- B: 1.5 fold stage embryo
- C: 3 fold stage embryo, first plane of focus
- D: 3 fold stage embryo, second plane of focus
- E: 3 fold stage, mosaic animal, 3-cells in a quadrant giving expression.

This demonstrates that immunofluorescence

provides a measure of the expression in the transgenic lines of UNC-53.

Fig. 20A is a photograph of C. elegans embryo containing DNA construct pTB110 (strain TBAIn76 (table 1)). Shown is expression of UNC-53 following heat shock.

Fig. 20B and C are photographs of C. elegans embryos containing DNA construct pTB111 (strain TB1Ex6 (table 1)). Shown is transgenic expression of UNC-53 in mechano-sensory neurons.

Fig. 21 shows photographs of the following:

- A: A wild-type UNC-53 L1 larva of genotype 4-25 (strain TB4Ex25) as in photographs 19B, C and D.
- B: L1 larva of 4-25 with morphological defects associated with muscle abnormalities.
- C: Lethal phenotype of 4-25.
- D: L1 larva of 4-25 showing misshapen animal and muscle cells with increased extensions. Also shows constipation problems associated with abnormal muscle pattern.
- E: L1 larva of the heat-shock line TBAIn76 (table 1) exhibiting morphological abnormalities following heat shock and recovery.
- F: L1 larva of line TBAIn76 (table 1) showing morphological defects in the pharynx.

All Figs. 19, 20 and 21 are Normarski optics of live embryos.

Fig. 22 is a map of plasmid pTB110 (tables 1 and 2) a heat shock promoter fusion, indicating restriction endonuclease sites.

Fig. 23 is a map of plasmid pTB112 (tables 1 and 2) a muscle specific UNC-54 fusion, indicating restriction endonuclease sites.

Fig. 24 is a map of plasmid pTB54 (the 8A clone variant) (tables 1 and 2). In the construction of this plasmid the complete unc-53 cDNA (tb3M5) of the

8A variant, including 5' and 3' UTRs was cloned as a NotI-ApaI fragment into the mammalian expression vector pCDNA3 (Invitrogen).

5 Figure 25 is a map of plasmid pTB72 (the construct encoding the 7A clone variant of UNC-53 cDNA of Figure 2).

Figure 26 is nucleotide sequence of the plasmid map of Figure 25.

Figure 27 is a map of plasmid pTB73.

10 Figure 28 is a nucleotide sequence of plasmid pTB73 of Figure 27.

Figure 29 is a map of plasmid pCB50.

Figure 30 is a nucleotide sequence of plasmid pCB50 of Figure 29.

15 Figure 31 is a map of plasmid pCB51.

Figure 32 is a nucleotide sequence of the plasmid pCB51 of Figure 31.

Figure 33 is a map of plasmid ppCB55.

20 Figure 34 is a nucleotide sequence of plasmid pCB55 of Figure 33.

Figure 35A illustrates a flowchart of the actin co-sedimentation assay. Soluble UNC53 protein was incubated with monomeric G-actin in a buffer containing ATP. Polymerization of G-actin to F-actin was induced by increasing the salt concentration to 100 mM, F-actin protein complexes were collected by centrifugation and analyzed by SDS-PAGE and fluorography.

30 Figure 35(B) illustrates the concentration series of the actin co-sedimentation assay. The full length UNC-53 encoding cDNA (pTB72) was transcribed and translated *in vitro* and co-sedimented with F-actin at a starting G-actin concentrations ranging from 0 to 250 mg/ml. See methods for details. S=supernatant after airfuging. P=pellet after airfuging.

35 Figure 35(C) illustrates both the full length

(pTB72) and amino terminal deleted UNC53 (pTB73) protein co-sediment with F-actin. Starting G-actin concentration was 500 mg/ml. S=supernatant, P=pellet, R= starting *in vitro* reaction.

5 Figure 36(A) is a flowchart of a SEM-5 binding experiment. The truncated UNC53 cDNA (pTB50) was transcribed and translated *in vitro* and incubated with SEM5-GST sepharose or GST sepharose. After four
10 washes, the remaining proteins bound to the matrix were analyzed by SDS-PAGE and fluorography.

 Figure 36(B) illustrates an immunoprecipitation experiment of radioactively labelled UNC53 proteins from the TnT pTB50 reaction shows that monoclonal antibody 16-48-2 recognizes both the native (=SDS
15 lanes) and denatured (+SDS) protein products *in vitro*. c=control reaction without anti-UNC53 monoclonal antibody 16-48-2. ab=reaction with monoclonal antibody 16-48-2. See methods for details.

 Figure 36(C) illustrates the results of SEM-5-GST
20 binding experiments outlined in (a). *In vitro* translated UNC53 protein were analyzed by SDS-PAGE and fluorography. See methods for details.
 sup=supernatant

 Figure 36(D) illustrates a western blot overlay
25 experiment of UNC-53 (construct pTB61) expressed in bacterial cells. Cell lysates were denatured in Laemmli buffer and the proteins separated by 5-25% gradient SDS-PAGE. The arrowhead indicates the
30 presence of full length UNC-53 in the induced bacterial lysate. Additional gels were blotted to nylon membrane, incubated with biotinylated GST or biotinylated GST-GRB2 protein and bound protein
 complexes subsequently detected with a streptavidin-alkaline phosphatase conjugated antibody. See methods
35 for details. U=uninduced bacterial cell lysate, I=induced bacterial cell lysate.

Figure 37 is a series of photographs of C. elegans which illustrates overexpression of UNC-53 in body muscle cells results in over-extension along the longitudinal axis. Transgenic C. elegans embryos carrying the construct PTB113 were analyzed for UNC-53 activity by immunohistochemistry with the 16-48-2 antibody. Starting from the photograph (a) of the top left panel of Figure 37.

(A) and (B) illustrate ectopic growth cone spikes (indicated by the arrowheads) are observed early in myogenesis in the comma stage embryo. (C) and (D) illustrate over-extension of muscle cells in the head region of a three fold embryo during outgrowth. (E) illustrates over-extension is clearly observed along the anterior-posterior axis (indicated by the arrowheads) of a late 3 fold embryo.

Figure 38 is a map of plasmid ptb113.

Figure 39 is a nucleotide sequence of the plasmid ptb113 of Figure 38.

Figure 40 illustrates neurite tree length and fraction positive cells enhancement in a transfected cell C9 compared to wild-type cells C0. Black bars indicate fraction positive cells whereas hatched bars indicate neurite tree length cells, as described in example 8.

Figure 41 illustrates the results obtained following application of compound (1-(1H-pyrrol-2-ylmethyl)-2-piperidinone) to N4 transfected cells. The dark coloured bars indicate fraction positive C0 clones whereas the hatched bars of the chart indicate fraction positive C9 clones.

The following sequence listings are referred to in the specification.

Sequence 1D No 1: is a nucleic acid sequence

corresponding to the 7A nucleic acid sequence variant of Figure 2.

5 Sequence 1D No 2: is a nucleic acid sequence corresponding to the 8A nucleic acid sequence variant of figure 1.

10 Sequence 1D No 3: is an amino acid sequence corresponding to the amino acid sequence of the 8A variant of figure 3.

15 Sequence 1D No 4: is an amino acid sequence corresponding to the amino acid sequence of the 7A variant of figure 2.

Sequence 1D No 5: is an amino acid corresponding to the amino acid sequence shown in figure 7.

20 Sequence 1D No 6: is a nucleic acid sequence of the oligo BGO3 sequence of figure 12.

Sequence 1D No 7: nucleic acid sequence of the oligo BGO1 sequence of figure 12.

25 Sequence 1D No 8: is a nucleic acid sequence of the oligo BGO2 sequence of figure 12.

30 Sequence 1D No 9: is an amino acid sequence corresponding to the amino acid UNC-53(a) sequence shown in figure 17.

35 Sequence ID No 10: is an amino acid sequence corresponding to amino acid sequence of sequence (b) of UNC-53 shown in figure 17.

Sequence ID No 11: is an amino acid sequence

corresponding to the sequence (c) of an SOS shown in figure 17.

5 Sequence ID No 12: is an amino acid sequence
corresponding to the sequence (d) of an SOS shown in figure 17.

10 Sequence ID No 13: is an amino acid sequence
corresponding to the sequence (d) of an SOS shown in figure 17.

15 Sequence ID No 14: is an amino acid sequence
corresponding to the sequence (f) of SOS 1359 shown in figure 17.

Sequence ID No 15: is an amino acid sequence
corresponding to the sequence (g) of SOS 1377 shown in figure 17.

20 Sequence ID No 16: is an amino acid sequence
corresponding to the sequence (h) of Dynamin shown in figure 17.

25 Sequence ID No 17: is an amino acid sequence
corresponding to the sequence (i) of dynamin shown in figure 17.

30 Sequence ID No 18: is an amino acid sequence
corresponding to the sequence (j) of PI3K p85 shown in figure 17.

Sequence ID No 19: is an amino acid sequence
corresponding to the sequence (k) of P13k p85 shown in figure 17.

35 Sequence ID NO 20: is an amino acid sequence

corresponding to the sequence (l) of AFAP-110 shown in figure 17.

5 Sequence No 21: is an amino acid sequence
corresponding to the sequence (m) of AFAP-110 shown in figure 17.

10 Sequence No 22: is an amino acid sequence
corresponding to the sequence (n) of 3BP-1 shown in figure 17.

15 Sequence ID No 23: is an amino acid sequence
corresponding to the sequence (o) of 3BP-1 shown in figure 17.

Sequence ID No 24: is an amino acid sequence which corresponds to the amino acid sequence from positions 106 to 133 of UNC-53 shown in figure 16.

20 Sequence ID No 25: is an amino acid sequence which corresponds to the amino acid sequence from positions 1093 to 1120 of UNC-53 shown in figure 16.

25 Sequence ID No 26: is a nucleotide sequence
corresponding to the nucleotide sequence of ptB72 shown in figure 26.

30 Sequence ID No 27: is a nucleotide sequence
corresponding to the nucleotide sequence of ptB73 shown in figure 28.

Sequence ID No 28: is a nucleotide sequence corresponding to the nucleotide sequence of pCB50 shown in figure 30.

35 Sequence ID No 29: is a nucleotide sequence

corresponding to the nucleotide sequence of pCB51
shown in figur 32.

5 Sequence ID No 30: is a nucleotide sequence
corresponding to the sequence of pCB55 shown in figure
34.

10 Sequence ID No 31: is a nucleotide sequence
corresponding to the nucleotide sequence of ptb113
shown in figure 39.

15 Sequence ID No 32: is an amino acid sequence
corresponding to the amino acid sequence as numbered
from amino acid 1 to 110 of the sequence figure 3.

Sequence ID No 33: is an amino acid sequence
corresponding to the sequence as numbered from amino
acid sequence 114 to 133 of the sequence of figure 3.

20 Sequence ID No 34: is an amino acid sequence
corresponding to the sequence as numbered from amino
acid sequence 487 to 495 of the sequence of figure 3.

25 Sequence ID No 35: is an amino acid sequence
corresponding to the sequence as numbered from amino
acid sequence 537 to 545 of the sequence of figure 3.

30 Sequence ID No 36: is an amino acid sequence
corresponding to the sequence as numbered from amino
acid sequence 1032 to 1037 of the sequence of figure
3.

35 Sequence ID No 37: is an amino acid sequence
corresponding to the sequence as numbered from amino
acid sequence 1097 to 1116 of the sequence of figure
3.

Sequence ID No 38: is an amino acid sequence corresponding to the sequence as number d from amino acid sequence 1300 to 1307 of the sequence shown in figure 3.

5

Sequence ID No 39: is an amino acid sequence corresponding to the amino acid sequence (a) of α -actinin (aact) shown in figure 15.

10

Sequence ID No 40: is an amino acid sequence corresponding to the amino acid sequence (b) of unc-53 shown in figure 15.

15

Sequence ID No 41: is an amino acid sequence corresponding to the amino acid sequence (c) of β -spectrin (spectrin) shown in figure 15.

20

Sequence ID No 42: is an amino acid sequence corresponding to the amino acid sequence (d) of α -actinin (aact) shown in figure 15.

25

Sequence ID No 43: is an amino acid sequence corresponding to the amino acid sequence (e) of UNC-53 shown in figure 15.

30

Sequence ID No 44: is a amino acid sequence corresponding to the amino acid sequence (f) of β -spectrin (spectrin) shown in figure 15.

Sequence ID No 45: is an amino acid sequence corresponding to the amino acid sequence (g) of α -actinin shown in figure 15.

35

Sequence ID No 46: is an amino acid sequence corresponding to the amino acid sequence (h) of UNC-53 shown in figure 15.

Sequence ID No 47: is an amino acid sequence corresponding to the amino acid sequence (I) of β -spectrin shown in figure 15.

5 Sequence ID No 48: is a nucleotide sequence corresponding to the nucleotide sequence of S4 lambda clone shown in figure 14(c).

10 The inventors have established a set of processes particularly in C. elegans to select for inhibitors or enhancers of UNC-53. This screen is based on transgenic or mutant organisms or cells in which we have introduced a nucleic acid sequence encoding UNC-
15 53 under the control of a specific promoter. In these organisms UNC-53 is over-stimulated as judged by increased extension of growth cones of muscle cells which over-express UNC-53 in C. elegans. This leads to a range of phenotypes in both embryonic and
20 postembryonic development (from death to defective morphology and motility). These phenotypes can be scored with simple means at high throughput. Similar results can be obtained with heat shock specific lines. The basis of our test for inhibitors of the
25 UNC-53 signal transduction pathway is reversal of this phenotype to an improved state of health.

 We have constructed transgenic strains of C. elegans which over-express UNC-53 in body muscle. This results in increased extension of muscle cells
30 and embryonic lethality (17 to 80% of transgenic organisms depending on the line used). These strains are used to directly screen for drugs which interfere with unc-53 genes, UNC-53 protein activity or any regulatory factor thereof to thereby suppress the
35 background lethality.

 Another process which may be used for selecting

inhibitors or enhancers of UNC-53 uses a constitutively active unc-53. This is achieved by mutating the nucleotide binding domain such that GTP or ATP is always bound or by covalently attaching SEM-

5 5. In this strategy, transgenics (tissue cultured cell lines, or organisms such as nematodes) are generated which maintain unc-53 in a higher endogenous level of activity. Over-extension and subsequent lethality results in a greater proportion than that

10 observed in the UNC-54/UNC-53 wild type lines. By screening for survivors after drug treatment, this assay specifically identifies inhibitors of downstream components in the signal transduction pathway.

Another process utilises an UNC-53 promoter. In

15 this approach, an UNC-53 promoter is fused to a nucleic acid sequence encoding a reporter molecule, for example green fluorescent protein (GFP). Cells will glow when trans-acting factors bind to the promoter to activate transcription. By screening for

20 cells which do not fluoresce, molecules which inhibit transcription of UNC-53 are identified.

The processes for selecting inhibitors and/or enhancers according to the invention are preferably carried out on whole animals. This can be done using

25 a C. elegans system. The advantages of these tests include:

- (1) The screening in a whole animal assay. C. elegans is a complex multicellular organism with a full nervous system, digestive system, etc. Its
- 30 anatomy and development has been described in extreme detail. It is one of the best-characterised higher organisms at the genetic, molecular, developmental and cell biological level. Any observed changes to phenotype can be checked against this database.
- 35 (2) To study effects on rate and directionality of cell migration and the change of cell shape it is

important to leave the cells under study in a setting where they are surrounded by the in vivo interacting tissues, cells and substrates for cell migration etc. This can be done using whole C. elegans subjects. A
5 situation has been created where the given pathway is over-stimulated leading to an easily scorable phenotype which can be reverted in any assay or process.

(3) The endpoint of the screen is the substantially
10 increased health of the organism. This permits the exclusion of non-specific and toxic compounds.

(4) A complete and specific inhibition of UNC-53 in the transgenics will lead at the worst to the phenotype of an UNC-53 reduction or loss of function
15 mutant which we have described, can recognise and have shown not to be essential for viability.

(5) The test can be adapted to make full use of the advantages of the C. elegans model system such as the possibility to conduct the test chronically over
20 several generations and the possibility to conduct the test in different genetic backgrounds, e.g. RTK constitutive or defective.

(6) C. elegans exhibits a complex set of wild type, drug- and mutation-induced phenotypes such as changes
25 in body shape, subtle changes in locomotion, mating behaviour, chemotaxis, pharyngeal pumping, egg laying behaviour, which can be used as part of a phenotype analysis or screen.

The results of C. elegans research described
30 herein has provided important breakthroughs in biomedical research fields such as programmed cell death, neuronal guidance, the Receptor Tyrosine Kinase/RAS signal transduction pathway, integrin/cell adhesion receptor signalling, etc.,

35 The biochemical association of UNC-53 in the RTK signal transduction pathway enables identification of

genes or of biochemical pathways which are targets for pharmacologically or pharmaceutically active compounds and the development of high throughput and mode of action specific drug screens using wild type, mutant and transgenic animal strains including, in particular, C. elegans.

Thus pharmacological manipulation of the UNC-53 pathway is now possible on the following rationale:

We have scientific arguments to expect C. elegans UNC-53 to interact in vivo with the other components of RTK signal transduction pathways based on:

(1) The observation that C. elegans SEM-5 and GRB-2 are mutually exchangeable in vivo, combined with our observed in vitro binding of both GRB-2 and SEM-5 to UNC-53. Thus, C. elegans UNC-53 will be able to interact with the activated GRB-2/RTK receptor in mammalian cells.

(2) UNC-53 interacts with the rabbit actin-cytoskeleton

Expression of C. elegans UNC-53 in mammalian cell lines represents a shortcut to develop pharmacological assays and screens to target this pathway. We have shown that over-expression of the C. elegans UNC-53 in C. elegans myoblasts leads to over-extension of these cells in the anterior/posterior axis of the embryo and ultimate disorganisation of the muscle cell and myofilament pattern. (Over)-expression of C. elegans UNC-53 in a human cell line leads to a detectable change in phenotype, in particular increased motility of cells, increased outgrowth of neurons and morphological changes in the elongation and cytoskeletal morphology of differentiating myotubes.

The C. elegans unc-53 Open Reading Frame (ORF) (with and without optimised Kozak consensus sequence) of both 7A and 8A clone variants has been cloned between the CMV major intermediate early

promoter/enhancer and bovine growth hormone polyA
signal sequence of expression vector pCDNA3
(Invitrogen). This vector is designed for high level
stable and transient expression in most mammalian
5 cells.

The following additional considerations require
mention:

(1) Genetic analysis of reduction in UNC-53 function
and ectopic expression experiments suggest that UNC-53
10 acts in a highly dosage-dependent manner. As is the
case for RAS, increased expression may lead to
lowering the threshold of RTK-signal required for a
given response or may remove the requirement for an
activating signal to obtain a phenotype response (Fig
15 10). In addition UNC-53 is an unusually low abundance
protein in wild type *C. elegans*. It is therefore
likely to be necessary or useful to control the
temporal and quantitative expression of UNC-53 in the
proposed assay conditions in all organisms or cells to
20 be assayed. The already available or a further
optimised expression cassette is then cloned in
expression vectors with IPTG- inducible or
tetracycline-repressible promoters. It is realised
that both the Lac and Tet expression systems are
25 leaky. Additional other repressible/inducible
expression systems (e.g. Mx promoter) or weak
mammalian promoters might be preferred.

(2) Over-expression of the endocytosis controlling
protein dynamin leads to phenotypes which are not
30 associated with dynamin function in the cell but which
are thought to be due to sequestration of the GRB-2
pool in the cell (GRB-2 is an adaptor for a variety of
signal transduction pathways). Such sequestration is
unlikely to lead to "positive effects" on the activity
35 of the cell such as is observed in the presently
described assay system (increased cell process

xtension or motility), see Fig 19. Based on the
homology between UNC-53 and GTP-binding, we can also
predict specific mutations in the nucleotide-binding
pocket or the predicted effector region which should
5 lead to loss of function. Sequence analysis of unc-53
alleles is instructive in determining which amino
acids of UNC-53 are essential for function, e.g. as
exemplified by the indication that an allele (n152)
which has a differential effect on anterior versus
10 posterior guidance has a deletion in a region of
differential splicing. The differential splices of
the C. elegans unc-53 gene encode different variants
of the protein which independently affect posterior or
anterior migration and/or cell specificity. One
15 predicted exon in C. elegans unc-53 is indicated in
Fig 1. It is conceivable that of two variants of the
same protein one is inhibited or enhanced by a
particular compound whereas the other is not (or to a
lesser degree). Such a compound could then be used to
20 control direction of migration or cell specificity by
selective inhibition or enhancement.

(3) To develop pharmacological screens for inhibitors
of a biochemical pathway a "gain of function"
phenotype has been invented which can be expected to
25 revert to wild type in the presence of specific
inhibitors. Overexpression of UNC-53 in C. elegans
myoblasts already leads to lethal subviable muscle
phenotypes which can be easily scored with high
throughput or a scorable heat shock inducible
30 phenotype (Fig 21). They may form the basis for a
pharmacological screen for inhibitors. A similar
screen is obtained for over-expressing UNC-53 in
mammalian cells. An alternative strategy is based on
the homology to GTP binding proteins, RAS and dynamin
35 and NTPases. We can introduce amino-acid changes in
the nucleotide binding pocket which are

predicted/expected to lead to a constitutively activated or inactivated UNC-53. Similar changes are based on homologies with SOS, dynamin or ATP/GTP binding proteins from homology tables.

- 5 (4) Correct expression of UNC-53 in each cell line may be assessed by immunofluorescence and western blot analysis with the monoclonal antibody (mab) designated as 16-48-2.

10 The inventors have thus expressed and stably integrate the expression constructs in the neuronal, myoblast and 3T3 cell lines.

These cell lines are primarily used to:

- 15 - Assess the effect of UNC-53 expression on the morphology, motility, metastatic potential and growth cone extension of the cell lines.
- Produce protein and mRNA
- Screen for pharmacological compounds inhibiting observed UNC-53 mediated phenotypes
- 20 - Analyse signal transduction pathways associated with UNC-53 activation (for example, phosphorylation,)
- Immunofluorescence studies with mab 16-48-2 to assess changes in subcellular localisation following growth factor treatment.

25 Thus, the present invention provides for the identification of compounds which inhibit or enhance the UNC-53 signal transduction pathway. Such compounds can be used in the control of cell directional migration, motility and differentiation. These compounds are useful in the treatment of
30 oncogenesis, psoriasis, neuronal degeneration and cell migration (metastasis).

The present invention also provides the ability to identify nucleic acid sequences and proteins which are involved in the UNC-53 pathway in C. elegans.
35 Such nucleic acid sequences and proteins may be UNC-53 equivalents, members of an UNC-53 pathway or may be

nucleic acid sequences or proteins which interact in the UNC-53 pathway, for example as demonstrated by the GRB-2/SEM-5 proteins. This knowledge of the UNC-53 pathway in C. elegans can be established as can factors which influence the functioning of the pathway, for example, factors/ proteins which feed into the pathway or are of a parallel pathway which at least, in vitro, compensates for steps in an UNC-53 pathway.

10 The identification of other components in the UNC-53 signal transduction pathway:

(1) help to determine the interaction of UNC-53 with known signal transduction pathways (RAC-, RHO-, cdc42-RAS-pathway exchange factors, downstream or regulating kinases)

15 (2) identify the new interacting proteins which may constitute additional potential pharmacological targets.

20 (3) may assign functions to the more than 1000 amino acids of UNC-53 which have no homology to known proteins.

Accordingly, proteins which cross-react with anti-C. elegans UNC-53 protein antibodies can be isolated. The basic experiment protocol for purifying antigen-antibody complexes is described in Example 11. This system can also be used to identify factors which interact with proteins which bind to anti-UNC-53 C. elegans antibodies.

25 The following tissue sources may be used for immuno-precipitation:

30 (1) Mammalian cells which exhibit a phenotype after transfection with unc-53 indicating that it interacts with vertebrate components of its signal transduction pathway.

35 (2) UNC-53 protein may be too low abundance to make affinity purification from wild type C. elegans

feasible. The inventors have affinity-purified UNC-53 from already constructed transgenic C. elegans lines which express UNC-53 under control of the hsp-16 promoter and/or the myosin promoter. These experiments in C. elegans are justified because with the vast amount of sequence information (genomic and cDNA) available, one has a good chance of identifying the corresponding genes in the databases with a minimum of peptide sequence.

Several types of proteins may be expected to co-purify with UNC-53, including GRB-2 and other proteins with SH3 domains of the Grb2 class or phosphorylation sites, RTK-receptors, subunits of an UNC-53 homo-heterodimer complex, downstream regulating kinases or proteins from the microfilament cytoskeleton.

This co-immuno-precipitation approach can also be used to dissect the order of events in this signal transduction pathway. For example: UNC-53 immuno-purified after stimulation of mammalian cell-lines with growth factors and pharmacological agents can also be assayed with respect to its state of phosphorylation, or complex formation with interacting proteins.

Proteins interacting with specific UNC-53 domains are identified using a yeast two-hybrid system, whereby two sets of hybrid proteins are used to assay for functional restoration of the GAL4 transcriptional activator: the first consisting of a GAL4 activation domain/UNC-53 structural domain of unknown function, the second derived from a cDNA library cloned into an expression vector to generate a library of hybrid proteins containing a GAL4 DNA binding domain. The yeast two-hybrid system is well known in the art.

A set of unc-53-fusion constructs can be constructed, including a fusion to

- (1) the full length protein,

- (2) the carboxyterminal domain (from second actin binding domain to the ATP/GTP binding domain),
(3) The aminotermminus (predicted cortical localisation domain up to the SH3 binding sites),
5 (4) a variety of overlapping constructs within the central domain of 1000 amino acids to which no function can as yet be assigned.

These are tested in yeast to exclude those which lead to activation of the reporter gene in the absence
10 of the cDNA-activator fusion. cDNA libraries were transformed into these reporter strains and positive clones identified. (In this strategy, screening of multiple libraries requires very little effort (transformation followed by plating on selective and
15 indicator medium)).

A preferred cDNA library is from cell lines in which a phenotypic change is observed following UNC-53 expression such as mouse N4 neuroblastoma cells or MCF-7 breast carcinoma cells. The yeast two hybrid
20 system can identify interacting proteins or "sections" of nucleic acid which may not be translated in vivo but which may inhibit UNC-53.

Candidate positives are tested for the fusion-protein dependence of the reporter gene activation.
25 The cDNA insert in remaining positive clones is sequenced. The obtained sequence is screened through the databases, which provides, especially in the case of C. elegans clones, significant extra sequence.

Another system also exists for the identification
30 of proteins which bind or modify UNC-53. An UNC-53 protein is bound by conventional techniques to a column. A sample to be tested is then passed over the column. This sample may be fractions from cells from C.elegans, mammals or any other organism. These
35 sample fractions may have been incubated with ³²ATP. In this course the "reaction" of the labelled fraction

with UNC-53 can be determined. If the UNC-53 on the column becomes ^{32}P phosphorylated then this indicates that the sample fraction contains an UNC-53 modifying protein. Alternatively a constituent of the sample may bind to the UNC-53 and remain bound therewith on the column. The retention of any fraction of the sample on the column and the identification of the fraction can easily be determined by techniques known in the art.

Example 9 describes the identification of sensitive, dependant or resistant mutations as direct tools for the development of screens for compounds with similar or antagonistic activities. Both resistant and sensitising mutations may have a phenotype in the absence of the compound and no or a different phenotype in the presence of the compound. This permits the introduction of action-specificity in the screens.

High throughput screens are a basic feature of C. elegans genetic methodology. Non-complementation screens for new alleles in a locus require setting up of up to 8000 separate worm populations starting from one hand-picked individual each. This is done in 24 well plates or small Petri-plates. These are subsequently (after 1 or 2 generations) visually screened for a complex behavioural phenotype. For pharmacological screens where populations can be started from multiple individuals pipetted from a pool of synchronised eggs, high throughput screens can also be developed. If the endpoint of the assay can be scored in liquid, populations can be set up in microtitreplates. If the end-point is linked to a reporter gene (e.g. β -galactosidase activity) ELISA type colour-metric assays can be used to score the end-point. C. elegans can also be introduced into soils, exposed to compounds and subsequently recovered

and assayed. Such endpoints are used in the heat-shock assay developed by Stressgen (Stringham & Candido (1994), Environ. Toxicology and Chemistry, 13(8), 1211-1220).

5 Gain of function mutants of C. elegans or transgenic C. elegans in which a pathway of interest has been over- or constitutively activated, causing a dominant phenotype which can be used to develop specific screens for inhibitors.

10 Transgenic lines expressing UNC-53 ectopically under the C. elegans heat-shock (hsp-16) promoter, and body wall muscle (unc-54) promoter have been constructed. These lines lead to dominant phenotypes in development and are used directly to screen a spectrum of compounds. Where necessary or deemed
15 useful endogenous C. elegans genes can be replaced by or complemented with human signal transduction pathways.

20 DEPOSITED CELL LINES AND PLASMIDS

	<u>STRAIN NAME</u>	<u>DATE OF DEPOSIT</u>	<u>LMBP ACCESSION NUMBER</u>
25	pTB54 Plasmid	22 MAY 1995	3296
	pTB112 Plasmid	22 MAY 1995	3295
30	pTB72	22 MAY 1996	3486
	TB4EX25 Cell Line	22 MAY 1995	1384 CB
35	TBAIn76 Cell Line	22 MAY 1995	1385 CB
	HYBRIDOMA Cell Line	22 MAY 1995	1383 CB
40	MCF-7 TRANSFECTED BREAST CARCINOMA		

	CELL LINE	24 MAY 1996	1550 CB
5	TRANSFECTED N4 NEUROBLASTOMA CELL LINE	24 MAY 1996	1549 CB
10	WILD TYPE MCF-7 BREAST CARCINOMA CELL LINE	24 MAY 1996	1551 CB

15 The above plasmids and cell-lines were deposited
at the Belgian Coordinated Collections of Micro
organisms (BCCM) at Laboratorium voor Moleculaire
Biologie - Plasmidencollective (LMBP) B-9000, Ghent,
Belgium, in accordance with the provisions of the
Budapest Treaty of 28 April 1977.

20 The present invention will now be described with
reference to the following Examples.

Examples

25 Example 1 - Molecular Characterisation of unc-53
gene in C. elegans
Screen for muscle pattern mutants :

30 C. elegans has two sets of muscles which are
suitable to study this problem, the body wall muscles
and the sex muscles. The sex muscles are a set of 16
muscle cells (4 muscle types) in the hermaphrodite and
41 cells in the male (10 muscle types) with distinct
attachments points on the hypodermis and gonads. The
sex muscles develop postembryonically and are not
35 required for viability. The body wall muscles are
arranged longitudinally (roughly 2 cells abreast) into
four quadrants. At birth there are 81 cells. In
postembryonic development, extra muscles interdigitate
with these bringing the total number of body wall

muscles in the hermaphrodite to 95. Head, neck and body muscles can be distinguished within these rows on the basis of their innervation and patterning within the rows.

5 We have screened 4800 haploid genomes using Nomarski and polarized microscopy for mutants with specific attachment or pattern defects in a subset of the male sex muscles but with wild type body wall muscle pattern and myofilament organization, wild
10 type movement and wild type male bursa anatomy (a sensitive indicator of wild type morphogenesis). Amongst the 21 identified mutants we selected for further study those with specific phenotypes in both the male and hermaphrodite sex muscles. As these
15 muscles lie in different regions of the animals this was thought to reduce the chance that the male tail phenotype is a pleiotropic consequence of changes in regional identity of the tail or defects in male tail hypodermal lineage or morphogenesis.

20

Muscle phenotype of e2432.

Mutant e2432 was isolated on the basis of its phenotype in the male spicule retractor muscles, a pair of bilaterally symmetrical muscles which attach
25 anteriorly to the body wall and posteriorly to the base of the spicules. The spicule retractors of mutant e2432 are shorter than wild type. Their attachment to the spicules is wild type, but their attachment point to the body wall is shifted posteriorly. The spicule
30 protractors sometimes extend processes onto the attachment point of the spicule retractors on the hypodermis, suggesting the defect is not in these attachment points, but rather in the extension of the muscles towards that point. The diagonal muscles are
35 in most specimens wild type but they are occasionally not parallel to one another or are have a dorsal

attachment point that is more ventrally positioned than in wild type. e2432 males have a nicely shaped fan with the normal pattern of rays, suggesting that the sex muscle defect is not pleiotropic due to defects in the hypodermis.

e2432 hermaphrodites have a reduced ability to lay eggs which is variable from animal to animal. This is due to a muscle pattern defect in the vulval sex muscles. The uterine muscles, 8 muscle cells which circle the hermaphrodite uterus, are wild type in e2432. The vulval muscles are a set of 4 pairs of cells arranged symmetrically in a cross-pattern around the vulval slit. Each pair consists of one vm1 and one vm2 muscle cell. The vm2 muscles attach to the junction between uterus and vulva and extend anteriorly to attach to the hypodermis in between two muscle cells of the ventral body wall muscle quadrant. In e2432 these muscles are shorter than in wild type small. In e2432 they can only be visualized by laser confocal microscopy (after FITC-phalloidin staining of the myofilaments). This showed that they attached to the uterus as in wild type, but that their attachment to the body wall is ectopic (in a random position lateral of the vulva, usually on the ventral edge of the muscle row). In e2432 vm2 myofilaments are oriented more dorsoventrally than in wild type (where their orientation is essentially in the longitudinal axis of the animal). This phenotype is not due to a defect in the attachment point on the epidermis to which these cells should attach in wild type, since we frequently observe that the vm1 sex muscles make an apparently wild type attachment to this unoccupied attachment point.

In wild type hermaphrodites, the vm1 muscle cells attach close to the junction between epidermis and vulva and in the adult extend dorsally and anteriorly

(under an angle of 45-50 degrees with respect of the vulval slit) to attach to the hypodermis at the dorsal edge of the ventral body wall muscle quadrants. In e2432 the attachment of the vm1 muscles to the vulva is wild type. With their other end they attach, like wild type vm1 cells, along the dorsal of the edge of the ventral body wall muscles. However the angle between the vulval slit and the myofilaments of the vm1 sex muscles is reduced (less than 45 degrees) so that their dorsal attachment point is closer to the vulva than in wild type. The forces acting on the vulva can be separated in an antero-posterior and a dorsal vector. In e2432, the antero-posterior vector of both the vm1 and vm2 muscle is significantly reduced, leading to a reduced ability to open the vulva upon contraction. Studies in which vulval muscles were ablated individually or in groups suggested that 2 vulval muscle cells of wild type orientation are sufficient for wild type function.

Adult C. elegans hermaphrodites have 95 body wall muscle cells arranged longitudinally (roughly 2 cells abreast) into four quadrants. In wild type cells these cells are spindle shaped.

e2432 adults have body wall muscles with a wild type muscle cell and myofilament pattern, except that cells with interdigitating tips occur more frequently than in wild type. Like the unc-53 phenotype in the male and hermaphrodite sex muscles, this body wall muscle defect, which can also be observed in other guidance and attachment mutants like unc-6 and mups, can also be attributed to a reduced ability to extend "growth cones" otherwise referred to as cell processes in the anterior-posterior axis of the animal.

Position on the genetic map :

e2432 was mapped to the left arm of chromosome II

and was found not to complement unc-53(e404). The unc-53 locus was originally identified by Brenner (1974), Genetics, 77, 71-94 as one of the uncoordinated mutants but has received only sporadic attention in general phenotypic surveys of the UNC-collection (Hedgecock et al (1987), Development, 100, 365-382 and Siddiqui (1990), Neurosci. Res. (Suppl) 13, 171-190, in a genome wide screen for egg laying defective mutants (Trent and Horvitz (1983), Genetics, 104, 619-647) and using e2432 as a tool to study the effect of body shape on the pattern of neuronal processes (Hekimi and Kershaw (1993), J. Neuroscience, 13(10) 4254-4271). We initiated a detailed genetic and phenotypic analysis of this locus using the existing available alleles which various colleagues isolated in different screens : The canonical unc-53 allele e404, a strong UNC was isolated by Sydney Brenner. Alleles n152, n166 and n1199 have been obtained in screens for egg laying defective mutants. Alleles NJ234 and NJ222 were isolated by Ed Hedgecock in a screen defective in excretory canal outgrowth. As these screens were aimed at isolating viable fertile alleles, we isolated additional alleles by pre-complementation screens designed to yield loss of function alleles irrespective of their phenotype. e2432/mnDf90 hermaphrodites are egl, weak unc's with a slightly stronger phenotype than e2432. Matings were set up on 3 cm petri dishes between 2 to 3 unc-53(e2432) sqt-1(sc13) /+ males and 2 e2431ts or dpy-6(e14) hermaphrodites mutagenized with EMS in the L4 stage (Brenner, 1974) , Genetics, 77 71-94. The F1 egl, unc-53 like hermaphrodites, which may be unc-53(e2432) sqt-1(sc13)/unc-53(new) were cloned on petri dishes and their offspring examined for the segregation of new unc-53 alleles. In two screens, two unc-53 alleles, 5 and 8 were isolated in an estimated 13000

F1 offspring, giving an approx. mutation rate 1/3250 mutagenized chromosomes. *sqt-1(sc13)*, an allele of *sqt-1* that confers a roller phenotype was included because it is closely linked to *unc-53* (0.2 m.u.) and marks the original allele *e2432*. *e2431ts*, an X-linked *ts* larval lethal with a *mup* phenotype was included to eliminate F1 hermaphrodites arising from selfing and F1 males which can mate. In the second screen *dpy-6(e14)* was included to prevent F1 males from mating with F1 hermaphrodites.

All *unc-53* alleles used in this study fail to complement to *e2432*. Complementation was tested by mating *unc-53(e2432) sqt-1(sc13)/+* males to hermaphrodites of the respective alleles. The male sex muscle phenotype described above for *e2432* was found to be the only 100% penetrant phenotype in the *unc-53* locus (see below) and was the primary phenotype used in complementation tests. Each of these alleles was also complemented to *mnDf90* by mating *unc-4 mnDf90/mnC1* males to *unc-53* homozygotes and temporary *unc-53/unc-4 mnDf90* lines were established to evaluate the phenotype. The male and hermaphrodite phenotypes of all alleles over deficiency is identical or slightly, but not substantially stronger than that of the homozygous lines (which is not unusual for a large deficiency).

S. Brenner mapped *unc-53* to 2.9 +/- 0.7 map units from *dpy-10* (chromosome II). We refined this map position by mapping *unc-53* with respect to different deficiencies in the region and doing three factor crosses between *unc-4* and *sqt-1*, a 1.5 map unit interval. *Unc-53(e2432)/+* males were mated in *unc-4 sqt-1* hermaphrodites. Non-rolling F1 offspring were cloned on petriplates and their broods screened for the segregation of *unc-53(e2432)*. *Unc-4 non sqt-1* and *sqt-1 non unc-4* hermaphrodites were picked from those

plates and cloned on petriplates. 6 out of 42 *sqt-1* non *unc-4* recombinants segregated *unc-53* and 3 out of 18 *unc-4* non *sqt-1* recombinants did not segregate *unc-53*. This yields a relative position of *unc-4* / 51 / *unc-53* / 9 / *sqt-1*. Or a calculated map position for *unc-53* on chromosome II, 0.23 map units left of *sqt-1*.

Unc-53(e2432) was mapped relative to three deficiencies in the region *mnDf90 mnDf87* and *mnDf77* by mating e2432/+ males to *unc-4 Dfx/mnC1* hermaphrodites and scoring for males and hermaphrodites with the *unc-53* phenotype in the F1. The experiment was also performed by mating *unc-4 mnDfx/mnC1* males to homozygous *unc-53. mnDf87* and *mnDf90* do not complement *unc-53* while *mnDf77* complements *unc-53*. *Ooc-3*, the only other gene on the genetic map in the region, was found to complement *unc-53* in identical crosses between e2432 and *unc-4 ooc-3/mnC1*. Further mapping of *unc-53* relative to RFLPs between wt strains in the region and the molecular cloning confirmed the map position of *unc-53* (see below).

Molecular characterization :

We started cloning the *unc-53* locus because the study and interpretation of the *unc-53* phenotype and the different mutants in the locus would be greatly facilitated by having information on and probes for the *unc-53* mRNA and gene product.

At the time we initiated cloning of *unc-53*, a contig extending between *unc-4* and *sqt-1* (approx. 1500 kb) had been identified by A. Coulson and J. Sulston (*C. elegans* genome project LMB Cambridge), with no clone markers in between. To correlate the genetic map with the physical map in this region we positioned cosmids of this contig relative to the deficiencies *mnDf77*, *mnD87* and *mnDf90* by comparing band intensities of Southern blots of *mnDfx/mnC1* strains probed with

- 53 -

cosmids throughout the region. Cosmid KO2F7 is deleted in mnDf90 but not deleted in mnDf87 and mnDf77 thus identifying a leftmost location for unc-53. Cosmids W10G4, T08D11 and F33G3 are in the unc-53 region (not deleted in mnDf77 but deleted in mnDf87 and mnDf90). Cosmid KO4H9 is deleted in mnDf77 and identifies a rightmost location for the gene. The distance between KO2F7 and KO4H9 is approx. 10 cosmids.

10 To narrow down the position of unc-53 further we looked for restriction fragment length polymorphisms between wild type strains in this interval and identified N2/RC301 RFLPs in cosmids W10G4, F40F8 and F22G3. We mapped these using three factor crosses with the strains unc-53 sqt-1/RC301 and unc-4 unc-53/RC301. We mapped F22G3 and F40F8 between unc-53 and sqt-1 at the following relative distances :

15 unc-4 / 9 / W10G4 / 2 / unc-53 / 1 / F40F8 / 1 / F22G3 / sqt-1.

20 These data localize unc-53 in an interval of approx. 80kb in which more than 15 differently overlapping cosmids are available. Pools of cosmids were injected in unc-53(n152) gonads together with the rol-6 selectable marker. Transient roller lines were established and scored for rescue of the unc-53 phenotype. Cosmid T28D2 was found to rescue the backward movement egg laying phenotypes of allele n152 .

30 A genomic library of N2 in lambda 2001 was screened with T28D2 and flanking overlapping cosmids. These were assayed in pools and individually for transformation rescue. Lambda clone, S4 carrying a sixteen kb insert was shown to give some rescue activity. Using restriction fragments of S4 as a probe, cDNA clones M5 (3.8 kb) and M18 (1-2 kb) were

35

isolated from a Lamda MGU1 cDNA library. Both M18 and M5 contain an identical 3'-end as judged by restriction fragment analysis. Partial sequence analysis showed that M18 is shorter version of M5.

- 5 Insert M5 was sequenced on both strands and was found not to be a poly-A tail at its 3'-end but appears not to full length at its 5'-end.

To find the 5' end of the unc-53 transcript we did nested PCR on L2 stage random primed cDNA, between
10 antisense oligos tab2 and tab (43 bp away from the 5' end of cDNA M5) and an oligo to the SL1 trans-spliced leader sequence. This sequence is transspliced to the 5'-end of most C. elegans mRNAs. This yielded at least 6 classes of PCR-fragments which have been subcloned
15 and sequenced. All contain the 43 bp between oligo tab2 and the 5' end of cDNA M5 (bp1281 to 1338). The longest PCR fragment (TB3) extends the sequence of cDNA M5 with 1280 bp. When added to the length of the cDNA M5, this unc-53 transcript which we constructed
20 in vitro and named tb3-M5 would then be 5073 bp long (including some poly-A tail) and have a 1528 AA open reading frame. Recently a 5 kb cDNA, was identified in an embryonic cDNA library which has the TB3-5'-end (including part of the SL1), and the same 3'-end as
25 M5, suggesting that TB3-M5 occurs in vivo. Similar PCR reactions in which the SL1 oligo was replaced by an SL2 transsplice oligo gave no reaction products. Preliminary Northern blot analysis identifies a major 5.0 kb transcript and at least 2 smaller transcripts
30 that are expressed in L2, L4 and adult worms. It needs to be examined whether the unc-53 5' ends reported here are made in vivo and encode different proteins or whether they represent PCR noise. The smaller PCR-fragments TB1b, TB16, TB1, TB6b and TB22
35 are "nested deletions" of clone TB3 with SL1's at their 5' end. The sequence of each is identical in the

regions of overlap. The shorter SL1 transspliced transcripts contain ATGs downstream of the SL1 addition sites at positions 466, 988 and 1324. Comparison to the sequence of genomic clones confirmed
5 that the SL1s are spliced onto intron exon boundaries. However not all intron-exon boundaries receive SL1, suggesting that there is some specificity to this differential trans-splicing.

Recently the C. elegans sequencing consortium has
10 sequenced cosmids F45E10. We mapped cDNA tb3-M5 onto these cosmids and found that unc-53 is an unusually large locus. It has 23 exons spread over more than 31 kb of genomic DNA.

The lambda clone S4 that rescues does not contain
15 the first 430 bp of the unc-53 transcript. This suggests that the ORF between positions 63 and 430 is not essential for transformation rescue. This rescue may derive from expression of transcripts TB6b or TB22 or from "non-specific" initiation of transcription on
20 the extrachromosomal arrays.

Additional confirmation that M5 was derived from the unc-53 transcription unit is provided by the observation that allele n152 has a 300 bp deletion, disrupting the sequence of cDNA M5 and leading to a
25 large (possibly complete) reduction of UNC-53 protein in n152 embryos stained in immunofluorescence with an anti-unc-53 antibody (16-48-2). In addition, allele e2432 was found to carry a 3-4 kb insertion in this transcription unit.

30

Sequence homology :

Antibody staining :

The NdeI-EcoRI fragment of cDNA M5, the 47 kd
35 fragment of UNC-53 encoded by the NdeI-EcoRI (position 3187 to 4458 (tb-M5 fig 3) protein sequence

fig 2) was subcloned in the T7 expression vector
prk172 (yielding vector TB66 and expressed in E. coli.
Inclusion bodies containing recombinant protein were
purified, by processes known in the art solubilized in
5 8 M Urea and the recombinant protein purified over a
DEAE column equilibrated in 8M urea. Purified protein
was mixed with complete Freund's adjuvant and injected
in a rabbit and 4 Lou rats. This was followed six
10 weeks later by bi-weekly boosts with antigen mixed
with incomplete adjuvant. All sera are active in
western blotting at titers of 1:30,000 on Western
blots of the 47 kd unc-53 fragment expressed in
E.coli. With this western blotting assay, a rat-
mouse hybridoma cell line was prepared producing a
15 monoclonal antibody to UNC-53. Mab 16-48-2 has the
following properties :

- protein G-binding
- binding activity on western blots of
 - (1) the 47 kd UNC-53 fragment expressed in E. coli,
20 (pTB66)
 - (2) the 57 kd carboxyterminal fragment of UNC-53
expressed in E. coli (construct pTB65.)
 - (3) the full length TB3-M5 UNC-53 expressed in E.
coli (construct pTB61) and mammalian cells (COS-cells;
25 constructs pTB54 and 56).
- immunoprecipitation of native and SDS denatured full
length TB3-M5 UNC-53 construct pTB50 expressed in
vitro-transcription translation reactions in
reticulocyte lysates.
- 30 - immuno-histochemistry in wild-type C. elegans fixed
with methanol, acetone or paraformaldehyde and
transgenic C. elegans expressing UNC-53 tb3-m5 pTB110,
111 or 112 in epidermis, neurones, gut and muscle.

Mab 16-48-2 fail to detect antigen of the correct
35 size on Western blots of total worm proteins or worm
proteins fractioned by progressive extraction with

deterg nts, urea and SDS.

Excretory canal phenotype :

5 The excretory canal of C. elegans is a large H-shaped cell. It's cell body is positioned ventrally at the level of the pharyngeal bulb and send out two processes dorsally. At the level of the lateral epidermis (seam) each of these bifurcates and extends anteriorly and posteriorly over the seam cells, until
10 they extend over most of the whole body length. It has been reported that in unc-53 the posterior process of the excretory cell does not extend up to the V6/T seam-cell boundary (E. Hedgecock et al., (1987), Development, 100 365-382).

15 We have done an extensive characterization of this phenotype in all alleles listed, either by direct in vivo Nomarski microscopy or UL6 rol6d marked unc-53 strains which express LacZ in the epidermis and excretory cell (Hope(1991) Development 113(2) 399-
20 408). In wild type the excretory cell processes are straight. In unc-53 the canal is often meandering from left to right over the seam before it arrests prematurely, as if it has lost directional cues in its migration. It never leaves the lateral epidermis
25 seam. Both the anterior and posteriorward processes are affected.

 In weak unc-53 alleles the posterior excretory canal processes arrest anywhere between the vulval region and the V6/T boundary. We noticed that in even
30 the strongest alleles or in unc-53/Df heterozygotes the canal arrests unusually frequently at or close to the vulva and never substantially before the vulva . We therefore set out to test whether the gonad dependent attractive signal which attracts the sex
35 myoblasts to the gonad also might attract the excretory canal in an unc-53 independent manner to the

vulval region. If this is the case we would expect that in a strong *unc-53* mutant *n152* in which the 2 somatic gonad cells (the source of the signal) have been ablated, the excretory canal migration would be fully arrested. As a control we ablated one germ cell and one somatic gonad cell (Z1 and Z2 or Z2 and Z4). Embryos were ablated in the comma to 2 fold stage and the position of the excretory canal scored double blind in hatched embryos. At the time of ablation, the canal may already have started growing out. At hatching, the endpoint of our experiment, the growth cone of the posterior canal process has reached just beyond the gonad. Although these are technically difficult laser ablations, the results show a substantial difference in excretory canal outgrowth between embryo with an ablated somatic gonad and control ablated embryos. In the experimental series the canal usually arrested a significant distance from the gonad or any other potentially damaged cells, suggesting the loss of a long range signal as described for the SM myoblast migration (Thomas *et al* (1990) and Stern (1991)). In the control series the excretory canal usually extended as far as unablated *n152* and into region of the partially ablated gonad. This indicates that the premature arrest observed in the experimental series was not due to encountering a damaged region.

A gonad dependent and independent pathway were found to act redundantly in the posteriorward migration of the sex myoblasts. The data suggest that in wild type the migration of excretory cell growth cones is also guided by a gonad dependent and a gonad independent cue. In both cases the gonad dependent cue acts towards the gonad, but from opposite directions. However the gonad independent signal act anteriorward on the SM myoblasts and posteriorward on

the posterior excretory cell growth cones. Since single mutants in both the gonad dependent pathway (sem-5) and independent pathway (unc-53) have no excretory cell phenotype these pathways may be redundant in the trajectory up to the gonad. An analogous redundancy has been observed for the sex myoblast migration. In the trajectory between gonad and tail the gonad independent pathway acts in different directions on the SM cells versus the excretory cell. In the excretory cell it acts in both anteriorward and posteriorward migration. A simple explanation which is elaborated in detail below is that unc-53 (like sem-5) may act downstream of a variety of receptors interpreting different cues.

The previously described interaction between the gonad and the sex myoblasts was rationalizable as an interaction between cells due to become part of the same organ. The interaction between the excretory cell and the gonad we report here suggests that the gonad may have a more general role as organizer cell migrations in the embryo. We wish to point out that the described dependent and independent pathways are formal genetic concepts. It is for example possible that in unc-53 embryos or unc-53 embryos in which the gonad dependent pathway has been genetically or laser ablated, as yet to be identified, pathway defining growth cones are misplaced leading indirectly to defective sex myoblast, neuronal (PLM, see below) or excretory canal migration. The observed highly restricted expression of unc-53 is an additional indication of this possibility.

Sex muscle phenotype :

All unc-53 alleles exhibit the sex muscle phenotype described for e2432. We quantified phenotype

in eight alleles :

Young adults grown at 20°C were mounted for polarized light or Nomarski microscopy on 2% agarose pads containing 0.2% phenoxypropanol as described in Sulston and Horvitz (1977) Dev. Biol. 56, 110-156 . The vm1 sex muscles were examined under polarized light with a 40x objective and a Brace Kohler compensator and photographed. In addition, adults were fixed, incubated with fitc-coupled phalloidin and mounted for fluorescence microscopy as described in Goh and Bogaert (1991) Dev. Biol. 56, 110-156. The angle between the longitudinal axis of the animal and the central bundle of myofilaments of the anterior and posterior vm1 was measured from the negatives with a protractor. As the vulva is a transverse slit at a right angle to the cylindrical body axis, the angle between the vm1 and the vulval slit can be measured independently of which side of the animal faces the observer.

20

Neuronal phenotype :

Unc-53 animals move poorly backwards when prodded but has good forward movement (Brenner (1974) Genetics 77 71-94). Various aspects of the neuronal phenotype of unc-53 has been reported in general phenotypic surveys of the UNC-collection (Brenner (1974) Genetics 77 71-94). : The posterior branch of the PDE neuron can be abnormal (Hedgecock et al. (1987) Development 100 365-382) and the mechanosensory PLMR & PLML neurons can have commissures into the ventral cord at a position much posterior than in the wild-type. There are also frequently multiple ventralward PLM commissures evenly spaced along the posterior half of the body (Siddiqui (1990) Neurosci. Res. (Suppl) 13 171-190), Hedgecock et al., (1987) Development 100 365-382).

35

Examples 2 to 5 - Biochemical Analysis of UNC-53

Example 2 - Immunoprecipitations of ³⁵S labelled unc-53 gene products.

5 The rat anti-UNC-53 monoclonal antibody, 16-48-2 (obtained from the hybridoma LMBP Accession no. 1383CB) elicited against a 47 kD fragment of the 3' end of UNC-53 from C. elegans was used to
10 immunoprecipitate UNC-53 proteins. In this experiment, the full length unc-53 construct pTB50 (Fig. 11) was transcribed and translated in vitro in rabbit reticulocyte lysates. The resulting radioactively labelled ³⁵S unc-53 gene products were
15 incubated with the monoclonal antibody under both denaturing (using SDS) and non-denaturing conditions, then incubated with protein G sepharose. The bound products were analysed by SDS-PAGE and fluorography. Monoclonal antibody 16-48-2 recognised both native and
20 SDS denatured radioactive UNC-53 products verifying that the protein translated in vitro was bona fide UNC-53. This result shows that immuno-precipitation is a useful tool in schemes to purify native protein and to identify UNC-53 protein complexes in biochemical
25 experiments.

Example 3 - Actin sedimentation assays (8A variant).

30 Besides the N-terminal region of the protein which is similar to actin binding proteins, the predicted protein sequence of UNC-53 identified two putative actin binding sites. The first borders on the 3' end of the region of α -actinin/ β -spectrin
35 homology and the second lies in the 3' end of the cDNA sequence. This suggests that UNC-53 could potentially

bind two actin molecules and via actin cross-linking, stabilise a particular growth cone spike to promote directional extension. Alternatively, the two actin binding sites may serve to anchor UNC-53 (and its shorter gene products) to the microfilament cytoskeleton to then transduce a signal via the NTPase domain to the downstream pathway.

To test the two site model, full length and truncated versions of UNC-53 (pTB50 and pTB52) were transcribed and translated in rabbit reticulocyte lysates for 90 minutes following standard protocols (Promega). To remove insoluble components, the reactions were airfuged for 1 hour at 100,000 x g and the supernatant containing ³⁵S labelled UNC-53 products introduced in actin co-sedimentation assays according to the method of Vancompernelle *et al.* (1992), EMBO J. 11, 4739-4746. In this procedure, radioactively labelled UNC-53 was incubated with monomeric G-actin in G buffer (2 mM Tris pH 7.5, 0.2 mM CaCl₂, 0.5 mM β-mercaptoethanol, 0.2 mM ATP) for one hour at room temperature. The salt concentration was then increased with F buffer (1 M KCl, 10 mM MgCl₂) to a final concentration of 100 mM to promote polymerisation of G-actin to F-actin. After an additional one hour incubation, polymerised F-actin/protein complexes were pelleted at 100,000 x g in an airfuge, washed with G buffer, resuspended in Laemmli buffer and separated by denaturing SDS-PAGE. The presence of actin in the pellets was confirmed by Coomassie staining while radioactively labelled UNC-53 products were detected by fluorography. Both the full length UNC-53 protein, pTB50, and the truncated construct, pTB52 translated *in vitro* in rabbit reticulocyte lysates cosedimented with F-actin at starting G-actin concentrations of 50-100 μg/ml. This suggests that UNC-53 binds to microfilament

cytoskeleton. Moreover, deletion of the first putative actin binding site (pTB52) did not eliminate actin binding.

5 Example 4 - UNC53 interacts with F-actin cytoskeleton (7A and 8A variant)

10 Analysis of the predicted protein sequence of UNC-53 identified two putative actin binding sites of the LKK class. The first borders the 3' end of the region of α -actinin/ β -spectrin homology in the amino terminus of the protein while the second lies in the 3' end of the protein sequence upstream of the putative nucleotide binding domain. A single UNC-53
15 monomer could thus potentially bind and crosslink two actin molecules.

20 To test whether UNC-53 associates with the actin cytoskeleton, a 7A (pTB72) and 8A version (pTB73) of unc-53 (Figures 25 and 27 respectively) were transcribed and translated in rabbit reticulocyte lysates and the 35 S labelled products introduced into F-actin co-sedimentation assays (Figure 35a). The full length UNC-53 protein (pTB72) translated *in vitro* cosedimented with F-actin at starting G-actin
25 concentrations of 100 mg/ml (Figure 35b) suggesting that UNC-53 interacts with F-actin. By 250 mg/ml, all of the UNC53 protein co-sedimented with the F-actin pellet. In contrast, no UNC53 was present in the pellet of the control reaction without actin. Thus,
30 sedimentation was purely actin dependent. This result also indicated that the *in vitro* UNC-53 protein remained soluble even after the salt concentration was raised.

Deletion of the first putative actin binding site

in pTB73 did not eliminate actin binding since the larger pTB73 products, including the largest fragment co-sedimented with F-actin under the identical set of conditions (Figure 35b). However, since the rabbit
5 reticulocyte lysates contain numerous proteins, it is possible that the interaction of UNC-53 with actin may not be direct but rather mediated through another associated protein.

Several smaller radiolabelled protein fragments
10 in the TnT reactions were observed in addition to the predicted protein products. Immunoprecipitation experiments confirmed that these products were UNC53 derived. Most likely they result from additional translational starts at internal methionines, since
15 the identical set of smaller products was observed from reaction to reaction; or from premature termination and proteolytic degradation. Many of these smaller fragments also co-sedimented with F-actin. Since the second predicted actin binding site
20 is within the 3' end of the molecule, truncated proteins that are the result of internal starts would be expected to have this site and to bind actin.

EXPERIMENTAL PROCEDURES:

25 Construction of UNC53 plasmids.

The complete unc53 cDNA was cloned as a 5.1 kb NotI-ApaI cassette in the mammalian expression vector pCDNA3 (Invitrogen) to generate plasmid pTB72, the 7A clone variant. To optimize translational initiation
30 at the first methionine, a mammalian KOZAK consensus sequence was engineered upstream of the start methionine by PCR amplification of DNA coding for the first 139 amino acids of the amino terminus with the

oligonucleotides BG03 (5'-
ataagaatgcggccgcccgcacgtcaaattgtagaattgata-3')
and BG02 (5'-cgcggtatcctcaaaccgcgggtggcataatggatg-3').
BG03 contains the mammalian Kozak consensus sequence
5 in addition to a NotI restriction site. pTB73 is a
deletion of the first 408 base pairs of the unc53
cDNA contained in the vector Bluescript II-KS. This
construction removes the first two methionines of the
unc53 cDNA sequence such that the first possible start
10 methionine in pTB73 is at amino acid position 165 in
the cDNA sequence. In all these constructs, (pTB72,
pTB73 and pTB50) the unc53 cDNA is inserted into the
multiple cloning site such that the T7 promoter is
immediately upstream of the 5' end of the cDNA
15 sequence.

The first 139 amino acids of the UNC53 cDNA were
amplified by PCR with oligonucleotides BG01
(5'-ggaattccaaccatatgacgacgtcaaattgtagaattgaata-3') and
BG02 (5'-cgcggtatcctcaaaccgcgggtggcataatggatg-3') to
20 generate a convenient NdeI cloning site immediately
upstream of the start methionine. This amplification
was cloned as an NdeI-BamHI fragment into the
prokaryotic expression vector pRK172 (Godedert M. and
Jakes R. (1990), EMBO J. Vol. 9, pp 4225-4230 and
25 McLeod M et al, 1987 EMBO. J. Vol 6, pp 729-736) to
generate construct pTB57. pTB61 contains the PCR
derived amino terminus of pTB57 in addition to the 3'
end of pTB50. Thus pTB61 contains the identical unc53
8A variant cDNA as in pTB50, but as an NdeI-NcoI
30 fragment in the vector pRK172 for prokaryotic
expression.

In vitro transcription/ translation reactions

The UNC53 cDNA constructs pTB72, pTB73 or pTB50 were transcribed and translated for 90' at 30°C in a cell free T7 polymerase expression system in rabbit reticulocyte lysates following the company's protocols (ProMega). Prior to further manipulations, the reactions were centrifuged for 1 hour at 100,000 x g to remove insoluble components. In all subsequent experiments, the supernatant containing the soluble fraction of ³⁵S labelled UNC-53 products was utilized.

10 Actin co-sedimentation assays

Soluble radioactively labelled ³⁵S-Met-UNC53 products were introduced in actin co-sedimentation assays according to the method of Vancompernelle et al. (1992). In this procedure, radioactively labelled UNC-53 was incubated with monomeric G-actin in G buffer (2 mM Tris-pH 7.5, 0.2 mM CaCl₂, 0.5 mM β-mercaptoethanol, 0.2 mM ATP) for one hour at room temperature and then the salt concentration increased with F buffer (1 M KCl, 10 mM MgCl₂) to a final concentration of 100 mM to promote polymerization of G-actin to F-actin. After an additional one hour incubation, polymerized F-actin/protein complexes were pelleted at 100,000 x g in an airfuge (Beckman), washed with G buffer, resuspended in Laemmli buffer and separated by denaturing SDS-PAGE. The presence of actin in the pellets was confirmed by Coomassie staining while radioactively labelled UNC-53 products were detected by fluorography. Briefly, after destaining, gels were soaked in 45 % methanol, 7.5 % acetic acid (vol/vol) for 30 minutes, followed by 30 min. in dimethyl sulfoxide (DMSO), and 1 hour in 10 % PPO dissolved in DMSO (wt/vol). The scintillant was precipitated by rehydrating the gels with four five

minute water washes. After drying, gels were exposed to Xray film (Hyperfilm-Amersham).

Immunoprecipitations

5 To confirm that the radioactively labelled proteins translated *in vitro* were of UNC53 origin, an anti-rat monoclonal antibody, 16-48-2, elicited against a 47 kD fragment of the 3' end of UNC-53 was used to immunoprecipitate UNC-53 proteins. In this
10 experiment, the unc-53 construct pTB50 was transcribed and translated *in vitro* in rabbit reticulocyte lysates. The resulting radioactively labelled ³⁵S UNC-53 gene products were incubated with the monoclonal antibody under both denaturing (0.4% SDS, 2.0% Triton
15 X-100) and non-denaturing conditions for 1 hour at room temperature, then incubated with protein G sepharose for 2 hours at room temperature, the beads washed 3 times with PBS and the bound products analyzed by SDS-PAGE and fluorography. Monoclonal
20 antibody 16-48-2 recognized both native and denatured radioactive UNC-53 products. As a control, a reaction without monoclonal antibody 16-48-2 was treated identically.

25 Example 5 - Interaction of UNC-53 with SEM-5/GRB-2

30 The observation that certain alleles of UNC-53 enhance the sex myoblast migration defect of sem-5 mutants is difficult to interpret. While the genetics suggests that UNC-53 and SEM-5 cooperate to regulate sex myoblast migration, it is unclear whether this is the result of a direct molecular interaction. To answer this question, two types of biochemical experiments were used to determine if UNC-53

physically interacts with SEM-5. In the first experiment, radioactively labelled ^{35}S UNC-53, synthesised in reticulocyte lysates, was incubated with SEM-5/GST (glutathione-S-transferase) fusion protein bound to glutathione resin or with GST protein bound to glutathione resin. After incubation, the beads were washed and the bound proteins analysed by SDS-PAGE and fluorography. This demonstrated that UNC-53 made in vitro specifically bound to the SEM-5/GST fusion protein resin. The GST fusion proteins have been previously described. Purification of GST-fusion proteins was facilitated by using a commercially available kit (Pharmacia). All purification methods followed the manufacturer's protocols.

To further characterise the nature of the interaction with SEM-5, a second experiment utilised Western blot overlays. UNC-53 fusion proteins were expressed in E.coli and the denatured protein lysates separated by SDS-PAGE and blotted to Immobilon-P nylon membrane (Milipore). Blots were incubated with biotin labelled SEM-5/GST, GRB-2/GST or GST protein, washed and bound multi-protein biotinylated complexes detected by probing with an avidin-alkaline phosphatase conjugate. The results from this experiment demonstrated that SEM-5 and its mammalian homologue GRB2 can interact with UNC-53 in vitro. Binding was observed in induced cell lysates only and probing with the UNC-53 monoclonal antibody 16-48-2 detected the identical sets of products. In addition, only the full length UNC-53 fusion, pTB61 (Fig. 7), which contained the SH3 binding sites gave a positive result (pTB52 was not tested) No signal was detectable for either of the SH3 binding site minus fusion proteins, pTB57 (Fig. 11) or pTB65 (Fig. 11). This provides supportive evidence that the polyproline

repeats of the UNC-53 directly bind to the SH3 domains of SEM-5. Moreover, these results show that a SEM-5 or GRB-2/GST glutathione resin may be used in schemes to affinity purify native UNC-53 from tissue culture
5 cells or nematodes or other organism extracts.

Detailed Methodology

Radioactively labelled ³⁵S UNC-53 synthesized in reticulocyte lysates was incubated with SEM-5/GST
10 (glutathione-S-transferase) fusion protein bound to glutathione resin or with GST protein alone bound to glutathione resin for one hour at 20°C. After incubation, the beads were washed four times with Phosphate Buffered Saline (PBS)/Triton X-100 (0.2%)
15 and the bound proteins analyzed by SDS-PAGE and fluorography. The SEM5 and GRB2 GST fusions have been previously described (Lowenstein et al., 1992; Stern et al., 1993). Purification of GST-fusion proteins was facilitated using a commercially available kit
20 (Pharmacia). All purification methods followed the company protocols.

Western blot overlays

Approximately 500-1000 mg each of purified GRB2-GST protein or GST protein were biotin labelled by the
25 following procedure. After overnight dialysis in PBS at 4°C, 1 M Hepes, pH7.4, was added to a final concentration of 100 mM and 50-100 mg of biotinylation reagent, dissolved in dimethyl sulfoxide, and the mixture incubated at 20°C for 90 minutes. The
30 biotinylation reaction was stopped by the addition of 1 M Tris, pH7.4 to a final concentration of 100 mM and the labelled proteins stored on ice.

The UNC-53 construct pTB61 was expressed in *E. coli* strain BL21 (DE3), and the denatured protein

lysate separated by SDS-PAGE and electroblotted to Immobilon-P nylon membrane (Millipore). Membranes were blocked with 1 % skim milk powder in TBS-T (20 mM Tris, pH7.6; 0.14 M NaCl; 0.1% Tween-20) for 1 hour at 37°C. Subsequently, membranes were incubated in equimolar amounts of either biotin labelled GRB-2/GST or biotin labelled GST protein for 1 hour at 20°C, washed 4 x with TBS-T and bound multi-protein biotinylated complexes detected by probing for 1 hour at 20°C with an avidin-alkaline phosphatase conjugate (dilution 1:5000). Biotinylated protein conjugate complexes were visualized with a chromogenic solution containing bromochloroindolyl phosphate (BCIP)/nitro blue tetrazolium (NBT) in 100 mM Tris(pH 9.5), 100 mM NaCl, 5 mM MgCl₂. Development was terminated with 10 mM Tris (pH8.0), 1 mM EDTA.

Example 6 - Transgenic Analysis

To further our understanding of the function of unc-53 we developed an in vivo assay to test gene fusions generated in vitro. Nematode expression vectors containing the full length unc-53 cDNA, TB3M5, downstream of various tissue specific and inducible promoters were constructed.

The mec-7 promoter of pTB112 (Fig. 7) confers tissue specific expression to the mechanosensory neurons, the unc-54 promoter of pTB111 (Fig. 7) confers tissue specific expression to body wall muscle and the hsp16-41 promoter of pTB109 (Fig. 7) confers and pTB110 (Fig. 7) confers heat inducible expression to somatic cells. pTB109 is a transcriptional fusion containing only the hsp16-41 gene promoter and has been shown to confer high levels of inducible expression in embryos. pTB110 contains a larger

portion of the hsp16-41/2 intergenic region in addition to a synthetic intron. This plasmid is expected to be highly inducible in embryos and post-embryonic stages in most somatic cell types.

5 Oocytes of both wild type (N2) and unc-53(n152) hermaphrodites were microinjected according to the method of Fire (1986), EMBO J., 5, 2673-2680. Coinjection of the unc-53 fusion with a selection
10 plasmid, pRF4, a dominant marker of rol-6, allowed identification of transgenic animals by their right rolling phenotype (Mello et al, (1991), EMBO J., 10, 3959-3970. In C. elegans, the injected DNA does not integrate into the genome but rather forms
15 extrachromosomal arrays which are heritable at a frequency ranging from 20-95% (Stinchcomb et al, (1985), Mol. Cell. Biol., 5, 3483-3496; Fire et al, (1990), Gene, 93, 189-198; Mello et al, (1991), EMBO J., 10, 3959-3970. Transgenic extrachromosomal lines were considered stable after the rolling phenotype had
20 passed through four generations. Some transgenic HS-unc-53 strains were mutagenised with 3550 rads of γ rays emanating from a ^{60}Co source which produces breaks in the chromosomes allowing for insertion of the extrachromosomal array. Stable integrants were
25 identified by screening for homozygous rolling F3 broods. The names and genotypes of all transgenic strains are listed in Table 1 with details of the unc-53 fusions (constructs/vectors) listed in Table 2:

30 Table 1 - Extend in other constructs

STRAIN NAME	PARENTAL STRAIN	unc53 FUSION	SELECTION	lacZ MARKER
TB3In54	n152	pTB109	pRF4	UL6
TBAIn8	N2	pTB110	pRF4	pPCZ1

35

5	TBAIn61	N2	pTB110	pRF4	pPCZ1
	TBAIn69	N2	pTB110	pRF4	pPCZ1
	TBAIn76 Accession No 1385CB (See Fig 17A)	N2	pTB110	pRF4	pPCZ1
	TBAIn90	N2	pTB110	pRF4	pPCZ1
	TBAIn210	N2	pTB110	pRF4	pPCZ1
10	TBAIn222	N2	pTB110	pRF4	pPCZ1
	TBAIn306	N2	pTB110	pRF4	pPCZ1
	TBAIn327	N2	pTB110	pRF4	pPCZ1
	TBBIn3	N2	pTB110	pRF4	pPCZ1
	TBBIn267	N2	pTB110	pRF4	pPCZ1
15	TB1Ex10	n152	pTB112	pRF4	none
	TB1Ex23	n152	pTB112	pRF4	none
	TB1Ex8	N2	pTB112	pRF4	none
	TB1Ex16	N2	pTB112	pRF4	none
	TB2Ex1	N2	pTB112	pRF4	none
20	TB2Ex37	N2	pTB112	pRF4	none
	TB3Ex10	N2	pTB112	pRF4	none
	TB3Ex12	N2	pTB112	pRF4	none
	TB3Ex20	N2	pTB112	pRF4	none
	TB3Ex37	N2	pTB112	pRF4	none
25	TB4Ex14	N2	pTB112	pRF4	none
	TB4Ex18	N2	pTB112	pRF4	none
	TB4Ex22	N2	pTB112	pRF4	none
	TB4Ex25 Accession No LMBP 1384CB (See Fig 16)	N2	pTB112	pRF4	none
	TB1Ex3	n152	pTB111	pRF4	none

TB1Ex6 (See Fig 17B, C)	n152	pTB111	pRF4	non
TB1Ex11	n152	pTB111	pRF4	none

5

Notes for Table 1:

Ex-extrachromosomal

In-integrated

pTB109, pTB110-Heat shock unc-53 fusions

10 pTB111-mec-7 fusion

pTB112-unc-54 fusion

pRF4-rol-6 (sul006) (Mello et al, (1991), EMBO J., 5,
3959-3970)

UL6-excretory canal promoter lacZ fusion

15 pPCZ1-Hsp16-48/1 lacZ fusion (Stringham et al, (1992)Molec.Biol.Cell 3, 221-233)Table 220 Full length cDNA tb3M5 (still has SL1 and 5' UTR)pTB50 (NotI-ApaI fragment in Bluescript II-KS, for
in vitro transcription)pTB51 (NotI-ApaI fragment in Bluescript II-SK, for
in vitro transcription)25 pTB54 (NotI-ApaI fragment in pCDNA3, for mammalian
expression)

(Deposited as accession no. LMBP3296)

pTB109 (NotI-ApaI fragment in hsp16-pucBM21, for in
vivo expression)

30 pTB67 (NotI-Apa fragment in pGEM5 +)

PCR1 of amino terminus of cDNA

(*PCR using oligos BG01 and BG02)

pTB57 (NdeI-BamHI fragment in pRK172, for E. coli
expression)

35

pTB58 (NdeI-NcoI fragment in pGEM5)

pTB63 (SacI-NcoI fragment in pRSETA, for E. coli
expression)

pTB64 (BamHI fragment in pBluescriptII-KS)

5 Full length cDNA utilizing PCR1 amino terminus

pTB61 (NdeI-NcoI fragment in pRK172, for E. coli
expression)

pTB110 (XbaI-KpnI fragment in pPD49.83, for in vivo
expression)

10 pTB111 (XbaI-KpnI fragment in pPD52.102, for in
vivo expression)

pTB112 (XbaI-KpnI fragment in pPD30.38, for in vivo
expression)
(Deposited as accession no. LMBP3295)

15

PCR2 of amino terminus of cDNA

(*PCR using oligos BG03 and BG01)

pTB59 (NotI-BamHI fragment in pBluescript II-KS)

20 pTB60 (NotI-XhoI fragment in pCDNA3, for mammalian
expression)

Full length cDNA utilizing PCR2 amino terminus

pTB55 (NotI-EaeI fragment in pBluescriptII-KS)

25 pTB56 (NotI-ApaI fragment in pCDNA3, for mammalian
expression)

Other constructs

pTB52 (SacII deletion of amino terminus of pTB50)

pTB53 (SacII deletion of amino terminus of pTB51)

30 pTB62 (SmaI fragment of pTB52 in pGEX2T, for
prokaryotic expression)

pTB65 (NdeI-NcoI fragment of 3' terminus in
pRK172, for prokaryotic expression)

35 pTB66 (NdeI-EcoRI fragment of 3' terminus in
pRK172, for prokaryotic expression, MAB 16-
48-2)

Initially, the phenotype of each transgenic line was characterised by inspection with a dissecting microscope and/or Nomarski optics. Transgenic strains were directly analysed for expression of unc-53 by immunohistochemistry. Briefly, embryos were adhered to polylysine coated slides and permeabilised by a combination of freeze fracturing and immersion in cold methanol and acetone (3-4 minutes each). Embryos were rehydrated through an acetone/distilled water series and then incubated for 30 minutes at room temperature in TBS-Tween (0.1%). The anti-UNC-53 monoclonal 16-48-2 anti-sera was applied undiluted and the slides incubated at 4°C overnight. The embryos were washed three times with TBS-T and then incubated in a secondary rhodamine like (Cy3-M) conjugated antibody for 1 hour at 37°C. After 3-4 washes in TBS-T the slides were mounted for fluorescence microscopy in 2% propylgallate, 80% glycerol-pH 8.0.

20 Characterisation of transgenic strains carrying pTB112

UNC-53 was over-expressed in the muscle of wild type animals (pTB112 in N2). Each extrachromosomal pTB112/N2 line consisted of wild type and rolling animals as expected, but in addition, several mutant phenotypes were observed at low frequency. These animals varied considerably in phenotype and included embryos which arrested at the two fold stage, larvae which hatched but died soon afterward, animals with extra protrusions on the epidermis and animals with a truncated posterior end. This phenotype is consistent with that of the mup or mua classes of muscle mutants in which the positioning and/or integrity of muscle attachments to the hypodermis has been disrupted. Most of these animals were either inviable or sterile. The progeny of the viable mutants contained the same

frequency of rollers, wild type and mutants as did the progeny of rolling individuals. Since the extrachromosomal array may be lost at each cell division, every animal is a mosaic. The healthy rollers may have lost the transgene from most muscle cells and may represent weak phenotypes whereas the 2 fold arrests represent the situation where the array has been lost from few muscle cells. Nomarski and polarised light microscopy of the severe larval lethals showed that the muscle cells were disorganised and over-extended.

Detailed analysis of the underlying defect in embryonic development that leads to this terminal phenotype were performed with immunofluorescence microscopy (Fig 21).

Since the *unc-54* gene encodes the myosin heavy chain, we expected that this promoter would be active in body muscle descendants from the comma stage onwards. In the *unc-54 - unc-53* strains, signal was indeed localised to the body muscle cells in comma and later stages as predicted. The immunofluorescence was localised to the cytoplasm of the cell bodies and was particularly intense at the tips of the extending processes. Increased process length was observed very early in muscle development (comma to 1.5 fold stage) and increased up to the three fold stage. No other abnormalities in shape or muscle myofilament pattern were observed in the anterior-posterior axis of the animal. Two and three fold embryos which were stained with the monoclonal antibody NE8(4c6.3) (Goh and Bogaert, (1991), Dev. Biol. 56, 110-156) appeared to have a relatively wild type myofilament structure. As these animals are mosaic, it may be possible that severe cases die in late morphogenesis and those which survive through embryogenesis to adulthood can tolerate a few distorted muscle cells.

pTB111 transgenic lines

Immunostains indicates that the transgene is expressed efficiently in the mechanosensory neurons of a transgenic extrachromosomal line carrying the pTB111 transgene in an unc-53 (n152) genetic background (Fig 20).

pTB109 and pTB110 lines

10

Twelve integrated lines derived from three separate mutageneses of extrachromosomal lines have been isolated. TB3In54 carries the pTB109 fusion in addition to pRF4. Nine TBA strains were isolated after mutagenesis of an extrachromosomal strain, HSA. There are two strains (TBB) derived from mutagenesis of the extrachromosomal strain HS B. Both TBA and TBB strains contain the transgenes pTB110, pPCZ1 and pRF4. Inclusion of the HS-lacZ plasmid, pPCZ1 (Stringham et al, (1992), Molec.Bio.Cell 3, 221-233) allows one to monitor the strength of the heat shock induction by assaying for β -galactosidase activity.

Immunostains of embryos freeze fractured after a two hour heat shock showed that the signal was most prominent in the pharynx, gut and neurons. Surprisingly, the signal had a speckled appearance. This may be a feature of heat shock. Heat shock proteins may sequester UNC-53 to "chaperone" it during stress. Alternatively, UNC-53 may be targeted for degradation. In one experiment, embryos were heat shocked for two hours, allowed to recover overnight and then freeze fractured the next morning. While levels were reduced, there was a little residual UNC-53 signal in the gut cells. Thus, about 16 hours later most the protein has gone.

35

Level of heat shock and recovery times are

therefore important factors in the mutant rescue experiments and the preferred assay system described in example 10. In addition, experiments suggest that heat shock induction in liquid culture versus agar plates or dry incubators versus water baths need careful calibration.

After a strong three hour heat shock, a high percentage of animals were not able to recover from the stress. Embryos which were not subjected to a double shock (2-two hour heat shocks at 33°C separated by a two-hour recovery) hatch out as malformed worms reminiscent of the muscle overexpression lines (Fig 21). The heat shock promoter used is especially active in the pharynx. Consistent with this, a strong pharyngeal morphogenetic phenotype was observed (Fig 21). Pharyngeal phenotypes are easy to score and quantify (feeding rate, dye uptake, LacZ lines staining the pharynx) by anyone skilled in the C. elegans field and may form a preferred embodiment of the assay.

Example 7

Over-expression of UNC-53 results in directional over-extension : Assay with 7A variant.

25

In wild type *C. elegans*, body muscle cells are normally spindle shaped while in UNC53 mutants, a number of these cells have a reduced process which results in a fork shaped tip. This phenotype is consistent with the general reduction of extension observed in many growth cone types along the longitudinal axis of the animal in unc-53 mutants. Recalling the extremely limited pattern of UNC53 expression in embryogenesis detected by immunostaining with monoclonal antibody 16-48-2; no UNC53 activity was

35

discernable in wild type body muscle cells during outgrowth suggesting that the levels of UNC53 activity required for this extension may be extremely low.

We overexpressed unc-53 in the muscle of wild type animals by expressing the full length cDNA under the control of the unc-54 myosin heavy chain promoter in the fusion pTB113. Plasmid pTB113 is a translational fusion containing the 7A variant unc-53 cDNA sequence as an XbaI-KpnI fragment starting from the first methionine and including the unc-53 cDNA poly adenylation tail under control of the myosin heavy chain unc-54 promoter of the nematode expression vector pPD30.38 available on Internet web site ftp archive: ciwl, ciwemb.edu. Plasmid pTB114 contains the identical cDNA fragment under control of the hsp16-41 -2 promoter (Jones et al., 1995, Dev. Biol. VOL. 171, PAGES 60-72) which confers heat inducible expression to somatic cells, in the expression vector pPD 49.83 (Fire, pers. comm.) The amino terminus of the UNC53 cDNA is identical to the PCR amplification with BG01 and BG02 of pTB57. Thus, both pTB113 and pTB114 are in frame translational fusions devoid of the SL1 leader sequence and upstream untranslated region of the cDNA.

Each transgenic mosaic line (3 were examined) consisted of wild type and rolling animals as expected, but in addition, several mutant phenotypes were observed at a low frequency. These animals varied considerably in phenotype and included, embryos which arrested at the two fold stage, larvae which hatched but died soon afterwards, animals with extra protrusions on the epidermis and animals with a truncated posterior end. Most of these latter animals

were either inviable or sterile. The progeny of the viable mutants contained the same frequency of rollers, wild type and mutants as did the progeny of rolling individuals. Since the extrachromosomal array may be lost at each cell division, every animal is a mosaic. The healthy rollers may have lost the transgene from most muscle cells and may represent weak phenotypes whereas the 2 fold arrests represent the situation where the array has been retained in most muscle cells. The truncated posterior end may be the result of lethality in the D lineage due to mosaicism. Nomarski and polarized light microscopy of the severe larval lethals showed that the muscle cells were disorganized and over-extended in the longitudinal axis. In some cases the muscle cells appeared detached from the hypodermis. As these animals are mosaic, it may be possible that severe cases die early in morphogenesis whereas those which survive through embryogenesis to adulthood can tolerate a few distorted muscle cells.

In transgenic pTB113 strains, UNC53 expression, as detected by immunostaining with monoclonal antibody 16-48-2, was localized to the body muscle cells in comma and later stages as predicted for the UNC-53 promoter (myosin heavy chain). The pattern of immunofluoresence with the anti UNC-53 antibody was localized to the cytoplasm of the cell bodies and was particularly intense at the tips of the extending processes and in the cytoskeleton, when compared to phalloidin staining which specifically stains the actin cytoskeleton. The identical pattern of sub-cellular localization, in the cytoplasm and cytoskeleton, was also observed in the intestinal

- 81 -

cells of pTB114 transgenic embryos expressing UNC-53 ectopically after heat shock.

In addition, the growth cone processes appeared to be overextended specifically in the anterior-posterior axis of the animal. To verify this, the length of body muscle cells over-expressing the UNC53 cDNA in the pTB113 strains were measured and compared to the length of wild-type muscle growth cones expressing an unc-54 promoter-GFP (green fluorescent protein) fusion, pPD49.83 (available on Internet Web Ste Ftp archive: ciwl.ciwemb.edu. The GFP reporter allowed visualization of the entire cell body and boundaries of the muscle cells in wild-type animals. We estimated that the processes of the pTB113 expressing cells were roughly 1½ times the length of pPD49.83 expressing wild type cells.

The lethality in the transgenic progeny of the three pTB113 strains examined ranged from 32% to 78%. Thus a significant proportion of the transformed mosaic progeny did not survive morphogenesis. In contrast, no lethality was observed in the pPD93.48 (unc-54-GFP) control strains. The lethality observed in the pTB113 lines is likely the consequence of overextension of muscle cells during embryogenesis because (a) both pTB113 and pPD93.48 utilize the identical promoter and should be expressed in the same cells at the same point in development, and (b) rol-6 selection was used to identify transformants for both constructs.

30

Example 8

Transient and stable transfection of UNC-53 in N4 neuroblastoma cells.

- 82 -

pTB72 and a plasmid expressing LacZ under the CMV promoter were transfected transiently with the Calcium phosphate method in N4 neuroblastoma cells.

- N4 cells and their stably transfected counterparts were grown in Minimum Essential Medium (MEM)-REGA 3 (GIBCO BRL) supplemented with 10% Foetal Calf Serum, 1% L-Glutamine, 2% Sodium Bicarbonate, 200 units/ml penicilline and 200 µg/ml Streptomycin, in a humidified atmosphere of 90% air and 10% CO₂ at 37°C.
- Transfections were performed by the Lipofectamine method (GIBCO BRL). 18 to 24 hrs before transfection cells were seeded in complete growth medium at a density of 7x10⁵ per well in a six well tissue culture plate, and incubated at 37°C in a CO₂ incubator. For each transfection the following solutions were prepared.:
- SolA = 4 µg of DNA diluted in 200 µl of Optimem (GIBCO BRL)
- SolB = 12 µl of Lipofectamine reagent diluted in 200 µl of Optimem (GIBCO BRL)
- Solutions A and B were combined, gently mixed and incubated at room temperature for 30 minutes. For each transfection 0.6 ml of Optimem was added to the lipid-DNA complex to reach the final volume of 1 ml.
- This mixture was then added onto the cells (which had been previously rinsed once with 2 ml of Optimem). The cells were incubated in the transfection mixture for 5 hrs at 37°C in a CO₂ incubator. At the beginning of the sixth hour from transfection, 1 ml of complete growth medium supplemented with 20% of Foetal calf serum was added to the transfected cells. The cells were incubated for 18 hrs at 37°C in a CO₂ incubator. 24 hrs following the beginning of transfection the supernatants were replaced with fresh growth medium.
- 72hrs post transfection cell cultures from each well were harvested, diluted 1:24 and distributed over 24

- 83 -

well plates with the growth medium containing 500, 750 ug/ml or 1mg/ml of geneticin (G418, GIBCO BRL). After ~12 days from the start of selection, single clones were picked and allowed to grow in the absence of selection. Of 27 initial clones, 7 were lost while expanding the clones because of their slow growth rate and the apparent general toxicity of caused by the transfected construct. Clone 9 was selected for further analysis.

10

Functional assay for neurite extension in N4 neuroblastoma

Step (1): Quantitative determination of neuronal morphology, i.e. length of neurites and fraction of positive cells is performed fully automatically. As an example we studied the degree of morphological differentiation in the wild-type N4 cells to a stably transfected C9 clone.

20

Step (2): Quantitative neuronal morphology

Morphological changes of neurones were quantitated as described in GEERTS et al (1992 Restorative Neurology and Neuroscience 4: 21-32 and Katsuhito et al Neurodegeneration, 2: 173-181). Briefly, at appropriate times, glutaraldehyde was applied to cell cultures. No washing steps were performed. This ensured that the morphology of the cells at that time point was frozen. The cells were observed in transmitted light mode on an Axiovert microscope, equipped with a Marzhauser scanning stage driven by an Indy workstation (Silicon graphics). Images were captured using a MC5 video camera (HCS). About 3000 cells were detected in 64 neatly aligned images, forming a 8x8 square matrix of images. The exact alignment of the images ensured that neurites

35

could be followed from one image field to the next. The analysis software automatically detected cell bodies and neurites and saved cell body size and length of each individual neurite on a file.

5 Different parameters were subsequently calculated. The neurite length per cell was calculated on freely lying cells (not within a cluster). The fraction positive cells is the fraction of cells having at least one neurite with a length exceeding twice the

10 cell body diameter. Figure 40 clearly shows that clone C9 increases both neurite length (free length) and fraction of positive cells, compared to wild-type N4 cells clone.

15 Example 9

Transient and stable transfection of UNC-53 in MCF-7 breast carcinoma cells.

pTB72 and a plasmid expressing Lac Z under the CMV promoter were transfected transiently with the

20 Ca-phosphate method in MCF-7 breast carcinoma cells.

MCF7 cells and their stably transfected counterparts were grown in Dulbecco's Modified Eagle's Medium (DMEM, GIBCO BRL) supplemented with 10% foetal Calf Serum, 1% L-Glutamine, 1% of a 5mg/ml stock of

25 Gentamicine and 1% of a 100mM stock of Sodium Pyruvate in an humidified atmosphere of 90% air and 10% CO₂ at 37 C. Construct pTB72 was transfected by the Calcium-phosphate method (ref): 18-24hrs before transfection. cells were seeded at a density of 3×10^5 in a six well

30 tissue culture plate with complete growth medium. Two hours before transfection the culture medium was removed and replaced with 1.8 ml of fresh medium. The cells were put back in the incubator until the moment of transfection. DNA-Ca₃(PO₄)₂ precipitates were

35 prepared one hour before transfection : For each transfection (1 well): 4 ug of DNA (=3-4 ul) was

- 85 -

combined with 76 ul of TE (Tris HCl-EDTA pH 8) 0.1M to a final volume of 80 ul. To these DNA's diluted in TE, 20 ul of CaCl₂ Hepes solution was added to a final volume of 100 ul of DNA/CaCl₂ mixture. The 100 ul of DNA/CaCl₂ mixture was added very slowly, drop-by-drop to 100ul of 2x BS/Hepes while shaking, to a final volume of 200 ul. The resulting 200 ul DNA/Calcium Phosphate mixture was added to the cells and the mixture incubated for 8 hrs at 37 C in a CO₂ incubator. At the beginning of the ninth hour from the start of transfection, the supernatants with the DNA/Calcium phosphate mixture was replaced with 3 ml of complete culture medium. 72hrs post transfection, cells from each well were harvested, split 1:24 in complete growth medium supplemented with 1mg/ml of Geneticin (G418, GIBCO-BRL) and plated out in 24 well plates. 15 days from the start of selection, single clones were picked and allowed to grow without selection. Three clones MCF7-pTB72-clone9, MCF7-pTB72-14 and MCF7-pTB72-15 were retained all of which have a similar phenotype.

1) Phenotyping UNC-53 transfected MCF-7 breast carcinoma cells:

The general morphology and motile behaviour of the three transfected MCF-7 clones are different from non-transfected cells.

The assay consists of a tyramide amplification of a classical immunofluorescent reaction. The cells were grown in defined medium with 10% charcoal treated serum and supplemented by 10 µg/ml insulin (final concentration) and 5 ng/ml basic fibroblast growth factor (final concentration). The substrate consisted of 50 µg/ml poly-L-lysine in chamber slides; cultures were maintained in a humidified atmosphere of 95/5% air/CO₂.

Induction of expression of vimentin and f
increased levels of fosfotyrosine was found in the
transfected subclones. Vimentin formed dense clusters
around the cell nucleus with some filamentous
5 structures in the pseudo-podes. Fosfotyrosine, on the
other hand, was predominantly found at the border of
the cell ruffles, at the same subcellular area where
UNC53 expression was found. This provides evidence of
a controlling molecule functioning in a signal
10 transduction pathway and that vimentin is an indicator
of metastasis in cancerous cell lines.

2) Functional assay to establish the signal
transduction role of UNC-53.

15 Cells locomote in tissues and on substrates. The
type and amount of cell locomotion depends on
different factors: (1) the physiological conditions
perceived through receptors, which can be - for
example - stimulation with or deprivation of serum,
20 growth factor(s), cytokine(s), chemokine(s) or (pro-)
inflammatory mediators; (2) the type and functionality
of cell adhesion molecules expressed by cells and
extracellular matrix molecules present in tissue or in
culture model, (3) the actin, tubulin and/or
25 intermediate filament cytoskeleton and (4) proper
functioning of integrator proteins such as UNC-53,
homologues or other molecules that translate
physiological stimuli (or lack of stimuli) into
increased or decreased cell motility, directional or
30 random motility or different types of motility. Cell
locomotion can be measured in different types of
assays, such as disperse cells or in monolayer
cultures, as cellular outgrowth from tissues in
culture or in organotype cultures. Motility of live
35 cells can be quantified microscopically as in example
8 or by time-lapse video or cinematography or by

phagokinetic assays (Albrecht-Buehler, 1977, Cell, 11:395) amongst other methods.

Cell motility assays are interesting tools to study the functioning and pharmacology of UNC-53 and the unc-53 pathway.

All previous observations were performed on MCF-7 cells grown in defined medium supplemented by 10 µg/ml insulin (final concentration) and 5ng/ml basic fibroblast growth factor (final concentration). This approach offers the possibility of investigating the role of FGF in the UNC53 role of signal transmission. Indeed, by comparing wild-type versus UNC53 transfected cells cultured in medium with or without FGF/insulin and/or by microinjection of UNC53 protein, it can be investigated if UNC53 is responsible directly for regulating a signal transduction pathway linking extracellular growth factors to the assembly of, amongst others, focal adhesions.

Example 10: Enhanced phagokinesis in Ce-unc-53 transfected MCF-7 cells.

In this example evidence is presented that transfection of a plasmid containing the Ce-unc-53 sequence under a suitable promoter enhances cell motility in the phagokinesis assay.

When culture plastics are coated with colloidal gold particles, a variety of cells types were shown to migrate over the plate and displace or phagocytose the gold lawn on their way while locomoting. The track left bare is a qualitative and quantitative measure of cell motility and/or locomotion. The basic methods have been described in detail elsewhere (Albrecht-Buehler, 1977, Cell, 11:395; Zetter, 1980, Nature, 285:41; O'Keefe et al., 1983, J. Invest. Dermatol., 85:130).

Methods

12 well plates were coated for 15 minutes with 5 µg/ml gelatin in water and gold coated as described by Albrecht-Bueller (1977). Ce-unc-53 transfected MCF-7 cells and the parent MCF-7 were cultured in parallel, trypsinised dispersed in culture medium and seeded in 12-well plates at a density of 2550 cells per well. The cells were allowed to adhere to the plate and to locomote for 16 hours. After incubation the cells were chemically fixed to the plate using paraformaldehyde, washed with distilled water and finally air-dried.

Subsequently, images of the gold lawns were captured using automated videomicroscopy, composite images of the wells were generated and single-cell phagokinetic tracks were measured using a home-made routine in SCILTM software.

Results

The parent MCF-7 line displayed two cell populations with different motile behaviour in phagokinesis assays. In table 3 the fraction of parent and Ce-unc-53 transfected MCF-7 cells that produced linear tracks in the phagokinesis assay are shown. In the parent MCF-7 cells, 88% of the cells produce a round track (long and short axis less than 2-fold different) and 12% cells produce 'linear' tracks (long and short axis more than 2-fold different). Ce-unc-53 transfection of MCF-7 cells produced an increase of the fraction of cells displaying 'linear' tracks to 28% at the cost of the cells producing round tracks.

These observations suggest that Ce-unc-53 transfection into MCF-7 is capable of increasing *in situ* locomotion of MCF-7 e.g. by increased spreading, ruffling or other forms of non-directional motility in

the 'round' population as well as by driving a fraction of transfect d MCF-7 cells from non-directional motility (round tracks) into directional migration (linear tracks).

5 In tissue culture, cells are provided with non-directional signals. It is likely that providing directionality to these signals will enhance observed effects. Significant enhancement was observed for the fraction of linear tracks.

10 In addition, a significant increase of 35% in the area of tracks was observed in the Ce-unc-53 transfected MCF-7 cells versus the parent MCF-7 cells (Table 3). This increase occurred in the round track population; the area of linear tracks was found not to
15 be changed by transfection.

These observations in phagokinesis suggest that Ce-unc-53 transfection into MCF-7 cells is capable of increasing insitu locomotion in Ce-unc-53 MCF-7, e.g. by increasing spreading, ruffling, or other forms of
20 non-directional motility in the "round" population. In addition the Ce-unc-53 transgene in MCF-7 cells drives a fraction of the MCF-7 cells from non-directional motility (round tracks) into directional migration (linear tracks).

25

Table 3. Analysis of phagokinesis assays with parent and Ce-unc-53 transfected MCF-7 cells.

	parent MCF-7		Ce-unc-53 MCF-7		Increase
30 Fraction linear tracks (*)	% +- SD(n) 12+-3 (8)		%+-SD(n) 28+-6 (8)		2.33
Track area (**)	pixels+-SD(n)		picels+-SD (n)		
all tracks	1261+-128(8)		1698+-179(8)		1.35
round tracks	1229+-162(8)		1464+-204(8)		1.19
linear tracks	2367+-424(8)		2300+-319(8)		0.97
35 (*) the fraction of linear tracks in 8 wells was pooled.					

5 MCF-7 cells expressing low levels of UNC-53
exhibit increased motility.

Individual transfected cells are much more
flattened in appearance than wild type and have a
broad lamellipodium extending from the edge of the
cell. Ruffling edges are more frequent than in wild
10 type. Transfected cells in clusters have a broad
lamellipodium edge around the cluster while cluster of
the non-transfected. Within the cluster the nuclei are
more widely spaced from one-another than in wild type
cells (also due to a lamellipodium edge).

15

Example 11

Method for Protein micro-sequencing of co-
affinity purifying proteins

20 UNC-53 protein was immuno-affinity purified from
extracts of cells expressing C. elegans UNC-53 using
monoclonal antibody 16-48-2. One to five mg of Mab
16-48-2 was prepared, purified on protein-G sepharose
and subsequently covalently linked to sepharose beads.
A column of such beads was loaded with both crude
25 cytosolic and Triton-X100 extracts (containing
solubilised RTKs) and eluted with 4M MgCl₂ or other
chaotropic agents. A co-immuno-purifying band was
identified on SDS-denaturing PAGE gels, eluted from
these gels and micro-sequenced. This protein sequence
30 or mass information of peptides generated by
proteolysis was used to identify the co-
immunoprecipitation directly from the sequence
databases.

Alternatively the sequence was reverse translated

- 91 -

and oligonucleotides based on the sequence prepared. This is used to clone the corresponding gene as well as other techniques well known in the art.

5 Example 12 C. elegans as a model assay system.

We have constructed transgenic strains which overexpress UNC-53 in body muscle. This results in increased extension of muscle cells and embryonic lethality at low frequency. These strains were used
10 to screen for drugs which interfere with UNC-53 activity and thereby suppress the background lethality.

Another related assay was used to screen specifically to identify inhibitors of downstream
15 components in the signal transduction pathway. This assay utilised constitutively active mutant cDNA (or corresponding nucleic acid sequence). Such a mutant may be formed by mutating the nucleotide binding domain such that GTP or ATP is always bound or by
20 covalently attaching SEM-5. In this strategy, transgenics/mutants (nematodes or tissue cultured cell lines) were generated which maintain the pathway in a permanently switched on state. Over-extension and subsequent lethality results in a greater frequency
25 than that observed in the unc-54 - unc-53 wild-type lines. By screening for survivors after drug treatment, this assay specifically identifies inhibitors of downstream components in the signal transduction pathway.

30 A range of other embodiments of the assay are obvious to a person skilled in the art of C. elegans genetics, including the use of alternative selectable markers, genetic backgrounds, histochemical detection and visual detection systems to identify phenotypic

changes following contacting a single worm or a population of worms with a compound.

Another assay previously described herein utilizes the *unc-53* promoter. The *unc-53* promoter is fused to a nucleic acid sequence encoding a reporter molecule. By screening for cells which do not express the wild type pattern, molecules which increase or reduce transcription of *unc-53* may be identified.

10 Example 13 - Heterologous expression of
C. elegans UNC-53 in insect cells.

C. elegans UNC53 cDNAs have been expressed in a Baculovirus system to obtain sufficient amounts of protein for biochemical and structural studies.

15 Two UNC53 cDNA clones (UNC53(7A) and UNC53(8A) have been documented differing in the number of adenosine (A) residues (7 or 8) in a polyA stretch of the of the 3' coding region; the two clones therefore have different reading frames in the carboxyterminal
20 coding region.

 The 5' (N-terminal) part of the UNC53 coding region was excised from pTB564 with *SacII* after linearizing the plasmid with *NdeI*. The *NdeI* site was blunted with Klenow. The remaining C-terminal part of
25 the coding region was excised from pTB68(7A) and pTB50(8A) with *SacII* plus *KpnI*. The *NdeI/SacII* fragment from pTB64 and the *SacII/KpnI* fragment from either pTB68 or pTB50 were ligated simultaneously into pBacPAK9 (Clontech) which had been linearized with
30 *Ecl136II* (blunt end) and *KpnI*. In this way, a minimum amount of 5' untranslated region is left in the final construct.

 The desired recombinant viruses were obtained by

co-transfection of *Sf21* cells (*Spodoptera frugiperda*) with one of the aforementioned pBacPAK9 constructs and BacPAK6 *Bsu*361-digested DNA (Clontech). Several candidate recombinant viruses plaques were picked and screened by PCR for the presence of the target gene and the absence of wild-type virus.

Sf9 cells were infected at a high multiplicity with UNC53(7A) or UNC53(8A) recombinant Baculoviruses for protein expression. Proteins from whole cell lysates were separated by denaturing (SDS) polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. The expression of UNC53 in those cell lysates was confirmed by immunoreaction with a monoclonal antibody (16-49-2) to UNC53 and subsequent chemiluminescent detection (ECL™ Amersham). A Coomassie-stained band of the expected size was observed in lysates of *Sf9* cells infected with UNC-53(7A) or UNC53(8A) recombinant baculoviruses, but not with control constructs. Within the accuracy of the methods, this Coomassie-stained band coincided with the largest immunoreactive band. Their estimated mass was approximately 180 kDa, which is compatible with the theoretically calculated mass (167 kDa). We therefore conclude that this band most likely corresponds to intact UNC53.

For both UNC53(7A) and UNC53(8A) baculoviral expression constructs, mostly intact recombinant UNC53-protein was detected by immunoblotting in lysates from infected cells harvested 24 hours post infection. Larger amounts of recombinant protein could be detected in lysates from cells prepared during later stages of infection (48 and 72 hours post infection) but in those preparations a considerable amount of smaller fragments (presumptive degradation products) is observed.

Example 14

The UNC-53 protein expressed in Sf9 cells using a Baculovirus expression system is a valid tool to study its biochemical functions and a valid tool to identify interacting proteins.

3x10⁶ SF9 cells infected with recombinant virus UNC53 7A(L2.3)/pBacPAK9 were resuspended in 100 microliter Phosphate Buffered Saline supplemented with 0.14 micromolar of pepstatin, 10 mM of benzamidine and 0.015 micromolar aprotinin. The cells were briefly sonicated and the obtained material was centrifuged at 30,000 g for 30 minutes at 4 degrees centrigade. The clear supernatant (soluble fraction) was frozen in 50% glycerol. An aliquot of this fraction was incubated in the cold room for 48 hrs. The protein samples were analyzed by SDS-PAGE, blotted to nitrocellulose and probed with mab 16-48-2. This showed that UNC-53 protein made in SF9 cells is soluble and stable under the conditions tested.

20 microlitres of the UNC-53 SF9 lysate were incubated with 5 microlitre GST-Sepharose beads loaded with equal amouts (approx. 10 microgram) of GST-GRB-2 or GST alone. The beads were rinsed 3 times in 500 microlitres of solution PBS-0.2% Tween 20 and eluted with 50 microliter SDS sample buffer. The eluted material was analyzed by SDS-PAGE and Western blot analysis with mab 16-48-2. UNC-53 was retained on the GST-GRB2 column and not on the GST demonstrating that UNC-53 interacts in vitro with GRB-2.

-95-

Example 15

Identification of proteins interacting with UNC-53 :

5 Vectors pCB50 and pCB51 were constructed as bait vectors for the yeast two hybrid system expressing resp. the full length and the carboxyterminal part of UNC-53.

10 pCB50 was constructed by cloning the full length UNC-53 cDNA (7A variant; *NdeI-NcoI* fragment from pTB74) into pAS1-CYH2 vector from Clontech. (Figure 30).

15 pCB51 (Figure 32) was constructed by cloning the 1880 bp *NdeI-NcoI* fragment from pTB74 into vector pAS1-CYH2 from Clontech. This protein encodes among others, the GTP/ATP binding domains, a leucine zipper domain, and an additional coiled-coil domain.

20 pCB50 and pCB51 were transformed in yeast strain Hf7C (YRG2). Expression was confirmed by western blotting using antibodies to the GAL4 protein fused to UNC-53 in these constructs. Bands of expected size (190 kd for pCB50 and 90 kd for pCB51) were observed both in yeast strains with pCB50 and pCB51 indicating that both fusion proteins are expressed in the yeast.

25 The expression of the pCB50 and pCB51 fusion proteins in yeast strain Hf7C does not lead to expression of the LacZ or HIS reporter genes. These experiments demonstrate that the constructed fusions are useful baits in yeast two hybrid screens.

30 Vector pCB55 was made by cloning the 984 bp *BamHI-BglIII* of pTB74 construct into the yeast two

-96-

hybrid activation vector (pGAD-424 vector from Clontech) (Figure 34). In order to check the possible interactions of UNC-53 either with itself (homodimerization) or other proteins.

- 5 This vector expresses a Gal-4 activation domain fused to amongst others the predicted coiled coil or leucine zipper domain of UNC-53.

10 The following combinations of plasmids were co-transformed in yeast strain HF7C : (1) pCB51 and pCB55 (2) pCB55 with control plasmid- pTD1 and (3) positive control plasmids pTD1 and PVA3 (two proteins known to interact (Bartel, P.L et al., Biotechniques Vol. 14 nr.6 (1993)). Yeast cotransformed with combination (1) and (3) grew well on -LEU;-TRYP plates and -LEU;-

15 TRYP;-HIS plates indicating that an interacting protein is present in both co-transformations. Only yeast co-transformed with (3) was positive in a lacZ assay indicating that the observed interaction in (1) (between pCB50 and pCB 55) is weak. For co-

20 transformation (2), colonies grew on -LEU;-TRYP plates and as expected not on -LEU;-TRYP;-HIS plates. The positive control were thus positive whereas the negative controls were negative. We conclude that there is a weak but significant interaction between

25 pCB51 and pCB55, which is strong enough to activate the HIS but not the lacZ reporter gene in this Hf7c strain.

Example 16

- 30 Protocol to screen for components which inhibit or enhance UNC-53 using C. elegans cell line pTBIn76

-97-

Embryos from large liquid C. elegans cultures of line pTBIn76 (table 1) are collected by sucrose flotation of a bleached population (Goh and Bogaert (1991), Dev. Biol. 56, 110-156). Embryos are

5 dispensed in 96 well microtiter plates with M9 medium and various concentrations of the compound to be tested. The embryos are allowed to hatch and are synchronised in the L1 stage by starvation. After a

10 suitable exposure to the compound (by standard calibration) a standard quantity of E. coli (food) is dispersed in the 96 well plates, which starts C. elegans post-embryonic development. The microtiter

15 plates are then placed in an incubator to induce heat shock and subsequently placed at 25°C to permit continued development. After 0 to 1 generations of C. elegans development wells are inspected to assess the

20 degree of population growth inhibition. This inspection can consist of an optical density measurement to assess the amount of food consumed by the developing nematodes. Very little food is

25 consumed when no test compound is present: most food is consumed if an UNC-53 inhibitor has blocked the lethal or subviable phenotype induced by the transgene. The inspection can also be a visual

inspection of the number of healthy or subviable worms or a histochemical measurement of C. elegans viability or of the remainder of E. coli (food).

Example 17 - Protocol to screen for compounds

30 which inhibit or enhance cell regulation or motility.

Transfected cells used in this example were the same as those obtained from example 8. Compounds to be tested were added to each of the cells and their


35 effects on the cells monitored. Functional assays to determine neurite extension were also the same as used

in example 8 as described by Geests et al. One compound (of the Formula I below) was used for further testing.

5 Example 18 - Compounds targetted at the unc-53 pathway.

Synthesis of (1-(1H-pyrrol-2-ylmethyl)-2-piperidone.

10



15

Step 1

To a stirred solution of 150g of 1H-pyrrol-2-carboxaldehyde in 1500g parts of trichloromethane were
20 added 690, of 5Å molecular Sieves. A kit solution of 264, of methyl 5-aminopentanoate hydrochloride in 1500g of trichloromethane was added. After stirring for 5 minutes, 465g of thiethylamine were added over
10 minutes. Upon complete addition, the reaction
25 mixture was stirred for 20 hours at ambient temperature. The mixture was filtered over diatomaceous earth and the filtrate was concentrated by evaporation of the solvent. The concentrate was triturated in 1,1'-oxybisethane. The precipitate was
30 filtered off and the filtrate was concentrated, yielding 300g (91.1%) of 5-[(1H-pyrrol-2-

Step 2

A mixture of 150g of 5-[[(1H-pyrrol-2-yl)methylen]amino]pentanoate hydrogenated at $3 \cdot 10^5$ Pa and at ambient temperature with 3.3 parts of platinum oxide. After the calculated amount of hydrogen was consumed, the catalyst was filtered off and the filtrate was evaporated. The residue was dissolved in dichloromethane and the organic phase was washed three times with a sodium hydroxide 3 N solution. The product was distilled at 13.30 Pa (bp 100-130°C). The residue was crystallized from cyclohexane and hexane. The product was filtered off and dried, yielding 193 parts (100%) of 1-(1H-pyrrol-2-ylmethyl)-2-piperidone. ; mp. 105.8°C.

The compound (1-(1H-pyrrol-2-ylmethyl)-2-piperidinone) when applied for 24 hours to cultures of both wild-type and transfected N4 (mouse neuroblastoma) cells displays a differential behaviour. There is no effect (or at most a small stimulatory) effect on the wild-type N4 cells, up to concentrations of 1 μ M, the compound clearly becomes toxic for both types of cells. The results indicate that this compound counteracts the effects of overexpression of UNC-53 and may have beneficial effects therefore in for example metastasis.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

(A) NAME: BOGAERT; THIERRY
(B) STREET: Voorstraat 36 bus 11
(C) CITY: Kortrijk
(E) COUNTRY: Belgium
(F) POSTAL CODE (ZIP): B-8500

(A) NAME: STRINGHAM; EVE
(B) STREET: 9326-133 A Street
(C) CITY: Surrey
(D) STATE: British Columbia
(E) COUNTRY: Canada
(F) POSTAL CODE (ZIP): V3V 5R5

(A) NAME: VANDEKERCKHOVE; JOEL
(B) STREET: Rode Benkendreef 27
(C) CITY: Loppem
(D) STATE: -
(E) COUNTRY: Belgium
(F) POSTAL CODE (ZIP): none

(ii) TITLE OF INVENTION: Processes for the identification of compounds which control cell behaviour, the compounds identified and pharmaceutical compositions containing them and their use in the control of cell behaviour

(iii) NUMBER OF SEQUENCES: 48

(iv) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

(v) CURRENT APPLICATION DATA:

APPLICATION NUMBER: EP PCT/EP96/02311

(vi) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: GB 9510944.3
(B) FILING DATE: 31-MAY-1995

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5073 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Caenorhabditis elegans

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

SUBSTITUTE SHEET (RULE 26)

GGTTTAATTA	CCCAAGTTTG	AGACATCAAT	TCCATCGAAC	GAAATGTTGG	TGCTCCGAAT	60
AAAATGACGA	CGTCAAATGT	AGAATTGATA	CCAATCTACA	CGGATTGGGC	CAATCGGCAC	120
CTTTCGAAGG	GCAGCTTATC	AAAGTCGATT	AGGGATATTT	CCAATGATTT	TCGCGACTAT	180
CGACTGGTTT	CTCAGCTTAT	TAATGTGATC	GTTCCGATCA	ACGAATTCTC	GCCTGCATTC	240
ACGAAACGTT	TGGCAAAAAT	CACATCGAAC	CTGGATGGCC	TCGAAACGTG	TCTCGACTAC	300
CTGAAAAATC	TGGGTCTCGA	CTGCTCGAAA	CTCACCAAAA	CCGATATCGA	CAGCGGAAAC	360
TTGGGTGCAG	TTCTCCAGCT	GCTCTTCCTG	CTCTCCACCT	ACAAGCAGAA	GCTTCGGCAA	420
CTGAAAAAAG	ATCAGAAGAA	ATTGGAGCAA	CTACCCACAT	CCATTATGCC	ACCCGCGGTT	480
TCTAAATTAC	CCTCGCCACG	TGTCGCCACG	TCAGCAACCG	CTTCAGCAAC	TAACCCAAAT	540
TCCAACTTTC	CACAAATGTC	AACATCCAGG	CTTCAGACTC	CACAGTCAAG	AATATCGAAA	600
ATTGATTCAT	CAAAGATTGG	TATCAAGCCA	AAGACGTCTG	GACTTAAACC	ACCCTCATCA	660
TCAACCACTT	CATCAAATAA	TACAAATTCA	TTCCGTCCGT	CGAGCCGTTT	GAGTGGCAAT	720
AATAATGTTG	GCTCGACGAT	ATCCACATCT	GCGAAGAGCT	TAGAATCATC	ATCAACGTAC	780
AGCTCTATTT	CGAATCTAAA	CCGACCTACC	TCCCAACTCC	AAAAACCTTC	TAGACCACAA	840
ACCCAGCTAG	TTCGTGTTGC	TACAACTACA	AAAATCGGAA	GCTCAAAGCT	AGCCGCTCCG	900
AAAGCCGTGA	GCACCCCAAA	ACTTGCTTCT	GTGAAGACTA	TTGGAGCAAA	ACAAGAGCCC	960
GATAACAGCG	GTGGTGGTGG	TGGTGGAAATG	CTGAAATTAA	AGTTATTTCAG	TAGCAAAAAC	1020
CCATCTTCCT	CATCGAATAG	CCCACAACCT	ACGAGAAAGG	CGGCGGCGGT	GCCTCAACAA	1080
CAAACTTTGT	CGAAAATCGC	TGCCCCAGTG	AAAAGTGGCC	TGAAGCCGCC	GACCAGTAAG	1140
CTGGGAAGTG	CCACGTCTAT	GTCGAAGCTT	TGTACGCCAA	AAGTTTCCTA	CCGTAAAACG	1200
GACGCCCCAA	TCATATCTCA	ACAAGACTCG	AAACGATGCT	CAAAGAGCAG	TGAAGAAGAG	1260
TCCGGATACG	CTGGATTCAA	CAGCACGTCG	CCAACGTCAT	CATCGACGGA	AGGTTCCCTA	1320
AGCATGCATT	CCACATCTTC	CAAGAGTTCA	ACGTGAGACG	AAAAGTCTCC	GTCATCAGAC	1380
GATCTTACTC	TTAACGCCTC	CATCGTGACA	GCTATCAGAC	AGCCGATAGC	CGCAACACCG	1440
GTTTCTCCAA	ATATTATCAA	CAAGCCTGTT	GAGGAAAAAC	CAAACTGGC	AGTGAAAGGA	1500
GTGAAAAGCA	CAGCGAAAAA	AGATCCACCT	CCAGCTGTTC	CGCCACGTGA	CACCCAGCCA	1560
ACAATCGGAG	TTGTTAGTCC	AATTATGGCA	CATAAGAAGT	TGACAAATGA	CCCCGTGATA	1620
TCTGAAAAAC	CAGAACCCTGA	AAAGCTCCAA	TCAATGAGCA	TCGACACGAC	GGACGTTCCA	1680
CCGCTTCCAC	CTCTAAAATC	AGTTGTTCCA	CTTAAAATGA	CTTCAATCCG	ACAACCACCA	1740
ACGTACGATG	TTCTTCTAAA	ACAAGGAAAA	ATCACATCGC	CTGTCAAGTC	GTTTGGATAT	1800
GAGCAGTCGT	CCGCGTCTGA	AGACTCCATT	GTGGCTCATG	CGTCGGCTCA	GGTGACTCCG	1860
CCGACAAAAA	CTTCTGGTAA	TCATTCGCTG	GAGAGAAGGA	TGGGAAAGAA	TAAGACATCA	1920

GAATCCAGCG	GCTACACCTC	TGACGCCGGT	GTTGCGATGT	GCGCCAAAAT	GAGGGAGAAG	1980
CTGAAAGAAT	ACGATGACAT	GACTCGTCGA	GCACAGAACG	GCTATCCTGA	CAACTTCGAA	2040
GACAGTTCCT	CCTTGTCGTC	TGGAATATCC	GATAACAACG	AGCTCGACGA	CATATCCACG	2100
GACGATTTGT	CCGGAGTAGA	CATGGCAACA	GTCGCCTCCA	AACATAGCGA	CTATTCCCAC	2160
TTTGTTCGCC	ATCCCACGTC	TTCTTCCTCA	AAGCCCCGAG	TCCCCAGTCG	GTCCTCCACA	2220
TCAGTCGATT	CTCGATCTCG	AGCAGAACAG	GAGAATGTGT	ACAAACTTCT	GTCCCAGTGC	2280
CGAACGAGCC	AACGTGGCGC	CGCTGCCACC	TCAACCTTCG	GACAACATTC	GCTAAGATCC	2340
CCGGGATACT	CATCCTATTC	TCCACACTTA	TCAGTGTCTAG	CTGATAAGGA	CACAATGTCT	2400
ATGCACTCAC	AGACTAGTCG	ACGACCTTCT	TCACAAAAAC	CAAGCTATTC	AGGCCAATTT	2460
CATTCACTTG	ATCGTAAATG	CCACCTTCAA	GAGTTCACAT	CCACCGAGCA	CAGAATGGCG	2520
GCTCTCTTGA	GCCCGAGACG	GGTGCCGAAC	TCGATGTCGA	AATATGATTC	TTCAGGATCC	2580
TACTCGGCGC	GTTCCCGAGG	TGGAAGCTCT	ACTGGTATCT	ATGGAGAGAC	GTTCCAACCTG	2640
CACAGACTAT	CCGATGAAAA	ATCCCCCGCA	CATTCTGCCA	AAAGTGAGAT	GGGATCCCAA	2700
CTATCACTGG	CTAGCACGAC	AGCATATGGA	TCTCTCAATG	AGAAGTACGA	ACATGCTATT	2760
CGGGACATGG	CACGTGACTT	GGAGTGTTAC	AAGAACACTG	TCGACTCACT	AACCAAGAAA	2820
CAGGAGAACT	ATGGAGCATT	GTTTGATCTT	TTTGAGCAAA	AGCTTAGAAA	ACTCACTCAA	2880
CACATTGATC	GATCCAACCT	GAAGCCTGAA	GAGGCAATAC	GATTTCAGGCA	GGACATTGCT	2940
CATTTGAGGG	ATATTAGCAA	TCATCTTGCA	TCCAACTCAG	CTCATGCTAA	CGAAGGCGCT	3000
GGTGAGCTTC	TTCGTCAACC	ATCTCTGGAA	TCAGTTGCAT	CCCATCGATC	ATCGATGTCA	3060
TCGTCGTCGA	AAAGCAGCAA	GCAGGAGAAG	ATCAGCTTGA	GCTCGTTTGG	CAAGAACAAG	3120
AAGAGCTGGA	TCCGCTCCTC	ACTCTCCAAG	TTCACCAAGA	AGAAGAACAA	GAACACGAC	3180
GAAGCACATA	TGCCATCAAT	TTCCGGATCT	CAAGGAACTC	TTGACAACAT	TGATGTGATT	3240
GAGTTGAAGC	AAGAGCTCAA	AGAACGCGAT	AGTGCACTTT	ACGAAGTCCG	CCTTGACAAT	3300
CTGGATCGTG	CCCGCGAAGT	TGATGTTCTG	AGGGAGACAG	TGAACAAGTT	GAAAACCGAG	3360
AACAAGCAAT	TAAAGAAAGA	AGTGGACAAA	CTCACCAACG	GTCCAGCCAC	TCGTGCTTCT	3420
TCCCGCGCCT	CAATTCCAGT	TATCTACGAC	GATGAGCATG	TCTATGATGC	AGCGTGTAGC	3480
AGTACATCAG	CTAGTCAATC	TTCGAAACGA	TCCTCTGGCT	GCAACTCAAT	CAAGGTTACT	3540
GTAAACGTGG	ACATCGCTGG	AGAAATCAGT	TCGATCGTTA	ACCCGGACAA	AGAGATAATC	3600
GTAGGATATC	TTGCCATGTC	AACCAGTCAG	TCATGCTGGA	AAGACATTGA	TGTTTCTATT	3660
CTAGGACTAT	TTGAAGCTA	CCTATCCAGA	ATTGATGTGG	AGCATCAACT	TGGAATCGAT	3720
GCTCGTGATT	CTATCCTTGG	CTATCAAATT	GGTGAACCTC	GACGCGTCAT	TGGAGACTCC	3780
ACAACCATGA	TAACCAGCCA	TCCAACGTAC	ATTCTTACTT	CCTCAACTAC	AATCCGAATG	3840

SUBSTITUTE SHEET (RULE 26)

103

TTCATGCACG GTGCCGCACA GAGTCGCGTA GACAGTCTGG TCCTTGATAT GCTTCTTCCA	3900
AAGCAAATGA TTCTCCAAC TGTCAAAGTCA ATTTTGACAG AGAGACGTCT GGTGTTAGCT	3960
GGAGCAACTG GAATTGGAAA GAGCAAAC TGCAGAGCCC TGGCTGCTTA TGTATCTATT	4020
CGAACAAATC AATCCGAAGA TAGTATTGTT AATATCAGCA TTCCTGAAAA CAATAAAGAA	4080
GAATTGCTTC AAGTGAACG ACGCCTGGAA AAGATCTTGA GAAGCAAAGA ATCATGCATC	4140
GTAATTCTAG ATAATATCCC AAAGAATCGA ATTGCATTG TTGTATCCGT TTTTGCAAAT	4200
GTCCCACTTC AAAACAACGA AGGTCCATTT GTAGTATGCA CAGTCAACCG ATATCAAATC	4260
CCTGAGCTTC AAATTCACCA CAATTTCAAA ATGTCAGTAA TGTCGAATCG TCTCGAAGGA	4320
TTCATCCTAC GTTACCTCCG ACGACGGGCG GTAGAGGATG AGTATCGTCT AACTGTACAG	4380
ATGCCATCAG AGCTCTTCAA AATCATTGAC TTCTTCCCAA TAGCTCTTCA GGCCGTC AAT	4440
AATTTTATTG AGAAAACGAA TTCTGTTGAT GTGACAGTTG GTCCAAGAGC ATGCTTGAAC	4500
TGTCCTCTAA CTGTCGATGG ATCCCGTGAA TGGTTCATTC GATTGTGGAA TGAGAACTTC	4560
ATTCCATATT TGGAACGTGT TGCTAGAGAT GGCAAAAAAA ACCTTCGGTC GCTGCACTTC	4620
CTTCGAGGAT CCCACCGACA TCGTCTCTAA AAAATGGCCG TGGTTCGATG GTGAAAACCC	4680
GGAGAATGTG CTCAAACGTC TTCAACTCCA AGACCTCGTC CCGTCACCTG CCAACTCATC	4740
CCGACAACAC TTCAATCCCC TCGAGTCGTT GATCCAATTG CATGCTACCA AGCATCAGAC	4800
CATCGACAAC ATTTGAACAG AAGACTCTAA TCTTCTCTCG CCTCTCCCCC GCTTTCCTTA	4860
TCTTCGTACC GGTACCTGAT GATTCCCCAT TTTCCCCCTT TTCCCCC CAA TTTCCAGAA	4920
CCTCCTGTTT CCTTTGTTCC TAGTCCTCCC GGGTGCCGAC GCCGAAGCGA TTTAAAAACC	4980
TTTTTCTTTC CGAAACATTT CCCATTGCTC ATTAATAGTC AAATTGAATA AACAGTGTAT	5040
GTACTTAAAA AAAAAAAAAA AAAAAAAAAA AAA	5073

(2) INFORMATION FOR SEQ ID NO: 2:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 5072 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

GGTTTAATTA CCCAAGTTTG AGACATCAAT TCCATCGAAC GAAATGTTGG TGCTCCGAAT	60
AAAATGACGA CGTCAAATGT AGAATTGATA CCAATCTACA CGGATTGGGC CAATCGGCAC	120
CTTTCGAAGG GCAGCTTATC AAAGTCGATT AGGGATATTT CCAATGATTT TCGCGACTAT	180

SUBSTITUTE SHEET (RULE 26)

CGACTGGTTT CTCAGCTTAT TAATGTGATC GTTCCGATCA ACGAATTCTC GCCTGCATTC	240
ACGAAACGTT TGGCAAAAT CACATCGAAC CTGGATGGCC TCGAAACGTG TCTCGACTAC	300
CTGAAAATC TGGGTCTCGA CTGCTCGAAA CTCACCAAAA CCGATATCGA CAGCGGAAAC	360
TTGGGTGCAG TTCTCCAGCT GCTCTTCCTG CTCTCCACCT ACAAGCAGAA GCTTCGGCAA	420
CTGAAAAAG ATCAGAAGAA ATTGGAGCAA CTACCCACAT CCATTATGCC ACCCGCGGTT	480
TCTAAATTAC CCTCGCCACG TGTCGCCACG TCAGCAACCG CTTAGCAAC TAACCCAAAT	540
TCCAACCTTC CACAAATGTC AACATCCAGG CTTAGACTC CACAGTCAAG AATATCGAAA	600
ATTGATTCAT CAAAGATTGG TATCAAGCCA AAGACGTCTG GACTTAAACC ACCCTCATCA	660
TCAACCACTT CATCAAATAA TACAAATTCA TTCCGTCCGT CGAGCCGTTC GAGTGGCAAT	720
AATAATGTTG GCTCGACGAT ATCCACATCT GCGAAGAGCT TAGAATCATC ATCAACGTAC	780
AGCTCTATTT CGAATCTAAA CCGACCTACC TCCCAACTCC AAAACCTTC TAGACCACAA	840
ACCCAGCTAG TTCGTGTTGC TACAACTACA AAAATCGGAA GCTCAAAGCT AGCCGCTCCG	900
AAAGCCGTGA GCACCCCAA ACTTGCTTCT GTGAAGACTA TTGGAGCAA ACAAGAGCCC	960
GATAACAGCG GTGGTGGTGG TGGTGGAAATG CTGAAATTAA AGTTATTCAG TAGCAAAAAC	1020
CCATCTTCCT CATCGAATAG CCCACAACCT ACGAGAAAGG CGGCGGCGGT GCCTCAACAA	1080
CAAACCTTGT CGAAAATCGC TGCCCCAGTG AAAAGTGGCC TGAAGCCGCC GACCAGTAAG	1140
CTGGGAAGTG CCACGTCTAT GTCGAAGCTT TGTACGCCAA AAGTTTCTTA CCGTAAAACG	1200
GACGCCCCAA TCATATCTCA ACAAGACTCG AAACGATGCT CAAAGAGCAG TGAAGAAGAG	1260
TCCGGATACG CTGGATTCAA CAGCACGTCG CCAACGTCAT CATCGACGGA AGGTTCCTTA	1320
AGCATGCATT CCACATCTTC CAAGAGTTCA ACGTCAGACG AAAAGTCTCC GTCATCAGAC	1380
GATCTTACTC TTAACGCCTC CATCGTGACA GCTATCAGAC AGCCGATAGC CGCAACACCG	1440
GTTTCTCCAA ATATTATCAA CAAGCCTGTT GAGGAAAAAC CAACACTGGC AGTGAAAGGA	1500
GTGAAAAGCA CAGCGAAAAA AGATCCACCT CCAGCTGTTT CGCCACGTGA CACCCAGCCA	1560
ACAATCGGAG TTGTTAGTCC AATTATGGCA CATAAGAAGT TGACAAATGA CCCCGTGATA	1620
TCTGAAAAAC CAGAACCCTGA AAAGCTCCAA TCAATGAGCA TCGACACGAC GGACGTTCCA	1680
CCGCTTCCAC CTCTAAAATC AGTTGTTCCA CTTAAAATGA CTTCAATCCG ACAACCACCA	1740
ACGTACGATG TTCTTCTAAA ACAAGGAAAA ATCACATCGC CTGTCAAGTC GTTTGGATAT	1800
GAGCAGTCGT CCGCGTCTGA AGACTCCATT GTGGCTCATG CGTCGGCTCA GGTGACTCCG	1860
CCGACAAAAA CTTCTGGTAA TCATTCGCTG GAGAGAAGGA TGGGAAAGAA TAAGACATCA	1920
GAATCCAGCG GCTACACCTC TGACGCCGGT GTTGCGATGT GCGCCAAAAT GAGGGAGAAG	1980
CTGAAAGAAT ACGATGACAT GACTCGTCGA GCACAGAACG GCTATCCTGA CAACTTCGAA	2040
GACAGTTCCT CCTTGTCGTC TGGAATATCC GATAACAACG AGCTCGACGA CATATCCACG	2100

SUBSTITUTE SHEET (RULE 26)

GACGATTTGT	CCGGAGTAGA	CATGGCAACA	GTCGCCTCCA	AACATAGCGA	CTATTTCCAC	2160
TTTGTTCGCC	ATCCCACGTC	TTCTTCCTCA	AAGCCCCGAG	TCCCCAGTCG	GTCTCCACA	2220
TCAGTCGATT	CTCGATCTCG	AGCAGAACAG	GAGAATGTGT	ACAAACTTCT	GTCCCAGTGC	2280
CGAACGAGCC	AACGTGGCGC	CGCTGCCACC	TCAACCTTCG	GACAACATTC	GCTAAGATCC	2340
CCGGGATACT	CATCCTATTC	TCCACACTTA	TCAGTGTCTAG	CTGATAAGGA	CACAAATGTCT	2400
ATGCACTCAC	AGACTAGTCG	ACGACCTTCT	TCACAAAAAC	CAAGCTATTC	AGGCCAATTT	2460
CATTCACTTG	ATCGTAAATG	CCACCTTCAA	GAGTTCACAT	CCACCGAGCA	CAGAATGGCG	2520
GCTCTCTTGA	GCCCGAGACG	GGTGCCGAAC	TCGATGTCTGA	AATATGATTC	TTCAGGATCC	2580
TACTCGGCGC	GTTCCCGAGG	TGGAAGCTCT	ACTGGTATCT	ATGGAGAGAC	GTTCCAACTG	2640
CACAGACTAT	CCGATGAAAA	ATCCCCCGCA	CATTCTGCCA	AAAGTGAGAT	GGGATCCCAA	2700
CTATCACTGG	CTAGCACGAC	AGCATATGGA	TCTCTCAATG	AGAAGTACGA	ACATGCTATT	2760
CGGGACATGG	CACGTGACTT	GGAGTGTAC	AAGAACACTG	TCGACTCACT	AACCAAGAAA	2820
CAGGAGAACT	ATGGAGCATT	GTTTGATCTT	TTTGAGCAAA	AGCTTAGAAA	ACTCACTCAA	2880
CACATTGATC	GATCCAACCT	GAAGCCTGAA	GAGGCAATAC	GATTCAGGCA	GGACATTGCT	2940
CATTTGAGGG	ATATTAGCAA	TCATCTTGCA	TCCAACCTCAG	CTCATGCTAA	CGAAGGCGCT	3000
GGTGAGCTTC	TTCGTCAACC	ATCTCTGGAA	TCAGTTGCAT	CCCATCGATC	ATCGATGTCA	3060
TCGTCGTCGA	AAAGCAGCAA	GCAGGAGAAG	ATCAGCTTGA	GCTCGTTTGG	CAAGAACAAG	3120
AAGAGCTGGA	TCCGCTCCTC	ACTCTCCAAG	TTCACCAAGA	AGAAGAACAA	GAATACGAC	3180
GAAGCACATA	TGCCATCAAT	TTCCGGATCT	CAAGGAACTC	TTGACAACAT	TGATGTGATT	3240
GAGTTGAAGC	AAGAGCTCAA	AGAACGCGAT	AGTGCACTTT	ACGAAGTCCG	CCTTGACAAT	3300
CTGGATCGTG	CCCGCGAAGT	TGATGTTCTG	AGGGAGACAG	TGAACAAGTT	GAAAACCGAG	3360
AACAAGCAAT	TAAAGAAAGA	AGTGGACAAA	CTCACCACG	GTCCAGCCAC	TCGTGCTTCT	3420
TCCCGCGCCT	CAATTCCAGT	TATCTACGAC	GATGAGCATG	TCTATGATGC	AGCGTGTAGC	3480
AGTACATCAG	CTAGTCAATC	TTCGAAACGA	TCCTCTGGCT	GCAACTCAAT	CAAGGTTACT	3540
GTAAACGTGG	ACATCGCTGG	AGAAATCAGT	TCGATCGTTA	ACCCGGACAA	AGAGATAATC	3600
GTAGGATATC	TTGCCATGTC	AACCAGTCAG	TCATGCTGGA	AAGACATTGA	TGTTTCTATT	3660
CTAGGACTAT	TTGAAGTCTA	CCTATCCAGA	ATTGATGTGG	AGCATCAACT	TGGAATCGAT	3720
GCTCGTGATT	CTATCCTTGG	CTATCAAATT	GGTGAACCTC	GACGCGTCAT	TGGAGACTCC	3780
ACAACCATGA	TAACCAGCCA	TCCAACGAC	ATTCTTACTT	CCTCAACTAC	AATCCGAATG	3840
TTCATGCACG	GTGCCGCACA	GAGTCGCGTA	GACAGTCTGG	TCCTTGATAT	GCTTCTTCCA	3900
AAGCAAATGA	TTCTCCAACCT	CGTCAAGTCA	ATTTTGACAG	AGAGACGTCT	GGTGTTAGCT	3960
GGAGCAACTG	GAATTGGAAA	GAGCAAACCTG	GCGAAGACCC	TGGCTGCTTA	TGTATCTATT	4020

106

```

CGAACAAATC AATCCGAAGA TAGTATTGTT AATATCAGCA TTCCTGAAAA CAATAAAGAA 4080
GAATTGCTTC AAGTGGAACG ACGCCTGGAA AAGATCTTGA GAAGCAAAGA ATCATGCATC 4140
GTAATTCTAG ATAATATCCC AAAGAATCGA ATTGCATTG TGTATCCGT TTTTGCAAAT 4200
GTCCCACTTC AAAACAACGA AGGTCCATTT GTAGTATGCA CAGTCAACCG ATATCAAATC 4260
CCTGAGCTTC AAATTCACCA CAATTTCAA ATGTCAGTAA TGTCGAATCG TCTCGAAGGA 4320
TTCATCCTAC GTTACCTCCG ACGACGGGCG GTAGAGGATG AGTATCGTCT AACTGTACAG 4380
ATGCCATCAG AGCTCTTCAA AATCATTGAC TTCTTCCCAA TAGCTCTTCA GGCCGTCAAT 4440
AATTTTATTG AGAAAACGAA TTCTGTTGAT GTGACAGTTG GTCCAAGAGC ATGCTTGAAC 4500
TGTCCTCTAA CTGTCGATGG ATCCCCTGAA TGGTTCATTC GATTGTGGAA TGAGAACTTC 4560
ATCCCATATT TGGAACGTGT TGCTAGAGAT GGCAAAAAAA CCTTCGGTCG CTGCACTTCC 4620
TTCGAGGATC CCACCGACAT CGTCTCTAAA AAATGGCCGT GGTTCGATGG TGAAAACCCG 4680
GAGAATGTGC TCAAACGTCT TCAACTCCAA GACCTCGTCC CGTCACCTGC CAACTCATCC 4740
CGACAACACT TCAATCCCT CGAGTCGTTG ATCCAATTGC ATGCTACCAA GCATCAGACC 4800
ATCGACAACA TTTGAACAGA AGACTCTAAT CTTCTCTCGC CTCTCCCCCG CTTTCCTTAT 4860
CTTCGTACCG GTACCTGATG ATTCCCCATT TTCCCCCTT TCCCCCAAT TTCCAGAAC 4920
CTCCTGTTCC CTTTGTTCT AGTCCTCCCG GGTGCCGACG CCGAAGCGAT TTA AAAACCT 4980
TTTTCTTTCC GAAACATTT CCATTGCTCA TTAATAGTCA AATTGAATAA ACAGTGTATG 5040
TACTTAAAAA AAAAAAAAAA AAAAAAAAAA AA 5072

```

(2) INFORMATION FOR SEQ ID NO: 3:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 1528 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

```

Met Thr Thr Ser Asn Val Glu Leu Ile Pro Ile Tyr Thr Asp Trp Ala
1           5           10           15
Asn Arg His Leu Ser Lys Gly Ser Leu Ser Lys Ser Ile Arg Asp Ile
20           25           30
Ser Asn Asp Phe Arg Asp Tyr Arg Leu Val Ser Gln Leu Ile Asn Val
35           40           45
Ile Val Pro Ile Asn Glu Phe Ser Pro Ala Phe Thr Lys Arg Leu Ala
50           55           60

```

SUBSTITUTE SHEET (RULE 26)

107

Lys Ile Thr Ser Asn Leu Asp Gly Leu Glu Thr Cys Leu Asp Tyr Leu
 65 70 75 80
 Lys Asn Leu Gly Leu Asp Cys Ser Lys Leu Thr Lys Thr Asp Ile Asp
 85 90 95
 Ser Gly Asn Leu Gly Ala Val Leu Gln Leu Leu Phe Leu Leu Ser Thr
 100 105 110
 Tyr Lys Gln Lys Leu Arg Gln Leu Lys Lys Asp Gln Lys Lys Leu Glu
 115 120 125
 Gln Leu Pro Thr Ser Ile Met Pro Pro Ala Val Ser Lys Leu Pro Ser
 130 135 140
 Pro Arg Val Ala Thr Ser Ala Thr Ala Ser Ala Thr Asn Pro Asn Ser
 145 150 155 160
 Asn Phe Pro Gln Met Ser Thr Ser Arg Leu Gln Thr Pro Gln Ser Arg
 165 170 175
 Ile Ser Lys Ile Asp Ser Ser Lys Ile Gly Ile Lys Pro Lys Thr Ser
 180 185 190
 Gly Leu Lys Pro Pro Ser Ser Ser Thr Thr Ser Ser Asn Asn Thr Asn
 195 200 205
 Ser Phe Arg Pro Ser Ser Arg Ser Ser Gly Asn Asn Asn Val Gly Ser
 210 215 220
 Thr Ile Ser Thr Ser Ala Lys Ser Leu Glu Ser Ser Ser Thr Tyr Ser
 225 230 235 240
 Ser Ile Ser Asn Leu Asn Arg Pro Thr Ser Gln Leu Gln Lys Pro Ser
 245 250 255
 Arg Pro Gln Thr Gln Leu Val Arg Val Ala Thr Thr Thr Lys Ile Gly
 260 265 270
 Ser Ser Lys Leu Ala Ala Pro Lys Ala Val Ser Thr Pro Lys Leu Ala
 275 280 285
 Ser Val Lys Thr Ile Gly Ala Lys Gln Glu Pro Asp Asn Ser Gly Gly
 290 295 300
 Gly Gly Gly Gly Met Leu Lys Leu Lys Leu Phe Ser Ser Lys Asn Pro
 305 310 315 320
 Ser Ser Ser Ser Asn Ser Pro Gln Pro Thr Arg Lys Ala Ala Ala Val
 325 330 335
 Pro Gln Gln Gln Thr Leu Ser Lys Ile Ala Ala Pro Val Lys Ser Gly
 340 345 350
 Leu Lys Pro Pro Thr Ser Lys Leu Gly Ser Ala Thr Ser Met Ser Lys
 355 360 365
 Leu Cys Thr Pro Lys Val Ser Tyr Arg Lys Thr Asp Ala Pro Ile Ile
 370 375 380
 Ser Gln Gln Asp Ser Lys Arg Cys Ser Lys Ser Ser Glu Glu Glu Ser
 385 390 395 400

SUBSTITUTE SHEET (RULE 26)

108

Gly Tyr Ala Gly Phe Asn Ser Thr Ser Pro Thr Ser Ser Ser Thr Glu
 405 410 415
 Gly Ser Leu Ser Met His Ser Thr Ser Ser Lys Ser Ser Thr Ser Asp
 420 425 430
 Glu Lys Ser Pro Ser Ser Asp Asp Leu Thr Leu Asn Ala Ser Ile Val
 435 440 445
 Thr Ala Ile Arg Gln Pro Ile Ala Ala Thr Pro Val Ser Pro Asn Ile
 450 455 460
 Ile Asn Lys Pro Val Glu Glu Lys Pro Thr Leu Ala Val Lys Gly Val
 465 470 475 480
 Lys Ser Thr Ala Lys Lys Asp Pro Pro Pro Ala Val Pro Pro Arg Asp
 485 490 495
 Thr Gln Pro Thr Ile Gly Val Val Ser Pro Ile Met Ala His Lys Lys
 500 505 510
 Leu Thr Asn Asp Pro Val Ile Ser Glu Lys Pro Glu Pro Glu Lys Leu
 515 520 525
 Gln Ser Met Ser Ile Asp Thr Thr Asp Val Pro Pro Leu Pro Pro Leu
 530 535 540
 Lys Ser Val Val Pro Leu Lys Met Thr Ser Ile Arg Gln Pro Pro Thr
 545 550 555 560
 Tyr Asp Val Leu Leu Lys Gln Gly Lys Ile Thr Ser Pro Val Lys Ser
 565 570 575
 Phe Gly Tyr Glu Gln Ser Ser Ala Ser Glu Asp Ser Ile Val Ala His
 580 585 590
 Ala Ser Ala Gln Val Thr Pro Pro Thr Lys Thr Ser Gly Asn His Ser
 595 600 605
 Leu Glu Arg Arg Met Gly Lys Asn Lys Thr Ser Glu Ser Ser Gly Tyr
 610 615 620
 Thr Ser Asp Ala Gly Val Ala Met Cys Ala Lys Met Arg Glu Lys Leu
 625 630 635 640
 Lys Glu Tyr Asp Asp Met Thr Arg Arg Ala Gln Asn Gly Tyr Pro Asp
 645 650 655
 Asn Phe Glu Asp Ser Ser Ser Leu Ser Ser Gly Ile Ser Asp Asn Asn
 660 665 670
 Glu Leu Asp Asp Ile Ser Thr Asp Asp Leu Ser Gly Val Asp Met Ala
 675 680 685
 Thr Val Ala Ser Lys His Ser Asp Tyr Ser His Phe Val Arg His Pro
 690 695 700
 Thr Ser Ser Ser Ser Lys Pro Arg Val Pro Ser Arg Ser Ser Thr Ser
 705 710 715 720
 Val Asp Ser Arg Ser Arg Ala Glu Gln Glu Asn Val Tyr Lys Leu Leu
 725 730 735

SUBSTITUTE SHEET (RULE 26)

109

Ser Gln Cys Arg Thr Ser Gln Arg Gly Ala Ala Ala Thr Ser Thr Phe
 740 745 750
 Gly Gln His Ser Leu Arg Ser Pro Gly Tyr Ser Ser Tyr Ser Pro His
 755 760 765
 Leu Ser Val Ser Ala Asp Lys Asp Thr Met Ser Met His Ser Gln Thr
 770 775 780
 Ser Arg Arg Pro Ser Ser Gln Lys Pro Ser Tyr Ser Gly Gln Phe His
 785 790 795 800
 Ser Leu Asp Arg Lys Cys His Leu Gln Glu Phe Thr Ser Thr Glu His
 805 810 815
 Arg Met Ala Ala Leu Leu Ser Pro Arg Arg Val Pro Asn Ser Met Ser
 820 825 830
 Lys Tyr Asp Ser Ser Gly Ser Tyr Ser Ala Arg Ser Arg Gly Gly Ser
 835 840 845
 Ser Thr Gly Ile Tyr Gly Glu Thr Phe Gln Leu His Arg Leu Ser Asp
 850 855 860
 Glu Lys Ser Pro Ala His Ser Ala Lys Ser Glu Met Gly Ser Gln Leu
 865 870 875 880
 Ser Leu Ala Ser Thr Thr Ala Tyr Gly Ser Leu Asn Glu Lys Tyr Glu
 885 890 895
 His Ala Ile Arg Asp Met Ala Arg Asp Leu Glu Cys Tyr Lys Asn Thr
 900 905 910
 Val Asp Ser Leu Thr Lys Lys Gln Glu Asn Tyr Gly Ala Leu Phe Asp
 915 920 925
 Leu Phe Glu Gln Lys Leu Arg Lys Leu Thr Gln His Ile Asp Arg Ser
 930 935 940
 Asn Leu Lys Pro Glu Glu Ala Ile Arg Phe Arg Gln Asp Ile Ala His
 945 950 955 960
 Leu Arg Asp Ile Ser Asn His Leu Ala Ser Asn Ser Ala His Ala Asn
 965 970 975
 Glu Gly Ala Gly Glu Leu Leu Arg Gln Pro Ser Leu Glu Ser Val Ala
 980 985 990
 Ser His Arg Ser Ser Met Ser Ser Ser Ser Lys Ser Ser Lys Gln Glu
 995 1000 1005
 Lys Ile Ser Leu Ser Ser Phe Gly Lys Asn Lys Lys Ser Trp Ile Arg
 1010 1015 1020
 Ser Ser Leu Ser Lys Phe Thr Lys Lys Lys Asn Lys Asn Tyr Asp Glu
 1025 1030 1035 1040
 Ala His Met Pro Ser Ile Ser Gly Ser Gln Gly Thr Leu Asp Asn Ile
 1045 1050 1055
 Asp Val Ile Glu Leu Lys Gln Glu Leu Lys Glu Arg Asp Ser Ala Leu
 1060 1065 1070

SUBSTITUTE SHEET (RULE 26)

110

Tyr Glu Val Arg Leu Asp Asn Leu Asp Arg Ala Arg Glu Val Asp Val
 1075 1080 1085
 Leu Arg Glu Thr Val Asn Lys Leu Lys Thr Glu Asn Lys Gln Leu Lys
 1090 1095 1100
 Lys Glu Val Asp Lys Leu Thr Asn Gly Pro Ala Thr Arg Ala Ser Ser
 1105 1110 1115 1120
 Arg Ala Ser Ile Pro Val Ile Tyr Asp Asp Glu His Val Tyr Asp Ala
 1125 1130 1135
 Ala Cys Ser Ser Thr Ser Ala Ser Gln Ser Ser Lys Arg Ser Ser Gly
 1140 1145 1150
 Cys Asn Ser Ile Lys Val Thr Val Asn Val Asp Ile Ala Gly Glu Ile
 1155 1160 1165
 Ser Ser Ile Val Asn Pro Asp Lys Glu Ile Ile Val Gly Tyr Leu Ala
 1170 1175 1180
 Met Ser Thr Ser Gln Ser Cys Trp Lys Asp Ile Asp Val Ser Ile Leu
 1185 1190 1195 1200
 Gly Leu Phe Glu Val Tyr Leu Ser Arg Ile Asp Val Glu His Gln Leu
 1205 1210 1215
 Gly Ile Asp Ala Arg Asp Ser Ile Leu Gly Tyr Gln Ile Gly Glu Leu
 1220 1225 1230
 Arg Arg Val Ile Gly Asp Ser Thr Thr Met Ile Thr Ser His Pro Thr
 1235 1240 1245
 Asp Ile Leu Thr Ser Ser Thr Thr Ile Arg Met Phe Met His Gly Ala
 1250 1255 1260
 Ala Gln Ser Arg Val Asp Ser Leu Val Leu Asp Met Leu Leu Pro Lys
 1265 1270 1275 1280
 Gln Met Ile Leu Gln Leu Val Lys Ser Ile Leu Thr Glu Arg Arg Leu
 1285 1290 1295
 Val Leu Ala Gly Ala Thr Gly Ile Gly Lys Ser Lys Leu Ala Lys Thr
 1300 1305 1310
 Leu Ala Ala Tyr Val Ser Ile Arg Thr Asn Gln Ser Glu Asp Ser Ile
 1315 1320 1325
 Val Asn Ile Ser Ile Pro Glu Asn Asn Lys Glu Glu Leu Leu Gln Val
 1330 1335 1340
 Glu Arg Arg Leu Glu Lys Ile Leu Arg Ser Lys Glu Ser Cys Ile Val
 1345 1350 1355 1360
 Ile Leu Asp Asn Ile Pro Lys Asn Arg Ile Ala Phe Val Val Ser Val
 1365 1370 1375
 Phe Ala Asn Val Pro Leu Gln Asn Asn Glu Gly Pro Phe Val Val Cys
 1380 1385 1390
 Thr Val Asn Arg Tyr Gln Ile Pro Glu Leu Gln Ile His His Asn Phe
 1395 1400 1405

SUBSTITUTE SHEET (RULE 26)

111

Lys Met Ser Val Met Ser Asn Arg Leu Glu Gly Phe Ile Leu Arg Tyr
 1410 1415 1420
 Leu Arg Arg Arg Ala Val Glu Asp Glu Tyr Arg Leu Thr Val Gln Met
 1425 1430 1435 1440
 Pro Ser Glu Leu Phe Lys Ile Ile Asp Phe Phe Pro Ile Ala Leu Gln
 1445 1450 1455
 Ala Val Asn Asn Phe Ile Glu Lys Thr Asn Ser Val Asp Val Thr Val
 1460 1465 1470
 Gly Pro Arg Ala Cys Leu Asn Cys Pro Leu Thr Val Asp Gly Ser Arg
 1475 1480 1485
 Glu Trp Phe Ile Arg Leu Trp Asn Glu Asn Phe Ile Pro Tyr Leu Glu
 1490 1495 1500
 Arg Val Ala Arg Asp Gly Lys Lys Asn Leu Arg Ser Leu His Phe Leu
 1505 1510 1515 1520
 Arg Gly Ser His Arg His Arg Leu
 1525

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1583 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

Met Thr Thr Ser Asn Val Glu Leu Ile Pro Ile Tyr Thr Asp Trp Ala
 1 5 10 15
 Asn Arg His Leu Ser Lys Gly Ser Leu Ser Lys Ser Ile Arg Asp Ile
 20 25 30
 Ser Asn Asp Phe Arg Asp Tyr Arg Leu Val Ser Gln Leu Ile Asn Val
 35 40 45
 Ile Val Pro Ile Asn Glu Phe Ser Pro Ala Phe Thr Lys Arg Leu Ala
 50 55 60
 Lys Ile Thr Ser Asn Leu Asp Gly Leu Glu Thr Cys Leu Asp Tyr Leu
 65 70 75 80
 Lys Asn Leu Gly Leu Asp Cys Ser Lys Leu Thr Lys Thr Asp Ile Asp
 85 90 95
 Ser Gly Asn Leu Gly Ala Val Leu Gln Leu Leu Phe Leu Leu Ser Thr
 100 105 110
 Tyr Lys Gln Lys Leu Arg Gln Leu Lys Lys Asp Gln Lys Lys Leu Glu
 115 120 125

SUBSTITUTE SHEET (RULE 26)

112

Gln Leu Pro Thr Ser Ile Met Pro Pro Ala Val Ser Lys Leu Pro Ser
 130 135 140
 Pro Arg Val Ala Thr Ser Ala Thr Ala Ser Ala Thr Asn Pro Asn Ser
 145 150 155 160
 Asn Phe Pro Gln Met Ser Thr Ser Arg Leu Gln Thr Pro Gln Ser Arg
 165 170 175
 Ile Ser Lys Ile Asp Ser Ser Lys Ile Gly Ile Lys Pro Lys Thr Ser
 180 185 190
 Gly Leu Lys Pro Pro Ser Ser Ser Thr Thr Ser Ser Asn Asn Thr Asn
 195 200 205
 Ser Phe Arg Pro Ser Ser Arg Ser Ser Gly Asn Asn Asn Val Gly Ser
 210 215 220
 Thr Ile Ser Thr Ser Ala Lys Ser Leu Glu Ser Ser Ser Thr Tyr Ser
 225 230 235 240
 Ser Ile Ser Asn Leu Asn Arg Pro Thr Ser Gln Leu Gln Lys Pro Ser
 245 250 255
 Arg Pro Gln Thr Gln Leu Val Arg Val Ala Thr Thr Thr Lys Ile Gly
 260 265 270
 Ser Ser Lys Leu Ala Ala Pro Lys Ala Val Ser Thr Pro Lys Leu Ala
 275 280 285
 Ser Val Lys Thr Ile Gly Ala Lys Gln Glu Pro Asp Asn Ser Gly Gly
 290 295 300
 Gly Gly Gly Gly Met Leu Lys Leu Lys Leu Phe Ser Ser Lys Asn Pro
 305 310 315 320
 Ser Ser Ser Ser Asn Ser Pro Gln Pro Thr Arg Lys Ala Ala Ala Val
 325 330 335
 Pro Gln Gln Gln Thr Leu Ser Lys Ile Ala Ala Pro Val Lys Ser Gly
 340 345 350
 Leu Lys Pro Pro Thr Ser Lys Leu Gly Ser Ala Thr Ser Met Ser Lys
 355 360 365
 Leu Cys Thr Pro Lys Val Ser Tyr Arg Lys Thr Asp Ala Pro Ile Ile
 370 375 380
 Ser Gln Gln Asp Ser Lys Arg Cys Ser Lys Ser Ser Glu Glu Glu Ser
 385 390 395 400
 Gly Tyr Ala Gly Phe Asn Ser Thr Ser Pro Thr Ser Ser Ser Thr Glu
 405 410 415
 Gly Ser Leu Ser Met His Ser Thr Ser Ser Lys Ser Ser Thr Ser Asp
 420 425 430
 Glu Lys Ser Pro Ser Ser Asp Asp Leu Thr Leu Asn Ala Ser Ile Val
 435 440 445
 Thr Ala Ile Arg Gln Pro Ile Ala Ala Thr Pro Val Ser Pro Asn Ile
 450 455 460

SUBSTITUTE SHEET (RULE 26)

113

Ile	Asn	Lys	Pro	Val	Glu	Glu	Lys	Pro	Thr	Leu	Ala	Val	Lys	Gly	Val	465	470	475	480
Lys	Ser	Thr	Ala	Lys	Lys	Asp	Pro	Pro	Pro	Ala	Val	Pro	Pro	Arg	Asp	485	490	495	
Thr	Gln	Pro	Thr	Ile	Gly	Val	Val	Ser	Pro	Ile	Met	Ala	His	Lys	Lys	500	505	510	
Leu	Thr	Asn	Asp	Pro	Val	Ile	Ser	Glu	Lys	Pro	Glu	Pro	Glu	Lys	Leu	515	520	525	
Gln	Ser	Met	Ser	Ile	Asp	Thr	Thr	Asp	Val	Pro	Pro	Leu	Pro	Pro	Leu	530	535	540	
Lys	Ser	Val	Val	Pro	Leu	Lys	Met	Thr	Ser	Ile	Arg	Gln	Pro	Pro	Thr	545	550	555	560
Tyr	Asp	Val	Leu	Leu	Lys	Gln	Gly	Lys	Ile	Thr	Ser	Pro	Val	Lys	Ser	565	570	575	
Phe	Gly	Tyr	Glu	Gln	Ser	Ser	Ala	Ser	Glu	Asp	Ser	Ile	Val	Ala	His	580	585	590	
Ala	Ser	Ala	Gln	Val	Thr	Pro	Pro	Thr	Lys	Thr	Ser	Gly	Asn	His	Ser	595	600	605	
Leu	Glu	Arg	Arg	Met	Gly	Lys	Asn	Lys	Thr	Ser	Glu	Ser	Ser	Gly	Tyr	610	615	620	
Thr	Ser	Asp	Ala	Gly	Val	Ala	Met	Cys	Ala	Lys	Met	Arg	Glu	Lys	Leu	625	630	635	640
Lys	Glu	Tyr	Asp	Asp	Met	Thr	Arg	Arg	Ala	Gln	Asn	Gly	Tyr	Pro	Asp	645	650	655	
Asn	Phe	Glu	Asp	Ser	Ser	Ser	Leu	Ser	Ser	Gly	Ile	Ser	Asp	Asn	Asn	660	665	670	
Glu	Leu	Asp	Asp	Ile	Ser	Thr	Asp	Asp	Leu	Ser	Gly	Val	Asp	Met	Ala	675	680	685	
Thr	Val	Ala	Ser	Lys	His	Ser	Asp	Tyr	Ser	His	Phe	Val	Arg	His	Pro	690	695	700	
Thr	Ser	Ser	Ser	Ser	Lys	Pro	Arg	Val	Pro	Ser	Arg	Ser	Ser	Thr	Ser	705	710	715	720
Val	Asp	Ser	Arg	Ser	Arg	Ala	Glu	Gln	Glu	Asn	Val	Tyr	Lys	Leu	Leu	725	730	735	
Ser	Gln	Cys	Arg	Thr	Ser	Gln	Arg	Gly	Ala	Ala	Ala	Thr	Ser	Thr	Phe	740	745	750	
Gly	Gln	His	Ser	Leu	Arg	Ser	Pro	Gly	Tyr	Ser	Ser	Tyr	Ser	Pro	His	755	760	765	
Leu	Ser	Val	Ser	Ala	Asp	Lys	Asp	Thr	Met	Ser	Met	His	Ser	Gln	Thr	770	775	780	
Ser	Arg	Arg	Pro	Ser	Ser	Gln	Lys	Pro	Ser	Tyr	Ser	Gly	Gln	Phe	His	785	790	795	800

SUBSTITUTE SHEET (RULE 26)

114

Ser Leu Asp Arg Lys Cys His Leu Gln Glu Phe Thr Ser Thr Glu His
 805 810 815
 Arg Met Ala Ala Leu Leu Ser Pro Arg Arg Val Pro Asn Ser Met Ser
 820 825 830
 Lys Tyr Asp Ser Ser Gly Ser Tyr Ser Ala Arg Ser Arg Gly Gly Ser
 835 840 845
 Ser Thr Gly Ile Tyr Gly Glu Thr Phe Gln Leu His Arg Leu Ser Asp
 850 855 860
 Glu Lys Ser Pro Ala His Ser Ala Lys Ser Glu Met Gly Ser Gln Leu
 865 870 875 880
 Ser Leu Ala Ser Thr Thr Ala Tyr Gly Ser Leu Asn Glu Lys Tyr Glu
 885 890 895
 His Ala Ile Arg Asp Met Ala Arg Asp Leu Glu Cys Tyr Lys Asn Thr
 900 905 910
 Val Asp Ser Leu Thr Lys Lys Gln Glu Asn Tyr Gly Ala Leu Phe Asp
 915 920 925
 Leu Phe Glu Gln Lys Leu Arg Lys Leu Thr Gln His Ile Asp Arg Ser
 930 935 940
 Asn Leu Lys Pro Glu Glu Ala Ile Arg Phe Arg Gln Asp Ile Ala His
 945 950 955 960
 Leu Arg Asp Ile Ser Asn His Leu Ala Ser Asn Ser Ala His Ala Asn
 965 970 975
 Glu Gly Ala Gly Glu Leu Leu Arg Gln Pro Ser Leu Glu Ser Val Ala
 980 985 990
 Ser His Arg Ser Ser Met Ser Ser Ser Ser Lys Ser Ser Lys Gln Glu
 995 1000 1005
 Lys Ile Ser Leu Ser Ser Phe Gly Lys Asn Lys Lys Ser Trp Ile Arg
 1010 1015 1020
 Ser Ser Leu Ser Lys Phe Thr Lys Lys Lys Asn Lys Asn Tyr Asp Glu
 1025 1030 1035 1040
 Ala His Met Pro Ser Ile Ser Gly Ser Gln Gly Thr Leu Asp Asn Ile
 1045 1050 1055
 Asp Val Ile Glu Leu Lys Gln Glu Leu Lys Glu Arg Asp Ser Ala Leu
 1060 1065 1070
 Tyr Glu Val Arg Leu Asp Asn Leu Asp Arg Ala Arg Glu Val Asp Val
 1075 1080 1085
 Leu Arg Glu Thr Val Asn Lys Leu Lys Thr Glu Asn Lys Gln Leu Lys
 1090 1095 1100
 Lys Glu Val Asp Lys Leu Thr Asn Gly Pro Ala Thr Arg Ala Ser Ser
 1105 1110 1115 1120
 Arg Ala Ser Ile Pro Val Ile Tyr Asp Asp Glu His Val Tyr Asp Ala
 1125 1130 1135

SUBSTITUTE SHEET (RULE 26)

115

Ala Cys Ser Ser Thr Ser Ala Ser Gln Ser Ser Lys Arg Ser Ser Gly
1140 1145 1150

Cys Asn Ser Ile Lys Val Thr Val Asn Val Asp Ile Ala Gly Glu Ile
1155 1160 1165

Ser Ser Ile Val Asn Pro Asp Lys Glu Ile Ile Val Gly Tyr Leu Ala
1170 1175 1180

Met Ser Thr Ser Gln Ser Cys Trp Lys Asp Ile Asp Val Ser Ile Leu
1185 1190 1195 1200

Gly Leu Phe Glu Val Tyr Leu Ser Arg Ile Asp Val Glu His Gln Leu
1205 1210 1215

Gly Ile Asp Ala Arg Asp Ser Ile Leu Gly Tyr Gln Ile Gly Glu Leu
1220 1225 1230

Arg Arg Val Ile Gly Asp Ser Thr Thr Met Ile Thr Ser His Pro Thr
1235 1240 1245

Asp Ile Leu Thr Ser Ser Thr Thr Ile Arg Met Phe Met His Gly Ala
1250 1255 1260

Ala Gln Ser Arg Val Asp Ser Leu Val Leu Asp Met Leu Leu Pro Lys
1265 1270 1275 1280

Gln Met Ile Leu Gln Leu Val Lys Ser Ile Leu Thr Glu Arg Arg Leu
1285 1290 1295

Val Leu Ala Gly Ala Thr Gly Ile Gly Lys Ser Lys Leu Ala Lys Thr
1300 1305 1310

Leu Ala Ala Tyr Val Ser Ile Arg Thr Asn Gln Ser Glu Asp Ser Ile
1315 1320 1325

Val Asn Ile Ser Ile Pro Glu Asn Asn Lys Glu Glu Leu Leu Gln Val
1330 1335 1340

Glu Arg Arg Leu Glu Lys Ile Leu Arg Ser Lys Glu Ser Cys Ile Val
1345 1350 1355 1360

Ile Leu Asp Asn Ile Pro Lys Asn Arg Ile Ala Phe Val Val Ser Val
1365 1370 1375

Phe Ala Asn Val Pro Leu Gln Asn Asn Glu Gly Pro Phe Val Val Cys
1380 1385 1390

Thr Val Asn Arg Tyr Gln Ile Pro Glu Leu Gln Ile His His Asn Phe
1395 1400 1405

Lys Met Ser Val Met Ser Asn Arg Leu Glu Gly Phe Ile Leu Arg Tyr
1410 1415 1420

Leu Arg Arg Arg Ala Val Glu Asp Glu Tyr Arg Leu Thr Val Gln Met
1425 1430 1435 1440

Pro Ser Glu Leu Phe Lys Ile Ile Asp Phe Phe Pro Ile Ala Leu Gln
1445 1450 1455

Ala Val Asn Asn Phe Ile Glu Lys Thr Asn Ser Val Asp Val Thr Val
1460 1465 1470

SUBSTITUTE SHEET (RULE 26)

116

Gly Pro Arg Ala Cys Leu Asn Cys Pro Leu Thr Val Asp Gly Ser Arg
 1475 1480 1485
 Glu Trp Phe Ile Arg Leu Trp Asn Glu Asn Phe Ile Pro Tyr Leu Glu
 1490 1495 1500
 Arg Val Ala Arg Asp Gly Lys Lys Thr Phe Gly Arg Cys Thr Ser Phe
 1505 1510 1515 1520
 Glu Asp Pro Thr Asp Ile Val Ser Lys Lys Trp Pro Trp Phe Asp Gly
 1525 1530 1535
 Glu Asn Pro Glu Asn Val Leu Lys Arg Leu Gln Leu Gln Asp Leu Val
 1540 1545 1550
 Pro Ser Pro Ala Asn Ser Ser Arg Gln His Phe Asn Pro Leu Glu Ser
 1555 1560 1565
 Leu Ile Gln Leu His Ala Thr Lys His Gln Thr Ile Asp Asn Ile
 1570 1575 1580

(2) INFORMATION FOR SEQ ID NO: 5:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 47 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

ATAAGAATGC GGCCGCCGCC ATGACGACGT CAAATGTAGA ATTGATA

47

(2) INFORMATION FOR SEQ ID NO: 6:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 41 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

GGAATTCCAA CCATATGACG ACGTCAAATG TAGAATTGAT A

41

SUBSTITUTE SHEET (RULE 26)

117

(2) INFORMATION FOR SEQ ID NO: 7:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 35 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

CGCGGATCCT CAAACCGCGG GTGGCATAAT GGATG

35

(2) INFORMATION FOR SEQ ID NO: 8:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 13 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

Lys	Lys	Asp	Pro	Pro	Pro	Ala	Val	Pro	Pro	Arg	Asp	Thr
1				5						10		

(2) INFORMATION FOR SEQ ID NO: 9:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 12 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

Thr	Thr	Asp	Val	Pro	Pro	Leu	Pro	Pro	Leu	Lys	Ser
1				5					10		

(2) INFORMATION FOR SEQ ID NO: 10:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 12 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

SUBSTITUTE SHEET (RULE 26)

118

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

Glu Val Pro Val Pro Pro Pro Val Pro Pro Arg Arg
1 5 10

(2) INFORMATION FOR SEQ ID NO: 11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 11 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

His Leu Asp Ser Pro Pro Ala Ile Pro Pro Arg
1 5 10

(2) INFORMATION FOR SEQ ID NO: 12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 11 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

His Ser Ile Ala Gly Pro Pro Val Pro Pro Arg
1 5 10

(2) INFORMATION FOR SEQ ID NO: 13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 13 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

Tyr Arg Ala Val Pro Pro Pro Leu Pro Pro Arg Arg Lys
1 5 10

SUBSTITUTE SHEET (RULE 26)

(2) INFORMATION FOR SEQ ID NO: 14:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 13 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

Gly Glu Leu Ser Pro Pro Pro Ile Pro Pro Arg Leu Asn
1 5 10

(2) INFORMATION FOR SEQ ID NO: 15:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

Ala Pro Ala Val Pro Pro Ala Arg Pro Gly Ser
1 5 10

(2) INFORMATION FOR SEQ ID NO: 16:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

Pro Ala Val Pro Pro Ala Arg Pro
1 5

(2) INFORMATION FOR SEQ ID NO: 17:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 11 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

120

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

Pro	Pro	Arg	Pro	Leu	Pro	Val	Ala	Pro	Gly	Ser
1			5						10	

(2) INFORMATION FOR SEQ ID NO: 18:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 10 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

Pro	Ala	Pro	Ala	Pro	Pro	Lys	Pro	Pro	Lys
1			5						10

(2) INFORMATION FOR SEQ ID NO: 19:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 13 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

Pro	Pro	Asp	Asn	Gly	Pro	Pro	Pro	Leu	Pro	Thr	Ser	Ser
1				5								10

(2) INFORMATION FOR SEQ ID NO: 20:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 13 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

Pro	Pro	Gln	Met	Pro	Leu	Pro	Glu	Ile	Pro	Gln	Gln	Trp
1				5								10

(2) INFORMATION FOR SEQ ID NO: 21:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 13 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

SUBSTITUTE SHEET (RULE 26)

121

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

Ala	Pro	Thr	Met	Pro	Pro	Pro	Leu	Pro	Pro	Val	Pro	Pro
1				5				10				

(2) INFORMATION FOR SEQ ID NO: 22:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 12 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

Phe	Pro	Ala	Tyr	Pro	Pro	Pro	Pro	Val	Pro	Val	Pro
1				5				10			

(2) INFORMATION FOR SEQ ID NO: 23:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 28 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

Leu	Leu	Phe	Leu	Leu	Ser	Thr	Tyr	Lys	Gln	Lys	Leu	Arg	Gln	Leu	Lys
1				5				10						15	
Lys	Asp	Gln	Lys	Lys	Leu	Glu	Gln	Leu	Pro	Thr	Ser				
			20					25							

(2) INFORMATION FOR SEQ ID NO: 24:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 28 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

Glu	Thr	Val	Asn	Val	Asn	Lys	Leu	Lys	Thr	Glu	Asn	Lys	Gln	Leu	Lys
1				5				10						15	
Lys	Glu	Val	Asp	Lys	Leu	Thr	Asn	Gly	Pro	Ala	Thr				
			20					25							

SUBSTITUTE SHEET (RULE 26)

122

(2) INFORMATION FOR SEQ ID NO: 25:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10443 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: circular

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "plasmid"

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:

```

GGCCGCCGCC ATGACGACGT CAAATGTAGA ATTGATACCA ATCTACACGG ATTGGGCCAA      60
TCGGCACCTT TCGAAGGGCA GCTTATCAAA GTCGATTAGG GATATTTCCA ATGATTTTCG      120
CGACTATCGA CTGGTTTCTC AGCTTATTAA TGTGATCGTT CCGATCAACG AATTCTCGCC      180
TGCATTACAG AAACGTTTGG CAAAAATCAC ATCGAACCTG GATGGCCTCG AAACGTGTCT      240
CGACTACCTG AAAAATCTGG GTCTCGACTG CTCGAAACTC ACCAAAACCG ATATCGACAG      300
CGGAAACTTG GGTGCAGTTC TCCAGCTGCT CTTCTGCTC TCCACCTACA AGCAGAAGCT      360
TCGGCAACTG AAAAAGATC AGAAGAAATT GGAGCAACTA CCCACATCCA TTATGCCACC      420
CGCGGTTTCT AAATTACCTT CGCCACGTGT CGCCACGTCA GCAACCGCTT CAGCAACTAA      480
CCCAAATTCC AACTTTCCAC AAATGTCAAC ATCCAGGCTT CAGACTCCAC AGTCAAGAAT      540
ATCGAAAATT GATTCATCAA AGATTGGTAT CAAGCCAAAG ACGTCTGGAC TTAAACCACC      600
CTCATCATCA ACCACTTCAT CAAATAATAC AAATTCATTC CGTCCGTCGA GCCGTTGAG      660
TGGCAATAAT AATGTTGGCT CGACGATATC CACATCTGCG AAGAGCTTAG AATCATCATC      720
AACGTACAGC TCTATTTCTG ATCTAAACCG ACCTACCTCC CAACTCCAAA AACCTTCTAG      780
ACCACAAACC CAGCTAGTTC GTGTTGCTAC AACTACAAA ATCGGAAGCT CAAAGCTAGC      840
CGCTCCGAAA GCCGTGAGCA CCCCAAACCT TGCTTCTGTG AAGACTATTG GAGCAAAACA      900
AGAGCCCGAT AACAGCGGTG GTGGTGGTGG TGAATGCTG AAATTAAAGT TATTCAGTAG      960
CAAAAACCCA TCTTCCTCAT CGAATAGCCC ACAACCTACG AGAAAGGCGG CGGCGGTGCC     1020
TCAACAACAA ACTTTGTCGA AAATCGCTGC CCCAGTGAAA AGTGGCCTGA AGCCGCCGAC     1080
CAGTAAGCTG GGAAGTGCCA CGTCTATGTC GAAGCTTTGT ACGCCAAAAG TTTCCTACCG     1140
TAAAACGGAC GCCCAATCA TATCTCAACA AGACTCGAAA CGATGCTCAA AGAGCAGTGA     1200
AGAAGAGTCC GGATACGCTG GATTCAACAG CACGTCGCCA ACGTCATCAT CGACGGAAGG     1260
TTCCCTAAGC ATGCATTCCA CATCTTCCAA GAGTTCAACG TCAGACGAAA AGTCTCCGTC     1320
ATCAGACGAT CTTACTCTTA ACGCTCCAT CGTGACAGCT ATCAGACAGC CGATAGCCGC     1380
AACACCGGTT TCTCCAAATA TTATCAACAA GCCTGTTGAG GAAAACCAA CACTGGCAGT     1440

```

SUBSTITUTE SHEET (RULE 26)

GAAAGGAGTG AAAAGCACAG CGAAAAAGA TCCACCTCCA GCTGTTCCGC CACGTGACAC	1500
CCAGCCAACA ATCGGAGTTG TTAGTCCAAT TATGGCACAT AAGAAGTTGA CAAATGACCC	1560
CGTGATATCT GAAAAACCAG AACCTGAAAA GCTCCAATCA ATGAGCATCG ACACGACGGA	1620
CGTTCCACCG CTTCCACCTC TAAATCAGT TGTTCACCTT AAAATGACTT CAATCCGACA	1680
ACCACCAACG TACGATGTTT TTCTAAAACA AGGAAAAATC ACATCGCCTG TCAAGTCGTT	1740
TGGATATGAG CAGTCGTCCG CGTCTGAAGA CTCCATTGTG GTCATGCGT CGGCTCAGGT	1800
GA TCCGCCG ACAA AACTT CTGGTAATCA TTCGCTGGAG AGAAGGATGG GAAAGAATAA	1860
GACATCAGAA TCCAGCGGCT ACACCTCTGA CGCCGGTGTT GCGATGTGCG CCAAATGAG	1920
GGAGAAGCTG AAAGAATACG ATGACATGAC TCGTCGAGCA CAGAACGGCT ATCCTGACAA	1980
CTTCGAAGAC AGTTCCTCCT TGTCTCTGG AATATCCGAT AACACGAGC TCGACGACAT	2040
ATCCACGGAC GATTGTCCG GAGTAGACAT GGCAACAGTC GCCTCCAAAC ATAGCGACTA	2100
TTCCCACTTT GTTCGCCATC CCAGTCTTC TTCTCAAAG CCCCAGTCC CCAGTCGGTC	2160
CTCCACATCA GTCGATTCTC GATCTCGAGC AGAACAGGAG AATGTGTACA AACTTCTGTC	2220
CCAGTGCCGA ACGAGCCAAC GTGGCGCCGC TGCCACCTCA ACCTTCGGAC AACATTGCT	2280
AAGATCCCCG GGATACTCAT CCTATTCTCC ACACTTATCA GTGTCAGCTG ATAAGGACAC	2340
AATGTCTATG CACTCACAGA CTAGTCGACG ACCTTCTTCA CAAAAACCA GCTATTCAGG	2400
CCAAATTTCAT TCACTTGATC GTAAATGCCA CCTTCAAGAG TTCACATCCA CCGAGCACAG	2460
AATGGCGGCT CTCTTGAGCC CGAGACGGGT GCCGAACCTG ATGTCGAAAT ATGATTCTTC	2520
AGGATCCTAC TCGGCGCGTT CCCGAGGTGG AAGCTCTACT GGTATCTATG GAGAGACGTT	2580
CCAACTGCAC AGACTATCCG ATGAAAAATC CCCCACAT TCTGCCAAA GTGAGATGGG	2640
ATCCCAACTA TCACTGGCTA GCACGACAGC ATATGGATCT CTCAATGAGA AGTACGAACA	2700
TGCTATTCCG GACATGGCAC GTGACTTGGA GTGTTACAAG AACACTGTCG ACTCACTAAC	2760
CAAGAAACAG GAGAACTATG GAGCATTGTT TGATCTTTTT GAGCAAAGC TTAGAAAAC	2820
CACTCAACAC ATTGATCGAT CCAACTTGAA GCCTGAAGAG GCAATACGAT TCAGGCAGGA	2880
CATTGCTCAT TTGAGGGATA TTAGCAATCA TCTTGCATCC AACTCAGCTC ATGCTAACGA	2940
AGGCGCTGGT GAGCTTCTTC GTCAACCATC TCTGGAATCA GTTGCATCCC ATCGATCATC	3000
GATGTCATCG TCGTCGAAA GCAGCAAGCA GGAGAAGATC AGCTTGAGCT CGTTTGCCAA	3060
GAACAAGAAG AGCTGGATCC GCTCCTCACT CTCCAAGTTC ACCAAGAAGA AGAACAAGAA	3120
CTACGACGAA GCACATATGC CATCAATTTT CGGATCTCAA GGAACCTTTG ACAACATTGA	3180
TGTGATTGAG TTGAAGCAAG AGCTCAAAGA ACGCGATAGT GCACTTTACG AAGTCCGCCT	3240
TGACAATCTG GATCGTGCCC GCGAAGTTGA TGTTCTGAGG GAGACAGTGA ACAAGTTGAA	3300
AACCGAGAAC AAGCAATTAA AGAAAGAAGT GGACAACTC ACCAACGGTC CAGCCACTCG	3360

124

TGCTTCTTCC	CGCGCCTCAA	TTCCAGTTAT	CTACGACGAT	GAGCATGTCT	ATGATGCAGC	3420
GTGTAGCAGT	ACATCAGCTA	GTCAATCTTC	GAAACGATCC	TCTGGCTGCA	ACTCAATCAA	3480
GGTTACTGTA	AACGTGGACA	TCGCTGGAGA	AATCAGTTCG	ATCGTTAACC	CGGACAAAGA	3540
GATAATCGTA	GGATATCTTG	CCATGTCAAC	CAGTCAGTCA	TGCTGGAAAG	ACATTGATGT	3600
TTCTATTCTA	GGACTATTTG	AAGTCTACCT	ATCCAGAATT	GATGTGGAGC	ATCAACTTGG	3660
AATCGATGCT	CGTGATTCTA	TCCTTGGCTA	TCAAATTGGT	GAACTTCGAC	GCGTCATTGG	3720
AGACTCCACA	ACCATGATAA	CCAGCCATCC	AACTGACATT	CTTACTTCCT	CAACTACAAT	3780
CCGAATGTTC	ATGCACGGTG	CCGCACAGAG	TCGCGTAGAC	AGTCTGGTCC	TTGATATGCT	3840
TCTTCCAAAG	CAAATGATTG	TCCAACTCGT	CAAGTCAATT	TTGACAGAGA	GACGTCTGGT	3900
GTTAGCTGGA	GCAACTGGAA	TTGGAAAGAG	CAAAGTGGCG	AAGACCCTGG	CTGCTTATGT	3960
ATCTATTCEA	ACAAATCAAT	CCGAAGATAG	TATTGTTAAT	ATCAGCATTC	CTGAAAACAA	4020
TAAAGAAGAA	TTGCTTCAAG	TGGAACGACG	CCTGGAAAAG	ATCTTGAGAA	GCAAAGAATC	4080
ATGCATCGTA	ATTCTAGATA	ATATCCCAAA	GAATCGAATT	GCATTTGTTG	TATCCGTTTT	4140
TGCAAATGTC	CCACTTCAAA	ACAACGAAGG	TCCATTTGTA	GTATGCACAG	TCAACCGATA	4200
TCAAATCCCT	GAGCTTCAAA	TTCACCACAA	TTTCAAATG	TCAGTAATGT	CGAATCGTCT	4260
CGAAGGATTC	ATCCTACGTT	ACCTCCGACG	ACGGGCGGTA	GAGGATGAGT	ATCGTCTAAC	4320
TGTACAGATG	CCATCAGAGC	TCTTCAAAAT	CATTGACTTC	TTCCCAATAG	CTCTTCAGGC	4380
CGTCAATAAT	TTTATTGAGA	AAACGAATTC	TGTTGATGTG	ACAGTTGGTC	CAAGAGCATG	4440
CTTGAAGTGT	CCTCTAACTG	TCGATGGATC	CCGTGAATGG	TTCATTGATG	TGTGGAATGA	4500
GAACTTCATT	CCATATTTGG	AACGTGTTGC	TAGAGATGGC	AAAAAAACCT	TCGGTCGCTG	4560
CACTTCCTTC	GAGGATCCCA	CCGACATCGT	CTCTAAAAAA	TGGCCGTGGT	TCGATGGTGA	4620
AAACCCGGAG	AATGTGCTCA	AACGTCTTCA	ACTCCAAGAC	CTCGTCCCGT	CACCTGCCAA	4680
CTCATCCCGA	CAACACTTCA	ATCCCTCGA	GTCGTTGATC	CAATTGCATG	CTACCAAGCA	4740
TCAGACCATC	GACAACATTT	GAACAGAAGA	CTCTAATCTT	CTCTCGCCTC	TCCCCCGCTT	4800
TCCTTATCTT	CGTACCGGTA	CCTGATGATT	CCCCATTTTC	CCCCTTTTCC	CCCCAATTTT	4860
CCAGAACCTC	CTGTTCCCTT	TGTTCCTAGT	CCTCCCGGGT	GCCGACGCCG	AAGCGATTTA	4920
AAAACCTTTT	TCTTTCCGAA	ACATTTCCTA	TTGCTCATTG	ATAGTCAAAT	TGAATAAACA	4980
GTGTATGTAC	TTAAAAAAA	AAAAAAA	ACTCGAGGGG	GGGCCCTATT	CTATAGTGTC	5040
ACCTAAATGC	TAGAGCTCGC	TGATCAGCCT	CGACTGTGCC	TTCTAGTTGC	CAGCCATCTG	5100
TTGTTTGCCC	CTCCCCCGTG	CCTTCCTTGA	CCCTGGAAGG	TGCCACTCCC	ACTGTCCTTT	5160
CCTAATAAAA	TGAGGAAATT	GCATCGCATT	GTCTGAGTAG	GTGTCATTCT	ATTCTGGGGG	5220
GTGGGGTGGG	GCAGGACAGC	AAGGGGAGG	ATTGGGAAGA	CAATAGCAGG	CATGCTGGGG	5280

SUBSTITUTE SHEET (RULE 26)

125

ATGCGGTGGG CTCTATGGCT TCTGAGGCGG AAAGAACCAG CTGGGGCTCT AGGGGGTATC	5340
CCACGCGGCC CTGTAGCGGC GCATTAAGCG CGGCGGGTGT GGTGGTTACG CGCAGCGTGA	5400
CCGCTACACT TGCCAGCGCC CTAGCGCCCG CTCCTTTCGC TTTCTTCCCT TCCTTTCCTG	5460
CCACGTTTCG CGGCTTTCCC CGTCAAGCTC TAAATCGGGG CATCCCTTTA GGGTTCCGAT	5520
TTAGTGCTTT ACGGCACCTC GACCCCAAAA AACTTGATTA GGGTGATGGT TCACGTAGTG	5580
GGCCATCGCC CTGATAGACG GTTTTTCGCC CTTTGACGTT GGAGTCCACG TTCTTTAATA	5640
GTGGACTCTT GTTCCAAACT GGAACAACAC TCAACCCTAT CTCGGTCTAT TCTTTTGATT	5700
TATAAGGGAT TTTGGGGATT TCGGCCTATT GGTAAAAAA TGAGCTGATT TAACAAAAAT	5760
TTACGCGAA TTAATTCTGT GGAATGTGTG TCAGTTAGGG TGTGGAAGT CCCCAGGCTC	5820
CCCAGGCAGG CAGAAGTATG CAAAGCATGC ATCTCAATTA GTCAGCAACC AGGTGTGGAA	5880
AGTCCCCAGG CTCCCCAGCA GGCAGAAGTA TGCAAAGCAT GCATCTCAAT TAGTCAGCAA	5940
CCATAGTCCC GCCCCTAACT CCGCCCATCC CGCCCCTAAC TCCGCCCAGT TCCGCCCAT	6000
CTCCGCCCA TGGCTGACTA ATTTTTTTTA TTTATGCAGA GGCCGAGGCC GCCTCTGCCT	6060
CTGAGCTATT CCAGAAAGTAG TGAGGAGGCT TTTTGGAGG CCTAGGCTTT TGCAAAAAGC	6120
TCCCGGGAGC TTGTATATCC ATTTTCGGAT CTGATCAAGA GACAGGATGA GGATCGTTTC	6180
GCATGATTGA ACAAGATGGA TTGCACGCAG GTTCTCCGGC CGCTTGGGTG GAGAGGCTAT	6240
TCGGCTATGA CTGGGCACAA CAGACAATCG GCTGCTCTGA TGCCGCCGTG TTCCGGCTGT	6300
CAGCGCAGGG GCGCCCGGTT CTTTTTGTCA AGACCGACCT GTCCGGTGCC CTGAATGAAC	6360
TGCAGGACGA GGCAGCGCGG CTATCGTGGC TGGCCACGAC GGGCGTTCCT TGCAGCTG	6420
TGCTCGACGT TGCTACTGAA GCGGGAAGGG ACTGGCTGCT ATTGGGCGAA GTGCCGGGGC	6480
AGGATCTCCT GTCATCTCAC CTGCTCCTG CCGAGAAAGT ATCCATCATG GCTGATGCAA	6540
TGCGGCGGCT GCATACGCTT GATCCGGCTA CCTGCCCAT TCGACCACCA GCGAAACATC	6600
GCATCGAGCG AGCACGTA CTGATGGAAG CCGGTCTTGT CGATCAGGAT GATCTGGACG	6660
AAGAGCATCA GGGGCTCGCG CCAGCCGAAC TGTTCGCCAG GCTCAAGGCG CGCATGCCCG	6720
ACGGCGAGGA TCTCGTCGTG ACCCATGGCG ATGCCTGCTT GCCGAATATC ATGGTGGA	6780
ATGGCCGCTT TTCTGGATT CACTGACTGT GCCGGCTGGG TGTGGCGGAC CGCTATCAGG	6840
ACATAGCGTT GGCTACCCGT GATATTGCTG AAGAGCTTGG CGGCGAATGG GCTGACCGCT	6900
TCCTCGTGCT TTACGGTATC GCCGCTCCCG ATTCGACGCG CATCGCCTTC TATCGCCTTC	6960
TTGACGAGTT CTCTGAGCG GGA CTCTGGG GTTCGAAATG ACCGACCAAG CGACGCCCAA	7020
CCTGCCATCA CGAGATTTTCG ATTCCACCGC CGCCTTCTAT GAAAGGTTGG GCTTCGGAAT	7080
CGTTTCCGG GACGCCGGCT GGATGATCCT CCAGCGCGGG GATCTCATGC TGGAGTTCTT	7140
CGCCCAACCC AACTTGTTTA TTGCAGCTTA TAATGGTTAC AAATAAGCA ATAGCATCAC	7200

SUBSTITUTE SHEET (RULE 26)

AAATTTTCACA	AATAAAGCAT	TTTTTTCAC	GCATTCTAGT	TGTGGTTTGT	CCAAACTCAT	7260
CAATGTATCT	TATCATGTCT	GTATACCGTC	GACCTCTAGC	TAGAGCTTGG	CGTAATCATG	7320
GTCATAGCTG	TTTCCTGTGT	GAAATTGTTA	TCCGCTCACA	ATTCCACACA	ACATACGAGC	7380
CGGAAGCATA	AAGTGTAAG	CCTGGGGTGC	CTAATGAGTG	AGCTAACTCA	CATTAAATTGC	7440
GTTGCGCTCA	CTGCCCCTT	TCCAGTCGGG	AAACCTGTCG	TGCCAGCTGC	ATTAATGAAT	7500
CGGCCAACGC	GCGGGGAGAG	GCGGTTTGC	TATTGGGCGC	TCTTCCGCTT	CCTCGCTCAC	7560
TGACTCGCTG	CGCTCGGTCG	TTCGGCTGCG	GCGAGCGGTA	TCAGCTCACT	CAAAGGCGGT	7620
AATACGGTTA	TCCACAGAAT	CAGGGGATAA	CGCAGGAAAG	AACATGTGAG	CAAAAGGCCA	7680
GCAAAAGGCC	AGGAACCGTA	AAAAGGCCGC	GTGCTGGCG	TTTTTCCATA	GGCTCCGCCC	7740
CCCTGACGAG	CATCACAAAA	ATCGACGCTC	AAGTCAGAGG	TGGCGAAACC	CGACAGGACT	7800
ATAAAGATAC	CAGGCGTTTC	CCCCTGGAAG	CTCCCTCGTG	CGCTCTCCTG	TTCCGACCCT	7860
GCCGCTTACC	GGATACCTGT	CCGCCTTTCT	CCCTTCGGGA	AGCGTGGCGC	TTTCTCAATG	7920
CTCACGCTGT	AGGTATCTCA	GTTGCGGTGA	GGTCGTTGCG	TCCAAGCTGG	GCTGTGTGCA	7980
CGAACCCCCC	GTTTCAGCCCG	ACCGCTGCGC	CTTATCCGGT	AACTATCGTC	TTGAGTCCAA	8040
CCCGGTAAGA	CACGACTTAT	CGCCACTGGC	AGCAGCCACT	GGTAACAGGA	TTAGCAGAGC	8100
GAGGTATGTA	GGCGGTGCTA	CAGAGTTCTT	GAAGTGGTGG	CCTAACTACG	GCTACACTAG	8160
AAGGACAGTA	TTTGGTATCT	GCGCTCTGCT	GAAGCCAGTT	ACCTTCGGAA	AAAGAGTTGG	8220
TAGCTCTTGA	TCCGGCAAAC	AAACCACCGC	TGGTAGCGGT	GGTTTTTTTG	TTTGCAAGCA	8280
GCAGATTACG	CGCAGAAAAA	AAGGATCTCA	AGAAGATCCT	TTGATCTTTT	CTACGGGGTC	8340
TGACGCTCAG	TGGAACGAAA	ACTCACGTTA	AGGGATTTTG	GTCATGAGAT	TATCAAAAAG	8400
GATCTTCACC	TAGATCCTTT	TAAATTAAAA	ATGAAGTTTT	AAATCAATCT	AAAGTATATA	8460
TGAGTAAACT	TGGTCTGACA	GTTACCAATG	CTTAATCAGT	GAGGCACCTA	TCTCAGCGAT	8520
CTGTCTATTT	CGTTCATCCA	TAGTTGCCTG	ACTCCCCGTC	GTGTAGATAA	CTACGATACG	8580
GGAGGGCTTA	CCATCTGGCC	CCAGTGCTGC	AATGATACCG	CGAGACCCAC	GCTCACCGGC	8640
TCCAGATTTA	TCAGCAATAA	ACCAGCCAGC	CGGAAGGGCC	GAGCGCAGAA	GTGGTCCTGC	8700
AACTTTATCC	GCCTCCATCC	AGTCTATTAA	TTGTTGCCGG	GAAGCTAGAG	TAAGTAGTTC	8760
GCCAGTTAAT	AGTTTGCGCA	ACGTTGTTGC	CATTGCTACA	GGCATCGTGG	TGTCACGCTC	8820
GTCGTTTGGT	ATGGCTTCAT	TCAGCTCCGG	TTCCCAACGA	TCAAGGCGAG	TTACATGATC	8880
CCCCATGTTG	TGCAAAAAAG	CGGTTAGCTC	CTTCGGTCCT	CCGATCGTTG	TCAGAAGTAA	8940
GTTGGCCGCA	GTGTTATCAC	TCATGGTTAT	GGCAGCACTG	CATAATTCTC	TTACTGTGAT	9000
GCCATCCGTA	AGATGCTTTT	CTGTGACTGG	TGAGTACTCA	ACCAAGTCAT	TCTGAGAATA	9060
GTGTATGCGG	CGACCGAGTT	GCTCTTGCCC	GGCGTCAATA	CGGGATAATA	CCGCGCCACA	9120

SUBSTITUTE SHEET (RULE 26)

TAGCAGAACT	TTAAAAGTGC	TCATCATTGG	AAAACGTTCT	TCGGGGCGAA	AACTCTCAAG	9180
GATCTTACCG	CTGTTGAGAT	CCAGTTCGAT	GTAACCCACT	CGTGCACCCA	ACTGATCTTC	9240
AGCATCTTTT	ACTTTCACCA	GCGTTTCTGG	GTGAGCAAAA	ACAGGAAGGC	AAAATGCCGC	9300
AAAAAAGGGA	ATAAGGGCGA	CACGGAAATG	TTGAATACTC	ATACTCTTCC	TTTTTCAATA	9360
TTATTGAAGC	ATTTATCAGG	GTTATTGTCT	CATGAGCGGA	TACATATTTG	AATGTATTTA	9420
GAAAAATAAA	CAATAGGGG	TTCCGCGCAC	ATTTCCCCGA	AAAGTGCCAC	CTGACGTCGA	9480
CGGATCGGGA	GATCTCCCGA	TCCCCTATGG	TCGACTCTCA	GTACAATCTG	CTCTGATGCC	9540
GCATAGTTAA	GCCAGTATCT	GCTCCCTGCT	TGTGTGTTGG	AGGTCGCTGA	GTAGTGCGCG	9600
AGCAAAATTT	AAGCTACAAC	AAGGCAAGGC	TTGACCGACA	ATTGCATGAA	GAATCTGCTT	9660
AGGGTTAGGC	GTTTTGCGCT	GCTTCGCGAT	GTACGGGCCA	GATATACGCG	TTGACATTGA	9720
TTATTGACTA	GTTATTAATA	GTAATCAATT	ACGGGGTCAT	TAGTTCATAG	CCCATATATG	9780
GAGTTCCGCG	TTACATAACT	TACGGTAAAT	GGCCCGCCTG	GCTGACCGCC	CAACGACCCC	9840
CGCCCATTTGA	CGTCAATAAT	GACGTATGTT	CCCATAGTAA	CGCCAATAGG	GACTTTCCAT	9900
TGACGTCAAT	GGGTGGACTA	TTACGGTAA	ACTGCCCACT	TGGCAGTACA	TCAAGTGTAT	9960
CATATGCCAA	GTACGCCCCC	TATTGACGTC	AATGACGGTA	AATGGCCCCG	CTGGCATTAT	10020
GCCCAGTACA	TGACCTTATG	GGACTTTCCT	ACTTGGCAGT	ACATCTACGT	ATTAGTCATC	10080
GCTATTACCA	TGGTGATGCG	GTTTTGGCAG	TACATCAATG	GGCGTGGATA	GCGGTTTGAC	10140
TCACGGGGAT	TTCCAAGTCT	CCACCCCAT	GACGTCAATG	GGAGTTTGTT	TTGGCACCAA	10200
AATCAACGGG	ACTTTCCAA	ATGTCGTAAC	AACTCCGCC	CATTGACGCA	AATGGGCGGT	10260
AGGCGTGTAC	GGTGGGAGGT	CTATATAAGC	AGAGCTCTCT	GGCTAACTAG	AGAACCCACT	10320
GCTTACTGGC	TTATCGAAAT	TAATACGACT	CACTATAGGG	AGACCCAAGC	TTGGTACCGA	10380
GCTCGGATCC	ACTAGTAACG	GCCGCCAGTG	TGCTGGAATT	CTGCAGATAT	CCATCACACT	10440
GGC						10443

(2) INFORMATION FOR SEQ ID NO: 26:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7474 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: circular

(ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "plasmid"

(iii) HYPOTHETICAL: NO

SUBSTITUTE SHEET (RULE 26)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:

CTAAATTGTA AGCGTTAATA TTTTGTAAAA ATTCGCGTTA AATTTTGTGTT AAATCAGCTC	60
ATTTTTTAAC CAATAGGCCG AAATCGGCCAA AATCCCTTAT AAATCAAAAG AATAGACCGA	120
GATAGGGTTG AGTGTGTGTC CAGTTTGGAA CAAGAGTCCA CTATTAAAGA ACGTGGACTC	180
CAACGTCAAA GGGCGAAAAA CCGTCTATCA GGGCGATGGC CCACTACGTG AACCATCACC	240
CTAATCAAGT TTTTGGGGT CGAGGTGCCG TAAAGCACTA AATCGGAACC CTAAAGGGAG	300
CCCCGATTT AGAGCTTGAC GGGGAAAGCC GGGCAACGTG GCGAGAAAGG AAGGGAAGAA	360
AGCGAAAGGA GCGGGCGCTA GGGCGCTGGC AAGTGTAGCG GTCACGCTGC GCGTAACCAC	420
CACACCCGCC GCGCTTAATG CGCCGCTACA GGGCGCGTCC CATTGCCCAT TCAGGCTGCG	480
CAACTGTTGG GAAGGGCGAT CCGTGCGGGC CTCTTCGCTA TTACGCCAGC TGGCGAAAGG	540
GGGATGTGCT GCAAGGCGAT TAAGTTGGGT AACGCCAGGG TTTTCCCAGT CACGACGTTG	600
TAAACGACG GCCAGTGAGC GCGCGTAATA CGACTCACTA TAGGGCGAAT TGGAGCTCCA	660
CCGCGGTTTC TAAATTACCC TCGCCACGTG TCGCCACGTC AGCAACCGCT TCAGCAACTA	720
ACCCAAATTC CAACTTTCCA CAAATGTCAA CATCCAGGCT TCAGACTCCA CAGTCAAGAA	780
TATCGAAAAT TGATTCATCA AAGATTGGTA TCAAGCCAAA GACGTCTGGA CTTAAACCAC	840
CCTCATCATC AACCATTCA TCAAATAATA CAAATTCATT CCGTCCGTCG AGCCGTTCGA	900
GTGGCAATAA TAATGTTGGC TCGACGATAT CCACATCTGC GAAGAGCTTA GAATCATCAT	960
CAACGTACAG CTCTATTTTCG AATCTAAACC GACCTACCTC CCAACTCCAA AAACCTTCTA	1020
GACCACAAAC CCAGCTAGTT CGTGTTGCTA CAACTACAAA AATCGGAAGC TCAAGCTAG	1080
CCGCTCCGAA AGCCGTGAGC ACCCCAAAAC TTGCTTCTGT GAAGACTATT GGAGCAAAAC	1140
AAGAGCCCGA TAACAGCGGT GGTGGTGGTG GTGGAATGCT GAAATTAAAG TTATTCAGTA	1200
GCAAAAACCC ATCTTCTCTCA TCGAATAGCC CACAACCTAC GAGAAAGGCG GCGGCGGTGC	1260
CTCAACAACA AACTTTGTCTG AAAATCGCTG CCCAGTGAA AAGTGGCCTG AAGCCGCCGA	1320
CCAGTAAGCT GGGAAAGTGC ACGTCTATGT CGAAGCTTTG TACGCCAAAA GTTTCCTACC	1380
GTAAACGGA CGCCCCAATC ATATCTCAAC AAGACTCGAA ACGATGCTCA AAGAGCAGTG	1440
AAGAAGAGTC CGGATACGCT GGATTCAACA GCACGTCGCC AACGTCATCA TCGACGGAAG	1500
GTTCCCTAAG CATGCATTCC ACATCTTCCA AGAGTTCAAC GTCAGACGAA AAGTCTCCGT	1560
CATCAGACGA TCTTACTCTT AACGCCTCCA TCGTGACAGC TATCAGACAG CCGATAGCCG	1620
CAACACCGGT TTCTCCAAAT ATTATCAACA AGCCTGTTGA GGAAAACCA ACACTGGCAG	1680
TGAAAGGAGT GAAAAGCACA GCGAAAAAAG ATCCACCTCC AGCTGTTCCG CCACGTGACA	1740
CCCAGCCAAC AATCGGAGTT GTTAGTCCAA TTATGGCACA TAAGAAGTTG ACAAATGACC	1800
CCGTGATATC TGAAAACCA GAACCTGAAA AGCTCCAATC AATGAGCATC GACACGACGG	1860

SUBSTITUTE SHEET (RULE 26)

ACGTTCCACC	GCTTCCACCT	CTAAAATCAG	TTGTTCCACT	TAAAATGACT	TCAATCCGAC	1920
AACCACCAAC	GTACGATGTT	CTTCTAAAAC	AAGGAAAAAT	CACATCGCCT	GTCAAGTCGT	1980
TTGGATATGA	GCAGTCGTCC	GCGTCTGAAG	ACTCCATTGT	GGCTCATGCG	TCGGCTCAGG	2040
TGACTCCGCC	GACAAAAACT	TCTGGTAATC	ATTGCTGGA	GAGAAGGATG	GGAAAGAATA	2100
AGACATCAGA	ATCCAGCGGC	TACACCTCTG	ACGCCGGTGT	TGCGATGTGC	GCCAAAATGA	2160
GGGAGAAGCT	GAAAGAATAC	GATGACATGA	CTCGTCGAGC	ACAGAACGGC	TATCCTGACA	2220
ACTTCGAAGA	CAGTTCCTCC	TTGTCGTCTG	GAATATCCGA	TAACAACGAG	CTCGACGACA	2280
TATCCACGGA	CGATTTGTCC	GGAGTAGACA	TGGCAACAGT	CGCCTCCAAA	CATAGCGACT	2340
ATTCCCACTT	TGTTCGCCAT	CCCACGTCTT	CTTCTCAAA	GCCCCGAGTC	CCCAGTCGGT	2400
CCTCCACATC	AGTCGATTCT	CGATCTCGAG	CAGAACAGGA	GAATGTGTAC	AAACTTCTGT	2460
CCCAGTGCCG	AACGAGCCAA	CGTGGCGCCG	CTGCCACCTC	AACCTTCGGA	CAACATTGCG	2520
TAAGATCCCC	GGGATACTCA	TCCTATTCTC	CACACTTATC	AGTGTGAGCT	GATAAGGACA	2580
CAATGTCTAT	GCACTCACAG	ACTAGTCGAC	GACCTTCTTC	ACAAAAACCA	AGCTATTGAG	2640
GCCAATTTC	TTCATTGAT	CGTAAATGCC	ACCTTCAAGA	GTTACATCC	ACCGAGCACA	2700
GAATGGCGGC	TCTCTTGAGC	CCGAGACGGG	TGCCGAATC	GATGTCGAAA	TATGATTCTT	2760
CAGGATCCTA	CTCGGCGCGT	TCCCGAGGTG	GAAGCTCTAC	TGGTATCTAT	GGAGAGACGT	2820
TCCAACGCA	CAGACTATCC	GATGAAAAAT	CCCCCGCACA	TTCTGCCAAA	AGTGAGATGG	2880
GATCCCAACT	ATCACTGGCT	AGCACGACAG	CATATGGATC	TCTCAATGAG	AAGTACGAAC	2940
ATGCTATTTC	GGACATGGCA	CGTGACTTGG	AGTGTTACAA	GAACACTGTC	GACTCACTAA	3000
CCAAGAAACA	GGAGAACTAT	GGAGCATTGT	TTGATCTTTT	TGAGCAAAAG	CTTAGAAAAC	3060
TCACTCAACA	CATTGATCGA	TCCAACCTGA	AGCCTGAAGA	GGCAATACGA	TTCAGGCAGG	3120
ACATTGCTCA	TTTGAGGGAT	ATTAGCAATC	ATCTTGCATC	CAACTCAGCT	CATGCTAACG	3180
AAGGCGCTGG	TGAGCTTCTT	CGTCAACCAT	CTCTGGAATC	AGTTGCATCC	CATCGATCAT	3240
CGATGTCATC	GTCGTCGAAA	AGCAGCAAGC	AGGAGAAGAT	CAGCTTGAGC	TCGTTTGGCA	3300
AGAACAAGAA	GAGCTGGATC	CGCTCCTCAC	TCTCCAAGTT	CACCAAGAAG	AAGAACAAGA	3360
ACTACGACGA	AGCACATATG	CCATCAATTT	CCGGATCTCA	AGGAACTCTT	GACAACATTG	3420
ATGTGATTGA	GTTGAAGCAA	GAGCTCAAAG	AACGCGATAG	TGCACTTTAC	GAAGTCCGCC	3480
TTGACAATCT	GGATCGTGCC	CGCGAAGTTG	ATGTTCTGAG	GGAGACAGTG	AACAAGTTGA	3540
AAACCGAGAA	CAAGCAATTA	AAGAAAGAAG	TGGACAAACT	CACCAACGGT	CCAGCCACTC	3600
GTGCTTCTTC	CCGCGCCTCA	ATTCCAGTTA	TCTACGACGA	TGAGCATGTC	TATGATGCAG	3660
CGTGATAGCAG	TACATCAGCT	AGTCAATCTT	CGAAACGATC	CTCTGGCTGC	AACTCAATCA	3720
AGGTTACTGT	AAACGTGGAC	ATCGCTGGAG	AAATCAGTTC	GATCGTTAAC	CCGACAAAG	3780

SUBSTITUTE SHEET (RULE 26)

AGATAATCGT	AGGATATCTT	GCCATGTCAA	CCAGTCAGTC	ATGCTGGAAA	GACATTGATG	3840
TTTCTATTCT	AGGACTATTT	GAAGTCTACC	TATCCAGAAT	TGATGTGGAG	CATCAACTTG	3900
GAATCGATGC	TCGTGATTCT	ATCCTTGGCT	ATCAAATTGG	TGAACTTCGA	CGCGTCATTG	3960
GAGACTCCAC	AACCATGATA	ACCAGCCATC	CAACTGACAT	TCTTACTTCC	TCAACTACAA	4020
TCCGAATGTT	CATGCACGGT	GCCGCACAGA	GTCGCGTAGA	CAGTCTGGTC	CTTGATATGC	4080
TTCTTCCAAA	GCAAATGATT	CTCCAACTCG	TCAAGTCAAT	TTTGACAGAG	AGACGTCTGG	4140
TGTTAGCTGG	AGCAACTGGA	ATTGGAAAGA	GCAAACTGGC	GAAGACCCTG	GCTGCTTATG	4200
TATCTATTCT	AACAAATCAA	TCCGAAGATA	GTATTGTAA	TATCAGCATT	CCTGAAAACA	4260
ATAAAGAAGA	ATTGCTTCAA	GTGGAACGAC	GCCTGGAAAA	GATCTTGAGA	AGCAAAGAAT	4320
CATGCATCGT	AATTCTAGAT	AATATCCCAA	AGAATCGAAT	TGCATTGTGT	GTATCCGTTT	4380
TTGCAAATGT	CCCACTTCAA	AACAACGAAG	GTCCATTGTG	AGTATGCACA	GTCAACCGAT	4440
ATCAAATCCC	TGAGCTTCAA	ATTCAACACA	ATTTCAAAAT	GTCAGTAATG	TCGAATCGTC	4500
TCGAAGGATT	CATCCTACGT	TACCTCCGAC	GACGGGCGGT	AGAGGATGAG	TATCGTCTAA	4560
CTGTACAGAT	GCCATCAGAG	CTCTTCAAAA	TCATTGACTT	CTTCCCAATA	GCTCTTCAGG	4620
CCGTCAATAA	TTTTATTGAG	AAAACGAATT	CTGTTGATGT	GACAGTTGGT	CCAAGAGCAT	4680
GCTTGAAC TG	TCCTCTAACT	GTGATGGAT	CCCGTGAATG	GTTCATTCGA	TTGTGGAATG	4740
AGAACTTCAT	TCCATATTTG	GAACGTGTG	CTAGAGATGG	CAAAAAAACC	TTCGGTCGCT	4800
GCACTTCCTT	CGAGGATCCC	ACCGACATCG	TCTCTAAAAA	ATGGCCGTGG	TTCGATGGTG	4860
AAAACCCGGA	GAATGTGCTC	AAACGTCTTC	AACTCCAAGA	CCTCGTCCCG	TCACCTGCCA	4920
ACTCATCCCG	ACAACACTTC	AATCCCCTCG	AGTCGTTGAT	CCAATTGCAT	GCTACCAAGC	4980
ATCAGACCAT	CGACAACATT	TGAACAGAAG	ACTCTAATCT	TCTCTCGCCT	CTCCCCGCT	5040
TTCTTATCT	TCGTACCGGT	ACCTGATGAT	TCCCCATTTT	CCCCCTTTTC	CCCCCAATTT	5100
CCCAGAACCT	CCTGTTCCCT	TTGTTCCTAG	TCCTCCCGGG	TGCCGACGCC	GAAGCGATTT	5160
AAAAACCTTT	TTCTTTCCGA	AACATTTCCC	ATTGCTCATT	AATAGTCAAA	TTGAATAAAC	5220
AGTGTATGTA	CTTAAAAAAA	AAAAAAAAAA	AACTCGAGGG	GGGGCCCGGT	AACCAGCTTT	5280
TGTTCCCTTT	AGTGAGGGTT	AATTGCGCGC	TTGGCGTAAT	CATGGTCATA	GCTGTTTCCT	5340
GTGTGAAATT	GTTATCCGCT	CACAATTCCA	CACAACATAC	GAGCCGGAAG	CATAAAGTGT	5400
AAAGCCTGGG	GTGCCTAATG	AGTGAGCTAA	CTCACATTAA	TTGCGTTGCG	CTCACTGCCC	5460
GCTTTCCAGT	CGGGAAACCT	GTCGTGCCAG	CTGCATTAA	GAATCGGCCA	ACGCGCGGGG	5520
AGAGGCGGTT	TGCGTATTGG	GCGCTCTTCC	GCTTCCTCGC	TCACTGACTC	GCTGCGCTCG	5580
GTCGTTCCGG	TGCGGCGAGC	GGTATCAGCT	CACTCAAAGG	CGGTAATACG	GTTATCCACA	5640
GAATCAGGGG	ATAACGCAGG	AAAGAACATG	TGAGCAAAAG	GCCAGCAAAA	GGCCAGGAAC	5700

SUBSTITUTE SHEET (RULE 26)

CGTAAAAAGG	CCGCCTTGCT	GGCGTTTTTC	CATAGGCTCC	GCCCCCTGA	CGAGCATCAC	5760
AAAAATCGAC	GCTCAAGTCA	GAGGTGGCGA	AACCCGACAG	GA CTATAAAG	ATACCAGGCG	5820
TTTCCCCCTG	GAAGCTCCCT	CGTGCGCTCT	CCTGTTCCGA	CCCTGCCGCT	TACCGGATAC	5880
CTGTCCGCCT	TTCTCCCTTC	GGGAAGCGTG	GCGCTTTCTC	ATAGCTCAGG	CTGTAGGTAT	5940
CTCAGTTCGG	TGTAGGTCGT	TCGCTCCAAG	CTGGGCTGTG	TGCACGAACC	CCCCGTTTCTCAG	6000
CCCGACCGCT	GCGCCTTATC	CGGTAAGTAT	CGTCTTGAGT	CCAACCCGGT	AAGACACGAC	6060
TTATCGCCAC	TGGCAGCAGC	CACTGGTAAC	AGGATTAGCA	GAGCGAGGTA	TGTAGGCGGT	6120
GCTACAGAGT	TCTTGAAGTG	GTGGCCTAAC	TACGGCTACA	CTAGAAGGAC	AGTATTTGGT	6180
ATCTGCGCTC	TGCTGAAGCC	AGTTACCTTC	GGAAAAAGAG	TTGGTAGCTC	TTGATCCGGC	6240
AAACAAACCA	CCGCTGGTAG	CGGTGGTTTT	TTTGTTTGCA	AGCAGCAGAT	TACGCGCAGA	6300
AAAAAAGGAT	CTCAAGAAGA	TCCTTTGATC	TTTTCTACGG	GGTCTGACGC	TCAGTGGAAC	6360
GAAACTCAC	GTTAAGGGAT	TTTGGTCATG	AGATTATCAA	AAAGGATCTT	CACCTAGATC	6420
CTTTTAAATT	AAAAATGAAG	TTTTAAATCA	ATCTAAAGTA	TATATGAGTA	AACTTGGTCT	6480
GACAGTTACC	AATGCTTAAT	CAGTGAGGCA	CCTATCTCAG	CGATCTGTCT	ATTTTCGTTCA	6540
TCCATAGTTG	CCTGACTCCC	CGTCGTGTAG	ATAACTACGA	TACGGGAGGG	CTTACCATCT	6600
GGCCCCAGTG	CTGCAATGAT	ACCGCGAGAC	CCACGCTCAC	CGGCTCCAGA	TTTATCAGCA	6660
ATAAACCAGC	CAGCCGGAAG	GGCCGAGCGC	AGAAGTGGTC	CTGCAACTTT	ATCCGCCTCC	6720
ATCCAGTCTA	TTAATTGTTG	CCGGGAAGCT	AGAGTAAGTA	GTTCGCCAGT	TAATAGTTTG	6780
CGCAACGTTG	TTGCCATTGC	TACAGGCATC	GTGGTGTAC	GCTCGTCGTT	TGGTATGGCT	6840
TCATTTCAGCT	CCGGTTCCCA	ACGATCAAGG	CGAGTTACAT	GATCCCCCAT	GTTGTGCAAA	6900
AAAGCGGTTA	GCTCCTTCGG	TCCTCCGATC	GTTGTGAGAA	GTAAGTTGGC	CGCAGTGTTA	6960
TCACTCATGG	TTATGGCAGC	ACTGCATAAT	TCTCTTACTG	TCATGCCATC	CGTAAGATGC	7020
TTTTCTGTGA	CTGGTGAGTA	CTCAACCAAG	TCATTCTGAG	AATAGTGTAT	GCGGCGACCG	7080
AGTTGCTCTT	GCCCCGCGTC	AATACGGGAT	AATACCGCGC	CACATAGCAG	AACTTTAAAA	7140
GTGCTCATCA	TTGGAAAACG	TTCTTCGGGG	CGAAAACCTCT	CAAGGATCTT	ACCGCTGTTG	7200
AGATCCAGTT	CGATGTAACC	CACTCGTGCA	CCCAACTGAT	CTTCAGCATC	TTTTACTTTC	7260
ACCAGCGTTT	CTGGGTGAGC	AAAAACAGGA	AGGCAAAATG	CCGCAAAAAA	GGGAATAAGG	7320
GCGACACGGA	AATGTTGAAT	ACTCATACTC	TTCTTTTTTC	AATATTATTG	AAGCATTTAT	7380
CAGGGTTATT	GTCTCATGAG	CGGATACATA	TTTGAATGTA	TTTAGAAAAA	TAAACAAATA	7440
GGGGTTCCGC	GCACATTTCC	CCGAAAAGTG	CCAC			7474

132

(2) INFORMATION FOR SEQ ID NO: 27:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 13414 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: circular

(ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "plasmid"

(iii) HYPOTHETICAL: NO

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION: 11582
- (D) OTHER INFORMATION: /note= "N is A,G,C or T"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:

TATGACGACG TCAAATGTAG AATTGATACC ATTCTACACG GATTGGGCCA ATCGGCACCT	60
TTCGAAGGGC AGCTTATCAA AGTCGATTAG GGATATTTCC AATGATTTTC GCGACTATCG	120
ACTGGTTTCT CAGCTTATTA ATGTGATCGT TCCGATCAAC GAATTCTCGC CTGCATTAC	180
GAAACGTTTG GCAAAAATCA CATCGAACCT GGATGGCCTC GAAACGTGTC TCGACTACCT	240
GAAAAATCTG GGTCTCGACT GCTCGAACT CACCAAAACC GATATCGACA GCGGAACTT	300
GGGTGCAGTT CTCCAGCTGC TCTTCTGCT CTCCACCTAC AAGCAGAAGC TTCGGCAACT	360
GAAAAAAGAT CAGAAGAAAT TGGAGCAACT ACCCACATCC ATTATGCCAC CCGCGGTTTC	420
TAAATTACCC TCGCCACGTG TCGCCACGTC AGCAACCGCT TCAGCAACTA ACCCAAATTC	480
CAACTTTCCA CAAATGTCAA CATCCAGGCT TCAGACTCCA CAGTCAAGAA TATCGAAAAT	540
TGATTCATCA AAGATTGGTA TCAAGCCAAA GACGTCTGGA CTAAACCAC CCTCATCATC	600
AACCACTTCA TCAAATAATA CAAATTCATT CCGTCCGTCG AGCCGTTTCA GTGGCAATAA	660
TAATGTTGGC TCGACGATAT CCACATCTGC GAAGAGCTTA GAATCATCAT CAACGTACAG	720
CTCTATTTTCG AATCTAAACC GACCTACCTC CCAACTCCAA AAACCTTCTA GACCACAAAC	780
CCAGCTAGTT CGTGTGCTA CAACTACAAA AATCGGAAGC TCAAAGCTAG CCGCTCCGAA	840
AGCCGTGAGC ACCCCAAAAC TTGCTTCTGT GAAGACTATT GGAGCAAAAC AAGAGCCCGA	900
TACAGCGGT GGTGGTGGTG GTGGAATGCT GAAATTAAAG TTATTAGTA GCAAAAACCC	960
ATCTTCCTCA TCGAATAGCC CACAACCTAC GAGAAAGGCG GCGGCGGTGC CTCACAACA	1020
AACTTTGTGCG AAAATCGCTG CCCCAGTGAA AAGTGGCCTG AAGCCGCCGA CCAGTAAGCT	1080
GGGAAGTGCC ACGTCTATGT CGAAGCTTTG TACGCCAAA GTTTCCTACC GTAAAACGGA	1140
CGCCCCAATC ATATCTCAAC AAGACTCGAA ACGATGCTCA AAGAGCAGTG AAGAAGAGTC	1200
CGGATACGCT GGATTCAACA GCACGTCGCC AACGTCATCA TCGACGGAAG GTTCCCTAAG	1260

SUBSTITUTE SHEET (RULE 26)

CATGCATTCC	ACATCTTCCA	AGAGTTCAAC	GTCAGACGAA	AAGTCTCCGT	CATCAGACGA	1320
TCTTACTCTT	AACGCCTCCA	TCGTGACAGC	TATCAGACAG	CCGATAGCCG	CAACACCGGT	1380
TTCTCCAAAT	ATTATCAACA	AGCCTGTTGA	GGAAAAACCA	ACACTGGCAG	TGAAAGGAGT	1440
GAAAAGCACA	GCGAAAAAAG	ATCCACCTCC	AGCTGTTCCG	CCACGTGACA	CCCAGCCAAC	1500
AATCGGAGTT	GTTAGTCCAA	TTATGGCACA	TAAGAAGTTG	ACAAATGACC	CCGTGATATC	1560
TGAAAAACCA	GAACCTGAAA	AGCTCCAATC	AATGAGCATC	GACACGACGG	ACGTTCCACC	1620
GCTTCCACCT	CTAAAATCAG	TTGTTCCACT	TAAAATGACT	TCAATCCGAC	AACCACCAAC	1680
GTACGATGTT	CTTCTAAAAC	AAGGAAAAAT	CACATCGCCT	GTCAAGTCGT	TTGGATATGA	1740
GCAGTCGTCC	GCGTCTGAAG	ACTCCATTGT	GGCTCATGCG	TCGGCTCAGG	TGACTCCGCC	1800
GACAAAAACT	TCTGGTAATC	ATTGCTGGA	GAGAAGGATG	GGAAAGAATA	AGACATCAGA	1860
ATCCAGCGGC	TACACCTCTG	ACGCCGGTGT	TGCGATGTGC	GCCAAAATGA	GGGAGAAGCT	1920
GAAAGAATAC	GATGACATGA	CTCGTCGAGC	ACAGAACGGC	TATCCTGACA	ACTTCGAAGA	1980
CAGTTCCTCC	TTGTCGTCTG	GAATATCCGA	TAACAACGAG	CTCGACGACA	TATCCACGGA	2040
CGATTTGTCC	GGAGTAGACA	TGGCAACAGT	CGCTCCAAA	CATAGCGACT	ATTCCCCTT	2100
TGTTGCGCAT	CCCACGTCTT	CTTCCTCAAA	GCCCCGAGTC	CCCAGTCGGT	CCTCCACATC	2160
AGTCGATTCT	CGATCTCGAG	CAGAACAGGA	GAATGTGTAC	AACTTCTGT	CCCAGTGCCG	2220
AACGAGCCAA	CGTGCGCGCG	CTGCCACCTC	AACCTTCGGA	CAACATTCGC	TAAGATCCCC	2280
GGGATACTCA	TCCTATTCTC	CACACTTATC	AGTGTCAGCT	GATAAGGACA	CAATGTCTAT	2340
GCACTCACAG	ACTAGTCGAC	GACCTTCTTC	ACAAAAACCA	AGCTATTGAG	GCCAATTTCA	2400
TTCACTTGAT	CGTAAATGCC	ACCTTCAAGA	GTTCAATCC	ACCGAGCACA	GAATGGCGGC	2460
TCTCTTGAGC	CCGAGACGGG	TGCCGAACTC	GATGTCGAAA	TATGATTCTT	CAGGATCCTA	2520
CTCGGCGCGT	TCCCGAGGTG	GAAGCTCTAC	TGGTATCTAT	GGAGAGACGT	TCCAACTGCA	2580
CAGACTATCC	GATGAAAAAT	CCCCCGCACA	TTCTGCCAAA	AGTGAGATGG	GATCCCAACT	2640
ATCACTGGCT	AGCACGACAG	CATATGGATC	TCTCAATGAG	AAGTACGAAC	ATGCTATTG	2700
GGACATGGCA	CGTGACTTGG	AGTGTTACAA	GAACACTGTC	GACTCACTAA	CCAAGAAACA	2760
GGAGAACTAT	GGAGCATTGT	TTGATCTTTT	TGAGCAAAAG	CTTAGAAAAC	TCACTCAACA	2820
CATTGATCGA	TCCAACTTGA	AGCCTGAAGA	GGCAATACGA	TTCAGGCAGG	ACATTGCTCA	2880
TTTGAGGGAT	ATTAGCAATC	ATCTTGCATC	CAACTCAGCT	CATGCTAACG	AAGGCGCTGG	2940
TGAGCTTCTT	CGTCAACCAT	CTCTGGAATC	AGTTGCATCC	CATCGATCAT	CGATGTCATC	3000
GTCGTCGAAA	AGCAGCAAGC	AGGAGAAGAT	CAGCTTGAGC	TCGTTTGGCA	AGAACAAGAA	3060
GAGCTGGATC	CGCTCCTCAC	TCTCCAAGTT	CACCAAGAAG	AAGAACAAGA	ACTACGACGA	3120
AGCACATATG	CCATCAATTT	CCGGATCTCA	AGGAACTCTT	GACAACATTG	ATGTGATTGA	3180

GTTGAAGCAA GAGCTCAAAG AACGCGATAG TGCACCTTAC GAAGTCCGCC TTGACAATCT	3240
GGATCGTGCC CGCGAAGTTG ATGTTCTGAG GGAGACAGTG AACAAAGTTGA AAACCGAGAA	3300
CAAGCAATTA AAGAAAGAAG TGGACAAACT CACCAACGGT CCAGCCACTC GTGCTTCTTC	3360
CCGCGCCTCA ATTCCAGTTA TCTACGACGA TGAGCATGTC TATGATGCAG CGTGTAGCAG	3420
TACATCAGCT AGTCAATCTT CGAAACGATC CTCTGGCTGC AACTCAATCA AGGTACTGT	3480
AAACGTGGAC ATCGCTGGAG AAATCAGTTC GATCGTTAAC CCGGACAAAG AGATAATCGT	3540
AGGATATCTT GCCATGTCAA CCAGTCAGTC ATGCTGAAA GACATTGATG TTTCTATTCT	3600
AGGACTATTT GAAGTCTACC TATCCAGAAT TGATGTGGAG CATCAACTTG GAATCGATGC	3660
TCGTGATTCT ATCCTTGGCT ATCAAATTGG TGAACCTCGA CGCGTCATTG GAGACTCCAC	3720
AACCATGATA ACCAGCCATC CAACTGACAT TCTTACTTCC TCAACTACAA TCCGAATGTT	3780
CATGCACGGT GCCGCACAGA GTCGCGTAGA CAGTCTGGTC CTTGATATGC TTCTTCCAAA	3840
GCAAATGATT CTCCAACCTG TCAAGTCAAT TTTGACAGAG AGACGTCTGG TGTTAGCTGG	3900
AGCAACTGGA ATTGGAAAGA GCAAACTGGC GAAGACCCTG GCTGCTTATG TATCTATTCG	3960
AACAAATCAA TCCGAAGATA GTATTGTAA TATCAGCATT CCTGAAAACA ATAAAGAAGA	4020
ATTGCTTCAA GTGGAACGAC GCCTGGAAAA GATCTTGAGA AGCAAAGAAT CATGCATCGT	4080
AATTCTAGAT AATATCCCAA AGAATCGAAT TGCAATTTGT GTATCCGTTT TGGCAAATGT	4140
CCCCTTCAA AACAACGAAG GTCCATTTGT AGTATGCACA GTCAACCGAT ATCAAATCCC	4200
TGAGCTTCAA ATTCACCACA ATTTCAAAAT GTCAGTAATG TCGAATCGTC TCGAAGGATT	4260
CATCCTACGT TACCTCCGAC GACGGGCGGT AGAGGATGAG TATCGTCTAA CTGTACAGAT	4320
GCCATCAGAG CTCTTCAAAA TCATTGACTT CTTCCCAATA GCTCTTCAGG CCGTCAATAA	4380
TTTTATTGAG AAAACGAATT CTGTTGATGT GACAGTTGGT CCAAGAGCAT GCTTGAAC TG	4440
TCCTCTAACT GTCGATGGAT CCCGTGAATG GTTCATTGCA TTGTGGAATG AGAACTTCAT	4500
TCCATATTTG GAACGTGTTG CTAGAGATGG CAAAAAACC TTCGGTCGCT GCACTTCCTT	4560
CGAGGATCCC ACCGACATCG TCTCTAAAAA ATGGCCGTGG TTCGATGGTG AAAACCCGGA	4620
GAATGTGCTC AAACGTCTTC AACTCCAAGA CCTCGTCCCG TCACCTGCCA ACTCATCCCG	4680
ACAACACTTC AATCCCCTCG AGTCGTTGAT CCAATTGCAT GCTACCAAGC ATCAGACCAT	4740
CGACAACATT TGAACAGAAG ACTCTAATCT TCTCTGCCT CTCCCCGCT TTCCTTATCT	4800
TCGTACCGGT ACCTGATGAT TCCCCATTTT CCCCCTTTTC CCCCCAATTT CCCAGAACCT	4860
CCTGTTCCCT TTGTTCTAG TCCTCCCGGG TGCCGACGCC GAAGCGATTT AAAAACCTTT	4920
TTCTTTCCGA AACATTTCCC ATTGCTCATT AATAGTCAAA TTGAATAAAC AGTGTATGTA	4980
CTTAAAAAAA AAAAAAAAAA AAAAAAAAAA GGCCTATGCG GCCGGGCCAT GGAGGCCGAA	5040
TTCCCGGGGA TCCGTGACC TGCAGCCAAG CTAATTCGG GCGAATTTCT TATGATTTAT	5100

GATTTTATT	ATTAAATAAG	TTATAAAAAA	AATAAGTGTA	TACAAATTTT	AAAGTGACTC	5160
TTAGGTTT	AAACGAAAAT	TCTTGTTCTT	GAGTAACTCT	TTCCTGTAGG	TCAGGTTGCT	5220
TTCTCAGGTA	TAGCATGAGG	TCGCTCTTAT	TGACCACACC	TCTACCGGCA	TGCAAGCTTG	5280
GCGTAATCAT	GGTCATAGCT	GTTCCTGTG	TGAAATTGTT	ATCCGCTCAC	AATTCCACAC	5340
AACATACGAG	CCGGAAGCAT	AAAGTGTA	GCCTGGGGTG	CCTAATGAGT	GAGGTAATC	5400
ACATTAATTG	CGTTGCGCTC	ACTGCCCGCT	TTCCAGTCGG	GAAACCTGTC	GTGCCAGCTG	5460
GATTAATGAA	TCGGCCAACG	CGCGGGGAGA	GGCGGTTTGC	GTATTGGGCG	CTCTTCCGCT	5520
TCCTCGCTCA	CTGACTCGCT	GCGCTCGGTC	GTTCGGCTGC	GGCGAGCGGT	ATCAGCTCAC	5580
TCAAAGGCGG	TAATACGGTT	ATCCACAGAA	TCAGGGGATA	ACGCAGGAAA	GAACATGTGA	5640
GCAAAAGGCC	AGCAAAAGGC	CAGGAACCGT	AAAAAGGCCG	CGTTGCTGGC	GTTTTTCCAT	5700
AGGCTCCGCC	CCCCTGACGA	GCATCACAAA	AATCGACGCT	CAAGTCAGAG	GTGGCGAAAC	5760
CCGACAGGAC	TATAAAGATA	CCAGGCGTTT	CCCCCTGGAA	GCTCCCTCGT	GCGCTCTCCT	5820
GTTCCGACCC	TGCCGCTTAC	CGGATACCTG	TCCGCTTTTC	TCCCTTCGGG	AAGCGTGGCG	5880
CTTCTCATA	GCTCAGCTG	TAGGTATCTC	AGTTCGGTGT	AGGTCGTTTC	CTCCAAGCTG	5940
GGCTGTGTGC	ACGAACCCCC	CGTTCAGCCC	GACCGCTGCG	CCTTATCCGG	TAATATCGT	6000
CTTGAGTCCA	ACCCGGTAAG	ACACGACTTA	TCGCCACTGG	CAGCAGCCAC	TGGTAACAGG	6060
ATTAGCAGAG	CGAGGTATGT	AGGCGGTGCT	ACAGAGTTCT	TGAAGTGGTG	GCCTAACTAC	6120
GGCTACACTA	GAAGGACAGT	ATTGGTATC	TGCGCTCTGC	TGAAGCCAGT	TACCTTCGGA	6180
AAAAGAGTTG	GTAGCTCTTG	ATCCGGCAAA	CAAACCACCG	CTGGTAGCGG	TGGTTTTTTT	6240
GTTTGCAAGC	AGCAGATTAC	GCGCAGAAAA	AAAGGATCTC	AAGAAGATCC	TTTGATCTTT	6300
TCTACGGGGT	CTGACGCTCA	GTGGAACGAA	AATCAGCTT	AAGGGATTTT	GGTCATGAGA	6360
TTATCAAAAA	GGATCTTCAC	CTAGATCCTT	TTAAATTAAA	AATGAAGTTT	TAAATCAATC	6420
TAAAGTATAT	ATGAGTAAAC	TTGGTCTGAC	AGTTACCAAT	GCTTAATCAG	TGAGGCACCT	6480
ATCTCAGCGA	TCTGTCTATT	TCGTTTATCC	ATAGTTGCCT	GACTCCCCGT	CGTGTAGATA	6540
ACTACGATAC	GGGAGGGCTT	ACCATCTGGC	CCAGTGCTG	CAATGATACC	GCGAGACCCA	6600
CGCTCACCGG	CTCCAGATTT	ATCAGCAATA	AACCAGCCAG	CCGGAAGGGC	CGAGCGCAGA	6660
AGTGGTCTCTG	CAACTTTATC	CGCCTCCATC	CAGTCTATTA	ATTGTTGCCG	GGAAGCTAGA	6720
GTAAGTAGTT	CGCCAGTTAA	TAGTTTGCGC	AACGTTGTTG	CCATTGCTAC	AGGCATCGTG	6780
GTGTCACGCT	CGTCGTTTGG	TATGGCTTCA	TTCAGCTCCG	GTTCCCAACG	ATCAAGGCGA	6840
GTTACATGAT	CCCCATGTT	GTGCAAAAAA	GCGGTTAGCT	CCTTCGGTCC	TCCGATCGTT	6900
GTCAGAAGTA	AGTTGGCCGC	AGTGTATCA	CTCATGGTTA	TGGCAGCACT	GCATAATTCT	6960
CTTACTGTCA	TGCCATCCGT	AAGATGCTTT	TCTGTGACTG	GTGAGTACTC	AACCAAGTCA	7020

SUBSTITUTE SHEET (RULE 26)

TTCTGAGAAT	AGTGTATGCG	GCGACCGAGT	TGCTCTTGCC	CGGCGTCAAT	ACGGGATAAT	7080
ACCGCGCCAC	ATAGCAGAAC	TTTAAAAGTG	CTCATCATTG	GAAAACGTTT	TTCGGGGCGA	7140
AAACTCTCAA	GGATCTTACC	GCTGTTGAGA	TCCAGTTCGA	TGTAACCCAC	TCGTGCACCC	7200
AACTGATCTT	CAGCATCTTT	TACTTTTACC	AGCGTTTCTG	GGTGAGCAAA	AACAGGAAGG	7260
CAAAATGCCG	CAAAAAAGGG	AATAAGGGCG	ACACGGAAAT	GTGAATACT	CATACTCTTC	7320
CTTTTTCAAT	ATTATTGAAG	CATTATCAG	GGTTATTGTC	TCATGAGCGG	ATACATATTT	7380
GAATGTATTT	AGAAAAATAA	ACAAATAGGG	GTTCCGCGCA	CATTTCCCCG	AAAAGTGCCA	7440
CCTGAACGAA	GCATCTGTGC	TTCATTTTGT	AGAACAAAAA	TGCAACGCGA	GAGCGCTAAT	7500
TTTTCAAACA	AAGAATCTGA	GCTGCATTTT	TACAGAACAG	AAATGCAACG	CGAAAGCGCT	7560
ATTTTACCAA	CGAAGAATCT	GTGCTTCATT	TTTGTA AAC	AAAAATGCAA	CGCGAGAGCG	7620
CTAATTTTTC	AAACAAAGAA	TCTGAGCTGC	ATTTTACAG	AACAGAAATG	CAACGCGAGA	7680
GCGCTATTTT	ACCAACAAAG	AATCTATACT	TCTTTTTTGT	TCTACAAAAA	TGCATCCCGA	7740
GAGCGCTATT	TTTCTAACAA	AGCATCTTAG	ATTACTTTTT	TTCTCCTTTG	TGCGCTCTAT	7800
AATGCACTCT	CTTGATAACT	TTTGCACTG	TAGGTCCGTT	AAGGTTAGAA	GAAGGCTACT	7860
TTGCTGTCTA	TTTCTCTTTC	CATAAAAAAA	GCCTGACTCC	ACTTCCCGCG	TTTACTGATT	7920
ACTAGCGAAG	CTGCGGGTGC	ATTTTTTCAA	GATAAAGGCA	TCCCGGATTA	TATTCTATAC	7980
CGATGTGGAT	TGCGCATACT	TTGTGAACAG	AAAGTGATAG	CGTTGATGAT	TCTTCATTGG	8040
TCAGAAAATT	ATGAACGGTT	TCTTCTATTT	TGTCTCTATA	TACTACGTAT	AGGAAATGTT	8100
TACATTTTCG	TATTGTTTTT	GATTCACTCT	ATGAATAGTT	CTTACTACAA	TTTTTTTGTC	8160
TAAAGAGTAA	TACTAGAGAT	AAACATAAAA	AATGTAGAGG	TCGAGTTTAG	ATGCAAGTTC	8220
AAGGAGCGAA	AGGTGGATGG	GTAGGTTATA	TAGGGATATA	GCACAGAGAT	ATATAGCAAA	8280
GAGATACTTT	TGAGCAATGT	TTGTGGAAGC	GGTATTCGCA	ATATTTTAGT	AGCTCGTTAC	8340
AGTCCGGTGC	GTTTTTGGTT	TTTTGAAAGT	GCGTCTTCAG	AGCGCTTTTG	GTTTTCAAAA	8400
GCGCTCTGAA	GTTCTATAC	TTTCTAGAGA	ATAGGAACTT	CGGAATAGGA	ACTTCAAAGC	8460
GTTTCCGAAA	ACGAGCGCTT	CCGAAAATGC	AACGCGAGCT	GCGCACATAC	AGCTCACTGT	8520
TCACGTCGCA	CCTATATCTG	CGTGTGCCT	GTATATATAT	ATACATGAGA	AGAACGGCAT	8580
AGTGCGTGTT	TATGCTTAAA	TGCGTACTTA	TATGCGTCTA	TTTATGTAGG	ATGAAAGGTA	8640
GTCTAGTACC	TCCTGTGATA	TTATCCCAT	CCATGCGGGG	TATCGTATGC	TTCCTTCAGC	8700
ACTACCCTTT	AGCTGTTCTA	TATGCTGCCA	CTCCTCAATT	GGATTAGTCT	CATCCTTCAA	8760
TGCTATCATT	TCCTTTGATA	TTGGATCATA	TTAAGAAACC	ATTATTATCA	TGACATTAAC	8820
CTATAAAAAT	AGGCGTATCA	CGAGGCCCTT	TCGTCTCGCG	CGTTTCGGTG	ATGACGGTGA	8880
AAACCTCTGA	CACATGCAGC	TCCCGGAGAC	GGTCACAGCT	TGTCTGTAAG	CGGATGCCGG	8940

GAGCAGACAA	CCCCGTCAGG	GCGCGTCAGC	GGGTGTTGGC	GGGTGTCGGG	GCTGGCTTAA	9000
CTATGCGGCA	TCAGAGCAGA	TTGTACTGAG	AGTGCACCAT	AGATCAACGA	CATTACTATA	9060
TATATAATAT	AGGAAGCATT	TAATAGACAG	CATCGTAATA	TATGTGTACT	TTGCAGTTAT	9120
GACGCCAGAT	GGCAGTAGTG	GAAGATATTC	TTTATTGAAA	AATAGCTTGT	CACCTTACGT	9180
ACAATCTTGA	TCCGGAGCTT	TTCTTTTTTT	GCCGATTAA	AATTAATTCG	GTCGAAAAAA	9240
GAAAAGGAGA	GGGCCAAGAG	GGAGGGCATT	GGTGAATATT	GAGCACGTGA	GTATACGTGA	9300
TTAAGCACAC	AAAGGCAGCT	TGGAGTATGT	CTGTTATTAA	TTTCACAGGT	AGTTCTGGTC	9360
CATTGGTGAA	AGTTTGCGGC	TTGCAGAGCA	CAGAGGCCGC	AGAATGTGCT	CTAGATTCCG	9420
ATGCTGACTT	GCTGGGTATT	ATATGTGTGC	CCAATAGAAA	GAGAACAATT	GACCCGGTTA	9480
TTGCAAGGAA	AATTTCAAGT	CTTGTAAGAG	CATATAAAAA	TAGTTCAGGC	ACTCCGAAAT	9540
ACTTGGTTGG	CGTGTTCGT	AATCAACCTA	AGGAGGATGT	TTTGGCTCTG	GTCAATGATT	9600
ACGGCATTGA	TATCGTCCAA	CTGCATGGAG	ATGAGTCGTG	GCAAGAATAC	CAAGAGTTCC	9660
TCGGTTTGCC	AGTTATTAAA	AGACTCGTAT	TTCCAAAAGA	CTGCAACATA	CTACTCAGTG	9720
CAGCTTCACA	GAAACCTCAT	TCGTTTATTC	CCTTGTTTGA	TTCAGAAGCA	GGTGGGACAG	9780
GTGAACTTTT	GGATTGGAAC	TCGATTTCTG	ACTGGGTGG	AAGGCAAGAG	AGCCCCGAAA	9840
GCTTACATTT	TATGTTAGCT	GGTGGACTGA	CGCCAGAAAA	TGTTGGTGAT	GCGCTTAGAT	9900
TAAATGGCGT	TATTGGTGTT	GATGTAAGCG	GAGGTGTGGA	GACAAATGGT	GTAAAAGACT	9960
CTAACAAAAT	AGCAAATTTT	GTCAAAAATG	CTAAGAAATA	GGTTATTACT	GAGTAGTATT	10020
TATTTAAGTA	TTGTTTGTGC	ACTTGCCGAT	CTATGCGGTG	TGAAATACCG	CACAGATGCG	10080
TAAGGAGAAA	ATACCGCATC	AGGAAATTGT	AAACGTTAAT	ATTTTGTAA	AATTCGCGTT	10140
AAATTTTTGT	TAAATCAGCT	CATTTTTTAA	CCAATAGGCC	GAAATCGGCA	AAATCCCTTA	10200
TAAATCAAAA	GAATAGACCG	AGATAGGGTT	GAGTGTGTGT	CCAGTTTGGA	ACAAGAGTCC	10260
ACTATTAAAG	AACGTGGACT	CCAACGTCAA	AGGGCGAAAA	ACCGTCTATC	AGGGCGATGG	10320
CCCACTACGT	GAACCATCAC	CCTAATCAAG	TTTTTTGGGG	TCGAGGTGCC	GTAAAGCACT	10380
AAATCGGAAC	CCTAAAGGGA	GCCCCGATT	TAGAGCTTGA	CGGGGAAGC	CGGCGAACGT	10440
GGCGAGAAAG	GAAGGGAAGA	AAGCGAAAGG	AGCGGGCGCT	AGGGCGCTGG	CAAGTGTAGC	10500
GGTCACGCTG	CGCGTAACCA	CCACACCCGC	CGCGCTTAAT	GCGCCGCTAC	AGGGCGCGTC	10560
GCGCCATTTC	CCATTCAGGC	TGCGCAACTG	TTGGGAAGGG	CGATCGGTGC	GGGCCTCTTC	10620
GCTATTACGC	CAGCTGGCGA	AAGGGGGATG	TGCTGCAAGG	CGATTAAAGT	GGGTAACGCC	10680
AGGGTTTTCC	CAGTCACGAC	GTTGTAAAAC	GACGGCCAGT	CGTCCAAGCT	TTGCGGAGCT	10740
CGAGATCCCG	AGCTTTGCAA	ATTAAAGCCT	TCGAGCGTCC	CAAAACCTTC	TCAAGCAAGG	10800
TTTTCAGTAT	AATGTTACAT	GCGTACACGC	GTCTGTACAG	AAAAAAAGA	AAAATTTGAA	10860

SUBSTITUTE SHEET (RULE 26)

ATATAAATAA CGTTCTTAAT ACTAACATAA CTATAAAAAA ATAAATAGGG ACCTAGACTT	10920
CAGGTTGTCT AACTCCTTCC TTTTCGGTTA GAGCGGATGT GGGGGGAGGG CGTGAATGTA	10980
AGCGTGACAT AACTAATTAC ATGATATCGA CAAAGGAAAA GGGGCCTGTT TACTCACAGG	11040
CTTTTTTCAA GTAGGTAATT AAGTCGTTTC TGTCTTTTTT CTTCTTCAAC CCACCAAAGG	11100
CCATCTGGT ACTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT	11160
TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTCATA GAAATAATAC	11220
AGAAGTAGAT GTTGAATTAG ATTAACTGA AGATATATAA TTTATTGGAA AATACATAGA	11280
GCTTTTTGTT GATGCGCTTA AGCGATCAAT TCAACAACAC CACCAGCAGC TCTGATTTTT	11340
TCTTCAGCCA ACTTGGAGAC GAATCTAGCT TTGACGATAA CTGGAACATT TGGGATTCTA	11400
CCCTTACCCA AGATCTTACC GTAACCGGCT GCCAAAGTGT CAATAACTGG AGCAGTTTCC	11460
TTAGAAGCAG ATTTCAAGTA TTGGTCTCTC TTGTCTCTG GGATCAATGT CCACAATTTG	11520
TCCAAGTTCA AGACTGGCTT CCAGAAATGA GCTTGTGCT TGTGGAAGTA TCTCATACCA	11580
ANCCTTACCG AAATAACCTG GATGGTATTT ATCCATGTTA ATTCTGTGGT GATGTTGACC	11640
ACCGGCCATA CCTCTACCAC CGGGGTGCTT TCTGTGCTTA CCGATACGAC CTTTACCGGC	11700
TGAGACGTGA CCTCTGTGCT TTCTAGTCTT AGTGAATCTG GAAGGCATT CTTGATTAGT	11760
GGATGATTGT TCTGGGATTT AATGCAAAAA AATCACTAAG AAGGAAAAAA ATCAACGGAG	11820
AAAGCAAACG CCATCTTAAA TATACGGGAT ACAGATGAAA GGTGGAACC TATCTGGGAA	11880
AATACGCATT AAACAAGCGA AAAACTGCGA GGAAATTTGT TTGCGTCTCT GCGGGCTATT	11940
CACGCGCCAG AGGAAAATAG GAAAAATAAC AGGGCATTAG AAAAATAATT TTGATTTTGG	12000
TAATGTGTGG GTCCCTGGTG TACAGATGTT ACATTGGTTA CAGTACTCTT GTTTTTGCTG	12060
TGTTTTTCGA TGAATCTCCA AAATGGTTGT TAGCACATGG AAGAGTCACC GATGCTAAGT	12120
TATCTCTATG TAAGCTACGT GGCCTGACTT TTGATGAAGC CGCACAAAGAG ATACAGGATT	12180
GGCAACTGCA AATAGAATCT GGGGATCTAG ATATCCTTTT GTTGTTCCTG GGTGTACAAT	12240
ATGGACTTCC TCTTTTCTGG CAACCAAACC CATACTCGG GATTCCTATA ATACCTTCGT	12300
TGGTCTCCCT AACATGTAGG TGGCGGAGGG GAGATATACA ATAGAACAGA TACCAGACAA	12360
GACATAATGG GCTAAACAAG ACTACACCAA TTACACTGCC TCATTGATGG TGGTACATAA	12420
CGAACTAATA CTGTAGCCCT AGACTTGATA GCCATCATCA TATCGAAGTT TCACTACCCT	12480
TTTTCCATTT GCCATCTATT GAAGTAATAA TAGGCGCATG CAACTTCTTT TCTTTTTTTT	12540
TCTTTTCTCT CTCCCCGTT GTTGTCTCAC CATATCCGCA ATGACAAAAA AAATGATGGA	12600
AGACACTAAA GGAAAAAATT AACGACAAAG ACAGCACCAA CAGATGTCGT TGTTCAGAG	12660
CTGATGAGGG GTATCTTCGA ACACACGAAA CTTTTTCCTT CCTTCATTCA CGCACACTAC	12720
TCTCTAATGA GCAACGGTAT ACGGCCTTCC TTCCAGTTAC TTGAATTTGA AATAAAAAAA	12780

SUBSTITUTE SHEET (RULE 26)

139

```

GTTTGCCGCT TTGCTATCAA GTATAAATAG ACCTGCAATT ATTAATCTTT TGTTTCCTCG 12840
TCATTGTTCT CGTTCCCTTT CTTCTTGTT TCTTTTCTG CACAATATTT CAAGCTATAC 12900
CAAGCATACA ATCAACTCCA AGCTTGAAGC AAGCCTCCTG AAAGATGAAG CTA CTGTCTT 12960
CTATCGAACA AGCATGCGAT ATTTGCCGAC TTAAAAAGCT CAAGTGCTCC AAAGAAAAAC 13020
CGAAGTGCGC CAAGTGCTG AAGAACAAC TGGAGTGTCG CTA CTCTCCC AAAACCAAAA 13080
GGTCTCCGCT GACTAGGGCA CATCTGACAG AAGTGGATC AAGGCTAGAA AGACTGGAAC 13140
AGCTATTTCT ACTGATTTTT CCTCGAGAAG ACCTTGACAT GATTTTGAAA ATGGATTCTT 13200
TACAGGATAT AAAAGCATTG TTAACAGGAT TATTTGTACA AGATAATGTG AATAAAGATG 13260
CCGTCACAGA TAGATTGGCT TCAGTGGAGA CTGATATGCC TCTAACATTG AGACAGCATA 13320
GAATAAGTGC GACATCATCA TCGGAAGAGA GTAGTAACAA AGGTCAAAGA CAGTTGACTG 13380
TATCGCCGGA ATTGCAATAC CCAGCTTTGA CTCA 13414

```

(2) INFORMATION FOR SEQ ID NO: 28:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10288 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: circular

(ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "plasmid"

(iii) HYPOTHETICAL: NO

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION: 8456
- (D) OTHER INFORMATION: /note= "N is A,C,G, or T"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:

```

TATGCCATCA ATTTCCGGAT CTCAAGGAAC TCTTGACAAC ATTGATGTGA TTGAGTTGAA 60
GCAAGAGCTC AAAGAACGCG ATAGTGCACT TTACGAAGTC CGCCTTGACA ATCTGGATCG 120
TGCCCGCGAA GTTGATGTTT TGAGGGAGAC AGTGAACAAG TTGAAAACCG AGAACAAGCA 180
ATTAAAGAAA GAAGTGGACA AACTCACCAA CGGTCCAGCC ACTCGTGCTT CTTCCCGCGC 240
CTCAATTCCA GTTATCTACG ACGATGAGCA TGTCTATGAT GCAGCGTGTA GCAGTACATC 300
AGCTAGTCAA TCTTCGAAAC GATCCTCTGG CTGCAACTCA ATCAAGGTTA CTGTAAACGT 360
GGACATCGCT GGAGAAATCA GTTCGATCGT TAACCCGGAC AAAGAGATAA TCGTAGGATA 420
TCTTGCCATG TCAACCAAGC AGTCATGCTG GAAAGACATT GATGTTTCTA TTCTAGGACT 480
ATTTGAAGTC TACCTATCCA GAATTGATGT GGAGCATCAA CTTGGAATCG ATGCTCGTGA 540

```

SUBSTITUTE SHEET (RULE 26)

140

TTCTATCCTT	GGCTATCAAA	TTGGTGAAC	TCGACGCGTC	ATTGGAGACT	CCACAACCAT	600
GATAACCAGC	CATCCAACTG	ACATTCTTAC	TTCCTCAACT	ACAATCCGAA	TGTTTCATGCA	660
CGGTGCCGCA	CAGAGTCGCG	TAGACAGTCT	GGTCCTTGAT	ATGCTTCTTC	CAAAGCAAAT	720
GATTCTCCAA	CTCGTCAAGT	CAATTTTGAC	AGAGAGACGT	CTGGTGTTAG	CTGGAGCAAC	780
TGGAATTGGA	AAGAGCAAAC	TGGCGAAGAC	CCTGGCTGCT	TATGTATCTA	TTCGAACAAA	840
TCAATCCGAA	GATAGTATTG	TTAATATCAG	CATTCTTGAA	AACAATAAAG	AAGAATTGCT	900
TCAAGTGGAA	CGACGCCTGG	AAAAGATCTT	GAGAAGCAAA	GAATCATGCA	TCGTAATTCT	960
AGATAATATC	CCAAAGAATC	GAATTGCATT	TGTTGTATCC	GTTTTTGCAA	ATGTCCCACT	1020
TCAAAACAAC	GAAGGTCCAT	TTGTAGTATG	CACAGTCAAC	CGATATCAAA	TCCCTGAGCT	1080
TCAAATTCAC	CACAATTTCA	AAATGTCAGT	AATGTCGAAT	CGTCTCGAAG	GATTCATCCT	1140
ACGTTACCTC	CGACGACGGG	CGGTAGAGGA	TGAGTATCGT	CTAACTGTAC	AGATGCCATC	1200
AGAGCTCTTC	AAAATCATTG	ACTTCTTCCC	AATAGCTCTT	CAGGCCGTCA	ATAATTTTAT	1260
TGAGAAAACG	AATTCTGTTG	ATGTGACAGT	TGGTCCAAGA	GCATGCTTGA	ACTGTCCTCT	1320
AACTGTCGAT	GGATCCCGTG	AATGGTTTCAT	TCGATTGTGG	AATGAGAACT	TCATTCCATA	1380
TTTGGAACGT	GTTGCTAGAG	ATGGCAAAAA	AACCTTCGGT	CGCTGCACTT	CCTTCGAGGA	1440
TCCCACCGAC	ATCGTCTCTA	AAAAATGGCC	GTGGTTCGAT	GGTGAAAACC	CGGAGAATGT	1500
GCTCAAACGT	CTTCAACTCC	AAGACCTCGT	CCCGTCACCT	GCCAACCTCAT	CCCGACAACA	1560
CTTCAATCCC	CTCGAGTCGT	TGATCCAATT	GCATGCTACC	AAGCATCAGA	CCATCGACAA	1620
CATTTGAACA	GAAGACTCTA	ATCTTCTCTC	GCCTCTCCCC	CGCTTTCCTT	ATCTTCGTAC	1680
CGGTACCTGA	TGATTCCCCA	TTTTCCCCCT	TTTCCCCCCA	ATTTCCCAGA	ACCTCCTGTT	1740
CCCTTTGTTC	CTAGTCCTCC	CGGGTGCCGA	CGCCGAAGCG	ATTTAAAAAC	CTTTTCTTTT	1800
CCGAAACATT	TCCCATTGCT	CATTAAATAGT	CAAATTGAAT	AAACAGTGTA	TGTACTTAAA	1860
AAAAAAAAAA	AAAAAAAAAA	AAAAGGCCTA	TGCGGCCGGG	CCATGGAGGC	CGAATTCCCCG	1920
GGGATCCGTC	GACCTGCAGC	CAAGCTAATT	CCGGGCGAAT	TTCTTATGAT	TTATGATTTT	1980
TATTATTAAA	TAAGTTATAA	AAAAAATAAG	TGTATACAAA	TTTTAAAGTG	ACTCTTAGGT	2040
TTTAAACGA	AAATTCTTGT	TCTTGAGTAA	CTCTTTCCTG	TAGGTCAGGT	TGCTTCTCTCA	2100
GGTATAGCAT	GAGGTCGCTC	TTATTGACCA	CACCTCTACC	GGCATGCAAG	CTTGGCGTAA	2160
TCATGGTCAT	AGCTGTTTCC	TGTGTGAAAT	TGTTATCCGC	TCACAATTCC	ACACAACATA	2220
CGAGCCGGAA	GCATAAAGTG	TAAAGCCTGG	GGTGCCTAAT	GAGTGAGGTA	ACTCACATTA	2280
ATTGCGTTGC	GCTCACTGCC	CGCTTTCAG	TCGGGAAACC	TGTCGTGCCA	GCTGGATTAA	2340
TGAATCGGCC	AACGCGCGGG	GAGAGGCGGT	TTGCGTATTG	GGCGCTCTTC	CGCTTCCTCG	2400
CTCACTGACT	CGCTGCGCTC	GGTCGTTCCG	CTGCGGCGAG	CGGTATCAGC	TCACTCAAAG	2460

SUBSTITUTE SHEET (RULE 26)

GCGGTAATAC	GGTTATCCAC	AGAATCAGGG	GATAACGCAG	GAAAGAACAT	GTGAGCAAAA	2520
GGCCAGCAAA	AGGCCAGGAA	CCGTAAAAAG	GCCGCGTTGC	TGGCGTTTTT	CCATAGGCTC	2580
CGCCCCCTG	ACGAGCATCA	CAAAAATCGA	CGCTCAAGTC	AGAGGTGGCG	AAACCCGACA	2640
GGACTATAAA	GATACCAGGC	GTTTCCCCCT	GGAAGCTCCC	TCGTGCGCTC	TCCTGTTCCG	2700
ACCCTGCCGC	TTACCGGATA	CCTGTCCGCC	TTTCTCCCTT	CGGAAGCGT	GGCGCTTTCT	2760
CATAGCTCAC	GCTGTAGGTA	TCTCAGTTCG	GTGTAGGTCG	TTCGCTCCAA	GCTGGGCTGT	2820
GTGCACGAAC	CCCCCGTTCA	GCCCGACCGC	TGCGCCTTAT	CCGGTAACTA	TCGTCTTGAG	2880
TCCAACCCGG	TAAGACACGA	CTTATCGCCA	CTGGCAGCAG	CCACTGGTAA	CAGGATTAGC	2940
AGAGCGAGGT	ATGTAGGCGG	TGCTACAGAG	TTCTTGAAGT	GGTGGCCTAA	CTACGGCTAC	3000
ACTAGAAGGA	CAGTATTTGG	TATCTGCGCT	CTGCTGAAGC	CAGTTACCTT	CGGAAAAAGA	3060
GTTGGTAGCT	CTTGATCCGG	CAACAAACC	ACCGCTGGTA	GCGGTGGTTT	TTTTGTTTGC	3120
AAGCAGCAGA	TTACGCGCAG	AAAAAAGGA	TCTCAAGAAG	ATCCTTTGAT	CTTTTCTACG	3180
GGGTCTGACG	CTCAGTGGAA	CGAAACTCA	CGTTAAGGGA	TTTTGGTCAT	GAGATTATCA	3240
AAAAGGATCT	TCACCTAGAT	CCTTTTAAAT	TAAAAATGAA	GTTTTAAATC	AATCTAAAGT	3300
ATATATGAGT	AAACTTGGTC	TGACAGTTAC	CAATGCTTAA	TCAGTGAGGC	ACCTATCTCA	3360
GCGATCTGTC	TATTTGTTTC	ATCCATAGTT	GCCTGACTCC	CCGTCGTGTA	GATAACTACG	3420
ATACGGGAGG	GCTTACCATC	TGGCCCCAGT	GCTGCAATGA	TACCGCGAGA	CCCACGCTCA	3480
CCGGCTCCAG	ATTTATCAGC	AATAAACCCAG	CCAGCCGGAA	GGGCCGAGCG	CAGAAGTGGT	3540
CCTGCAACTT	TATCCGCCTC	CATCCAGTCT	ATTAATTGTT	GCCGGGAAGC	TAGAGTAAAGT	3600
AGTTCGCCAG	TTAATAGTTT	GCGCAACGTT	GTTGCCATTG	CTACAGGCAT	CGTGGTGTCA	3660
CGCTCGTCGT	TTGGTATGGC	TTCATTACAGC	TCCGGTTCCC	AACGATCAAG	GCGAGTTACA	3720
TGATCCCCCA	TGTTGTGCAA	AAAAGCGGTT	AGCTCCTTCG	GTCCTCCGAT	CGTTGTGAGA	3780
AGTAAGTTGG	CCGCAGTGTT	ATCACTCATG	GTTATGGCAG	CACTGCATAA	TTCTCTTACT	3840
GTCATGCCAT	CCGTAAGATG	CTTTTCTGTG	ACTGGTGAGT	ACTCAACCAA	GTCATTCTGA	3900
GAATAGTGTA	TGCGGCGACC	GAGTTGCTCT	TGCCCCGGCT	CAATACGGGA	TAATACCGCG	3960
CCACATAGCA	GAACTTTAAA	AGTGCTCATC	ATTGGAAAAC	GTTCTTCGGG	GCGAAAACCTC	4020
TCAAGGATCT	TACCGCTGTT	GAGATCCAGT	TCGATGTAAC	CCACTCGTGC	ACCCAACTGA	4080
TCTTCAGCAT	CTTTTACTTT	CACCAGCGTT	TCTGGGTGAG	CAAAAACAGG	AAGGCAAAAT	4140
GCCGCAAAAA	AGGGAATAAG	GGCGACACGG	AAATGTTGAA	TACTCATACT	CTTCCTTTTT	4200
CAATATTATT	GAAGCATTTA	TCAGGGTTAT	TGTCTCATGA	GCGGATACAT	ATTTGAATGT	4260
ATTTAGAAAA	ATAAACAAAT	AGGGGTTCCG	CGCACATTTC	CCCGAAAAGT	GCCACCTGAA	4320
CGAAGCATCT	GTGCTTCATT	TTGTAGAACA	AAAATGCAAC	GCGAGAGCGC	TAATTTTTCA	4380

142

AACAAAGAAT	CTGAGCTGCA	TTTTTACAGA	ACAGAAATGC	AACGCGAAAG	CGCTATTTTA	4440
CCAACGAAGA	ATCTGTGCTT	CATTTTTGTA	AAACAAAAAT	GCAACGCGAG	AGCGCTAATT	4500
TTTCAAACAA	AGAATCTGAG	CTGCATTTTT	ACAGAACAGA	AATGCAACGC	GAGAGCGCTA	4560
TTTTACCAAC	AAAGAATCTA	TACTTCTTTT	TTGTTCTACA	AAAATGCATC	CCGAGAGCGC	4620
TATTTTTCTA	ACAAAGCATC	TTAGATTACT	TTTTTCTCC	TTTGTGCGCT	CTATAATGCA	4680
GTCTCTTGAT	AACTTTTTGC	ACTGTAGGTC	CGTTAAGGTT	AGAAGAAGGC	TACTTTGGTG	4740
TCTATTTTCT	CTTCCATAAA	AAAAGCCTGA	CTCCACTTCC	CGCGTTTACT	GATTACTAGC	4800
GAAGCTGCGG	GTGCATTTTT	TCAAGATAAA	GGCATCCCCG	ATTATATTCT	ATACCGATGT	4860
GGATTGCGCA	TACTTTGTGA	ACAGAAAGTG	ATAGCGTTGA	TGATTCTTCA	TTGGTCAGAA	4920
AATTATGAAC	GGTTTCTTCT	ATTTTGTCTC	TATATACTAC	GTATAGGAAA	TGTTTACATT	4980
TTCGTATTGT	TTTCGATTCA	CTCTATGAAT	AGTTCCTACT	ACAATTTTTT	TGTCTAAGA	5040
GTAATACTAG	AGATAAACAT	AAAAATGTA	GAGGTCGAGT	TTAGATGCAA	GTTCAAGGAG	5100
CGAAAGGTGG	ATGGGTAGGT	TATATAGGGA	TATAGCACAG	AGATATATAG	CAAAGAGATA	5160
CTTTTGAGCA	ATGTTTGTGG	AAGCGGTATT	CGCAATATTT	TAGTAGCTCG	TTACAGTCCG	5220
GTGCGTTTTT	GGTTTTTTGA	AAGTGCGTCT	TCAGAGCGCT	TTTGGTTTTT	AAAAGCGCTC	5280
TGAAGTTCCT	ATACTTTCTA	GAGAATAGGA	ACTTCGGAAT	AGGAACTTCA	AAGCGTTTCC	5340
GAAAACGAGC	GCTTCCGAAA	ATGCAACGCG	AGCTGCGCAC	ATACAGCTCA	CTGTTACAGT	5400
CGCACCTATA	TCTGCGTGTT	GCCTGTATAT	ATATATACAT	GAGAAGAACG	GCATAGTGCG	5460
TGTTTATGCT	TAAATGCGTA	CTTATATGCG	TCTATTTATG	TAGGATGAAA	GGTAGTCTAG	5520
TACCTCCTGT	GATATTATCC	CATTCCATGC	GGGGTATCGT	ATGCTTCCTT	CAGCACTACC	5580
CTTTAGCTGT	TCTATATGCT	GCCACTCCTC	AATTGGATTA	GTCTCATCCT	TCAATGCTAT	5640
CATTTCCCTT	GATATTGGAT	CATATTAAGA	AACCATTATT	ATCATGACAT	TAACCTATAA	5700
AAATAGGCGT	ATCACGAGGC	CCTTTCGTCT	CGCGCGTTTC	GGTGATGACG	GTGAAAACCT	5760
CTGACACATG	CAGCTCCCGG	AGACGGTCAC	AGCTTGTCTG	TAAGCGGATG	CCGGGAGCAG	5820
ACAAGCCCCT	CAGGGCGCGT	CAGCGGGTGT	TGGCGGGTGT	CGGGGCTGGC	TTAACTATGC	5880
GGCATCAGAG	CAGATTGTAC	TGAGAGTGCA	CCATAGATCA	ACGACATTAC	TATATATATA	5940
ATATAGGAAG	CATTTAATAG	ACAGCATCGT	AATATATGTG	TACTTTGCAG	TTATGACGCC	6000
AGATGGCAGT	AGTGGAAGAT	ATTCTTTATT	GAAAAATAGC	TTGTCACCTT	ACGTACAATC	6060
TTGATCCGGA	GCTTTTCTTT	TTTTGCCGAT	TAAGAATTAA	TTCGGTCGAA	AAAAGAAAAG	6120
GAGAGGGCCA	AGAGGGAGGG	CATTGGTGAC	TATTGAGCAC	GTGAGTATAC	GTGATTAAGC	6180
ACACAAAGGC	AGCTTGAGAT	ATGTCTGTTA	TTAATTTTAC	AGGTAGTTCT	GGTCCATTGG	6240
TGAAAGTTTG	CGGCTTGACG	AGCACAGAGG	CCGCAGAATG	TGCTCTAGAT	TCCGATGCTG	6300

SUBSTITUTE SHEET (RULE 26)

ACTTGCTGGG TATTATATGT GTGCCCAATA GAAAGAGAAC AATTGACCCG GTTATTGCAA 6360
GGAAAATTTT AAGTCTTGTA AAAGCATATA AAAATAGTTC AGGCACTCCG AAATACTTGG 6420
TTGGCGTGTT TCGTAATCAA CCTAAGGAGG ATGTTTTTGGC TCTGGTCAAT GATTACGGCA 6480
TTGATATCGT CCAACTGCAT GGAGATGAGT CGTGGCAAGA ATACCAAGAG TTCCTCGGTT 6540
TGCCAGTTAT TAAAAGACTC GTATTTCCAA AAGACTGCAA CATACTACTC AGTGCAGCTT 6600
CACAGAAACC TCATTCTGTT ATTCCCTTGT TTGATTGAGA AGCAGGTGGG ACAGGTGAAC 6660
TTTTGGATTG GAACTCGATT TCTGACTGGG TTGGAAGGCA AGAGAGCCCC GAAAGCTTAC 6720
ATTTTATGTT AGCTGGTGGA CTGACGCCAG AAAATGTTGG TGATGCGCTT AGATTAAATG 6780
GCGTTATTGG TGTGATGTA AGCGGAGGTG TGGAGACAAA TGGTGTAAAA GACTCTAACA 6840
AAATAGCAAA TTTCGTCAA AATGCTAAGA AATAGGTTAT TACTGAGTAG TATTTATTTA 6900
AGTATTGTTT GTGCACTTGC CGATCTATGC GGTGTGAAAT ACCGCACAGA TCGCTAAGGA 6960
GAAAATACCG CATCAGGAAA TTGTAAACGT TAATATTTTG TTAAAATTCG CGTTAAATTT 7020
TTGTTAAATC AGCTCATTTT TTAACCAATA GGCCGAAATC GGCAAAATCC CTTATAAATC 7080
AAAAGAATAG ACCGAGATAG GGTGAGTGT TGTTCCAGTT TGGACAAGA GTCCACTATT 7140
AAAGAACGTG GACTCCAACG TCAAAGGGCG AAAAACCCTC TATCAGGGCG ATGGCCCACT 7200
ACGTGAACCA TCACCCTAAT CAAGTTTTTT GGGGTCGAGG TGCCGTAAAG CACTAAATCG 7260
GAACCCTAAA GGGAGCCCCC GATTTAGAGC TTGACGGGGA AAGCCGGCGA ACGTGGCGAG 7320
AAAGGAAGGG AAGAAAGCGA AAGGAGCGGG CGCTAGGGCG CTGGCAAGTG TAGCGGTCAC 7380
GCTGCGCGTA ACCACCACAC CCGCCGCGCT TAATGCGCCG CTACAGGGCG CGTCGCGCCA 7440
TTCGCCATTC AGGCTGCGCA ACTGTTGGGA AGGGCGATCG GTGCGGGCCT CTTGCTATT 7500
ACGCCAGCTG GCGAAAGGGG GATGTGCTGC AAGGCGATTA AGTTGGGTAA CGCCAGGGTT 7560
TTCCCACTCA CGACGTTGTA AAACGACGGC CAGTCGTCCA AGCTTTCGCG AGCTCGAGAT 7620
CCCGAGCTTT GCAAATTAAA GCCTTCGAGC GTCCCAAAC CTTCTCAAGC AAGGTTTTC 7680
GTATAATGTT ACATGCGTAC ACGCGTCTGT ACAGAAAAA AAGAAAAATT TGAATATAA 7740
ATAACGTTCT TAATACTAAC ATAACATAA AAAAATAAAT AGGGACCTAG ACTTCAGGTT 7800
GTCTAACTCC TTCCTTTTCG GTTAGAGCGG ATGTGGGGG AGGGCGTGAA TGTAAGCGTG 7860
ACATAACTAA TTACATGATA TCGACAAAGG AAAAGGGGCC TGTTTACTCA CAGGCTTTTT 7920
TCAAGTAGGT AATTAAGTCG TTTCTGTCTT TTTCTTCTT CAACCCACCA AAGGCCATCT 7980
TGGTACTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT 8040
TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT CATAGAAATA ATACAGAAGT 8100
AGATGTTGAA TTAGATTAAA CTGAAGATAT ATAATTTATT GGAATAACA TAGAGCTTTT 8160
TGTTGATGCG CTTAAGCGAT CAATTCAACA ACACCACCAG CAGCTCTGAT TTTTCTTCA 8220

GCCAACTTGG	AGACGAATCT	AGCTTTGACG	ATAACTGGAA	CATTTGGGAT	TCTACCCTTA	8280
CCCAAGATCT	TACCGTAACC	GGCTGCCAAA	GTGTCAATAA	CTGGAGCAGT	TTCCTTAGAA	8340
GCAGATTTCA	AGTATTGGTC	TCTCTTGTCT	TCTGGGATCA	ATGTCCACAA	TTTGTCCAAG	8400
TTCAAGACTG	GCTTCCAGAA	ATGAGCTTGT	TGCTTGTGGA	AGTATCTCAT	ACCAANCCTT	8460
ACCGAAATAA	CCTGGATGGT	ATTTATCCAT	GTTAATTCTG	TGGTGATGTT	GACCACCGGC	8520
CATACCTCTA	CCACCGGGGT	GC'TTCTGTG	CTTACCGATA	CGACCTTTAC	CGGCTGAGAC	8580
GTGACCTCTG	TGCTTTCTAG	TCTTAGTGAA	TCTGGAAGGC	ATTCTTGATT	AGTTGGATGA	8640
TTGTTCTGGG	ATTTAATGCA	AAAAAATCAC	TAAGAAGGAA	AAAAATCAAC	GGAGAAAGCA	8700
AACGCCATCT	TAAATATACG	GGATACAGAT	GAAAGGTTTG	AACCTATCTG	GGAAAAATACG	8760
CATTAAACAA	GCGAAAAACT	GCGAGGAAAA	TTGTTTGCGT	CTCTGCGGGC	TATTCACGCG	8820
CCAGAGGAAA	ATAGGAAAAA	TAACAGGGCA	TTAGAAAAAT	AATTTTGATT	TTGGTAATGT	8880
GTGGGTCCCT	GGTGTACAGA	TGTTACATTG	GTTACAGTAC	TCTTGTTTTT	GCTGTGTTTT	8940
TCGATGAATC	TCCAAAATGG	TTGTTAGCAC	ATGGAAGAGT	CACCGATGCT	AAGTTATCTC	9000
TATGTAAGCT	ACGTGGCGTG	ACTTTTGATG	AAGCCGCACA	AGAGATACAG	GATTGGCAAC	9060
TGCAAAATAGA	ATCTGGGGAT	CTAGATATCC	TTTTGTGTGT	TCCGGGTGTA	CAATATGGAC	9120
TTCTCTTTTT	CTGGCAACCA	AACCCATACA	TCGGGATTCC	TATAATACCT	TCGTTGGTCT	9180
CCCTAACATG	TAGTGGGCGG	AGGGGAGATA	TACAATAGAA	CAGATACCAG	ACAAGACATA	9240
ATGGGCTAAA	CAAGACTACA	CCAATTACAC	TGCCTCATTG	ATGGTGGTAC	ATAACGAACT	9300
AATACTGTAG	CCCTAGACTT	GATAGCCATC	ATCATATCGA	AGTTTCACTA	CCCTTTTTTCC	9360
ATTTGCCATC	TATTGAAGTA	ATAATAGGCG	CATGCAACTT	CTTTTCTTTT	TTTTTCTTTT	9420
CTCTCTCCCC	CGTTGTGTGC	TCACCATATC	CGCAATGACA	AAAAAAATGA	TGGAAGACAC	9480
TAAAGGAAAA	AATTAACGAC	AAAGACAGCA	CCAACAGATG	TCGTTGTTCC	AGAGCTGATG	9540
AGGGGTATCT	TCGAACACAC	GAAACTTTTT	CCTTCCTTCA	TTCACGCACA	CTACTCTCTA	9600
ATGAGCAACG	GTATACGGCC	TTCTTCCAG	TTACTTGAAT	TTGAAATAAA	AAAAGTTTGC	9660
CGCTTTGCTA	TCAAGTATAA	ATAGACCTGC	AATTATTAAT	CTTTTGTTTC	CTCGTCATTG	9720
TTCTCGTTCC	CTTCTTCCT	TGTTTCTTTT	TCTGCACAAT	ATTTCAAGCT	ATACCAAGCA	9780
TACAATCAAC	TCCAAGCTTG	AAGCAAGCCT	CCTGAAAGAT	GAAGCTACTG	TCTTCTATCG	9840
AACAAGCATG	CGATATTTGC	CGACTTAAAA	AGCTCAAGTG	CTCCAAAGAA	AAACCGAAGT	9900
GCGCCAAGTG	TCTGAAGAAC	AACTGGGAGT	GTGCTACTC	TCCCAAACC	AAAAGGTCTC	9960
CGCTGACTAG	GGCACATCTG	ACAGAAGTGG	AATCAAGGCT	AGAAAGACTG	GAACAGCTAT	10020
TTCTACTGAT	TTTTCTCTGA	GAAGACCTTG	ACATGATTTT	GAAAATGGAT	TCTTTACAGG	10080
ATATAAAAGC	ATTGTTAACA	GGATTATTTG	TACAAGATAA	TGTGAATAAA	GATGCCGTCA	10140

SUBSTITUTE SHEET (RULE 26)

145

CAGATAGATT GGCTTCAGTG GAGACTGATA TGCCTCTAAC ATTGAGACAG CATAGAATAA 10200
 GTGCGACATC ATCATCGGAA GAGAGTAGTA ACAAAGGTCA AAGACAGTTG ACTGTATCGC 10260
 CGGAATTGCA ATACCCAGCT TTGACTCA 10288

(2) INFORMATION FOR SEQ ID NO: 29:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7625 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: circular

(ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "plasmid"

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:

GCTTGCATGC AACTTCTTTT CTTTTTTTTT CTTTCTCTC TCCCCGTTG TTGTCTCACC 60
 ATATCCGCAA TGACAAAAA AATGATGGAA GACACTAAAG GAAAAAATTA ACGACAAAGA 120
 CAGCACCAAC AGATGTCGTT GTTCCAGAGC TGATGAGGGG TATCTTCGAA CACACGAAAC 180
 TTTTTCCTTC CTTCAATCAC GCACACTACT CTCTAATGAG CAACGGTATA CGGCCTTCCT 240
 TCCAGTTACT TGAATTGAA ATAAAAAAG TTTGCCGCTT TGCTATCAAG TATAAATAGA 300
 CCTGCAATTA TTAATCTTTT GTTTCCTCGT CATGTGTTCTC GTTCCCTTTC TTCCTTGTTT 360
 CTTTTTCTGC ACAATATTTT AAGCTATACC AAGCATACAA TCAACTCCAA GCTTTGCAAA 420
 GATGGATAAA GCGGAATTAA TTCCCGAGCC TCCAAAAAAG AAGAGAAAGG TCGAATTGGG 480
 TACCGCCGCC AATTTTAATC AAAGTGGGAA TATTGCTGAT AGCTCATTGT CCTTCACTTT 540
 CACTAACAGT AGCAACGGTC CGAACCTCAT AACAACTCAA ACAAATTCTC AAGCGCTTTC 600
 ACAACCAATT GCCTCCTCTA ACGTTCATGA TAACTTCATG AATAATGAAA TCACGGCTAG 660
 TAAAATTGAT GATGGTAATA ATTCAAAACC ACTGTCACCT GGTGGACGG ACCAAACTGC 720
 GTATAACGCG TTTGGAATCA CTACAGGGAT GTTAAATACC ACTACAATGG ATGATGTATA 780
 TAACTATCTA TTCGATGATG AAGATACCCC ACCAAACCCA AAAAAAGAGA TCGAATTCCC 840
 GGGGATCCGC TCCTCACTCT CCAAGTTCAC CAAGAAGAAG AACAGAAGT ACGACGAAGC 900
 ACATATGCCA TCAATTTCCG GATCTCAAGG AACTCTTGAC AACATTGATG TGATTGAGTT 960
 GAAGCAAGAG CTCAAAGAAC GCGATAGTGC ACTTTACGAA GTCCGCCTTG ACAATCTGGA 1020
 TCGTGCCCGC GAAGTTGATG TTCTGAGGGA GACAGTGAAC AAGTTGAAAA CCGAGAACAA 1080
 GCAATTAAAG AAAGAAGTGG ACAAACCTCAC CAACGGTCCA GCCACTCGTG CTTCTTCCCG 1140
 CGCCTCAATT CCAGTTATCT ACGACGATGA GCATGTCTAT GATGCAGCGT GTAGCAGTAC 1200

SUBSTITUTE SHEET (RULE 26)

ATCAGCTAGT	CAATCTTCGA	AACGATCCTC	TGGCTGCAAC	TCAATCAAGG	TTACTGTAAA	1260
CGTGGACATC	GCTGGAGAAA	TCAGTTCGAT	CGTTAACCCG	GACAAAGAGA	TAATCGTAGG	1320
ATATCTTGCC	ATGTCAACCA	GTCAGTCATG	CTGGAAAGAC	ATTGATGTTT	CTATTCTAGG	1380
ACTATTTGAA	GTCTACCTAT	CCAGAATTGA	TGTGGAGCAT	CAACTTGGAA	TCGATGCTCG	1440
TGATTCTATC	CTTGGCTATC	AAATTGGTGA	ACTTCGACGC	GTCATTGGAG	ACTCCACAAC	1500
CATGATAACC	AGCCATCCAA	CTGACATTCT	TACTTCCTCA	ACTACAATCC	GAATGTTTAT	1560
GCACGGTGCC	GCACAGAGTC	GCGTAGACAG	TCTGGTCCTT	GATATGCTTC	TTCCAAAGCA	1620
AATGATTCTC	CAACTCGTCA	AGTCAATTTT	GACAGAGAGA	CGTCTGGTGT	TAGCTGGAGC	1680
AACTGGAATT	GGAAAGAGCA	AACTGGCGAA	GACCCTGGCT	GCTTATGTAT	CTATTCGAAC	1740
AAATCAATCC	GAAGATAGTA	TTGTTAATAT	CAGCATTCTT	GAAAACAATA	AAGAAGAATT	1800
GCTTCAAGTG	GAACGACGCC	TGGAAAAGAT	CTATGAATCG	TAGATACTGA	AAAACCCCGC	1860
AAGTTCACCT	CAACTGTGCA	TCGTGCACCA	TCTCAATTTT	TTTCATTTAT	ACATCGTTTT	1920
GCCTTCTTTT	ATGTAACCTAT	ACTCCTCTAA	GTTTCAATCT	TGGCCATGTA	ACCTCTGATC	1980
TATAGAATTT	TTTAAATGAC	TAGAATTAAT	GCCCATCTTT	TTTTTGGACC	TAAATTCTTC	2040
ATGAAAATAT	ATTACGAGGG	CTTATTCAGA	AGCTTTGGAC	TTCTTCGCCA	GAGGTTTGGT	2100
CAAGTCTCCA	ATCAAGGTTG	TCGGCTTGTC	TACCTTGCCA	GAAATTTACG	AAAAGATGGA	2160
AAAGGGTCAA	ATCGTTGGTA	GATACGTTGT	TGACACTTCT	AAATAAGCGA	ATTTCTTATG	2220
ATTTATGATT	TTTATTATTA	AATAAGTTAT	AAAAAAAATA	AGTGTATACA	AATTTTAAAG	2280
TGACTCTTAG	GTTTTAAAAC	GAAAATTCTT	GTTCTTGAGT	AACTCTTTCC	TGTAGGTCAG	2340
GTTGCTTTCT	CAGGTATAGC	ATGAGGTCGC	TCTTATTGAC	CACACCTCTA	CCGGCATGCC	2400
CGAAATTCCC	CTACCCTATG	AACATATTCC	ATTTTGTAAT	TTCGTGTCGT	TTCTATTATG	2460
AATTTCATTT	ATAAAGTTTA	TGTACAAATA	TCATAAAAAA	AGAGAATCTT	TTTAAGCAAG	2520
GATTTTCTTA	ACTTCTTCGG	CGACAGCATC	ACCGACTTCG	GTGGTACTGT	TGGAACCACC	2580
TAAATCACCA	GTTCTGATAC	CTGCATCCAA	AACCTTTTTA	ACTGCATCTT	CAATGGCCTT	2640
ACCTTCTTCA	GGCAAGTTCA	ATGACAATTT	CAACATCATT	GCAGCAGACA	AGATAGTGGC	2700
GATAGGGTCA	ACCTTATTCT	TTGGCAAATC	TGGAGCAGAA	CCGTGGCATG	GTTTCGTACAA	2760
ACCAAATGCG	GTGTTCTTGT	CTGGCAAAGA	GGCCAAGGAC	GCAGATGGCA	ACAAACCCAA	2820
GGAACCTGGG	ATAACGGAGG	CTTCATCGGA	GATGATATCA	CCAAACATGT	TGCTGGTGAT	2880
TATAATACCA	TTTAGGTGGG	TTGGGTTCTT	AACTAGGATC	ATGGCGGCAG	AATCAATCAA	2940
TTGATGTTGA	ACCTTCAATG	TAGGAAATTC	GTTCTTGATG	GTTTCCTCCA	CAGTTTTTCT	3000
CCATAATCTT	GAAGAGGCCA	AAACATTAGC	TTTATCCAAG	GACCAAATAG	GCAATGGTGG	3060
CTCATGTTGT	AGGGCCATGA	AAGCGGCCAT	TCTTGATGAT	CTTTGCACTT	CTGGAACGGT	3120

GTATTGTTCA CTATCCCAAG CGACACCATC ACCATCGTCT TCCTTTCTCT TACCAAAGTA	3180
AATACCTCCC ACTAATTCTC TGACAACAAC GAAGTCAGTA CCTTTAGCAA ATTGTGGCTT	3240
GATTGGAGAT AAGTCTAAAA GAGAGTCGGA TGCAAAGTTA CATGGTCTTA AGTTGGCGTA	3300
CAATTGAAGT TCTTTACGGA TTTTGTAGTAA ACCTTGTTCA GGTCTAACAC TACCTGTACC	3360
CCATTTAGGA CCACCCACAG CACCTAACAA AACGGCATCA ACCTTCTTGG AGGCTTCCAG	3420
CGCCTCATCT GGAAGTGGGA CACCTGTAGC ATCGATAGCA GCACCACCAA TTAAATGATT	3480
TTCGAAATCG AACTTGACAT TGGAACGAAC ATCAGAAATA GCTTTAAGAA CCTTAATGGC	3540
TTCGGCTGTG ATTTCTTGAC CAACGTGGTC ACCTGGCAA ACGACGATCT TCTTAGGGGC	3600
AGACATTAGA ATGGTATATC CTTGAAATAT ATATATATAT TGCTGAAATG TAAAAGGTAA	3660
GAAAAGTTAG AAAGTAAGAC GATTGCTAAC CACCTATTGG AAAAAACAAT AGGTCCTTAA	3720
ATAATATTGT CAACTTCAAG TATTGTGATG CAAGCATTTA GTCATGAACG CTTCTCTATT	3780
CTATATGAAA AGCCGGTTCC GGCCTCTCAC CTTTCCTTTT TCTCCCAATT TTTCAATTGA	3840
AAAAGGTATA TGCCTCAGGC GACCTCTGAA ATTAACAAAA AATTTCAGT CATCGAATTT	3900
GATTCTGTGC GATAGCGCCC CTGTGTGTTT TCGTTATGTT GAGGAAAAAA ATAATGGTTG	3960
CTAAGAGATT CGAACTCTTG CATCTTACGA TACCTGAGTA TTCCACAGT TGGGGATCTC	4020
GACTCTAGCT AGAGGATCAA TTCGTAATCA TGGTCATAGC TGTTCCTGT GTGAAATTGT	4080
TATCCGCTCA CAATTCCACA CAACATACGA GCCGGAAGCA TAAAGTGTA AGCCTGGGGT	4140
GCCTAATGAG TGAGGTAAC CACATTAATT GCGTTGCGCT CACTGCCCCG TTTCCAGTCG	4200
GGAAACCTGT CGTGCCAGCT GGATTAATGA ATCGGCCAAC GCGCGGGGAG AGGCGGTTTG	4260
CGTATTGGGC GCTCTCCGC TTCCTCGCTC ACTGACTCGC TGCCTCGGT CGTTCGGCTG	4320
CGGCGAGCGG TATCAGCTCA CTCAAAGCG GTAATACGGT TATCCACAGA ATCAGGGGAT	4380
AACGCAGGAA AGAACATGTG AGCAAAAGGC CAGCAAAAGG CCAGGAACCG TAAAAAGGCC	4440
GCGTTGCTGG CGTTTTTCCA TAGGCTCCGC CCCCCTGACG AGCATCACAA AAATCGACGC	4500
TCAAGTCAGA GGTGGCGAAA CCCGACAGGA CTATAAAGAT ACCAGGCGTT TCCCCCTGGA	4560
AGCTCCCTCG TGCCTCTCC TGTTCGACC CTGCCGCTTA CCGGATACCT GTCCGCCTTT	4620
CTCCCTTCGG GAAGCGTGGC GCTTTCTCAT AGCTCACGCT GTAGGTATCT CAGTTCGGTG	4680
TAGGTCGTTT GCTCCAAGCT GGGCTGTGTG CACGAACCCC CCGTTCAGCC CGACCGCTGC	4740
GCCTTATCCG GTAACATATC TCTTGAGTCC AACCCGGTAA GACACGACTT ATCGCCACTG	4800
GCAGCAGCCA CTGGTAACAG GATTAGCAGA GCGAGGTATG TAGGCGGTGC TACAGAGTTC	4860
TTGAAGTGGT GGCCTAACTA CGGCTACACT AGAAGGACAG TATTTGGTAT CTGCGCTCTG	4920
CTGAAGCCAG TTACCTTCGG AAAAAGAGTT GGTAGCTCTT GATCCGGCAA ACAAACCACC	4980
GCTGGTAGCG GTGGTTTTTT TGTGTGCAAG CAGCAGATTA CGCGCAGAAA AAAAGGATCT	5040

CAAGAAGATC	CTTTGATCTT	TTCTACGGGG	TCTGACGCTC	AGTGGAACGA	AAACTCACGT	5100
TAAGGGATTT	TGGTCATGAG	ATTATCAAAA	AGGATCTTCA	CCTAGATCCT	TTTAAATTAA	5160
AAATGAAGTT	TTAAATCAAT	CTAAAGTATA	TATGAGTAAA	CTTGGTCTGA	CAGTTACCAA	5220
TGCTTAATCA	GTGAGGCACC	TATCTCAGCG	ATCTGTCTAT	TTCGTTTCATC	CATAGTTGCC	5280
TGACTCCCCG	TCGTGTAGAT	AACTACGATA	CGGGAGGGCT	TACCATCTGG	CCCCAGTGCT	5340
GCAATGATAC	CGCGAGACCC	ACGCTCACCG	GCTCCAGATT	TATCAGCAAT	AAACCAGCCA	5400
GCCGGAAGGG	CCGAGCGCAG	AAGTGGTCCT	GCAACTTTAT	CCGCCTCCAT	CCAGTCTATT	5460
AATTGTTGCC	GGGAAGCTAG	AGTAAGTAGT	TCGCCAGTTA	ATAGTTTGCG	CAACGTTGTT	5520
GCCATTGCTA	CAGGCATCGT	GGTGTACGCG	TCGTCGTTTG	GTATGGCTTC	ATTCAGCTCC	5580
GGTTCCCAAC	GATCAAGGCG	AGTTACATGA	TCCCCCATGT	TGTGCAAAA	AGCGGTTAGC	5640
TCCTTCGGTC	CTCCGATCGT	TGTCAGAAGT	AAGTTGGCCG	CAGTGTTATC	ACTCATGGTT	5700
ATGGCAGCAC	TGCATAATTC	TCTTACTGTC	ATGCCATCCG	TAAGATGCTT	TTCTGTGACT	5760
GGTGAGTACT	CAACCAAGTC	ATTCTGAGAA	TAGTGTATGC	GGCGACCGAG	TTGCTCTTGC	5820
CCGGCGTCAA	TACGGGATAA	TACCGCGCCA	CATAGCAGAA	CTTTAAAAGT	GCTCATCATT	5880
GGAAAACGTT	CTTCGGGGCG	AAAACCTCTCA	AGGATCTTAC	CGCTGTTGAG	ATCCAGTTCG	5940
ATGTAACCCA	CTCGTGCACC	CAACTGATCT	TCAGCATCTT	TTACTTTTAC	CAGCGTTTCT	6000
GGGTGAGCAA	AAACAGGAAG	GCAAAATGCC	GCAAAAAGG	GAATAAGGGC	GACACGGAAA	6060
TGTTGAATAC	TCATACTCTT	CCTTTTTCAA	TATTATTGAA	GCATTTATCA	GGGTTATTGT	6120
CTCATGAGCG	GATACATATT	TGAATGTATT	TAGAAAAATA	AACAAATAGG	GGTTCGCGCG	6180
ACATTTCCCC	GAAAAGTGCC	ACCTGACGTC	TAAGAAACCA	TTATTATCAT	GACATTAACC	6240
TATAAAAATA	GGCGTATCAC	GAGGCCCTTT	CGTCTCGCGC	GTTTCGGTGA	TGACGGTGAA	6300
AACCTCTGAC	ACATGCAGCT	CCCGGAGACG	GTACAGCTT	GTCTGTAAGC	GGATGCCGGG	6360
AGCAGACAAG	CCCGTCAGGG	CGCGTCAGCG	GGTGTGGCG	GGTGTGGGG	CTGGCTTAAC	6420
TATGCGGCAT	CAGAGCAGAT	TGTACTGAGA	GTGCACCATA	ACGCATTTAA	GCATAAACAC	6480
GCACTATGCC	GTTCTTCTCA	TGTATATATA	TATACAGGCA	ACACGCAGAT	ATAGGTGCGA	6540
CGTGAACAGT	GAGCTGTATG	TGCGCAGCTC	GCGTTGCATT	TTCGGAAGCG	CTCGTTTTTCG	6600
GAAACGCTTT	GAAGTTCCTA	TTCCGAAGTT	CCTATTCTCT	AGCTAGAAAAG	TATAGGAACT	6660
TCAGAGCGCT	TTTGAAAACC	AAAAGCGCTC	TGAAGACGCA	CTTTCAAAA	ACCAAAAACG	6720
CACCGGACTG	TAACGAGCTA	CTAAAATATT	GCGAATACCG	CTTCCACAAA	CATTGCTCAA	6780
AAGTATCTCT	TTGCTATATA	TCTCTGTGCT	ATATCCCTAT	ATAACCTACC	CATCCACCTT	6840
TCGCTCCTTG	AACTTGCATC	TAAACTCGAC	CTCTACATTT	TTTATGTTTA	TCTCTAGTAT	6900
TACTCTTTAG	ACAAAAAAT	TGTAGTAAGA	ACTATTCATA	GAGTGAATCG	AAAACAATAC	6960

149

GAAAATGTAA ACATTTCCCTA TACGTAGTAT ATAGAGACAA AATAGAAGAA ACCGTTTCATA 7020
 ATTTTCTGAC CAATGAAGAA TCATCAACGC TATCACTTTC TGTTCAAAA GTATGCGCAA 7080
 TCCACATCGG TATAGAATAT AATCGGGGAT GCCTTTATCT TGAAAAAATG CACCCGCAGC 7140
 TTCGCTAGTA ATCAGTAAAC GCGGGAAGTG GAGTCAGGCT TTTTATATGG AAGAGAAAAAT 7200
 AGACACCAAA GTAGCCTTCT TCTAACCTTA ACGGACCTAC AGTGCAAAAA GTTATCAAGA 7260
 GACTGCATTA TAGAGCGCAC AAAGGAGAAA AAAAGTAATC TAAGATGCTT TGTTAGAAAA 7320
 ATAGCGCTCT CGGGATGCAT TTTTGTAGAA CAAAAAGAA GTATAGATTC TTTGTTGTA 7380
 AAATAGCGCT CTCGCGTTGC ATTTCTGTTT TGTAATAATG CAGCTCAGAT TCTTTGTTTG 7440
 AAAAATTAGC GCTCTCGCGT TGCATTTTTG TTTTACAAA ATGAAGCACA GATTCTTCGT 7500
 TGGTAAAATA GCGCTTTCGC GTTGCAATTC TGTTCTGTAA AAATGCAGCT CAGATTCTTT 7560
 GTTTGAAAAA TTAGCGCTCT CGCGTTGCAT TTTTGTCTA CAAATGAAG CACAGATGCT 7620
 TCGTT 7625

(2) INFORMATION FOR SEQ ID NO: 30:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 9642 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: circular

(ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "plasmid"

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30:

ATGACCATGA TTACGCCAAG CTTGTCTTCT TCTAAATTC CATAAAATCC CGAAACTCCT 60
 TCCCTCTATC TTCTTTTCT TCTCGTTTTC AAATGTTTCT CTCTATCCCA TTCTCTCATC 120
 AATTGAGTGG GATGAGGCTA TCTCTGCCTC TCTTCTGAAT CTCTGAACCA TCTTACATTA 180
 CACTGTGGAT GACGAGCCCC ACAGGCTCCC TTGCATCAGA TACTGCCATT GGGGATGGCA 240
 AAGAAGAGAG AAGGTATTGT GAGGATATAT TTTTCTAAGA AAAACGTTT GAAGAAAAGA 300
 AGATGAAGAA GATCTGCTTG ATTCATTGCA CAAGTTAGAA GTAACAGGGG TCTATATTTT 360
 GAAGAACTTA AAGGGAATGC AACTGAACAT AAAATTAAAC AAAGGGATTG AATCCTGCAG 420
 TGAGTATTTT CGGTTTTTCA CTGGTTCTCT GTAAAAAGAG TAATGCAAAG GGCAAGTTAA 480
 CTTAGGTCGT AAATGTATTG AATTTGCTTA AAATCTGAAG ATCTAGTGGT GAACCGTGGA 540
 AGATTATCAA GAGGAGGCTG AAGATCTGTT TAAGAACCAT TAATCAAACCT GGTATTCTAT 600
 TTTCCTGGT TGTATGTAAA CATTCTATCT TATTCCTTTT ATCACTGTTC TGCACCTTCC 660

SUBSTITUTE SHEET (RULE 26)

150

TATAAAAAA	GTTGACCGAC	CGTACTCTCT	GAATTCATTT	TTCCCGATCT	TACCAACTCC	720
CGATCTATCT	CTATCCCTGG	TTTTTCTTC	GTGCTCCAAT	GGAATTCTTG	AGACTTCCAC	780
TATCTTCTCT	GGCACCTCC	ACTACGCGTA	GGCGTCTCTC	GCTTCGTGTA	TTCCCGGGAA	840
GCCGGTTCCC	GTCTCTCCCG	CCGCTGCCGC	TGCCGCACAC	AGCTTTACAC	CTCGTAGAAT	900
CCCCAAAGAG	GGGCGTGGCT	TGCGGGTGCC	AACATCCTCC	TGCCGAGGAA	GAAGCAGGCA	960
CTCATCACTC	GCATCATCAA	CCTCGGGATT	GGCCAAAGGA	CCCAAAGGTA	TGTTTCGAAT	1020
GATACTAACA	TAACATAGAA	CATTTTCAGG	AGGACCCTTG	GCTAGAACTA	GTGGATCCGA	1080
GCTCTCCCAT	ATGACGACGT	CAAATGTAGA	ATTGATACCA	ATCTACACGG	ATTGGGCCAA	1140
TGGGCACCTT	TCGAAGGGCA	GCTTATCAAA	GTGATTAGG	GATATTTCCA	ATGATTTTCG	1200
CGACTATCGA	CTGGTTTCTC	AGCTTATTAA	TGTGATCGTT	CCGATCAACG	AATTCTCGCC	1260
TGCATTCACG	AAACGTTTGG	CAAAAATCAC	ATCGAACCTG	GATGGCCTCG	AAACGTGTCT	1320
CGACTACCTG	AAAAATCTGG	GTCTCGACTG	CTCGAAACTC	ACCAAAACCG	ATATCGACAG	1380
CGEAAACTTG	GGTGCA GTT	TCCAGCTGCT	CTTCCTGCTC	TCCACCTACA	AGCAGAAGCT	1440
TCGGCAACTG	AAAAAAGATC	AGAAGAAATT	GGAGCAACTA	CCCACATCCA	TTATGCCACC	1500
CGCGGTTTCT	AAATTACCCT	CGCCACGTGT	CGCCACGTCA	GCAACCGCTT	CAGCAACTAA	1560
CCCCAATTCC	AACTTTCCAC	AAATGTCAAC	ATCCAGGCTT	CAGACTCCAC	AGTCAAGAAT	1620
ATCGAAATT	GATTCATCAA	AGATTGGTAT	CAAGCCAAAG	ACGTCTGGAC	TTAAACCACC	1680
CTCATCATCA	ACCACTTCAT	CAAATAATAC	AAATTCATT	CGTCCGTCGA	GCCGTTCGAG	1740
TGGCAATAAT	AATGTTGGCT	CGACGATATC	CACATCTGCG	AAGAGCTTAG	AATCATCATC	1800
AACGTACAGC	TCTATTTCGA	ATCTAAACCG	ACCTACCTCC	CAACTCCAAA	AACCTTCTAG	1860
ACCACAAACC	CAGCTAGTTC	GTGTTGCTAC	AACTACAAA	ATCGGAAGCT	CAAAGCTAGC	1920
CGCTCCGAAA	GCCGTGAGCA	CCCCAAACT	TGCTTCTGTG	AAGACTATTG	GAGCAAAACA	1980
AGAGCCCCGAT	AACAGCGGTG	GTGGTGGTGG	TGGAATGCTG	AAATTAAAGT	TATTCAGTAG	2040
CAAAAACCCA	TCTTCCTCAT	CGAATAGCCC	ACAACCTACG	AGAAAGGCGG	CGGCGGTGCC	2100
TCAACAACAA	ACTTTGTGCA	AAATCGCTGC	CCCAGTGAAA	AGTGGCCTGA	AGCCGCCGAC	2160
CAGTAAGCTG	GGAAGTGCCA	CGTCTATGTC	GAAGCTTTGT	ACGCCAAAAG	TTTCCTACCG	2220
TAAAACGGAC	GCCCCAATCA	TATCTCAACA	AGACTCGAAA	CGATGCTCAA	AGAGCAGTGA	2280
AGAAGAGTCC	GGATACGCTG	GATTCAACAG	CACGTCGCCA	ACGTCATCAT	CGACGGAAGG	2340
TTCCCTAAGC	ATGCATTCCA	CATCTTCCAA	GAGTTCAACG	TCAGACGAAA	AGTCTCCGTC	2400
ATCAGACGAT	CTTACTCTTA	ACGCCTCCAT	CGTGACAGCT	ATCAGACAGC	CGATAGCCGC	2460
AACACCGGTT	TCTCCAAATA	TTATCAACAA	GCCTGTTGAG	GAAAAACCAA	CACTGGCAGT	2520
GAAAGGAGTG	AAAAGCACAG	CGAAAAAGA	TCCACCTCCA	GCTGTTCCGC	CACGTGACAC	2580

SUBSTITUTE SHEET (RULE 26)

CCAGCCAACA ATCGGAGTTG TTAGTCCAAT TATGGCACAT AAGAAGTTGA CAAATGACCC	2640
CGTGATATCT GAAAAACCAG AACCTGAAAA GCTCCAATCA ATGAGCATCG ACACGACGGA	2700
CGTTCCACCG CTTCCACCTC TAAAATCAGT TGTTCCACTT AAAATGACTT CAATCCGACA	2760
ACCACCAACG TACGATGTTT TTCTAAAAACA AGGAAAAATC ACATCGCCTG TCAAGTCGTT	2820
TGGATATGAG CAGTCGTCCG CGTCTGAAGA CTCCATTGTG GTCATGCGT CGGCTCAGGT	2880
GACTCCGCCG ACAAAAACTT CTGGTAATCA TTCGTGGAG AGAAGGATGG GAAAGAATAA	2940
GACATCAGAA TCCAGCGGCT ACACCTCTGA CGCCGGTGTT GCGATGTGCG CCAAATGAG	3000
GGAGAAGCTG AAAGAATACG ATGACATGAC TCGTCGAGCA CAGAACGGCT ATCCTGACAA	3060
CTTCGAAGAC AGTTCCTCCT TGTCGTCTGG AATATCCGAT AACACGAGC TCGACGACAT	3120
ATCCACGGAC GATTTGTCCG GAGTAGACAT GGCAACAGTC GCCTCCAAAC ATAGCGACTA	3180
TTCCCACTTT GTTCGCCATC CCACGTCTTC TTCTCAAAG CCCCGAGTCC CCAGTCGGTC	3240
CTCCACATCA GTCGATTCTC GATCTCGAGC AGAACAGGAG AATGTGTACA AACTTCTGTC	3300
CCAGTGCCGA ACGAGCCAAC GTGGCGCCGC TGCCACCTCA ACCTTCGGAC AACATTGCT	3360
AAGATCCCCG GGATACTCAT CCTATTCTCC ACACTTATCA GTGTCAGCTG ATAAGGACAC	3420
AATGTCTATG CACTCACAGA CTAGTCGACG ACCTTCTTCA CAAAAACCA GCTATTGAGG	3480
CCAATTTTCA TCACTTGATC GTAAATGCCA CCTTCAAGAG TTCACATCCA CCGAGCACAG	3540
AATGGCGGCT CTCTTGAGCC CGAGACGGGT GCCGAACCTG ATGTCGAAAT ATGATTCTTC	3600
AGGATCCTAC TCGGCGCGTT CCCGAGGTGG AAGCTCTACT GGTATCTATG GAGAGACGTT	3660
CCAACGACAG AGACTATCCG ATGAAAAATC CCCCACAT TCTGCCAAAA GTGAGATGGG	3720
ATCCCAACTA TCACTGGCTA GCACGACAGC ATATGGATCT CTCAATGAGA AGTACGAACA	3780
TGCTATTGCG GACATGGCAC GTGACTTGA GTGTTACAAG AACACTGTCG ACTCACTAAC	3840
CAAGAAACAG GAGAACTATG GAGCATTGTT TGATCTTTTT GAGCAAAAGC TTAGAAAAC	3900
CACTCAACAC ATTGATCGAT CCAACTTGAA GCCTGAAGAG GCAATACGAT TCAGGCAGGA	3960
CATTGCTCAT TTGAGGGATA TTAGCAATCA TCTTGATCC AACTCAGCTC ATGCTAACGA	4020
AGGCGCTGGT GAGCTTCTTC GTCAACCATC TCTGGAATCA GTTGCATCCC ATCGATCATC	4080
GATGTCATCG TCGTCGAAAA GCAGCAAGCA GGAGAAGATC AGCTTGAGCT CGTTTGGCAA	4140
GAACAAGAAG AGCTGGATCC GCTCCTCACT CTCCAAGTTC ACCAAGAAGA AGAACAAGAA	4200
CTACGACGAA GCACATATGC CATCAATTTT CCGATCTCAA GGAACCTTG ACAACATTGA	4260
TGTGATTGAG TTGAAGCAAG AGCTCAAAGA ACGCGATAGT GCACTTTACG AAGTCCGCCT	4320
TGACAATCTG GATCGTGCCC GCGAAGTTGA TGTCTGAGG GAGACAGTGA ACAAGTTGAA	4380
AACCGAGAAC AAGCAATTAA AGAAAGAAGT GGACAACTC ACCAACGGTC CAGCCACTCG	4440
TGCTTCTTCC CGCGCTCAA TTCCAGTTAT CTACGACGAT GAGCATGTCT ATGATGCAGC	4500

GTGTAGCAGT	ACATCAGCTA	GTCAATCTTC	GAAACGATCC	TCTGGCTGCA	ACTCAATCAA	4560
GGTTACTGTA	AACGTGGACA	TCGCTGGAGA	AATCAGTTCG	ATCGTTAACC	CGGACAAAGA	4620
GATAATCGTA	GGATATCTTG	CCATGTCAAC	CAGTCAGTCA	TGCTGGAAAG	ACATTGATGT	4680
TTCTATTCTA	GGACTATTTG	AAGTCTACCT	ATCCAGAATT	GATGTGGAGC	ATCAACTTGG	4740
AATCGATGCT	CGTGATTCTA	TCCTTGGCTA	TCAAATTGGT	GAACTTCGAC	GCGTCATTGG	4800
AGACTCCACA	ACCATGATAA	CCAGCCATCC	AAGTGCATT	CTTACTTCCT	CAACTACAAT	4860
CCGAATGTTT	ATGCACGGTG	CCGCACAGAG	TCGCGTAGAC	AGTCTGGTCC	TTGATATGCT	4920
TCTTCCAAAG	CAAAATGATT	TCCAACTCGT	CAAGTCAATT	TTGACAGAGA	GACGTCTGGT	4980
GTTAGCTGGA	GCAACTGGAA	TTGGAAAGAG	CAAACTGGCG	AAGACCCTGG	CTGCTTATGT	5040
ATCTATTCTA	ACAAATCAAT	CCGAAGATAG	TATGTGTAAT	ATCAGCATTC	CTGAAAACAA	5100
TAAAGAAGAA	TTGCTTCAAG	TGGAACGACG	CCTGGAAAAG	ATCTTGAGAA	GCAAAGAATC	5160
ATGCATCGTA	ATTCTAGATA	ATATCCCAA	GAATCGAATT	GCATTTGTTG	TATCCGTTTT	5220
TGCAAATGTC	CCACTTCAAA	ACAACGAAGG	TCCATTTGTA	GTATGCACAG	TCAACCGATA	5280
TCAAATCCCT	GAGCTTCAAA	TTCAACCAAA	TTTCAAAATG	TCAGTAATGT	CGAATCGTCT	5340
CGAAGGATT	ATCCTACGTT	ACCTCCGACG	ACGGGCGGTA	GAGGATGAGT	ATCGTCTAAC	5400
TGTACAGATG	CCATCAGAGC	TCTTCAAAAT	CATTGACTTC	TTCCAATAG	CTCTTCAGGC	5460
CGTCAATAAT	TTTATTGAGA	AAACGAATTC	TGTTGATGTG	ACAGTTGGTC	CAAGAGCATG	5520
CTTGAAGTGT	CCTCTAACTG	TCGATGGATC	CCGTGAATGG	TTCATTGATG	TGTGGAATGA	5580
GAACTTCATT	CCATATTTGG	AACGTGTTGC	TAGAGATGGC	AAAAAACCT	TCGGTCGCTG	5640
CACTTCCTTC	GAGGATCCCA	CCGACATCGT	CTCTAAAAAA	TGGCCGTGGT	TCGATGGTGA	5700
AAACCCGGAG	AATGTGCTCA	AACGTCTTCA	ACTCCAAGAC	CTCGTCCCGT	CACCTGCCAA	5760
CTCATCCCGA	CAACACTTCA	ATCCCCTCGA	GTCGTTGATC	CAATTGCATG	CTACCAAGCA	5820
TCAGACCATC	GACAACATTT	GAACAGAAGA	CTCTAATCTT	CTCTCGCCTC	TCCCCGCTT	5880
TCCTTATCTT	CGTACCGGTA	CCATGGTATT	GATATCTGAG	CTCCGCATCG	GCCGCTGTCA	5940
TCAGATCGCC	ATCTCGCGCC	CGTGCCCTCG	ACTTCTAAGT	CCAATTACTC	TTCAACATCC	6000
CTACATGCTC	TTTCTCCCTG	TGCTCCCAAC	CCCTATTTTT	GTTATTATCA	AAAAAACTTC	6060
TTCTTAATTT	CTTTGTTTTT	TAGCTTCTTT	TAAGTCACCT	CTAACAATGA	AATTGTGTAG	6120
ATTCAAAAAT	AGAATTAATT	CGTAATAAAA	AGTCGAAAAA	AATTGTGCTC	CCTCCCCCCA	6180
TTAATAATAA	TTCTATCCCA	AAATCTACAC	AATGTTCTGT	GTACACTTCT	TATGTTTTTT	6240
TTACTTCTGA	TAAATTTTTT	TTGAAACATC	ATAGAAAAAA	CCGCACACAA	AATACCTTAT	6300
CATATGTTAC	GTTTCAGTTT	ATGACCGCAA	TTTTTATTTT	TTGCGACGTC	TGGGCCTCTC	6360
ATGACGTCAA	ATCATGCTCA	TCGTGAAAAA	GTTTGGAGT	ATTTTGGAA	TTTTTCAATC	6420

AAGTGAAAGT TTATGAAATT AATTTTCCTG CTTTTGCTTT TTGGGGGTTT CCCCTATTGT	6480
TTGTCAAGAG TTTCGAGGAC GGC GTTTTTTC TTGCTAAAAT CACAAGTATT GATGAGCACG	6540
ATGCAAGAAA GATCGGAAGA AGGTTTGGGT TTGAGGCTCA GTGGAAGGTG AGTAGAAGTT	6600
GATAATTTGA AAGTGGAGTA GTGTCTATGG GGTTTTTGCC TTAAATGACA GAATACATTC	6660
CCAATATACC AAACATAACT GTTTAAATTT AAACATTTTT CTAAATTTTA TATGATTTCT	6720
TTTAAATTTG CAAAAATTAC TTAAATTTGA ATTCCCGCGC AAATGAGTGA CTTCATTTTT	6780
TGCATTATTG TGT TTTCCGG CTATATTAAT AGGTATTGT TTGTGTTTTT CTTTATTTTA	6840
TGATTGGAAC TCCAATTTGT AAATTTTCGA ACATATTTCC CTAAAGAAAA AATATGATTA	6900
ATCTGGA AAA ATTGGA AAA TATTTTCAA ATAAAAACA AAGAAAAAA TGAAGAAAA	6960
CCTATTAGTT TGGCCATAAA ACGCAAAAAT GTCGAAAATG ACGTCACTCA TCTGCGCGGG	7020
AAATCAAGAA TAATTCGGCC TTTTTTATTT TTTTGGAAAA TCGTAAAAACA TTTAGAAAA	7080
TTTTTTAATA GTTATAGTGG GACTGTATTC TGTCATTTAG GGCAAAAGCC AGAGACGCTA	7140
CTCCACCGTT GGGGGATCCA CTAGTCGGCC GTACGGGCCC TTTCTCTCTG CGCGTTTCGG	7200
TGATGACGGT GAAAACCTCT GACACATGCA GCTCCCGGAG ACGGTCACAG CTTGTCTGTA	7260
AGCGGATGCC GGGAGCAGAC AAGCCCGTCA GGGCGCGTCA GCGGGTGTG GCGGGTGTG	7320
GGGCTGGCTT AACTATGCGG CATCAGAGCA GATTGTACTG AGAGTGCACC ATATGCGGTG	7380
TGAAATACCG CACAGATGCG TAAGGAGAAA ATACCGCATC AGGCGGCCTT AAGGGCCTCG	7440
TGATACGCCT ATTTTATAG GTTAATGTCA TGATAATAAT GGTTCCTTAG ACGTCAGGTG	7500
GCACTTTTCG GGGAAATGTG CGCGGAACCC CTATTTGTTT ATTTTCTAA ATACATTCAA	7560
ATATGTATCC GCTCATGAGA CAATAACCCT GATAAATGCT TCAATAATAT TGAAAAAGGA	7620
AGAGTATGAG TATTCACAT TTCCGTGTCG CCCTTATTC CTTTTTGCG GCATTTTGCC	7680
TTCTGTTTT TGCTCACCCA GAAACGCTGG TGAAAGTAAA AGATGCTGAA GATCAGTTGG	7740
GTGCACGAGT GGGTTACATC GAACTGGATC TCAACAGCGG TAAGATCCTT GAGAGTTTTT	7800
GCCCCGAAGA ACGTTTTCCA ATGATGAGCA CTTTAAAGT TCTGCTATGT GGCGCGGTAT	7860
TATCCCGTAT TGACGCCGGG CAAGAGCAAC TCGGTCGCCG CATACTAT TCTCAGAATG	7920
ACTTGGTTGA GTACTACCA GTCACAGAAA AGCATCTTAC GGATGGCATG ACAGTAAGAG	7980
AATTATGCAG TGCTGCCATA ACCATGAGTG ATAACACTGC GGCCAACTTA CTTCTGACAA	8040
CGATCGGAGG ACCGAAGGAG CTAACCGCTT TTTTGCACAA CATGGGGGAT CATGTAACTC	8100
GCCTTGATCG TTGGGAACCG GAGCTGAATG AAGCCATACC AAACGACGAG CGTGACACCA	8160
CGATGCCTGT AGCAATGGCA ACAACGTTGC GCAAATATT AACTGGCGAA CTACTTACTC	8220
TAGCTTCCCG GCAACAATTA ATAGACTGGA TGGAGGCGGA TAAAGTTGCA GGACCACTTC	8280
TGCGCTCGGC CCTTCCGGCT GGCTGGTTTA TTGCTGATAA ATCTGGAGCC GGTGAGCGTG	8340

154

```

GGTCTCGCGG TATCATTGCA GCACTGGGGC CAGATGGTAA GCCCTCCCGT ATCGTAGTTA      8400
TCTACACGAC GGGGAGTCAG GCAACTATGG ATGAACGAAA TAGACAGATC GCTGAGATAG      8460
GTGCCTCACT GATTAAGCAT TGGTAACTGT CAGACCAAGT TTACTCATAT ATACTTTAGA      8520
TTGATTAAAA ACTTCATTTT TAATTTAAAA GGATCTAGGT GAAGATCCTT TTTGATAATC      8580
TCATGACCAA AATCCCTTAA CGTGAGTTTT CGTTCCACTG AGCGTCAGAC CCCGTAGAAA      8640
AGATCAAAGG ATCTTCTTGA GATCCTTTTT TTCTGCGCGT AATCTGCTGC TTGCAAACAA      8700
AAAAACCACC GCTACCAGCG GTGGTTTGTT TGCCGGATCA AGAGCTACCA ACTCTTTTTC      8760
CGAAGGTAAC TGGCTTCAGC AGAGCGCAGA TACCAAATAC TGTCTTCTA GTGTAGCCGT      8820
AGTTAGGCCA CCACTTCAAG AACTCTGTAG CACCGCCTAC ATACCTCGCT CTGCTAATCC      8880
TGTTACCACT GGCTGCTGCC AGTGGCGATA AGTCGTGTCT TACCGGGTTG GACTCAAGAC      8940
GATAGTTACC GGATAAGGCG CAGCGGTCGG GCTGAACGGG GGGTTCGTGC ACACAGCCCA      9000
GCTTGAGCG AACGACCTAC ACCGAACTGA GATACCTACA GCGTGAGCAT TGAGAAAGCG      9060
CCACGCTTCC CGAAGGGAGA AAGGCGGACA GGTATCCGGT AAGCGGCAGG GTCGGAACAG      9120
GAGAGCGCAC GAGGGAGCTT CCAGGGGGAA ACGCCTGGTA TCTTTATAGT CCTGTGCGGT      9180
TTCGCCACCT CTGACTTGAG CGTCGATTTT TGTGATGCTC GTCAGGGGGG CGGAGCCTAT      9240
GGAAAAACGC CAGCAACGCG GCCTTTTTAC GGTTCCTGGC CTTTGCTGG CCTTTTGCTC      9300
ACATGTTCTT TCCTGCGTTA TCCCCTGATT CTGTGGATAA CCGTATTACC GCCTTTGAGT      9360
GAGCTGATAC CGCTCGCCGC AGCCGAACGA CCGAGCGCAG CGAGTCAGTG AGCGAGGAAG      9420
CGGAAGAGCG CCAATACGC AAACCGCCTC TCCCGCGCGG TTGGCCGATT CATTAAATGCA      9480
GCTGGCACGA CAGGTTTCCC GACTGGAAAG CGGGCAGTGA GCGCAACGCA ATTAATGTGA      9540
GTTAGCTCAC TCATTAGGCA CCCAGGCTT TACACTTTAT GCTTCCGGCT CGTATGTTGT      9600
GTGGAATTGT GAGCGGATAA CAATTCACA CAGGAAACAG CT                          9642

```

(2) INFORMATION FOR SEQ ID NO: 31:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 110 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31:

```

Met Thr Thr Ser Asn Val Glu Leu Ile Pro Ile Tyr Thr Asp Trp Ala
1           5           10           15
Asn Arg His Leu Ser Lys Gly Ser Leu Ser Lys Ser Ile Arg Asp Ile
20           25           30

```

SUBSTITUTE SHEET (RULE 26)

155

Ser Asn Asp Phe Arg Asp Tyr Arg Leu Val Ser Gln Leu Ile Asn Val
 35 40 45
 Ile Val Pro Ile Asn Glu Phe Ser Pro Ala Phe Thr Lys Arg Leu Ala
 50 55 60
 Lys Ile Thr Ser Asn Leu Asp Gly Leu Glu Thr Cys Leu Asp Tyr Leu
 65 70 75 80
 Lys Asn Leu Gly Leu Asp Cys Ser Lys Leu Thr Lys Thr Asp Ile Asp
 85 90 95
 Ser Gly Asn Leu Gly Ala Val Leu Gln Leu Leu Phe Leu Leu
 100 105 110

(2) INFORMATION FOR SEQ ID NO: 32:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 20 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32:

Lys Gln Lys Leu Arg Gln Leu Lys Lys Asp Gln Lys Lys Leu Glu Gln
 1 5 10 15
 Leu Pro Thr Ser
 20

(2) INFORMATION FOR SEQ ID NO: 33:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 9 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33:

Asp Pro Pro Pro Ala Val Pro Pro Arg
 1 5

(2) INFORMATION FOR SEQ ID NO: 34:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 9 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

SUBSTITUTE SHEET (RULE 26)

156

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34:

Asp Val Pro Pro Leu Pro Pro Leu Lys
1 5

(2) INFORMATION FOR SEQ ID NO: 35:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35:

Lys Lys Lys Asn Lys
1 5

(2) INFORMATION FOR SEQ ID NO: 36:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36:

Lys Thr Glu Asn Lys Gln Leu Lys Lys Glu Val Asp Lys Leu Thr Asn
1 5 10 15
Gly Pro Ala Thr
20

(2) INFORMATION FOR SEQ ID NO: 37:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 37:

Gly Ala Thr Gly Ile Gly Lys Ser
1 5

SUBSTITUTE SHEET (RULE 26)

157

(2) INFORMATION FOR SEQ ID NO: 38:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 58 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 38:

```

Met Ser Glu Glu Pro Thr Pro Val Ser Gly Asn Asp Lys Gln Leu Leu
 1              5              10              15

Asn Lys Ala Trp Glu Ile Thr Gln Lys Lys Thr Phe Thr Ala Trp Cys
      20              25              30

Asn Ser His Leu Arg Lys Leu Gly Ser Ser Ile Glu Gln Ile Asp Thr
      35              40              45

Asp Phe Thr Asp Gly Ile Lys Leu Ala Gln
      50              55

```

(2) INFORMATION FOR SEQ ID NO: 39:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 44 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 39:

```

Met Thr Thr Ser Asn Val Glu Leu Ile Pro Ile Tyr Thr Asp Trp Ala
 1              5              10              15

Asn Arg His Leu Ser Lys Gly Ser Leu Ser Lys Ser Ile Arg Asp Ile
      20              25              30

Ser Asn Asp Phe Arg Asp Tyr Arg Leu Val Ser Gln
      35              40

```

(2) INFORMATION FOR SEQ ID NO: 40:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 51 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

158

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 40:

Phe Glu Arg Ser Arg Ile Lys Ala Leu Ala Asp Glu Arg Glu Val Val
 1 5 10 15
 Gln Lys Lys Thr Phe Thr Lys Trp Val Asn Ser His Leu Ala Arg Val
 20 25 30
 Ser Cys Arg Ile Thr Asp Leu Tyr Lys Asp Leu Arg Asp Gly Arg Met
 35 40 45
 Leu Ile Lys
 50

(2) INFORMATION FOR SEQ ID NO: 41:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 59 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 41:

Leu Leu Glu Val Ile Ser Asn Asp Pro Val Phe Lys Val Asn Lys Thr
 1 5 10 15
 Pro Lys Leu Arg Arg Ile His Asn Ile Gln Asn Val Gly Leu Cys Leu
 20 25 30
 Lys His Ile Glu Ser His Gly Val Lys Leu Val Gly Ile Gly Ala Glu
 35 40 45
 Glu Leu Val Asp Lys Asn Leu Lys Met Thr Leu
 50 55

(2) INFORMATION FOR SEQ ID NO: 42:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 60 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 42:

Leu Ile Asn Val Ile Val Pro Ile Asn Glu Phe Ser Pro Ala Phe Thr
 1 5 10 15
 Lys Arg Leu Ala Lys Ile Thr Ser Asn Leu Asp Gly Leu Glu Thr Cys
 20 25 30
 Leu Asp Tyr Leu Lys Asn Leu Gly Leu Asp Cys Ser Lys Leu Thr Lys
 35 40 45
 Thr Asp Ile Asp Ser Gly Asn Leu Gly Ala Val Leu
 50 55 60

SUBSTITUTE SHEET (RULE 26)

159

(2) INFORMATION FOR SEQ ID NO: 43:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 57 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 43:

```

Leu Leu Glu Val Leu Ser Gly Glu Met Leu Pro Lys Pro Thr Lys Gly
1           5           10           15
Lys Met Arg Ile His Cys Leu Glu Asn Val Asp Lys Ala Leu Gln Phe
20           25           30
Leu Lys Glu Gln Arg Val His Leu Glu Asn Met Gly Ser His Asp Ile
35           40           45
Val Asp Gly Asn His Arg Leu Val Leu
50           55

```

(2) INFORMATION FOR SEQ ID NO: 44:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 42 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 44:

```

Gly Met Ile Trp Thr Ile Ile Leu Arg Phe Ala Ile Gln Asp Ile Ser
1           5           10           15
Ile Glu Glu Leu Ser Ala Lys Glu Ala Leu Leu Leu Trp Cys Gln Arg
20           25           30
Lys Thr Glu Gly Tyr Asp Arg Val Lys Val
35           40

```

(2) INFORMATION FOR SEQ ID NO: 45:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 46 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: unknown

SUBSTITUTE SHEET (RULE 26)

160

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 45:

Gln	Leu	Leu	Phe	Leu	Leu	Ser	Thr	Tyr	Lys	Gln	Lys	Leu	Arg	Gln	Leu
1			5					10					15		
Lys	Lys	Asp	Gln	Lys	Lys	Leu	Glu	Gln	Leu	Pro	Thr	Ser	Ile	Met	Pro
		20					25					30			
Pro	Ala	Val	Ser	Lys	Leu	Pro	Ser	Pro	Arg	Val	Ala	Thr	Ser		
		35				40						45			

(2) INFORMATION FOR SEQ ID NO: 46:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 48 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 46:

Gly	Leu	Ile	Trp	Thr	Ile	Ile	Leu	Arg	Phe	Gln	Ile	Gln	Asp	Ile	Val
1			5					10					15		
Val	Gln	Thr	Gln	Glu	Gly	Arg	Glu	Thr	Arg	Ser	Ala	Lys	Asp	Ala	Leu
		20					25					30			
Leu	Gln	Phe	Leu	Lys	Glu	Gln	Arg	Val	His	Leu	Glu	Asn	Met	Gly	Ser
		35				40					45				

(2) INFORMATION FOR SEQ ID NO: 47:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 100 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cosmid DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 47:

GATCAGAAGA	AATTGGAGCA	ACTACCCACA	TCCATTATGC	CACCCGCGGT	TTCTAAGTGA	60
GTTTAATTTT	GAGTTTACGA	CTACAAAAAT	GTGTTCTTTA			100

SUBSTITUTE SHEET (RULE 26)

161

(2) INFORMATION FOR SEQ ID NO: 48:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 91 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cosmid DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 48:

CCGCCTTCTG ACTTCGTGAC GACAGTCTCG ACACGTGGGG TTGCAGGTAG GAGTGGATGA	60
GTCGAAACTG ATAAGATAGT CATTGAGAT C	91

CLAIMS:

1. A cDNA encoding an UNC-53 protein of C. elegans or a functional equivalent derivative fragment or bioprecursor of said protein, which cDNA comprises at least from nucleotide position 431 to nucleotide position 4647 of the sequence shown in Figure 1.
5
2. A cDNA as claimed in claim 1 comprising at least from nucleotide position 431 to the 3' end of the sequence shown in Figure 1.
10
3. A cDNA as claimed in Claim 1 comprising at least from nucleotide position 64 to nucleotide position 4647 of the sequence as shown in Figure 1.
15
4. A cDNA as claimed in claim 3 comprising at least from nucleotide position 64 to the 3' end of the sequence shown in Figure 1.
20
5. A cDNA as claimed in Claims 1 to 4 comprising the nucleotide sequence shown in Figure 1.
6. A cDNA encoding an UNC-53 protein of C. elegans or a functional equivalent, derivative, fragment or bioprecursor of said protein, which cDNA comprises at least from nucleotide position 431 to nucleotide position 4812 of the 7A variant of the sequence shown in Figure 2.
25
7. A cDNA as claimed in claim 6 comprising at least
30

from nucleotide position 431 to the 3' end of the 7A variant of the sequences shown in figure 2.

5 8. A cDNA as claimed in Claim 6 comprising at least
from nucleotide position 64 to nucleotide position
4812 of the sequence shown in Figure 2.

10 9. A cDNA as claimed in claim 8 comprising at least
from nucleotide position 64 to the 3' end of the 7A
variant of the sequence shown in figure 2.

15 10. A cDNA as claimed in any of claims 6 to 9
comprising the nucleotide sequence of the 7A variant
of the sequence shown in Figure 2.

15

11. A DNA expression vector which comprises a cDNA
as claimed in any one of Claims 1 to 10.

20 12. A host cell transformed or transfected with the
vector of Claim 11.

13. A host cell as claimed in Claim 12 which is a
bacterial, an animal, a plant or an insect cell.

25 14. A transgenic cell comprising a transgene capable
of expressing UNC-53 protein of C. elegans or a
functional equivalent, derivative, fragment or
bioprecursor of said protein.

30 15. A transgenic cell as claimed in Claim 14 which

cell is a C. elegans cell, an N4 neuroblastoma cell or an MCF-7 breast carcinoma cell.

5 16. A transgenic organism comprising a transgene capable of expressing UNC-53 protein of C. elegans or a functional equivalent, derivative, fragment or bioprecursor of said protein.

10 17. A transgenic organism as claimed in Claim 16 wherein said organism is C. elegans.

18. A transgenic organism as claimed in Claim 16 wherein said organism is an insect, a non-human mammal or a plant.

15

19. A mutant of C. elegans which comprises an induced mutation in the wild-type unc-53 gene, which mutation affects the regulation of cell motility or the shape or direction of cell migration.

20

20. An UNC-53 protein encoded by the cDNA of Claim 1 and which protein has the amino acid sequence shown in Figure 4 from amino acid position 135 to amino acid position 1528.

25

21. An UNC-53 protein encoded by the cDNA sequence of any of Claims 2 to 5 and which protein has the amino acid sequence shown in Figure 4.

30 22. An UNC-53 protein encoded by the cDNA sequence of Claim 6 and which protein has the amino acid

sequence shown in Figure 6 from amino acid position 135 to amino acid position 1583.

23. An UNC-53 protein encoded by the cDNA sequence according to any of Claims 7 to 10 and which protein has the amino acid sequence shown in Figure 6.
24. An UNC-53 protein of C. elegans, or a functional equivalent, derivative, fragment or bioprecursor of said protein, for use as a medicament to promote neuronal regeneration, revascularisation or wound healing, or for treatment of chronic neuro-degenerative diseases or acute traumatic injuries.
25. An UNC-53 protein as claimed in any one of Claims 20 to 23 for use as a medicament to promote neuronal regeneration, revascularisation or wound healing, or for treatment of chronic neuro-degenerative diseases or acute traumatic injuries.
26. Use of an UNC-53 protein of C. elegans, or a functional equivalent, derivative, fragment or bioprecursor of said protein in the manufacture of a medicament for promoting neuronal regeneration, revascularisation or wound healing, or for treatment of chronic neuro-degenerative diseases or acute traumatic injuries.
27. Use of an UNC-53 protein as claimed in any one of Claims 20 to 23 in the manufacture of a medicament for promoting neuronal regeneration, revascularisation or wound healing, or for treatment of chronic neuro-degenerative or acute traumatic injuries.

28. A pharmaceutical composition comprising an UNC-53 protein of C. elegans, a functional equivalent, derivative, bioprecursor or fragment of said protein and an acceptable carrier, diluent or excipient
5 therefor.

29. A pharmaceutical composition as claimed in Claim 28 which comprises an UNC-53 protein as claimed in any one of Claims 20 to 23.

10

30. A nucleic acid sequence encoding an UNC-53 protein of C. elegans or a functional fragment, equivalent, derivative or bioprecursor of said protein, for use as a medicament to promote neuronal
15 regeneration, vascularisation or wound healing, or for treatment of chronic neuro-degenerative diseases or acute traumatic injuries.

31. A nucleic acid sequence for use as claimed in
20 Claim 27 wherein said sequence is a cDNA sequence as claimed in any one of Claims 1 to 10 or a functional fragment of said nucleic acid sequence.

32. Use of a nucleic acid sequence encoding and UNC-53 protein of C. elegans or a functional equivalent fragment, derivative or bioprecursor of said protein, in the manufacture of a medicament to promote neuronal
25 regeneration, vascularization or wound healing, or for treatment of chronic neuro-degenerative diseases or
30 acute traumatic injuries.

33. Use of a nucleic acid sequence as claimed in Claim 32 wherein said sequence is a cDNA sequence as

claimed in any one of Claims 1 to 10 or a functional fragment of said nucleic acid sequence.

- 5 34. A pharmaceutical composition comprising a nucleic sequence acid encoding an UNC-53 protein of C. elegans or a functional equivalent, derivative fragment or bioprecursor of said protein and an acceptable carrier, diluent, or excipient therefor.
- 10 35. A pharmaceutical composition as claimed in Claim 34 wherein said nucleic acid sequence is a cDNA sequence as claimed in any one of Claims 1 to 10.
- 15 36. A method of determining whether a compound is an inhibitor or an enhancer of the regulation of cell shape or motility or the direction of cell migration, which method comprises contacting said compound with a transgenic cell as claimed in Claims 14 or 15 and screening for a phenotypic change in said cell.
- 20 37. A method as claimed in Claim 36 wherein said compound is an inhibitor or an enhancer of a protein of the signal transduction pathway of said transgenic cell of which pathway UNC-53 protein or a functional equivalent, fragment or bioprecursor thereof is a component or said compound is an inhibitor or an enhancer of a parallel or redundant signal transduction pathway in said cell.
- 25 38. A method as claimed in Claim 36 or 37 wherein said protein is UNC-53 protein or a functional equivalent, fragment, derivative or bioprecursor thereof.
- 30

39. A method as claimed in any of Claims 36 to 38 wherein said phenotypic change to be screened is a change in cell shape or a change in cell motility.
- 5 40. A method as claimed in any of claims 36 to 38 wherein said phenotypic change to be screened is a change in filipodia outgrowth, ruffling behaviour, cell adhesion or the length of neurite growth.
- 10 41. A method as claimed in any of Claims 36 to 40 wherein said transgenic cell is an N4 neuroblastoma cell and the phenotypic change to be screened is the length of neurite growth.
- 15 42. A method as claimed in any of Claims 36 to 40 wherein said transgenic cell is an MCF-7 breast carcinoma cell and the phenotypic change to be screened is the extent of phagokinesis.
- 20 43. A method of determining whether a compound is an inhibitor or an enhancer of the regulation of cell shape or motility or of the direction of cell migration which method comprises administering said compound to a transgenic organism as claimed in any
25 one of Claims 16 to 20, or a mutant organism as claimed in Claim 19, and screening for a phenotypic change in said organism.
- 30 44. A method as claimed in Claim 43 wherein said compound is an inhibitor or enhancer of a protein of the signal transduction pathway of said transgenic or mutant organisms, of which pathway UNC-53 protein or a functional equivalent, derivative or bioprecursor

thereof is a component or said compound is an inhibitor or an enhancer of a parallel or redundant signal transduction pathway in said cell.

- 5 45. A method as claimed in Claim 44 wherein said protein of the signal transduction pathway is UNC-53 protein itself or a functional equivalent, fragment, derivative or bioprecursor of said protein.
- 10 46. A compound which is identifiable by the method according to any one of Claims 36 to 45 as an enhancer of the regulation of cell shape or motility or the direction of cell migration for use as a medicament for promoting neuronal regeneration, revascularisation
15 or wound healing, or for treatment of chronic neuro-degenerative diseases or acute traumatic injuries.
- 20 47. Use of a compound identifiable by the method of any one of Claims 36 to 45 as an enhancer of the regulation of cell shape or motility or the direction of cell migration in C. elegans in the manufacture of a medicament for promoting neuronal regeneration, revascularisation or wound healing, or for treatment of chronic neuro-degenerative diseases or acute
25 traumatic injuries.
- 30 48. A pharmaceutical composition comprising the compound as claimed in Claim 46 and an acceptable carrier, diluent or excipient therefor.
49. A compound which is identifiable by the method according to any one of Claims 36 to 45 as an inhibitor of the regulation of cell motility or shape

or the direction of cell migration of C. elegans for use as a medicament for alleviating the spread of disease inducing cells or metastasis.

- 5 50. Use of a compound identifiable by the method according to any one of Claims 36 to 45 in the manufacture of a medicament for alleviating the spread of disease inducing cells or metastasis.
- 10 51. A pharmaceutical composition comprising the compound as claimed in Claim 49 and an acceptable carrier diluent or excipient therefor.
- 15 52. A transgenic cell which has been constructed to comprise a promoter sequence of an unc-53 gene of C. elegans fused to a nucleic acid sequence encoding a reporter molecule.
- 20 53. A transgenic cell as claimed in Claim 52 wherein said reporter molecule is green fluorescent protein (GFP).
- 25 54. A method of determining whether a compound is an inhibitor or an enhancer of transcription of an unc-53 gene in C. elegans or a functional fragment of said gene, which method comprises the steps of (a) contacting said compound with a transgenic cell according to Claim 52 and (b) monitoring of said reporter molecule and comparing the results obtained
- 30 from said monitoring step with a control comprising a transgenic cell as claimed in Claim 48, which cell has not been contacted with said compound.

- 171 -

55. A method as claimed in Claim 54 wherein said reporter molecule detected is mRNA.

5 56. A method as claimed in Claim 54 wherein said reporter molecule detected is green fluorescent protein (GFP).

10 57. A compound which is identifiable by the method according to any one of Claims 54 to 56, as an enhancer of transcription of an unc-53 gene of C. elegans or a functional fragment of said gene for use in promoting neuronal regeneration, revascularisation or wound healing, or for treatment of chronic neuro-degenerative diseases or acute
15 traumatic injuries.

58. Use of a compound which is identifiable by the method of any one of Claims 54 to 56 as an enhancer of transcription of an unc-53 gene of C. elegans or a
20 functional fragment of said gene in the manufacture of a medicament for promoting neuronal regeneration, revascularisation or wound healing, or for treatment of chronic neuro-degenerative diseases or acute traumatic injuries.

25

59. A pharmaceutical composition which comprises the compound of Claim 57 and an acceptable carrier, diluent or excipient therefor.

30 60. A compound which is identifiable by the method of any one of Claims 54 to 56 as an inhibitor of transcription of an unc-53 gene of C. elegans or a functional fragment of said gene for use in

SUBSTITUTE SHEET (RULE 26)

- 172 -

alleviating the spread of disease inducing cells or metastasis.

5 61. Use of a compound which is identifiable by the method of any one of Claims 54 to 56 as an inhibitor of transcription of an unc-53 gene of C. elegans or a functional fragment of said gene in the manufacture of a medicament for alleviating spread of disease inducing cells or metastasis.

10

62. A pharmaceutical composition which comprises the compound of Claim 60 and an acceptable carrier, diluent or excipient therefor.

15 63. A kit for determining whether a compound is an enhancer or an inhibitor of the regulation of cell motility or shape or the direction of cell migration which kit comprises at least a plurality of transgenic cells as claimed in any one of Claims 14 or 15 and a
20 plurality of wild-type cells of the same cell or cell-line.

64. A kit for determining whether a compound is an inhibitor or an enhancer of transcription of an unc-53
25 gene of C. elegans or a functional fragment of said gene which kit comprises at least a plurality of transgenic cells as claimed in Claims 52 or 53 and means for monitoring the reporter molecule.

30 65. A kit for determining whether a compound is an enhancer or an inhibitor of the activity of UNC-53 protein or a functional equivalent, derivative, fragment or bioprecursor of said protein, which kit

SUBSTITUTE SHEET (RULE 26)

- 173 -

comprises at least, one mutant organism of C. elegans as claimed in claim 10 or a transgenic organism as claimed in any of claims 16 to 18 and a wild type organism of C. elegans.

5

66. An oligonucleotide probe which comprises the carboxy-terminal 1.5 kb of the coding nucleic acid sequence shown in Figure 1 or a fragment thereof comprising between 18 and 24 base pairs.

10

67. An oligonucleotide probe comprising a nucleic acid sequence encoding the amino acid sequence as numbered 1 to 110, 114 to 133, 487 to 495, 537 to 545, 1032 to 1037, 1097 to 1116 or 1300 to 1307 shown in Figure 3 or a fragment thereof.

15

68. A probe as claimed in Claim 66 or 67 which is labelled for detection.

20

69. A method of identifying homologues of a C. elegans unc-53 gene or a functional fragment thereof which method comprises hybridizing to a C. elegans DNA library an oligonucleotide probe as claimed in any one of Claims 66 to 68 under appropriate conditions of stringency to identify genes having statistically significant homology with the cDNA of any one of Claims 1 to 10.

25

70. A method of identifying a protein which is active in the signal transduction pathway of a cell of which an UNC-53 protein or a functional equivalent, fragment or bioprecursor of said UNC-53 protein is a component, which method comprises:

30

- 174 -

component, which method comprises:

- 5 (a) contacting an extract of said cell with an antibody to the UNC-53 protein of C.elegans or a functional equivalent, fragment, derivative or bioprecursor of said protein,
- (b) identifying the antibody/UNC-53 complex, and
- 10 (c) analysing the complex to identify any protein bound to the UNC-53 protein other than the antibody.

71. A method of identifying a further protein which is active in the signal transduction pathway of a cell of which an UNC-53 protein or a functional equivalent, fragment or bioprecursor of said UNC-53 protein is a component which method comprises:

- (a) forming an antibody to the identified protein bound to the UNC-53 protein in Claim 65,
- 20 (b) contacting a cell extract with said antibody and identifying the antibody/protein complex,
- (c) analysing the complex to identify any further protein bound to the first protein other than the antibody, and
- 25 (d) optionally repeating steps (a) to (c) to identify further proteins in said pathway.

72. A method of identifying a protein which is active in the signal transduction pathway of a cell of which an UNC-53 protein or a functional equivalent, fragment or bioprecursor of said UNC-53 protein is a component, which method comprises

- 175 -

- (a) contacting an extract of said cell with UNC-53 protein of C. elegans or a functional equivalent, derivative or bioprecursor of said UNC-53 protein
- 5 (b) identifying UNC-53 protein/protein complex formed and
- (c) analysing the complex to identify any protein bound to the UNC-53 protein other than another UNC-53 protein.
- 10
73. A method according to claim 72 which further comprises contacting a cell extract with any protein identified from step (c) not being UNC-53 protein and repeating steps (b) and (c) so as to identify any
- 15 further protein involved in the signal transduction pathway of said cell.
74. A method of identifying a protein involved in the signal transduction pathway of C. elegans which
- 20 method comprises:
- (a) constructing at least two nucleotide vectors, the first of which comprises a nucleotide segment encoding for a DNA binding domain of GAL4 protein fused to a sequence
- 25 encoding UNC-53 protein of C. elegans or a functional equivalent, derivative, fragment or bioprecursor thereof, the second vector comprising a nucleotide sequence encoding a protein binding domain of GAL4 protein fused to
- 30 a nucleotide sequence encoding a protein to be tested,
- (b) co-transforming each of said vectors into a yeast cell being deficient for transcription of genes encoding galactose metabolites, wherein

SUBSTITUTE SHEET (RULE 26)

- 176 -

interaction between said test protein and said UNC-53 protein leads to transcription of said galactose metabolite genes.

5 75. A protein identified by the method, of any one of claims 70 to 74 for use as a medicament to promote neuronal regeneration, revascularisation or wound healing, or for treatment of chronic neurodegenerative diseases or acute traumatic injuries.

10

76. Use of a protein identified by the methods of any one of claims 70 to 74 in the manufacture of a medicament for promoting neuronal regeneration, revascularisation or wound healing, or for treatment
15 of chronic neurodegenerative diseases or acute traumatic injuries.

77. A pharmaceutical composition comprising a protein identified by the methods of any one of Claims
20 70 to 74 and an acceptable carrier diluent, or excipient therefor.

78. A process for producing an UNC-53 protein of C. elegans or a functional equivalent fragment,
25 derivative or bioprecursor of said UNC-53 protein which process comprises culturing the transfected or transformed cells of Claim 12 or Claim 13 and recovering the expressed UNC-53 protein.

30 79. A process for producing an UNC-53 protein of C. elegans or a functional equivalent fragment, derivative or bioprecursor of said protein which process comprises culturing an insect cell transfected

SUBSTITUTE SHEET (RULE 26)

with a recombinant Baculovirus vector, said vector comprising a DNA insert encoding said UNC-53 protein or a functional equivalent, fragment or bioprecursor thereof, downstream of the Baculovirus polyhedrin promoter, and recovering the expressed UNC-53 protein.

80. A hybridoma cell line deposited under the LMBP Accession No. 1383CB.

10 81. Monoclonal antibody 16-48-2 obtainable from the hybridoma deposited under the LMBP Accession No. 1383CB.

15 82. Plasmid pTB54 deposited under the LMBP Accession No. 3296.

83. Plasmid pBT112 deposited under the Accession No. 3295.

20 84. Plasmid pTB72 deposited under the LMBP Accession No. 3486.

25 85. Transgenic cell-line of C.elegans designated TB4EX25 and deposited under the LMBP Accession No. 1384CB.

86. Transgenic cell-line of C. elegans designated TBAln76 and deposited under the Accession No. 1385CB.

30 87. A transgenic cell-line of MCF-7 breast carcinoma

- 178 -

cells deposited under the LMBP Accession No. 1550CB.

88. A transgenic cell-line of N4 neuroblastoma
cells deposited under LMBP Accession No. 1549CB.

SUBSTITUTE SHEET (RULE 26)

1/99

FIG. 1.

TB6 & TB3
|

BSP1286
HGIAI

GGTTTAATTACCCAAGTTTGAGACATCAATTCCATCGAACGAAATGTTGGTGCTCCGA AT

10 20 30 40 50 60

OUT OF FRAME ATG

TTHIIII
.AHAI
.. AATII

BANI

AAAATGACGACGTCAAATGTAGAATTGATACCAATCTACACGGATTGGGCCAATCGGC AC

70 80 90 100 110 120

M T T S N V E L I P I Y T D W A N R H

ATG1

ASUII BIVI NRUI

CTTTCGAAGGGCAGCTTATCAAAGTCGATTAGGGATATTTCCAATGATTTTCGCGACT AT

130 140 150 160 170 180

L S K G S L S K S I R D I S N D F R D Y

TB1B
|

ECORI BSMI

CGACTGGTTTCTCAGCTTATTAATGTGATCGTTCGGATCAACGAATTCTCGCCTGCAT TC

190 200 210 220 230 240

R L V S Q L I N V I V P I N E F S P A F

TB16
|

AFLIII
FOKI

ACGAAACGTTTGGCAAAAATCACATCGAACCTGGATGGCCTCGAAACGTGTCTCGACT AC

250 260 270 280 290 300

T K R L A K I T S N L D G L E T C L D Y

TB1
|

HPHI ECVI NSPBII

CTGAAAAATCTGGGTCTCGACTGCTCGAAACTCACCAAAACCGATATCGACAGCGGAA AC

310 320 330 340 350 360

L K N L G L D C S K L T K T D I D S G N

BBVI MBOII

NSPBII
PVUII

TTGGGTGCAGTTCTCCAGCTGCTCTTCTGCTCTCCACCTACAAGCAGAAGCTTCGGC AA

370 380 390 400 410 420

L G A V L Q L L F L L S T Y K Q K L R Q

FOKI
MBOII

NSPBII
.SACII

CTGAAAAAGATCAGAAGAAATTGGAGCAACTACCCACATCCATTATGCCACCCGCGG TT

430 440 450 460 470 480

L K K D Q K K L E Q L P T S I M P P A V

ATG 2

AFLIII

TCTAAATTACCCTCGCCACGTGTGCGCCACGTGAGCAACCGCTTCAGCAACTAACCCAA AT

490 500 510 520 530 540

S K L P S P R V A T S A T A S A T N P N

FOKI HINCII BSTNI

TCCAACCTTCCACAAATGTCAACATCCAGGCTTCAGACTCCACAGTCAAGAATATCGA AA

550 560 570 580 590 600

S N F P Q M S T S R L Q T P Q S R I S K

ATG3

SUBSTITUTE SHEET (RULE 26)

FIG. 1 CONTINUED.

2/99

TB6B
 |
 ATTGATTTCATCAAAGATTGGTATCAAGCCAAAGACGTCTGGACTTAAACCACCCTCAT CA
 610 620 630 640 650 660
 I D S S K I G I K P K T S G L K P P S S

AHAI I
 AATII
 TCAACCACTTCATCAAATAATAACAAATTCATTCCGTCGAGCCGTTTCGAGTGGCA AT
 670 680 690 700 710 720
 S T T S S N N T N S F R P S S R S S G N

ECORV
 AATAATGTTGGCTCGACGATATCCACATCTGCGAAGAGCTTAGAATCATCATCAACGT AC
 730 740 750 760 770 780
 N N V G S T I S T S A K S L E S S S T Y

ASUII
 AGCTCTATTTTTCGAATCTAAACCGACCTACCTCCCAACTCCAAAAACCTTCTAGACCAC AA
 790 800 810 820 830 840
 S S I S N L N R P T S Q L Q K P S R P Q

XBAI
 ACCCAGCTAGTTCGTGTTGCTACAACCTACAAAAATCGGAAGCTCAAAGCTAGCCGCTC CG
 850 860 870 880 890 900
 T Q L V R V A T T T K I G S S K L A A P

NHEI
 BSP1286
 HGIAI
 AAAGCCGTGAGCACCCCAAACTTGCTTCTGTGAAGACTATTGGAGCAAAACAAGAGC CC
 910 920 930 940 950 960
 K A V S T P K L A S V K T I G A K Q E P

MBOII
 BANII
 BSP1286
 GATAACAGCGGTGGTGGTGGTGGTGAATGCTGAAATTAAGTTATTCAGTAGCAAAA AC
 970 980 990 1000 1010 1020
 D N S G G G G G G M L K L K L F S S K N
 ATG4

BSMI
 MBOII
 CCATCTTCTCATCGAATAGCCCAACCTACGAGAAAGGCGGCGGTGCCTCAAC AA
 1030 1040 1050 1060 1070 1080
 P S S S S N S P Q P T R K A A A V P Q Q

BANI
 BBVI
 CAAACTTTGTCGAAAATCGCTGCCCCAGTGAAAAGTGGCCTGAAGCCGCCGACCAGTA AG
 1090 1100 1110 1120 1130 1140
 Q T L S K I A A P V K S G L K P P T S K

TB22
 BSTXI
 HINDIII
 |
 CTGGGAAGTGCCACGTCTATGTGCAAGCTTTGTACGCCAAAAGTTTCCTACCGTAAAA CG
 1150 1160 1170 1180 1190 1200
 L G S A T S M S K L C T P K V S Y R K T

AHAI I
 HGAI
 SFANI
 GACGCCCCAATCATATCTCAACAAGACTCGAAACGATGCTCAAAGAGCAGTGAAGAAG AG
 1210 1220 1230 1240 1250 1260
 D A P I I S Q Q D S K R C S K S S E E E

FIG. 1 CONTINUED.

3/99

MBOII
 .BSPMII
 .. MBOII
 TCCGGATACGCTGGATTCAACAGCACGTCGCCAACGTCATCATCGACGGAAGGTTCCC TA
 1270 1280 1290 1300 1310 1320
 S G Y A G F N S T S P T S S S T E G S L

BSMI
 SPHI
 . MBOII
 . NSII
 AGCATGCATTCCACATCTTCCAAGAGTTCAACGTCAGACGAAAAGTCTCCGTCATCAG AC
 1330 1340 1350 1360 1370 1380
 S M H S T S S K S S T S D E K S P S S D
 ATG5

GATCTTACTCTTAACGCCTCCATCGTGACAGCTATCAGACAGCCGATAGCCGCAACAC CG
 1390 1400 1410 1420 1430 1440
 D L T L N A S I V T A I R Q P I A A T P

SSPI
 GTTCTCCAAATATTATCAACAAGCCTGTTGAGGAAAAACCAACACTGGCAGTGAAAG GA
 1450 1460 1470 1480 1490 1500
 V S P N I I N K P V E E K P T L A V K G

BINI XHOII NSPBII
 PVUII
 GTGAAAAGCACAGCGAAAAAAGATCCACCTCCAGCTGTTCCGCCACGTGACACCCAGC CA
 1510 1520 1530 1540 1550 1560
 V K S T A K K D P P P A V P P R D T Q P

HINCII ECRV
 ACAATCGGAGTTGTTAGTCCAATTATGGCACATAAGAAGTTGACAAATGACCCCGTGA TA
 1570 1580 1590 1600 1610 1620
 T I G V V S P I M A H K K L T N D P V I

SFANI
 TCTGAAAAACCAGAACCTGAAAAGCTCCAATCAATGAGCATCGACACGACGGACGTTT CA
 1630 1640 1650 1660 1670 1680
 S E K P E P E K L Q S M S I D T T D V P

CCGCTTCCACCTCTAAAATCAGTTGTTCCACTTAAAATGACTTCAATCCGACAACCAC CA
 1690 1700 1710 1720 1730 1740
 P L P P L K S V V P L K M T S I R Q P P

MBOII
 ACGTACGATGTTCTTCTAAAACAAGGAAAAATCACATCGCCTGTCAAGTCGTTTGGAT AT
 1750 1760 1770 1780 1790 1800
 T Y D V L L K Q G K I T S P V K S F G Y

HGAI HGAI
 . MBOII
 GAGCAGTCGTCGCGCTCTGAAGACTCCATTGTGGCTCATGCGTCGGCTCAGGTGACTC CG
 1810 1820 1830 1840 1850 1860
 E Q S S A S E D S I V A H A S A Q V T P

HPHI FOKI
 CCGACAAAAACTTCTGGTAATCATTGCGTGGAGAGAAGGATGGGAAAGAATAAGACAT CA
 1870 1880 1890 1900 1910 1920
 P T K T S G N H S L E R R M G K N K T S

NSPBII AHAI HGAI
 GAATCCAGCGGCTACACCTCTGACGCCGGTGTTCGATGTGCGCCAAAATGAGGGAGA AG

SUBSTITUTE SHEET (RULE 26)

F/G. 1 CONTINUED. 4/99

NSPBII				ABAI				HGAI															
1930				1940				1950				1960				1970				1980			
E	S	S	G	Y	T	S	D	A	G	V	A	M	C	A	K	M	R	E	K				

BSP1286
 HGI AI
 ASUII
 CTGAAAGAATACGATGACATGACTCGTCGAGCAGAAACGGCTATCCTGACAACTTCGAA
 1990 2000 2010 2020 2030 2040
 L K E Y D D M T R R A Q N G Y P D N F E

MBOII
 .
 .
 .
 BANII
 BSP1286
 BGIAI
 SACI
 GACAGTTCCTCCTGTGCTGGAATATCCGATAACAACGAGCTCGACGACATATCCACG
 2050 2060 2070 2080 2090 2100
 D S S S L S S G I S D N N E L D D I S T

BSPMII
 . ACCI
 FOKI
 GACGATTGTCCGGAGTAGACATGGCAACAGTCGCCTCCAAACATAGCGACTATTCCCAC
 2110 2120 2130 2140 2150 2160
 D D L S G V D M A T V A S K E S D Y S E

MBOII
. MBOII
AVAI
AVAI
TTGTTCGCCATCCACGCTCTTCTCTCCTCAAAGCCCCGAGTCCCCAGTCGGTCTCTCCACA
2170 2180 2190 2200 2210 2220
F V R E P T S S S S K P R V P S R S S T

AVAI
 XHOI
 TCAGTCGATTCTCGATCTCGAGCAGAACAGGAGAATGTGTACAACTTCTGTCCCAGTGC
 2230 2240 2250 2260 2270 2280
 S V D S R S R A E Q E N V Y K L L S Q C

```

BBVI BGLI
. . BANI
. . .AHAI
. . .NARI
. . . HAEII
. . . . NSPBII
. . . . . BINI XHOII
. . . . . . FOKI
CGAACGAGCCAACGTGGCGCGCTGCCACCTCAACCTTCGGACAACATTGCGCTAAGATCC
2290      2300      2310      2320      2330      2340
R T S Q R G A A A T S T F G Q E S L R S

```

```

AVAI
.NCII
..NCII
..SMAI
NSPBII
PVUII
...
CCGGGATACTCATCCTATTCTCCACACTTATCAGTGTCACTGATAAGGACACAATGTCT
2350      2360      2370      2380      2390      2400
P  G  Y  S  S  Y  S  P  E  L  S  V  S  A  D  K  D  T  M  S

```

5/99

FIG. 1 CONTINUED.

SPEI
 . Sali
 . .ACCI
 . ..HINCII
MBOII
 ATGCACTCACAGACTAGTCGACGACCTTCTTCACAAAAACCAAGCTATTCAGGCCAAT TT
 2410 2420 2430 2440 2450 2460
 M H S Q T S R R P S S Q K P S Y S G Q F

FOKI BSP1286
 HGIAI
 CATTCACTTGATCGTAAATGCCACCTTCAAGAGTTCACATCCACCGAGCACAGAATGG CG
 2470 2480 2490 2500 2510 2520
 H S L D R K C H L Q E F T S T E H R M A

AVAI
 .BANII
 .BSP1286 BANI MBOII BINI BAMHI
 XHOII
 GCTCTCTTGAGCCCGAGACGGGTGCCGAACCTCGATGTCGAAATATGATTCTTCAGGAT CC
 2530 2540 2550 2560 2570 2580
 A L L S P R R V P N S M S K Y D S S G S

BINI AVAI
 TACTCGGCGCTTCCCGAGGTGGAAGCTCTACTGGTATCTATGGAGAGACGTTCCAAC TG
 2590 2600 2610 2620 2630 2640
 Y S A R S R G G S S T G I Y G E T F Q L

BINI BAMHI
 XHOII
 CACAGACTATCCGATGAAAAATCCCCGCACATTCTGCCAAAAGTGAGATGGGATCCC AA
 2650 2660 2670 2680 2690 2700
 H R L S D E K S P A H S A K S E M G S Q

BINI NHEI NDEI
 XHOII BINI
 CTATCACTGGCTAGCACGACAGCATATGGATCTCTCAATGAGAAGTACGAACATGCTA TT
 2710 2720 2730 2740 2750 2760
 L S L A S T T A Y G S L N E K Y E H A I

Sali
 .ACCI
 ..HINCII
 CGGGACATGGCAGTGACTTGGAGTGTTACAAGAACACTGTCGACTCACTAACCAAGA AA
 2770 2780 2790 2800 2810 2820
 R D M A R D L E C Y K N T V D S L T K K

HINDIII
 CAGGAGAACTATGGAGCATTGTTTGATCTTTTGAGCAAAAGCTTAGAAAACCTCACTC AA
 2830 2840 2850 2860 2870 2880
 Q E N Y G A L F D L F E Q K L R K L T Q

BINI
 CLAI MBOII
 CACATTGATCGATCCAACCTGAAGCCTGAAGAGGCAATACGATTTCAGGCAGGACATTG CT
 2890 2900 2910 2920 2930 2940
 H I D R S N L K P E E A I R F R Q D I A

SUBSTITUTE SHEET (RULE 26)

6/99

FIG. 1 CONTINUED.

FOKI
 . SFANI
 CATTGAGGGATATTAGCAATCATCTTGCATCCAACTCAGCTCATGCTAACGAAGGCG CT
 2950 2960 2970 2980 2990 3000
 H L R D I S N H L A S N S A H A N E G A
 MBOII HPHI
 . HINCII FOKI
 . SFANI
 GGTGAGCTTCTTCGTCAACCATCTCTGGAATCAGTTGCATCCCATCGATCATCGATGT CA
 3010 3020 3030 3040 3050 3060
 G E L L R Q P S L E S V A S H R S S M S
 ECOB BBVI MBOII
 . BANII
 . BSP1286
 . HGIAI
 . SACI
 TCGTCGTCGAAAAGCAGCAAGCAGGAGAAGATCAGCTTGAGCTCGTTTGGCAAGAACA AG
 3070 3080 3090 3100 3110 3120
 S S S K S S K Q E K I S L S S F G K N K
 BINI BAMHI
 . XHOII
 . MBOII
 . BINI HPHI MBOII
 . MBOII
 AAGAGCTGGATCCGCTCCTCACTCTCCAAGTTCACCAAGAAGAACAAGAACTACG AC
 3130 3140 3150 3160 3170 3180
 K S W I R S S L S K F T K K K N K N Y D
 NDEI XHOII
 . BSPMII BINI
 GAAGCACATATGCCATCAATTTCCGGATCTCAAGGAACCTTTGACAACATTGATGTGA TT
 3190 3200 3210 3220 3230 3240
 E A H M P S I S G S Q G T L D N I D V I
 BANII
 BSP1286
 HGIAI
 SACI ECOK APALI
 . BSP1286
 . HGIAI
 GAGTTGAAGCAAGAGCTCAAAGAACGCGATAGTGCACTTTACGAAGTCCGCCTTGACA AT
 3250 3260 3270 3280 3290 3300
 E L K Q E L K E R D S A L Y E V R L D N
 BINI
 . BSP1286
 CTGGATCGTGCCCGCGAAGTTGATGTTCTGAGGGAGACAGTGAACAAGTTGAAAACCG AG
 3310 3320 3330 3340 3350 3360
 L D R A R E V D V L R E T V N K L K T E
 HPHI AVAII MBOII
 AACAAAGCAATTAAAGAAAGAAGTGGACAAACTCACCAACGGTCCAGCCACTCGTGCTT CT
 3370 3380 3390 3400 3410 3420
 N K Q L K K E V D K L T N G P A T R A S

SUBSTITUTE SHEET (RULE 26)

7/99

FIG. 1 CONTINUED.

SFANI
 TCCC GCGCCTCAATTCCAGTTATCTACGACGATGAGCATGTCTATGATGCAGCGTGTA GC
 3430 3440 3450 3460 3470 3480
 S R A S I P V I Y D D E H V Y D A A C S
 BBVI MBOII ASUII
 . . .BINI
 . . BBVI
 AGTACATCAGCTAGTCAATCTTCGAAACGATCCTCTGGCTGCAACTCAATCAAGGTTA CT
 3490 3500 3510 3520 3530 3540
 S T S A S Q S S K R S S G C N S I K V T
 PVUI
 . HINCII
 . HPAI
 . . NCII
 GTAAACGTGGACATCGCTGGAGAAATCAGTTCGATCGTTAACCCGGACAAAGAGATAA TC
 3550 3560 3570 3580 3590 3600
 V N V D I A G E I S S I V N P D K E I I
 ECORV HINCII
 GTAGGATATCTTGCCATGTCAACCAAGTCAGTCATGCTGGAAAGACATTGATGTTTCTA TT
 3610 3620 3630 3640 3650 3660
 V G Y L A M S T S Q S C W K D I D V S I
 ACCI SFANI CLAI
 CTAGGACTATTTGAAGTCTACCTATCCAGAATTGATGTGGAGCATCAACTTGGGAATCG AT
 3670 3680 3690 3700 3710 3720
 L G L F E V Y L S R I D V E H Q L G I D
 SFANI STYI HGAI AFLIII
 . . .MLUI
 . .HPHI HGAI
 GCTCGTGATTCTATCCTTGGCTATCAAATTGGTGAACCTTCGACGCGTCATTGGAGACT CC
 3730 3740 3750 3760 3770 3780
 A R D S I L G Y Q I G E L R R V I G D S
 FOKI
 ACAACCATGATAACCAGCCATCCAAGTACATTCTTACTTCTCAACTACAATCCGAA TG
 3790 3800 3810 3820 3830 3840
 T T M I T S H P T D I L T S S T T I R M
 BANI ACCI AVAII MBOII
 TTCATGCACGGTGCCGCACAGAGTCGCGTAGACAGTCTGGTCCTTGATATGCTTCTTC CA
 3850 3860 3870 3880 3890 3900
 F M H G A A Q S R V D S L V L D M L L P
 AHAI
 . AATII
 AAGCAAATGATTCTCCAAGTCGTCAGTCAATTTTGACAGAGAGACGTCTGGTGTAG CT
 3910 3920 3930 3940 3950 3960
 K Q M I L Q L V K S I L T E R R L V L A
 BBVI BSTNI
 . . MBOII
 GGAGCAACTGGAATTGAAAGAGCAAAGTGGCGAAGACCCTGGCTGCTTATGTATCTA TT
 3970 3980 3990 4000 4010 4020
 G A T G I G K S K L A K T L A A Y V S I

SUBSTITUTE SHEET (RULE 26)

FIG. 1 CONTINUED. 8/99

```

ASUII                      MBOII      BSMI
CGAACAAATCAATCCGAAGATAGTATTGTTAATATCAGCATTCTGAAAACAATAAAG AA
      4030      4040      4050      4060      4070      4080
R   T   N   Q   S   E   D   S   I   V   N   I   S   I   P   E   N   N   K   E

      XMNI MBOII      AHAI
      .   .           .   BSTNI
      .   .           .   .   HGAI
      .   .           .   .   BGLII
      .   .           .   .   KHOII
GAATTGCTTCAAGTGAACGACGCCTGGAAAAGATCTTGAGAAGCAAAGAATCATGCA TC
      4090      4100      4110      4120      4130      4140
E   L   L   Q   V   E   R   R   L   E   K   I   L   R   S   K   E   S   C   I

      XBAI
GTAATTCTAGATAATATCCCAAAGAATCGAATTGCATTTGTTGTATCCGTTTTTGCAA AT
      4150      4160      4170      4180      4190      4200
V   I   L   D   N   I   P   K   N   R   I   A   F   V   V   S   V   F   A   N

      AVAI      HINCII ECORV
GTCCCACTTCAAACAACGAAGGTCCATTGTAGTATGCACAGTCAACCGATATCAAA TC
      4210      4220      4230      4240      4250      4260
V   P   L   Q   N   N   E   G   P   F   V   V   C   T   V   N   R   Y   Q   I

      HPHI      FOKI
CCTGAGCTTCAAAATTCACCACAATTTCAAATGTCAGTAATGTCGAATCGTCTCGAAG GA
      4270      4280      4290      4300      4310      4320
P   E   L   Q   I   H   H   N   F   K   M   S   V   M   S   N   R   L   E   G

      FOKI
TTCATCCTACGTTACCTCCGACGACGGGCGGTAGAGGATGAGTATCGTCTAACTGTAC AG
      4330      4340      4350      4360      4370      4380
F   I   L   R   Y   L   R   R   R   A   V   E   D   E   Y   R   L   T   V   Q

      MBOII
      .   SFANI
      .   .   BANII
      .   .   BSP1286
      .   .   HGIAI
      .   .   SACI      MBOII      MBOII
ATGCCATCAGAGCTCTTCAAATCATTGACTTCTTCCCAATAGCTCTTCAGGCCGTCA AT
      4390      4400      4410      4420      4430      4440
M   P   S   E   L   F   K   I   I   D   F   F   P   I   A   L   Q   A   V   N

      ECORI      AVAI      SPHI
AATTTTATTGAGAAAACGAATTCTGTTGATGTGACAGTTGGTCCAAGAGCATGCTTGA AC
      4450      4460      4470      4480      4490      4500
N   F   I   E   K   T   N   S   V   D   V   T   V   G   P   R   A   C   L   N

      BINI BAMHI
      .   .   XHOII      BINI
TGTCCTCTAACTGTCGATGGATCCCGTGAATGGTTCATTGATTGTGGAATGAGAACT TC
      4510      4520      4530      4540      4550      4560
C   P   L   T   V   D   G   S   R   E   W   F   I   R   L   W   N   E   N   F

      AFLIII      BBVI
ATTCCATATTTGGAACGTGTTGCTAGAGATGGCAAAAAACCTTCGGTCGCTGCACT TC
      4570      4580      4590      4600      4610      4620
I   P   Y   L   E   R   V   A   R   D   G   K   K   N   L   R   S   L   H   F

```

SUBSTITUTE SHEET (RULE 26)

FIG. 1 CONTINUED. 9/99

```

BINI BAMHI
. XHOII BINI TTHIIII EA EI NCII
CTTCGAGGATCCCACCGACATCGTCTCTAAAAAATGGCCGTGGTTCGATGGTGAAAAC CC
4630 4640 4650 4660 4670 4680
L R G S H R H R L

HPHI MBOII
. .BSP1286
. .HGIAI
. .
GGAGAATGTGCTCAAACGTCTTCAACTCCAAGACCTCGTCCCGTCACCTGCCAACTCA TC
4690 4700 4710 4720 4730 4740

AVAI
XHOI BINI SFANI
. SPHI
CCGACAACACTTCAATCCCCTCGAGTCGTTGATCCAATTGCATGCTACCAAGCATCAG AC
4750 4760 4770 4780 4790 4800

MBOII MBOII MBOII
CATCGACAACATTTGAACAGAAGACTCTAATCTTCTCTCGCCTCTCCCCCGCTTTCCT TA
4810 4820 4830 4840 4850 4860

BANI
KPN I
TCTTCGTACCGGTACCTGATGATTCCTCCCATTTTCCCCCTTTTCCCCCAATTTCCCAG AA
4870 4880 4890 4900 4910 4920

AVAI
.NCII
..NCII
..SMAI
... BANI AHAI HGAI DRAI
CCTCCTGTTCCCTTTGTTCTAGTCCTCCCGGTGCCGACGCCGAAGCGATTAAAAA CC
4930 4940 4950 4960 4970 4980

XMNI
TTTTTCTTTCCGAAACATTTCCCATTTGCTCATTAAATAGTCAAATTGAATAAACAGTGT AT
4990 5000 5010 5020 5030 5040

GTACTTAAAAAAAAAAAAAAAAAAAAA
5050 5060 5070

```

COMPARISON OF 7A VS 8A CLONE

10/99 FIG. 2.

TB6 & TB3
 BSP1286
 HGIAI
 GGTTTAATTACCCAAGTTTGAGACATCAATTCCATCGAACGAAATGTTGGTGCTCCGAAT
 10 20 30 40 50 60
 TTHIII
 .AHAI
 .. AATII
 BANI
 AAAATGACGACGTCAAATGTAGAATTGATACCAATCTACACGGATTGGGCCAATCGGCAC
 70 80 90 100 110 120
 M T T S N V E L I P I Y T D W A N R E
 ASUII BBVI NRUI
 CTTTCGAAGGGCAGCTTATCAAAGTCGATTAGGGATATTTCCAATGATTTTCGCGACTAT
 130 140 150 160 170 180
 L S K G S L S K S I R D I S N D F R D Y
 TB1B
 ECORI BSMI
 CGACTGGTTTCTCAGCTTATTAATGTGATCGTTCCGATCAACGAATTCTCGCCTGCATTCT
 190 200 210 220 230 240
 R L V S Q L I N V I V P I N E F S P A F
 TB16
 BSTNI AFLIII
 FOKI
 ACGAAACGTTTGGCAAAATCACATCGAACCTGGATGGCCTCGAAACGTGTCTCGACTAC
 250 260 270 280 290 300
 T K R L A K I T S N L D G L E T C L D Y
 TB1
 HPHI ECORV NSPBII
 CTGAAAAATCTGGGTCTCGACTGCTCGAAACTCACCAAAACCGATATCGACAGCGGAAAC
 310 320 330 340 350 360
 L K N L G L D C S K L T K T D I D S G N
 BBVI MBOII
 . NSPBII
 . PVUII
 HINDIII
 TTGGGTGCAGTTCTCCAGCTGCTCTTCCTGCTCTCCACCTACAAGCAGAAGCTTCGGCAA
 370 380 390 400 410 420
 L G A V L Q L L F L L S T Y K Q K L R Q
 FOKI
 . MBOII NSPBII
 . SACII
 CTGAAAAAAGATCAGAAGAAATTTGGAGCAACTACCCACATCCATTATGCCACCCGCGGTT
 430 440 450 460 470 480
 L K K D Q K K L E Q L P T S I M P P A V
 AFLIII
 TCTAAATTACCCTCGCCACGTGTCGCCACGTGAGCAACCGCTTCAGCAACTAACCCAAAT
 490 500 510 520 530 540
 S K L P S P R V A T S A T A S A T N P N
 FOKI HINCII BSTNI
 TCCAACCTTCCACAAATGTCAACATCCAGGCTTCAGACTCCACAGTCAAGAATATCGAAA
 550 560 570 580 590 600
 S N F P Q M S T S R L Q T P Q S R I S K

FIG. 2 CONTINUED.

11/99

TB6B
 |
 ATTGATTCATCAAAGATTGGTATCAAGCCAAAGACGTCTGGACTTAAACCACCCTCATCA
 610 620 630 640 650 660
 I D S S K I G I K P K T S G L K P P S S

AHAI I
 AATII
 TCAACCACTTCATCAAATAATACAAATTCATTCCGTCGAGCCGTTTCGAGTGGCAAT
 670 680 690 700 710 720
 S T T S S N N T N S F R P S S R S S G N

ECORV
 MBOII
 AATAATGTTGGCTCGACGATATCCACATCTGCGAAGAGCTTAGAATCATCATCAACGTAC
 730 740 750 760 770 780
 N N V G S T I S T S A K S L E S S S T Y

ASUII
 XBAI
 AGCTCTATTTGGAATCTAAACCGACCTACCTCCCAACTCCAAAAACCTTCTAGACCACAA
 790 800 810 820 830 840
 S S I S N L N R P T S Q L Q K P S R P Q

NHEI
 ACCCAGCTAGTTCGTGTTGCTACAACCTACAAAAATCGGAAGCTCAAAGCTAGCCGCTCCG
 850 860 870 880 890 900
 T Q L V R V A T T T K I G S S K L A A P

BSP1286
 HGIAI
 MBOII
 BANII
 BSP1286
 AAAGCCGTGAGCACCCCAAACCTTGCTTCTGTGAAGACTATTGGAGCAAACAAGAGCCC
 910 920 930 940 950 960
 K A V S T P K L A S V K T I G A K Q E P

NSPBII
 BSMI
 MBOII
 GATAACAGCGGTGGTGGTGGTGGTGAATGCTGAAATTAAAGTTATTCAGTAGCAAAAAC
 970 980 990 1000 1010 1020
 D N S G G G G G G M L K L K L F S S K N

BANI
 CCATCTTCTCATCGAATAGCCCAACCTACGAGAAAGCGCGCGGTGCCTCAACAA
 1030 1040 1050 1060 1070 1080
 P S S S S N S P Q P T R K A A A V P Q Q

BBVI
 CAAACTTTGTGAAAAATCGCTGCCCCAGTGAAAAGTGGCCTGAAGCCGCCGACCAGTAAG
 1090 1100 1110 1120 1130 1140
 Q T L S K I A A P V K S G L K P P T S K

TB22
 BSTXI
 HINDIII
 |
 CTGGGAAGTGCCACGTCTATGTCGAAGCTTTGTACGCCAAAAGTTTCTACCGTAAACG
 1150 1160 1170 1180 1190 1200
 L G S A T S M S K L C T P K V S Y R K T

AHAI I HGAI
 SFANI
 GACGCCCCAATCATATCTCAACAAGACTCGAAACGATGCTCAAAGAGCAGTGAAGAAGAG
 1210 1220 1230 1240 1250 1260
 D A P I I S Q Q D S K R C S K S S E E E

FIG. 2 CONTINUED.

12/99

MBOII
.BSPMII
.. MBOII
TCCGGATACGCTGGATTCAACAGCAGCGTCGCCAACGTCATCATCGACGGAAGGTTCCCTA
1270 1280 1290 1300 1310 1320
S G Y A G F N S T S P T S S S T E G S L

BSMI
SPHI
. MBOII
. NSII | START CE7
AGCATGATTCACATCTTCCAAGAGTTCAACGTCAGACGAAAAGTCTCCGTCATCAGAC
1330 1340 1350 1360 1370 1380
S M H S T S S K S S T S D E K S P S S D

GATCTTACTCTTAACGCCTCCATCGTGACAGCTATCAGACAGCCGATAGCCGCAACACCG
1390 1400 1410 1420 1430 1440
D L T L N A S I V T A I R Q P I A A T P

SSPI
GTTTCTCCAAATATTATCAACAAGCCTGTTGAGGAAAAACCAACTGGCAGTGAAAGGA
1450 1460 1470 1480 1490 1500
V S P N I I N K P V E E K P T L A V K G

BINI XBOII NSPBII
PVUII
GTGAAAAGCACAGCGAAAAAGATCCACCTCCAGCTGTTCCGCCACGTGACACCCAGCCA
1510 1520 1530 1540 1550 1560
V K S T A K K D P P P A V P P R D T Q P

HINCII ECORV
ACAATCGGAGTTGTTAGTCCAATTATGGCACATAAGAAGTTGACAAATGACCCCGTGATA
1570 1580 1590 1600 1610 1620
T I G V V S P I M A H K K L T N D P V I

SFANI
TCTGAAAAACCAGAACCTGAAAAGCTCCAATCAATGAGCATCGACACGACGGACGTTCCA
1630 1640 1650 1660 1670 1680
S E K P E P E K L Q S M S I D T T D V P

CCGCTTCCACCTCTAAAATCAGTTGTTCCACTTAAAATGACTTCAATCCGACAACCACCA
1690 1700 1710 1720 1730 1740
P L P P L K S V V P L K M T S I R Q P P

MBOII
ACGTACGATGTTCTTCTAAAACAAGGAAAAATCACATCGCCTGTCAAGTCGTTTGGATAT
1750 1760 1770 1780 1790 1800
T Y D V L L K Q G K I T S P V K S F G Y

HGAI HGAI
. MBOII
GAGCAGTCGTCCGCGTCTGAAGACTCCATTGTGGCTCATGCGTCCGCTCAGGTGACTCCG
1810 1820 1830 1840 1850 1860
E Q S S A S E D S I V A H A S A Q V T P

HPHI FOKI
CCGACAAAAACTTCTGGTAATCATTCGCTGGAGAGAAGGATGGGAAAGAATAAGACATCA
1870 1880 1890 1900 1910 1920
P T K T S G N H S L E R R M G K N K T S

SUBSTITUTE SHEET (RULE 26)

13/99

SUBSTITUTE SHEET (RULE 26)

FIG. 2 CONTINUED.

14/99

SPEI
 . SALI
 . .ACCI
 . ..HINCII
MBOII
 ATGCACTCACAGACTAGTCGACGACCTTCTTCACAAAAACCAAGCTATTTCAGGCCAATTT
 2410 2420 2430 2440 2450 2460
 M H S Q T S R R P S S Q K P S Y S G Q F

FOKI BSP1286
 HGIAI
 CATTCACTTGATCGTAAATGCCACCTTCAAGAGTTCACATCCACCGAGCACAGAATGGCG
 2470 2480 2490 2500 2510 2520
 H S L D R K C H L Q E F T S T E H R M A

AVAI
 .BANII
 .BSP1286 BANI MBOII BINI BAMHI
 XHOII
 GCTCTCTTGAGCCCGAGACGGGTGCCGAACGATGTCGAAATATGATTCTTCAGGATCC
 2530 2540 2550 2560 2570 2580
 A L L S P R R V P N S M S K Y D S S G S

BINI AVAI
 TACTCGGCGCGTCCCGAGGTGGAAGCTCTACTGGTATCTATGGAGAGACGTTCCAACG
 2590 2600 2610 2620 2630 2640
 Y S A R S R G G S S T G I Y G E T F Q L

BINI BAMHI
 XHOII
 CACAGACTATCCGATGAAAAATCCCCGCACATTCTGCCAAAAGTGAGATGGGATCCCAA
 2650 2660 2670 2680 2690 2700
 H R L S D E K S P A H S A K S E M G S Q

BINI NHEI NDEI
 XHOII BINI
 CTATCACTGGCTAGCACGACGACATATGGATCTCTCAATGAGAAGTACGAACATGCTATT
 2710 2720 2730 2740 2750 2760
 L S L A S T T A Y G S L N E K Y E H A I

SALI
 .ACCI
 ..HINCII
 CGGGACATGGCAGTGAAGTGTACAAGAACACTGTGACTCACTAACCAAGAAA
 2770 2780 2790 2800 2810 2820
 R D M A R D L E C Y K N T V D S L T K K

HINDIII
 CAGGAGAACTATGGAGCATTGTTTGATCTTTTGAGCAAAAGCTTAGAAAACCTCACTCAA
 2830 2840 2850 2860 2870 2880
 Q E N Y G A L F D L F E Q K L R K L T Q

BINI
 CLAI MBOII
 CACATTGATCGATCCAACCTTGAAGCCTGAAGAGGCAATACGATTTCAGGCAGGACATTGCT
 2890 2900 2910 2920 2930 2940
 H I D R S N L K P E E A I R F R Q D I A

SUBSTITUTE SHEET (RULE 26)

FIG. 2 CONTINUED.

15/99

FOKI
 . SFANI
 CATTGAGGGATATTAGCAATCATCTTGCATCCAACCTCAGCTCATGCTAACGAAGGCGCT
 2950 2960 2970 2980 2990 3000
 H L R D I S N H L A S N S A H A N E G A

MBOII HPBI
 . HINCII FOKI
 . SFANI CLAI CLAI
 GGTGAGCTTCTTCGTCAACCATCTCTGGAATCAGTTGCATCCCATCGATCATCGATGTCA
 3010 3020 3030 3040 3050 3060
 G E L L R Q P S L E S V A S H R S S M S

ECOB BBVI MBOII
 . BANII
 . BSP1286
 . HGIAI
 . SACI
 TCGTCGTCGAAAAGCAGCAAGCAGGAGAAGATCAGCTTGAGCTCGTTTGGCAAGAACAAG
 3070 3080 3090 3100 3110 3120
 S S S K S S K Q E K I S L S S F G K N K

BINI BAMHI
 . KHOII
 . MBOII
 . BINI HPBI MBOII
 . MBOII
 AAGAGCTGGATCCGCTCCTCACTCTCCAAGTTCACCAAGAAGAACAAGAACTACGAC
 3130 3140 3150 3160 3170 3180
 K S W I R S S L S K F T K K K N K N Y D

NDEI KHOII
 . BSPMII BINI
 GAAGCACATATGCCATCAATTTCCGGATCTCAAGGAACCTTTGACAACATTGATGTGATT
 3190 3200 3210 3220 3230 3240
 E A H M P S I S G S Q G T L D N I D V I

BANII
 BSP1286
 HGIAI
 SACI ECOK APALI
 . BSP1286
 . HGIAI
 GAGTTGAAGCAAGAGCTCAAAGAACGCGATAGTGCACCTTACGAAGTCCGCCTTGACAAT
 3250 3260 3270 3280 3290 3300
 E L K Q E L K E R D S A L Y E V R L D N

BINI
 . BSP1286
 CTGGATCGTGCCCGCAAGTTGATGTTCTGAGGGAGACAGTGAACAAGTTGAAAACCGAG
 3310 3320 3330 3340 3350 3360
 L D R A R E V D V L R E T V N K L K T E

HPBI AVAII MBOII
 AACCAAGCAATTAAAGAAAGAAGTGGACAACTCACCAACGGTCCAGCCACTCGTGCTTCT
 3370 3380 3390 3400 3410 3420
 N K Q L K K E V D K L T N G P A T R A S

16/99

SUBSTITUTE SHEET (RULE 26)

FIG. 2 CONTINUED.

17/99

ASUII |CE6 MBOII BSMI
 CGAACAAATCAATCCGAAGATAGTATTGTTAATATCAGCATTCCCTGAAAACAATAAAGAA
 4030 4040 4050 4060 4070 4080
 R T N Q S E D S I V N I S I P E N N K E

XMNI MBOII AHAI
 . . . BSTNI
 . . . HGAI
 . . . BGLII
 . . . XHOII SFANI NSII
 GAATTGCTTCAAGTGAACGACGCTGGAAGATCTTGAGAAGCAAAGAATCATGCATC
 4090 4100 4110 4120 4130 4140
 E L L Q V E R R L E K I L R S K E S C I

XBAI
 GTAATTCTAGATAATATCCCAAAGAATCGAATTGCATTGTTGTATCCGTTTTTGCAAAT
 4150 4160 4170 4180 4190 4200
 V I L D N I P K N R I A F V V S V F A N

AVAI HINCII ECORV
 GTCCCACTTCAAAACACGAAGGTCCATTTGTAGTATGCACAGTCAACCGATATCAAATC
 4210 4220 4230 4240 4250 4260
 V P L Q N N E G P F V V C T V N R Y Q I

HPHI FOKI
 CCTGAGCTTCAAATTCACCACAATTTCAAATGTCAGTAATGTCGAATCGTCTCGAAGGA
 4270 4280 4290 4300 4310 4320
 P E L Q I H H N F K M S V M S N R L E G

FOKI
 TTCATCCTACGTTACCTCCGACGACGGCGGTAGAGGATGAGTATCGTCTAACTGTACAG
 4330 4340 4350 4360 4370 4380
 F I L R Y L R R R A V E D E Y R L T V Q

MBOII
 . SFANI
 . . BANII
 . . BSP1286
 . . HGIAI
 . . SACI MBOII MBOII
 ATGCCATCAGAGCTCTTCAAATCATTGACTTCTTCCCAATAGCTCTTCAGGCCGTCAAT
 4390 4400 4410 4420 4430 4440
 M P S E L F K I I D F F P I A L Q A V N

ECOR1 USED FOR EXPRESSION
 ECORI AVAI SPHI
 AATTTTATTGAGAAAACGAATTCTGTTGATGTGACAGTTGGTCCAAGAGCATGCTTGAAC
 4450 4460 4470 4480 4490 4500
 N F I E K T N S V D V T V G P R A C L N

BINI BAMHI
 . XHOII BINI
 TGTCTCTAACTGTCGATGGATCCCGTGAATGGTTTCATTGCGATTGTGGAATGAGAACTTC
 4510 4520 4530 4540 4550 4560
 C P L T V D G S R E W F I R L W N E N F

AFLIII BBVI
 ATTCCATATTTGGAACGTGTTGCTAGAGATGGCAAAAAAACCTTCGGTCGCTGCACTTC
 AAAAAA-ACC...
 4570 4580 4590 4600 4610 4620
 I P Y L E R V A R D G K K N L R S L H F
 T F G R C T S

SUBSTITUTE SHEET (RULE 26)

18/99

FIG. 2 CONTINUED.

BINI BAMHI
 . XBOII BINI TTHIIII EA EI NCII
 CTCGAGGATCCCACCGACATCGTCTCTAAAAAATGGCCGTGGTTCGATGGTGAAAACCC
 4630 4640 4650 4660 4670 4680
 L R G S H R H R L *
 F E D P T D I V S E K W P W F D G E N P
 HP HI MBOII
 . . BSP1286
 . . HGIAI TTHIIII
 . . . HP HI FOKI BSPMI
 GGAGAATGTGCTCAAACGTCTTCAACTCCAAGACCTCGTCCCGTCACCTGCCAACTCATC
 4690 4700 4710 4720 4730 4740
 E N V L K R L Q L Q D L V P S P A N S S
 AVAI
 XHOI BINI SFANI
 . SPHI
 CCGACAACACTTCAATCCCCTCGAGTCGTTGATCCAATTGCATGCTACCAAGCATCAGAC
 4750 4760 4770 4780 4790 4800
 R Q H F N P L E S L I Q L . H A T K H Q T
 MBOII MBOII MBOII
 CATCGACAACATTTGAACAGAAGACTCTAATCTTCTCTCGCCTCTCCCCCGCTTTCCTTA
 4810 4820 4830 4840 4850 4860
 I D N I *
 BANI
 . KPNI
 TCTTCGTACCGGTACCTGATGATTCCCCATTTTCCCCCTTTCCCCCAATTTCAGAA
 4870 4880 4890 4900 4910 4920
 AVAI
 . NCII
 .. NCII
 .. SMAI
 ... BANI AHAI HGAI DRAI
 CCTCCTGTTCCCTTTGTTCTAGTCCTCCCGGTGCCGACGCCGAAGCGATTAAAAACC
 4930 4940 4950 4960 4970 4980
 XMNI
 TTTTCTTTCCGAAACATTTCCCATGCTCATTAATAGTCAAATTGAATAAACAGTGTAT
 4990 5000 5010 5020 5030 5040
 GTACTTAAAAAAAAAAAAAAAAAAAAA
 5050 5060 5070

FIG. 3

19/99

Sequences of low complexity in UNC-53 TB3-M5 identified with the FILTER and SEG algorithms of the BLAST sequence homology package.

MTTSNVELIPIYTDWANRHLSKGSLSKSIIRDISNDFRDYRLVSQLINVIVPINEFSPAFT
 KRLAKITSNLDGLETCLDYLNGLDCSKLTKTIDISGNLGAVLQLLFLLSTYXXXXXX
 XXXXXXXXXXXXPTSIMPPAVSKLXXXXXXXXXXXXXXXXXXXXPQMSTSRLOTPOXXXXXX
 XXXXXXXXXXXXSGLPXX
 XXXNLNRPTSQQLQKPSRPQTQLVRVATTTKIGSSKLAAPKAVSTPKLASVKTIGAKQEPD
 NSXXXXXXXXXXXXXXXXXXXXXXXXXQPTRKAAAVPQQOTLSKIAAPVKSGLPPTSKL
 GSATSMKLCCTPKVSYRKTDAPIIISQDSKRCCKXXXXXXGYAGFNXXXXXXXXXXXX
 XXXXXXXXXXXXXXXXXXXXDDLTLNASIVTAIRQPIAATPVSPNIINKPVEEKPTLAVKGV
 KSTAKKDPPIAVPPRDTQPTIGVVSPIMAHKKLTNDPVISEKPEPEKLQSMSIDTDDXXX
 XXXXXXXXXXXXMTSIRQPPTYDVLLKQKGKITSPVKSFGYEQSSASEDSIVAHASAQVTPP
 TKTSGNHSLERRMGKNKTSSESGYTS DAGVAMCAKMKREKLKEYDDMTTRAQNGYPDNFED
 XXXXXXXXXXXXNNELDDISTDDLSGVDMATVASKHSDYSHFVRHPXXXXXXXXXXXXXX
 XXXXXAEQENVYKLLSQCRTSQRGAATSTFGQHSRLSPGYSSYSPHLSVSADKDTMSM
 HSQTSRRPSSQKPSYSGQFHS LDRKCHLQEFSTTEHRMAALLSPRRVPNXXXXXXXXXXXX
 XXXXXXXXXXXXIYGETFQLHRLSDEKSPAHSKSEMGSQSLASTTAYGSLNEKYEHAIR
 DMARDLECYKNTVDSLTKKQENYGALFDLFEQKLRLKTQHIDRSNLKPEEAIRFRQDIAH
 LRDISNHLASNSAHANEGAGELLRQPSLEXXXXXXXXXXXXXXXXXXXXXXXXXXFGKNKK
 SWIRSSLSKFTKKKNKNYDEAHMPISIGSQGTLDNIDVIELKQELKERDSALYEVRLDNL
 DRAREVDVLRVTNKLKTENKQLKKEVDKLTNGPATRASSRASIPVIYDDEHVYDXXXXX
 XXXXXXXXXXXXGCNXXXXXXXXXXXXXXXXXXXXXXXXXDXKEIIVGYLAMSTSQSCWKDIDVSI
 GLFEVYLSRIDVEHQLGIDARDSILGYQIGELRRVIGDSTMITSHPTDILTSSTTIRMF
 MHGAAQSRVDSLVDMLLPQMILQLVKSILTERRLVLGATGIGKSKLAKTLAAVVSIR
 TNQSEDSIVNISIPENNKEELLOVERRLEKILRSKESCIVILDNIIPKNRIAFVVSFANV
 PLQNNEGFVCTVNRVYQIPELQIHNFKMSVMNSNRLEGFILRYLRRRAVEDEVRLTVQM
 PSELFKIIDFPFIALQAVNNFIEKTNSVDVTVGPRACLNCPPLTVDGSRWFIRLWNNFI
 PYLERVARDGKKNLRS LHLRGSRRRL

MTTSNVELIPIYTDWANRHLSKGSLSKSIIRDISNDFRDYRLVSQLINVIVPINEFSPAFT
 KRLAKITSNLDGLETCLDYLNGLDCSKLTKTIDISGNLGAVLQLLFLLSTYKOKLROL
KKDQKLEQLPTSIMPPAVSKLSPRVATSATASATNPNSNFPQMSTSRLOTPOSRIKI
DSSKIGIKPKTSGLKPPSSSTTSSNNTNSFRPSSRSSGNNVGSTISTSSAKSLESSSTYS
SISNLNRPTSQQLQKPSRPQTQLVRVATTTKIGSSKLAAPKAVSTPKLASVKTIGAKQEPD
NSGGGGGGMLKCLKLFSSKNPSSSSNSPQPTRKAAAVPQQOTLSKIAAPVKSGLPPTSKL
GSATSMKLCCTPKVSYRKTDAPIIISQDSKRCCKSSEEESGYAGFNSTSPTSSSTEGSL
MHSTSSKSSTSDEKSPSSDDTLNASIVTAIRQPIAATPVSPNIINKPVEEKPTLAVKGV
KSTAKKDPPIAVPPRDTQPTIGVVSPIMAHKKLTNDPVISEKPEPEKLQSMSIDTDDVPP
LPPLKSVVPLKMTSIRQPPTYDVLLKQKGKITSPVKSFGYEQSSASEDSIVAHASAQVTPP
TKTSGNHSLERRMGKNKTSSESGYTS DAGVAMCAKMKREKLKEYDDMTTRAQNGYPDNFED
SSSLSSGISDNNELDDISTDDLSGVDMATVASKHSDYSHFVRHPTSSSSKPRVPSRSSTS
VDSRSRAEQENVYKLLSQCRTSQRGAATSTFGQHSRLSPGYSSYSPHLSVSADKDTMSM
HSQTSRRPSSQKPSYSGQFHS LDRKCHLQEFSTTEHRMAALLSPRRVPNSMSKYDSSGSY
SARSRGGSSTGIYGETFQLHRLSDEKSPAHSKSEMGSQSLASTTAYGSLNEKYEHAIR
 DMARDLECYKNTVDSLTKKQENYGALFDLFEQKLRLKTQHIDRSNLKPEEAIRFRQDIAH
 LRDISNHLASNSAHANEGAGELLRQPSLESVASHRSSMSSSSKSSKQEKISLSSFGKNKK
 SWIRSSLSKFTKKKNKNYDEAHMPISIGSQGTLDNIDVIELKQELKERDSALYEVRLDNL
 DRAREVDVLRVTNKLKTENKQLKKEVDKLTNGPATRASSRASIPVIYDDEHVYDAACSS

20/99

FIG. 3 CONTINUED.

TSASOSSKRSSGCNSIKVTNVNDIAGEISSIVNPDKEIIVGYLAMSTSQSCWKDIDVSIL
GLFEVYLSRIDVEHQLGIDARDSILGYQIGELRRVIGDSTTMITSHPTDILTSSTTIRMF
MHGAAQSRVDSLVDMLLPQMILQLVKSI L T E R R L V L A G A T G I G K S K L A K T L A A Y V S I R
TNQSEDSIVNISIPENNKEELLQVERRLEKILRSKESCIVILDNIPKNRIAFVVSVFANV
PLQNNEGPFVVCTVNRYQIPELQIHNNFKMSVMSNRLEGFILRYLRRRAVEDEYRLTVQM
PSELFKIIDFFPIALQAVNNFIEKTNSVDVTVGPRACLNCLTVDGSREWFIRLWNENFI
PYLERVARDGKKNLRLSLHFLRGSHRHRL

*FIG. 4.**21/99*

Length of tb3-m5.pro from cDNA pTB54 : 1528 aa; +1 at: 1;
 Listed (Ordinary) from: 1 to: 1528; din, 23 apr 1996 11:49

Met Thr Thr Ser Asn Val Glu Leu Ile Pro Ile Tyr Thr Asp Trp	15
Ala Asn Arg His Leu Ser Lys Gly Ser Leu Ser Lys Ser Ile Arg	30
Asp Ile Ser Asn Asp Phe Arg Asp Tyr Arg Leu Val Ser Gln Leu	45
Ile Asn Val Ile Val Pro Ile Asn Glu Phe Ser Pro Ala Phe Thr	60
Lys Arg Leu Ala Lys Ile Thr Ser Asn Leu Asp Gly Leu Glu Thr	75
Cys Leu Asp Tyr Leu Lys Asn Leu Gly Leu Asp Cys Ser Lys Leu	90
Thr Lys Thr Asp Ile Asp Ser Gly Asn Leu Gly Ala Val Leu Gln	105
Leu Leu Phe Leu Leu Ser Thr Tyr Lys Gln Lys Leu Arg Gln Leu	120
Lys Lys Asp Gln Lys Lys Leu Glu Gln Leu Pro Thr Ser Ile Met	135
Pro Pro Ala Val Ser Lys Leu Pro Ser Pro Arg Val Ala Thr Ser	150
Ala Thr Ala Ser Ala Thr Asn Pro Asn Ser Asn Phe Pro Gln Met	165
Ser Thr Ser Arg Leu Gln Thr Pro Gln Ser Arg Ile Ser Lys Ile	180
Asp Ser Ser Lys Ile Gly Ile Lys Pro Lys Thr Ser Gly Leu Lys	195
Pro Pro Ser Ser Ser Thr Thr Ser Ser Asn Asn Thr Asn Ser Phe	210
Arg Pro Ser Ser Arg Ser Ser Gly Asn Asn Asn Val Gly Ser Thr	225
Ile Ser Thr Ser Ala Lys Ser Leu Glu Ser Ser Ser Thr Tyr Ser	240
Ser Ile Ser Asn Leu Asn Arg Pro Thr Ser Gln Leu Gln Lys Pro	255
Ser Arg Pro Gln Thr Gln Leu Val Arg Val Ala Thr Thr Thr Lys	270
Ile Gly Ser Ser Lys Leu Ala Ala Pro Lys Ala Val Ser Thr Pro	285
Lys Leu Ala Ser Val Lys Thr Ile Gly Ala Lys Gln Glu Pro Asp	300
Asn Ser Gly Gly Gly Gly Gly Gly Met Leu Lys Leu Lys Leu Phe	315
Ser Ser Lys Asn Pro Ser Ser Ser Ser Asn Ser Pro Gln Pro Thr	330
Arg Lys Ala Ala Ala Val Pro Gln Gln Gln Thr Leu Ser Lys Ile	345
Ala Ala Pro Val Lys Ser Gly Leu Lys Pro Pro Thr Ser Lys Leu	360
Gly Ser Ala Thr Ser Met Ser Lys Leu Cys Thr Pro Lys Val Ser	375
Tyr Arg Lys Thr Asp Ala Pro Ile Ile Ser Gln Gln Asp Ser Lys	390

SUBSTITUTE SHEET (RULE 26)

*FIG. 4 CONTINUED.**22/99*

Arg Cys Ser Lys Ser Ser Glu Glu Glu Ser Gly Tyr Ala Gly Phe	405
Asn Ser Thr Ser Pro Thr Ser Ser Ser Thr Glu Gly Ser Leu Ser	420
Met His Ser Thr Ser Ser Lys Ser Ser Thr Ser Asp Glu Lys Ser	435
Pro Ser Ser Asp Asp Leu Thr Leu Asn Ala Ser Ile Val Thr Ala	450
Ile Arg Gln Pro Ile Ala Ala Thr Pro Val Ser Pro Asn Ile Ile	465
Asn Lys Pro Val Glu Glu Lys Pro Thr Leu Ala Val Lys Gly Val	480
Lys Ser Thr Ala Lys Lys Asp Pro Pro Pro Ala Val Pro Pro Arg	495
Asp Thr Gln Pro Thr Ile Gly Val Val Ser Pro Ile Met Ala His	510
Lys Lys Leu Thr Asn Asp Pro Val Ile Ser Glu Lys Pro Glu Pro	525
Glu Lys Leu Gln Ser Met Ser Ile Asp Thr Thr Asp Val Pro Pro	540
Leu Pro Pro Leu Lys Ser Val Val Pro Leu Lys Met Thr Ser Ile	555
Arg Gln Pro Pro Thr Tyr Asp Val Leu Leu Lys Gln Gly Lys Ile	570
Thr Ser Pro Val Lys Ser Phe Gly Tyr Glu Gln Ser Ser Ala Ser	585
Glu Asp Ser Ile Val Ala His Ala Ser Ala Gln Val Thr Pro Pro	600
Thr Lys Thr Ser Gly Asn His Ser Leu Glu Arg Arg Met Gly Lys	615
Asn Lys Thr Ser Glu Ser Ser Gly Tyr Thr Ser Asp Ala Gly Val	630
Ala Met Cys Ala Lys Met Arg Glu Lys Leu Lys Glu Tyr Asp Asp	645
Met Thr Arg Arg Ala Gln Asn Gly Tyr Pro Asp Asn Phe Glu Asp	660
Ser Ser Ser Leu Ser Ser Gly Ile Ser Asp Asn Asn Glu Leu Asp	675
Asp Ile Ser Thr Asp Asp Leu Ser Gly Val Asp Met Ala Thr Val	690
Ala Ser Lys His Ser Asp Tyr Ser His Phe Val Arg His Pro Thr	705
Ser Ser Ser Ser Lys Pro Arg Val Pro Ser Arg Ser Ser Thr Ser	720
Val Asp Ser Arg Ser Arg Ala Glu Gln Glu Asn Val Tyr Lys Leu	735
Leu Ser Gln Cys Arg Thr Ser Gln Arg Gly Ala Ala Ala Thr Ser	750
Thr Phe Gly Gln His Ser Leu Arg Ser Pro Gly Tyr Ser Ser Tyr	765

SUBSTITUTE SHEET (RULE 26)

FIG. 4 CONTINUED.

23/99

Ser Pro His Leu Ser Val Ser Ala Asp Lys Asp Thr Met Ser Met	780
His Ser Gln Thr Ser Arg Arg Pro Ser Ser Gln Lys Pro Ser Tyr	795
Ser Gly Gln Phe His Ser Leu Asp Arg Lys Cys His Leu Gln Glu	810
Phe Thr Ser Thr Glu His Arg Met Ala Ala Leu Leu Ser Pro Arg	825
Arg Val Pro Asn Ser Met Ser Lys Tyr Asp Ser Ser Gly Ser Tyr	840
Ser Ala Arg Ser Arg Gly Gly Ser Ser Thr Gly Ile Tyr Gly Glu	855
Thr Phe Gln Leu His Arg Leu Ser Asp Glu Lys Ser Pro Ala His	870
Ser Ala Lys Ser Glu Met Gly Ser Gln Leu Ser Leu Ala Ser Thr	885
Thr Ala Tyr Gly Ser Leu Asn Glu Lys Tyr Glu His Ala Ile Arg	900
Asp Met Ala Arg Asp Leu Glu Cys Tyr Lys Asn Thr Val Asp Ser	915
Leu Thr Lys Lys Gln Glu Asn Tyr Gly Ala Leu Phe Asp Leu Phe	930
Glu Gln Lys Leu Arg Lys Leu Thr Gln His Ile Asp Arg Ser Asn	945
Leu Lys Pro Glu Glu Ala Ile Arg Phe Arg Gln Asp Ile Ala His	960
Leu Arg Asp Ile Ser Asn His Leu Ala Ser Asn Ser Ala His Ala	975
Asn Glu Gly Ala Gly Glu Leu Leu Arg Gln Pro Ser Leu Glu Ser	990
Val Ala Ser His Arg Ser Ser Met Ser Ser Ser Ser Lys Ser Ser	1005
Lys Gln Glu Lys Ile Ser Leu Ser Ser Phe Gly Lys Asn Lys Lys	1020
Ser Trp Ile Arg Ser Ser Leu Ser Lys Phe Thr Lys Lys Lys Asn	1035
Lys Asn Tyr Asp Glu Ala His Met Pro Ser Ile Ser Gly Ser Gln	1050
Gly Thr Leu Asp Asn Ile Asp Val Ile Glu Leu Lys Gln Glu Leu	1065
Lys Glu Arg Asp Ser Ala Leu Tyr Glu Val Arg Leu Asp Asn Leu	1080
Asp Arg Ala Arg Glu Val Asp Val Leu Arg Glu Thr Val Asn Lys	1095
Leu Lys Thr Glu Asn Lys Gln Leu Lys Lys Glu Val Asp Lys Leu	1110
Thr Asn Gly Pro Ala Thr Arg Ala Ser Ser Arg Ala Ser Ile Pro	1125
Val Ile Tyr Asp Asp Glu His Val Tyr Asp Ala Ala Cys Ser Ser	1140

*FIG. 4 CONTINUED.**24/99*

Thr Ser Ala Ser Gln Ser Ser Lys Arg Ser Ser Gly Cys Asn Ser	1155
Ile Lys Val Thr Val Asn Val Asp Ile Ala Gly Glu Ile Ser Ser	1170
Ile Val Asn Pro Asp Lys Glu Ile Ile Val Gly Tyr Leu Ala Met	1185
Ser Thr Ser Gln Ser Cys Trp Lys Asp Ile Asp Val Ser Ile Leu	1200
Gly Leu Phe Glu Val Tyr Leu Ser Arg Ile Asp Val Glu His Gln	1215
Leu Gly Ile Asp Ala Arg Asp Ser Ile Leu Gly Tyr Gln Ile Gly	1230
Glu Leu Arg Arg Val Ile Gly Asp Ser Thr Thr Met Ile Thr Ser	1245
His Pro Thr Asp Ile Leu Thr Ser Ser Thr Thr Ile Arg Met Phe	1260
Met His Gly Ala Ala Gln Ser Arg Val Asp Ser Leu Val Leu Asp	1275
Met Leu Leu Pro Lys Gln Met Ile Leu Gln Leu Val Lys Ser Ile	1290
Leu Thr Glu Arg Arg Leu Val Leu Ala Gly Ala Thr Gly Ile Gly	1305
Lys Ser Lys Leu Ala Lys Thr Leu Ala Ala Tyr Val Ser Ile Arg	1320
Thr Asn Gln Ser Glu Asp Ser Ile Val Asn Ile Ser Ile Pro Glu	1335
Asn Asn Lys Glu Glu Leu Leu Gln Val Glu Arg Arg Leu Glu Lys	1350
Ile Leu Arg Ser Lys Glu Ser Cys Ile Val Ile Leu Asp Asn Ile	1365
Pro Lys Asn Arg Ile Ala Phe Val Val Ser Val Phe Ala Asn Val	1380
Pro Leu Gln Asn Asn Glu Gly Pro Phe Val Val Cys Thr Val Asn	1395
Arg Tyr Gln Ile Pro Glu Leu Gln Ile His His Asn Phe Lys Met	1410
Ser Val Met Ser Asn Arg Leu Glu Gly Phe Ile Leu Arg Tyr Leu	1425
Arg Arg Arg Ala Val Glu Asp Glu Tyr Arg Leu Thr Val Gln Met	1440
Pro Ser Glu Leu Phe Lys Ile Ile Asp Phe Phe Pro Ile Ala Leu	1455
Gln Ala Val Asn Asn Phe Ile Glu Lys Thr Asn Ser Val Asp Val	1470
Thr Val Gly Pro Arg Ala Cys Leu Asn Cys Pro Leu Thr Val Asp	1485
Gly Ser Arg Glu Trp Phe Ile Arg Leu Trp Asn Glu Asn Phe Ile	1500
Pro Tyr Leu Glu Arg Val Ala Arg Asp Gly Lys Lys Asn Leu Arg	1515
Ser Leu His Phe Leu Arg Gly Ser His Arg His Arg Leu	

FIG. 5.

25/99

Annotated sequence of 7A variant of UNC-53

10 20 30 40 50 60
MTTSNVELIP IYTDWANRHL SKGSLSKSIR DISNDFRDYR LVSOLINVIV PINEFSPAFT
 start tb6 and tb3 similarity to amino-termini of alfa-actinin,

70 80 90 100 110 120
KRLAKITSNL DGLCTCLDYL KNLGLDCSKL TKTDIDSGNL GAVLOLLFLL STYKOKLROL
 beta-spectrin, dystrophin, fimbrin, filamin actin-binding site 1
 (114 - 133)

130 140 150 160 170 180
KKDQKKLEOL PTSIMPPAVS KLPSRPVATS ATASATNPNS NFPQMSTSR LQTPQSRISKI
 Start S4 poss. start tbb1 & tb6 & tbb1 lamda clone

190 200 210 220 230 240
 DSSKIGIKPK TSGLKPPSSS TTSSNNTNSF RPSSRSSGNN NVGSTISTSA KSLESSSTYS

250 260 270 280 290 300
 SISNLNRPTS QLQKPSRPQT QLVRVATTTK IGSSKLAAPK AVSTPKLASV KTIGAKQEPD

310 320 330 340 350 360
 NSGGGGGGML KLKLFSSKNP SSSSNSPQPT RKAAPVPQQQ TSKIAAPVK SGLKPPTSKL

370 380 390 400 410 420
 GSATSMKLC TPKVSYRKTD APIISQQDSK RCKSKSSEES GYAGFNSTSP TSSSTEGSL

430 440 450 460 470 480
 MHSTSSKSST SDEKSPSSDD LTLNASIVTA IRQPIAATPV SPNIINKPVE EKPTLAVKGV
 poss. start tb22

490 500 510 520 530 540
 KSTAKKDPPP AVPPRDTQPT IGVVSPIMAH KKLTNDPVIS EKPEPEKLQS MSIDTTDVPP
 SH3-binding 1 SH3-

550 560 570 580 590 600
 LPPLKSVVPL KMTSIRQPPT YDVLKQGGKI TSPVKSFGYE QSSASEDSIV AHASAQVTPP
 binding 2

610 620 630 640 650 660
 TKTSGNHSLE RRMGKNKTSE SSGYTSDAGV AMCAKMREKL KEYDDMTTRA QNGYPDNFED

670 680 690 700 710 720
 SSSLSSGISD NNELDDISTD DLSGVDMATV ASKHSYSHF VRHPTSSSSK PRVPSRSSTS

730 740 750 760 770 780
 VDSRSRAEQE NVYKLLSQCR TSQRGAAATS TFGQHSLSRP GYSSYSPLHS VSADKDTMSM

790 800 810 820 830 840
 HSQTSRRPSS OKPSYSGOFH SLDRKCHLOE FTSTEHRMAA LLSPRRVPNS MSKYDSSGSY
 Kohara Exon deleted in cDNA YK25D6

SUBSTITUTE SHEET (RULE 26)

26/99

FIG. 5 CONTINUED.

10	20	30	40	50	60	70
<u>AAINASGMSR SMILLESISP RPPRRHOSPA DSCIITASPS APRRSHSPRG PTARIPLSLA SSPVHVNNNW</u> predicted exon (alternative/additional to Kohara exon to be inserted after aminoacid 838)						
850	860	870	880	890	900	
SARSRGGSST	GIYGETFQLH	RLSDEKSPAH	SAKSEMGSQ	SLASTTAYGS	LNEKYEHAI	R
910	920	930	940	950	960	
DMARDLECYK	NTVDSLTKKQ	ENYGALFDLF	EQKLRKLTQH	IDRSNLKPEE	AIRFRQDIAH	
970	980	990	1000	1010	1020	
LRDISNHLAS	NSAHANEGAG	ELLRQPSLES	VASHRSSMSS	SSKSSKQEKI	SLSSFGKNKK	
1030	1040	1050	1060	1070	1080	
SWIRSSLSKF	TKKKKN NYDE	AHMPISGSQ	GTLDNIDVIE	LKQELKERDS	ALYEVRLDNL	
candidate nuclear Start GP45 localization signal						
1090	1100	1110	1120	1130	1140	
DRAREVDVLR	ETVNLKLTEN	KOLKKEVDKL	TNGPATRASS	RASIPVIYDD	EHVYDAACSS	
actin binding site 2 (1097-1116)						
* candidate leucine zipper.pattern						
1150	1160	1170	1180	1190	1200	
TSASQSSKRS	SGCNSIKVTV	NVDIAGEISS	IVNPDKEIIV	GYLAMSTSQS	CWKDIDVSIL	
1210	1220	1230	1240	1250	1260	
GLFEVYLSRI	DVEHQLGIDA	RDSILGYQIG	ELRRVIGDST	TMITSHPTDI	LTSSTTIRMF	
1270	1280	1290	1300	1310	1320	
MHGAAQSRVD	SLVLDMLLPK	QMILQLVKS	LTERRLVLAG	<u>ATGIGKSKLA</u>	KTAAAYVSIR	
* nucleotide binding pocket						
candidate leucine zipper.pattern						
1330	1340	1350	1360	1370	1380	
TNQSEDSIVN	ISIPENNKEE	LLQVERRLEK	ILRSKESCIV	ILDNIPKNRI	AFVVSVFANV	
1390	1400	1410	1420	1430	1440	
PLQNNEGPFV	VCTVNRYPQIP	ELQIHNNFKM	SVMSNRLEGF	ILRYLRRRAV	EDEYRLTVQM	
1450	1460	1470	1480	1490	1500	
PSELFKIIDF	FPIALQAVNN	FIEKTNSVDV	TVGPRACLNC	PLTVDGSREW	FIRLWNENFI	
end GP45						
1510	1520	1530	1540	1550	1560	
PYLERVARDG	KKTFGRCTSF	EDPTDIVSEK	WPWFDGENPE	NVLKRLQLQD	LVPSPANSSR	
1570	1580					
QHFNPLESLI	QLHATKHQTI	DNI				

FIG. 6.

27/99

Length of Untitled : 1583 aa from cDNA pTB72; +1 at: 1;
 Listed (Ordinary) from: 1 to: 1583; din, 23 apr 1996 11:37

Met Thr Thr Ser Asn Val Glu Leu Ile Pro Ile Tyr Thr Asp Trp	15
Ala Asn Arg His Leu Ser Lys Gly Ser Leu Ser Lys Ser Ile Arg	30
Asp Ile Ser Asn Asp Phe Arg Asp Tyr Arg Leu Val Ser Gln Leu	45
Ile Asn Val Ile Val Pro Ile Asn Glu Phe Ser Pro Ala Phe Thr	60
Lys Arg Leu Ala Lys Ile Thr Ser Asn Leu Asp Gly Leu Glu Thr	75
Cys Leu Asp Tyr Leu Lys Asn Leu Gly Leu Asp Cys Ser Lys Leu	90
Thr Lys Thr Asp Ile Asp Ser Gly Asn Leu Gly Ala Val Leu Gln	105
Leu Leu Phe Leu Leu Ser Thr Tyr Lys Gln Lys Leu Arg Gln Leu	120
Lys Lys Asp Gln Lys Lys Leu Glu Gln Leu Pro Thr Ser Ile Met	135
Pro Pro Ala Val Ser Lys Leu Pro Ser Pro Arg Val Ala Thr Ser	150
Ala Thr Ala Ser Ala Thr Asn Pro Asn Ser Asn Phe Pro Gln Met	165
Ser Thr Ser Arg Leu Gln Thr Pro Gln Ser Arg Ile Ser Lys Ile	180
Asp Ser Ser Lys Ile Gly Ile Lys Pro Lys Thr Ser Gly Leu Lys	195
Pro Pro Ser Ser Ser Thr Thr Ser Ser Asn Asn Thr Asn Ser Phe	210
Arg Pro Ser Ser Arg Ser Ser Gly Asn Asn Asn Val Gly Ser Thr	225
Ile Ser Thr Ser Ala Lys Ser Leu Glu Ser Ser Ser Thr Tyr Ser	240
Ser Ile Ser Asn Leu Asn Arg Pro Thr Ser Gln Leu Gln Lys Pro	255
Ser Arg Pro Gln Thr Gln Leu Val Arg Val Ala Thr Thr Thr Lys	270
Ile Gly Ser Ser Lys Leu Ala Ala Pro Lys Ala Val Ser Thr Pro	285
Lys Leu Ala Ser Val Lys Thr Ile Gly Ala Lys Gln Glu Pro Asp	300
Asn Ser Gly Gly Gly Gly Gly Gly Met Leu Lys Leu Lys Leu Phe	315
Ser Ser Lys Asn Pro Ser Ser Ser Ser Asn Ser Pro Gln Pro Thr	330
Arg Lys Ala Ala Ala Val Pro Gln Gln Gln Thr Leu Ser Lys Ile	345
Ala Ala Pro Val Lys Ser Gly Leu Lys Pro Pro Thr Ser Lys Leu	360
Gly Ser Ala Thr Ser Met Ser Lys Leu Cys Thr Pro Lys Val Ser	375

SUBSTITUTE SHEET (RULE 26)

*FIG. 6 CONTINUED.**28/99*

Tyr Arg Lys Thr Asp Ala Pro Ile Ile Ser Gln Gln Asp Ser Lys	390
Arg Cys Ser Lys Ser Ser Glu Glu Glu Ser Gly Tyr Ala Gly Phe	405
Asn Ser Thr Ser Pro Thr Ser Ser Ser Thr Glu Gly Ser Leu Ser	420
Met His Ser Thr Ser Ser Lys Ser Ser Thr Ser Asp Glu Lys Ser	435
Pro Ser Ser Asp Asp Leu Thr Leu Asn Ala Ser Ile Val Thr Ala	450
Ile Arg Gln Pro Ile Ala Ala Thr Pro Val Ser Pro Asn Ile Ile	465
Asn Lys Pro Val Glu Glu Lys Pro Thr Leu Ala Val Lys Gly Val	480
Lys Ser Thr Ala Lys Lys Asp Pro Pro Pro Ala Val Pro Pro Arg	495
Asp Thr Gln Pro Thr Ile Gly Val Val Ser Pro Ile Met Ala His	510
Lys Lys Leu Thr Asn Asp Pro Val Ile Ser Glu Lys Pro Glu Pro	525
Glu Lys Leu Gln Ser Met Ser Ile Asp Thr Thr Asp Val Pro Pro	540
Leu Pro Pro Leu Lys Ser Val Val Pro Leu Lys Met Thr Ser Ile	555
Arg Gln Pro Pro Thr Tyr Asp Val Leu Leu Lys Gln Gly Lys Ile	570
Thr Ser Pro Val Lys Ser Phe Gly Tyr Glu Gln Ser Ser Ala Ser	585
Glu Asp Ser Ile Val Ala His Ala Ser Ala Gln Val Thr Pro Pro	600
Thr Lys Thr Ser Gly Asn His Ser Leu Glu Arg Arg Met Gly Lys	615
Asn Lys Thr Ser Glu Ser Ser Gly Tyr Thr Ser Asp Ala Gly Val	630
Ala Met Cys Ala Lys Met Arg Glu Lys Leu Lys Glu Tyr Asp Asp	645
Met Thr Arg Arg Ala Gln Asn Gly Tyr Pro Asp Asn Phe Glu Asp	660
Ser Ser Ser Leu Ser Ser Gly Ile Ser Asp Asn Asn Glu Leu Asp	675
Asp Ile Ser Thr Asp Asp Leu Ser Gly Val Asp Met Ala Thr Val	690
Ala Ser Lys His Ser Asp Tyr Ser His Phe Val Arg His Pro Thr	705
Ser Ser Ser Ser Lys Pro Arg Val Pro Ser Arg Ser Ser Thr Ser	720
Val Asp Ser Arg Ser Arg Ala Glu Gln Glu Asn Val Tyr Lys Leu	735
Leu Ser Gln Cys Arg Thr Ser Gln Arg Gly Ala Ala Ala Thr Ser	750
Thr Phe Gly Gln His Ser Leu Arg Ser Pro Gly Tyr Ser Ser Tyr	765
Ser Pro His Leu Ser Val Ser Ala Asp Lys Asp Thr Met Ser Met	780

*FIG. 6 CONTINUED.**29/99*

His Ser Gln Thr Ser Arg Arg Pro Ser Ser Gln Lys Pro Ser Tyr	795
Ser Gly Gln Phe His Ser Leu Asp Arg Lys Cys His Leu Gln Glu	810
Phe Thr Ser Thr Glu His Arg Met Ala Ala Leu Leu Ser Pro Arg	825
Arg Val Pro Asn Ser Met Ser Lys Tyr Asp Ser Ser Gly Ser Tyr	840
Ser Ala Arg Ser Arg Gly Gly Ser Ser Thr Gly Ile Tyr Gly Glu	855
Thr Phe Gln Leu His Arg Leu Ser Asp Glu Lys Ser Pro Ala His	870
Ser Ala Lys Ser Glu Met Gly Ser Gln Leu Ser Leu Ala Ser Thr	885
Thr Ala Tyr Gly Ser Leu Asn Glu Lys Tyr Glu His Ala Ile Arg	900
Asp Met Ala Arg Asp Leu Glu Cys Tyr Lys Asn Thr Val Asp Ser	915
Leu Thr Lys Lys Gln Glu Asn Tyr Gly Ala Leu Phe Asp Leu Phe	930
Glu Gln Lys Leu Arg Lys Leu Thr Gln His Ile Asp Arg Ser Asn	945
Leu Lys Pro Glu Glu Ala Ile Arg Phe Arg Gln Asp Ile Ala His	960
Leu Arg Asp Ile Ser Asn His Leu Ala Ser Asn Ser Ala His Ala	975
Asn Glu Gly Ala Gly Glu Leu Leu Arg Gln Pro Ser Leu Glu Ser	990
Val Ala Ser His Arg Ser Ser Met Ser Ser Ser Ser Lys Ser Ser	1005
Lys Gln Glu Lys Ile Ser Leu Ser Ser Phe Gly Lys Asn Lys Lys	1020
Ser Trp Ile Arg Ser Ser Leu Ser Lys Phe Thr Lys Lys Lys Asn	1035
Lys Asn Tyr Asp Glu Ala His Met Pro Ser Ile Ser Gly Ser Gln	1050
Gly Thr Leu Asp Asn Ile Asp Val Ile Glu Leu Lys Gln Glu Leu	1065
Lys Glu Arg Asp Ser Ala Leu Tyr Glu Val Arg Leu Asp Asn Leu	1080
Asp Arg Ala Arg Glu Val Asp Val Leu Arg Glu Thr Val Asn Lys	1095
Leu Lys Thr Glu Asn Lys Gln Leu Lys Lys Glu Val Asp Lys Leu	1110
Thr Asn Gly Pro Ala Thr Arg Ala Ser Ser Arg Ala Ser Ile Pro	1125
Val Ile Tyr Asp Asp Glu His Val Tyr Asp Ala Ala Cys Ser Ser	1140
Thr Ser Ala Ser Gln Ser Ser Lys Arg Ser Ser Gly Cys Asn Ser	1155,
Ile Lys Val Thr Val Asn Val Asp Ile Ala Gly Glu Ile Ser Ser	1170
Ile Val Asn Pro Asp Lys Glu Ile Ile Val Gly Tyr Leu Ala Met	1185

SUBSTITUTE SHEET (RULE 26)

*FIG. 6 CONTINUED.**30/99*

Ser Thr Ser Gln Ser Cys Trp Lys Asp Ile Asp Val Ser Ile Leu	1200
Gly Leu Phe Glu Val Tyr Leu Ser Arg Ile Asp Val Glu His Gln	1215
Leu Gly Ile Asp Ala Arg Asp Ser Ile Leu Gly Tyr Gln Ile Gly	1230
Glu Leu Arg Arg Val Ile Gly Asp Ser Thr Thr Met Ile Thr Ser	1245
His Pro Thr Asp Ile Leu Thr Ser Ser Thr Thr Ile Arg Met Phe	1260
Met His Gly Ala Ala Gln Ser Arg Val Asp Ser Leu Val Leu Asp	1275
Met Leu Leu Pro Lys Gln Met Ile Leu Gln Leu Val Lys Ser Ile	1290
Leu Thr Glu Arg Arg Leu Val Leu Ala Gly Ala Thr Gly Ile Gly	1305
Lys Ser Lys Leu Ala Lys Thr Leu Ala Ala Tyr Val Ser Ile Arg	1320
Thr Asn Gln Ser Glu Asp Ser Ile Val Asn Ile Ser Ile Pro Glu	1335
Asn Asn Lys Glu Glu Leu Leu Gln Val Glu Arg Arg Leu Glu Lys	1350
Ile Leu Arg Ser Lys Glu Ser Cys Ile Val Ile Leu Asp Asn Ile	1365
Pro Lys Asn Arg Ile Ala Phe Val Val Ser Val Phe Ala Asn Val	1380
Pro Leu Gln Asn Asn Glu Gly Pro Phe Val Val Cys Thr Val Asn	1395
Arg Tyr Gln Ile Pro Glu Leu Gln Ile His His Asn Phe Lys Met	1410
Ser Val Met Ser Asn Arg Leu Glu Gly Phe Ile Leu Arg Tyr Leu	1425
Arg Arg Arg Ala Val Glu Asp Glu Tyr Arg Leu Thr Val Gln Met	1440
Pro Ser Glu Leu Phe Lys Ile Ile Asp Phe Phe Pro Ile Ala Leu	1455
Gln Ala Val Asn Asn Phe Ile Glu Lys Thr Asn Ser Val Asp Val	1470
Thr Val Gly Pro Arg Ala Cys Leu Asn Cys Pro Leu Thr Val Asp	1485
Gly Ser Arg Glu Trp Phe Ile Arg Leu Trp Asn Glu Asn Phe Ile	1500
Pro Tyr Leu Glu Arg Val Ala Arg Asp Gly Lys Lys Thr Phe Gly	1515
Arg Cys Thr Ser Phe Glu Asp Pro Thr Asp Ile Val Ser Lys Lys	1530
Trp Pro Trp Phe Asp Gly Glu Asn Pro Glu Asn Val Leu Lys Arg	1545
Leu Gln Leu Gln Asp Leu Val Pro Ser Pro Ala Asn Ser Ser Arg	1560
Gln His Phe Asn Pro Leu Glu Ser Leu Ile Gln Leu His Ala Thr	1575
Lys His Gln Thr Ile Asp Asn Ile	

SUBSTITUTE SHEET (RULE 26)

FIG. 7.

31/99

MTTSNVELIPIYTDWANRHLSKGSLSKSIRDISNDFRDYRLVSQLINVIVPINEFSPAFT
 KRLAKITSNLDGLETCLDYLNGLDCSKLTCTDIDSGNLGAVLQLLFLSTYXXXXXX
 XXXXXXXXXXXXPTSIMPPAVSKLXXXXXXXXXXXXXXXXXXXXXXXXXXXXPQMSTSRLOTPOXXXXXX
 XXXXXXXXXXXXSTGLKPKXX
 XXXNLNRPTSQLQKPSRPQTQLVRVATTTKIGSSKLAAPKAVSTPKLASVKTIGAKQEPD
 NSXXXXXXXXXXXXXXXXXXXXXXXXXXXXQPTRKAAAVPQQOTLSKIAAPVKSGLKPPSTKL
 GSATSMKSLCTPKVSYRKTDAPIIISQODSKRCSKXXXXXXXXGYAGFNXXXXXXXXXXXX
 XXXXXXXXXXXXXXXXXXXXDDLTLNASIVTAIROPIAATPVSPNIINKPVEEKPTLAVKGV
 KSTAKDPPPAVPPRDTQPTIGVVSPIMAHKKLTNDPVISEKPEPEKLQSMSIDTTDXXX
 XXXXXXXXXXXXMTSIRQPPTYDVLKQKITSVPKSFGEQSSASEDSIVAHASAQVTPP
 TKTSGNHSLERRMGKNKTSSESGYTS DAGVAMCAKMREKLKEYDDMTRRAQNGYPDNFED
 XXXXXXXXXXXXNNELDDISTDDL SGVDMATVASKHSDYSHFVRHPXXXXXXXXXXXXXXXXXX
 XXXXXAEQENVYKLLSQCRTSQRGAATSTFGQHSRLSPGYSSYSPHLSVSADKDTMSM
 HSQTSRRPSSQKPSYSGQFHS LDRKCHLQEFSTTEHRMAALLSPRRVPNXXXXXXXXXXXX
 XXXXXXXXXXXXIYGETFQLHRLSDEKSPAHSKSEMGSQSLASTTAYGSLNEKEYEHAIR
 DMARDLECYKNTVDSLTKKQENYGALFDLFEQKLRLKLTQHIDRSNLKPEEAIRFRQDIAH
 LRDISNHLASNSAHANEGAGELLRQPSLEXXXXXXXXXXXXXXXXXXXXXXXXXXXXFGKNKK
 SWIRSSLSKFTKKKNKNYDEAHMPSISGSQGTLDNIDVIELKQELKERDSALYEVRLDNL
 DRAREVDVLRET VNKLTENKQLKKEVDKLTNGPATRASSRASIPVIYDDEHVYDXXXXX
 XXXXXXXXXXXXGCNXXXXXXXXXXXXXXXXXXXXXXXXXDXKEIIVGYLAMSTSQCWKDIDVIL
 GLFEVYLSRIDVEHQLGIDARDSILGYQIGELRRVIGDSTMITSHPTDILTSSTIRMF
 MHGAAQSRVDSLVDMLLPKQMLQLVKSILTERRLVLAGATGIGKSKLAKTLAAYVSIR
 TNQSEDSIVNISIPENKKEELLQVERRLEKILRSKESCIVILDNIPKNRIAFVVSFANV
 PLQNNEGPFVCTVNRQIPELQIHNFKMSVMSNRLEGFILRYLRRRAVEDEYRLTVQM
 PSELFKIIDFFPIALQAVNNFIEKTNSVDVTVGPRACLNCLPTVDGSREWFIRLWNNENFI
 PYLERVARDGKKNLRLSLHFLRGSHRHRL

MTTSNVELIPIYTDWANRHLSKGSLSKSIRDISNDFRDYRLVSQLINVIVPINEFSPAFT
 KRLAKITSNLDGLETCLDYLNGLDCSKLTCTDIDSGNLGAVLQLLFLSTYKOKLROL
KKDOKKLEOLPTSIMPPAVSKLPSPRVATSATASNPNNSNFPQMSTSRLOTPOSRISKI
DSSKIGIKPKTSGLKPPSSSTTSSNNTNSFRPSSSRSSGNNVNGSTISTS AKSLESSTYS
SISNLNRPTSQLQKPSRPQTQLVRVATTTKIGSSKLAAPKAVSTPKLASVKTIGAKQEPD
NSGGGGGMLKLKLFSSKNPSSSSNSPQPTRKAAAVPQQOTLSKIAAPVKSGLKPPSTKL
GSATSMKSLCTPKVSYRKTDAPIIISQODSKRCSKSSEESGYAGFNSTSPTSSTEGSL
MHSTSSKSSTSDEKSPSSDDLTLNASIVTAIROPIAATPVSPNIINKPVEEKPTLAVKGV
KSTAKDPPPAVPPRDTQPTIGVVSPIMAHKKLTNDPVISEKPEPEKLQSMSIDTTDVPP
LPPLKSVVPLKMTSIRQPPTYDVLKQKITSVPKSFGEQSSASEDSIVAHASAQVTPP
TKTSGNHSLERRMGKNKTSSESGYTS DAGVAMCAKMREKLKEYDDMTRRAQNGYPDNFED
SSSLSSGISDNNEELDDISTDDL SGVDMATVASKHSDYSHFVRHPTSSSSSKPRVPSRSSTS
VDSRSRAEQENVYKLLSQCRTSQRGAATSTFGQHSRLSPGYSSYSPHLSVSADKDTMSM
HSQTSRRPSSQKPSYSGQFHS LDRKCHLQEFSTTEHRMAALLSPRRVPNSMSKYDSSGSY
SARSRGGSSTGIYGETFQLHRLSDEKSPAHSKSEMGSQSLASTTAYGSLNEKEYEHAIR
 DMARDLECYKNTVDSLTKKQENYGALFDLFEQKLRLKLTQHIDRSNLKPEEAIRFRQDIAH
 LRDISNHLASNSAHANEGAGELLRQPSLESVASHRSSMSSSSKSSKOEKISLSSFGKNKK
 SWIRSSLSKFTKKKNKNYDEAHMPSISGSQGTLDNIDVIELKQELKERDSALYEVRLDNL
 DRAREVDVLRET VNKLTENKQLKKEVDKLTNGPATRASSRASIPVIYDDEHVYDAACSS

SUBSTITUTE SHEET (RULE 26)

32/99

FIG. 7 CONTINUED.

TSASOSSKRSSGCNSIKVTVNVDIAGEISSIVNPDKII VGYLAMSTSQSCWKDIDVSIL
GLFEVYLSRIDVEHQLGIDARDSILGYQIGELRRVIGDSTTMITSHPTDILTSSTTIRMF
MHGAAQSRVDSLVLDMLLPKQMILQLVKSI LERRLVLAGATGIGKSKLAKTLAAYVSIR
TNQSEDSIVNISIPENNKEELLQVERRLEKILRSKESCIVILDNIPKNRIAFVVSVFANV
PLQNNEGPFVVCTVNRYQIPELQIHNFKMSVMSNRLEGFILRYLRRRAVEDEYRLTVQM
PSELFKIIDFFPIALQAVNNFIEKTNSVDVTVGPRACLNCP LTVDGSREWFIRLWNENFI
PYLERVARDGKKNLRS LHF LRGSHRHRL

33/99





FIG. 9.

34/99




FIG. 10.





FIG. 11.



36/99

FIG. 12.

5' ataagaatcggccgcgcgcatgacgacggtcaaatgtagaattgata (oligo BG03)

5' ggaattcccaaccatgatgacgacggtcaaatgtagaattgata (oligo BG01)

ATGACGACGTCAAAATGTAGAAATTGATACCAATCTACACGGATTGGGCCAATCGGCACCTTTTCG

AAGGCGAGCTTATCAAAAGTCGATTAGGGATATTTCCAAATGATTTTCGGACTATCGACTGGTT

TCTCAGCTTATTAATGTGATCGTTCCGATCAACGAAATTCGCGCTGCATTTCACGAAACGTTTG

GCATAAATCACAATCGAACCTGATGGCCCTCGAAACGTGTCTCGACTACCTGAAATAATCTGGGT

CTCGACTGCTCGAAACTCACCAAAACCGATATCGACAGCGGAACCTTGGGTGCAGTTCTCCAG


CTGCTCTTCTCTCTCCACCTACAGCAGAGCTTCGGCACTGAAATAAAGATCAGAAAGAA

TTGGAGCAACTACCCACATCCATTATGCCACCCGGGTTTCTAAATTACCTCGCCACGTCGC

(oligo BG02) GTAGGTAATACGGTGGGCCCAAAactctagcgc-5'

37/99

FIG. 13.



38/99

FIG. 14a.





FIG. 14b. 39/99

MOLECULAR DATA ON UNC-53



40/99

FIG. 14c.

S4

5'
gatcagaagaaattggagcaactacccacatccattatgccacccgcggtttctaagtgagt
ttaattttgagtttacgactacaaaaatgtgttcttta

.....

ccgccttctgacttcgtgacgacagtctcgacacgtgggggttgcaggtaggagtgatgagt
cgaaactgataagatagtcatttgagatc 3'

Co-ordinates in ACEDB.
5' begins at position 2260 in C09H10.
3' finishes at 3287 in F45 E10.

Total 16818 bp.

42/99

FIG. 16.

LLFLLSTYKQKLRQLKKDQKKLEQLPTS unc-53 106 to 133
 : | :|||: || |::
 ETVNVNKLKTENKQLKKEVDKLTNGPAT unc-53 1093 to 1120

FIG. 17.

side on helix 1 4 7

XphPpxP

(a)	UNC-53	KKDPPPPAVPPRDT
(b)	UNC-53	TTDVPPLPPLKS
(c)	mSOS	EVPVPPPVPPRR
(d)	mSOS	HLDSPPAIPPR
(e)	mSOS	HSIAGPPVPPR
(f)	SOS 1359	YRAVPPPLPPRRK
(g)	SOS 1377	GELSPPPIPPRLN
(h)	Dynamin	APAVPPARPGS
(i)	dynamin	PAVPPARP
(j)	PI3K p85	PPRPLPVAPGS
(k)	PI3K p85	PAPALPPKPPK
(l)	AFAP-110	PPDNGPPPLPTSS
(m)	AFAP-110	PPQMPLPEIQQW
(n)	3BP-1	APTMPPLPPVPP
(o)	3BP-2	FPAYPPPVVP

FIG. 18.

43/99

```

V      1      11      21      31      41      51
      MTTSNVELIP IYTDWANRHL SKGSLSKSIR DISNDFRDYR LVSQILINVIV PINEFSPAFT
-----
H      1      11      21      31      41      51
V      61      71      81      91      101      111
      KRLAKITSNL DGLETCLDYL KNLGLDCSKL TKTDIDSGNL GAVIQLLLFL STYKQKLRQL
-----
H      61      71      81      91      101      111
V      121      131      141      151      161      171
      KKDQKKLEQL PTSIMPPAVS KLPSPRVATS ATASATNPNS NFPQMSTSR L QTPQSRISKI
-----
H      121      131      141      151      161      171
V      181      191      201      211      221      231
      DSSKIGIKPK TSGLKPPSSS TTSSNNTNSF RPSSRSSGNN NVGSTISTSA KSLESSSTYS
-----
H      181      191      201      211      221      231
V      241      251      261      271      281      291
      SISNLNRPTS QLQKPSRPQT QLVRVATTTK IGSSKLAAPK AVSTPKLASV KTIGAKQEPD
-----
H      241      251      261      271      281      291
V      301      311      321      331      341      351
      NSGGGGGGML KKLKLFSSKNP SSSSNSPQPT RKAAPVPOQQ TSKIAAPVK SGLKPPTS KL
      .. .....
      -----ML KKLKLFSSKNP SSSSNSPQPT RKAAPVPOQQ TSKIAAPVK SGLKPPTS KL
H      301      311      321      331      341      351
V      361      371      381      391      401      411
      GSATSMKLC TPKVSYRKTD APIISQODSK RCSKSSEEEES GYAGFNSTSP TSSSTEGSLS
      .....
      GSATSMKLC TPKVSYRKTD APIISQODSK RCSKSSEEEES GYAGFNSTSP TSSSTEGSLS
H      361      371      381      391      401      411
V      421      431      441      451      461      471
      MHSTSSKSST SDEKSPSSDD LTLNASIVTA IRQPIAATPV SPNIINKPVE EKPTLAVKGV
      .....
      MHSTSSKSST SDEKSPSSDD LTLNASIVTA IRQPIAATPV SPNIINKPVE EKPTLAVKGV
H      421      431      441      451      461      471
V      481      491      501      511      521      531
      KSTAKKDPPP AVPPRDTQPT IGVVSPIMAH KKLNDPVIS EKPEPEKLQS MSIDTTDVPP
      .....
      KSTAKKDPPP AVPPRDTQPT IGVVSPIMAH KKLNDPVIS EKPEPEKLQS MSIDTTDVPP
H      481      491      501      511      521      531
V      541      551      561      571      581      591
      LPPLKSVVPL KMTSIRQPPT YDVLLKQGKI TSPVKSFGYE QSSASEDSIV AHASQVTPP
      .....
      LPPLKSVVPL KMTSIRQPPT YDVLLKQGKI TSPVKSFGYE QSSASEDSIV AHASQVTPP
H      541      551      561      571      581      591
V      601      611      621      631      641      651
      TKTSGNHSLE RRMGKNKTSE SSGYTSDAGV AMCAKMREKL KEYDDMTRRA QNGYPDNFED
      .....
      TKTSGNHSLE RRMGKNKTSE SSGYTSDAGV AMCAKMREKL KEYDDMTRRA QNGYPDNFED
H      601      611      621      631      641      651
V      661      671      681      691      701      711
      SSSLSSGISD NNELDDISTD DLGGVDMATV ASKHSYSHF VRHPTSSSSK PRVPSRSSTS
      .....
      SSSLSSGISD NNELDDISTD DLGGVDMATV ASKHSYSHF VRHPTSSSSK PRVPSRSSTS
H      661      671      681      691      701      711
V      721      731      741      751      761      771
      VDSRSRAEQE NVYKLLSQCR TSQRGAAATS TFGQHSLSRP GYSSSYSPHLS VSADKDTMSM
      .....

```

SUBSTITUTE SHEET (RULE 26)

44/99

FIG. 18 CONTINUED.

```

VDSRSRAEQE NVYKLLSQCR TSQRGAAATS TFGQHSLSRP GYSSSPHLS VSADKDTMSH
H 721      731      741      751      761      771
V 781      791      801      811      821      831
HSQTSRRPSS QKPSYSGQFH SLDRKCHLQE FTSTEHRMAA LLSPRRVPNS MSKYDSSGSY
.....
HSQTSRRPSS QKPSYSGQFH SLDRKCHLQE FTSTEHRMAA LLSPRRVPNS MSKYDSSGSY
H 781      791      801      811      821      831
V 841      851      861      871      881      891
SARSRGGSST GIYGETFQLH RLSDEKSPAH SAKSEMGSQ LSLATTAYGS LNEKYEHAIR
.....
SARSRGGSST GIYGETFQLH RLSDEKSPAH SAKSEMGSQ LSLATTAYGS LNEKYEHAIR
H 841      851      861      871      881      891
V 901      911      921      931      941      951
DMARDLECYK NTVDSLTKKQ ENYGALFDLF EQKLRKLTQH IDRSNLKPFE AIRFRQDIAH
.....
DMARDLECYK NTVDSLTKKQ ENYGALFDLF EQKLRKLTQH IDRSNLKPFE AIRFRQDIAH
H 901      911      921      931      941      951
V 961      971      981      991      1001     1011
LRDISNHLAS NSAHANEGAG ELLRQPSLES VASHRSSMSS SSKSSKQEKI SLSSFGKNKK
.....
LRDISNHLAS NSAHANEGAG ELLRQPSLES VASHRSSMSS SSKSSKQEKI SLSSFGKNKK
H 961      971      981      991      1001     1011
V 1021     1031     1041     1051     1061     1071
SWIRSSLSKF TKKKKNKYDE AHMPSISGSQ GTLDNIDVIE LKQELKERDS ALYEVRLDNL
.....
SWIRSSLSKF TKKKKNKYDE AHMPSISGSQ GTLDNIDVIE LKQELKERDS ALYEVRLDNL
H 1021     1031     1041     1051     1061     1071
V 1081     1091     1101     1111     1121     1131
DRAREVDVLR ETVNKLKTEN KQLKKEVDKL TNGPATRASS RASIPVIYDD EHVYDAACSS
.....
DRAREVDVLR ETVNKLKTEN KQLKKEVDKL TNGPATRASS RASIPVIYDD EHVYDAACSS
H 1081     1091     1101     1111     1121     1131
V 1141     1151     1161     1171     1181     1191
TSASQSSKRS SGCNSIKVTV NVDIAGEISS IVNPDKEIIV GYLAMTSQS CWKDIDVSIL
.....
TSASQSSKRS SGCNSIKVTV NVDIAGEISS IVNPDKEIIV GYLAMTSQS CWKDIDVSIL
H 1141     1151     1161     1171     1181     1191
V 1201     1211     1221     1231     1241     1251
GLFEVYLSRI DVEHQLGIDA RDSILGYQIG ELRRVIGDST TMITSHPTDI LTSSTTIRMF
.....
GLFEVYLSRI DVEHQLGIDA RDSILGYQIG ELRRVIGDST TMITSHPTDI LTSSTTIRMF
H 1201     1211     1221     1231     1241     1251
V 1261     1271     1281     1291     1301     1311
MHGAAQSRVD SLVLDMLLPK QMILQLVKSI LTERRLVLAG ATGIGKSKLA KTLAAYVSIR
.....
MHGAAQSRVD SLVLDMLLPK QMILQLVKSI LTERRLVLAG ATGIGKSKLA KTLAAYVSIR
H 1261     1271     1281     1291     1301     1311
V 1321     1331     1341     1351     1361     1371
TNQSEDSIVN ISIPENNKEE LLQVERRLEK ILRSKESCIV ILDNIPKNRI AFVVSVFANV
.....
TNQSEDSIVN ISIPENNKEE LLQVERRLEK ILRSKESCIV ILDNIPKNRI AFVVSVFANV
H 1321     1331     1341     1351     1361     1371
V 1381     1391     1401     1411     1421     1431
PLQNNEGPFV VCTVNRYQIP ELQIHNNFKM SVMSNRLEGF ILRYLRRRAV EDEYRLTVQM
.....
PLQNNEGPFV VCTVNRYQIP ELQIHNNFKM SVMSNRLEGF ILRYLRRRAV EDEYRLTVQM
H 1381     1391     1401     1411     1421     1431
V 1441     1451     1461     1471     1481     1491
PSELFKIIDF FPIALQAVNM FIEKTNVSDV TVGPRACLNC PLTVDGSREW FIRLWNNENFI
.....
PSELFKIIDF FPIALQAVNM FIEKTNVSDV TVGPRACLNC PLTVDGSREW FIRLWNNENFI

```

SUBSTITUTE SHEET (RULE 26)

45/99

FIG. 18 CONTINUED


```

      PSELFKIIDF FPIALQAVNN FIEKTSVDV TVGPRACLNC PLTVDGSREW FIRLWNENFI
H  1441      1451      1461      1471      1481      1491
V  1501      1511      1521      1531      1541      1551
      PYLERVARDG KKNLRSLHFL RGSRRHRL-- -----
      *****
      PYLERVARDG KKTFGRCTSF EDPTDIVSEK WPFWDGENPE NVLKRLQLQD LVSPANSSR
H  1501      1511      1521      1531      1541      1551
V  -----
      QHFNPLESLI QLHATKHQTI DNI
H  1561      1571      1581

```

46/99


FIG. 19.



SUBSTITUTE SHEET (RULE 26)


47/99

FIG. 20.




48/99

FIG. 21.




49/99

FIG. 22.




50/99

FIG. 23.




51/99

FIG. 24.



52/99

FIG. 25.



53/99

FIG. 26.

GGCCGCCGCC ATGACGACGT CAAATGTAGA ATTGATACCA ATCTACACGG ATTGGGCCAA	60
TCGGCACCTT TCGAAGGGCA GCTTATCAAA GTCGATTAGG GATATTTCCA ATGATTTTCG	120
CGACTATCGA CTGGTTTCTC AGCTTATTAA TGTGATCGTT CCGATCAACG AATTCTCGCC	180
TGCATTACAG AAACGTTTGG CAAAATCAC ATCGAACCTG GATGGCCTCG AAACGTGTCT	240
CGACTACCTG AAAAATCTGG GTCTCGACTG CTCGAAACTC ACCAAAACCG ATATCGACAG	300
CGGAAACTTG GGTGCAGTTC TCCAGCTGCT CTTCTGCTC TCCACCTACA AGCAGAAGCT	360
TCGGCAACTG AAAAAGATC AGAAGAAAT GGAGCAACTA CCCACATCCA TTATGCCACC	420
CGCGGTTTCT AAATTACCCT CGCCACGTGT CGCCACGTCA GCAACCGCTT CAGCAACTAA	480
CCCAAATTCC AACTTTCCAC AAATGTCAAC ATCCAGGCTT CAGACTCCAC AGTCAAGAAT	540
ATCGAAAATT GATTCATCAA AGATTGGTAT CAAGCCAAAG ACGTCTGGAC TTAAACCACC	600
CTCATCATCA ACCACTTCAT CAAATAATAC AAATTCATTC CGTCCGTCGA GCCGTCGAG	660
TGGCAATAAT AATGTTGGCT CGACGATATC CACATCTGCG AAGAGCTTAG AATCATCATC	720
AACGTACAGC TCTATTTCTGA ATCTAAACCG ACCTACCTCC CAACTCCAAA AACCTTCTAG	780
ACCACAAACC CAGCTAGTTC GTGTTGCTAC AACTACAAAA ATCGGAAGCT CAAAGCTAGC	840
CGCTCCGAAA GCCGTGAGCA CCCCCAACT TGCTTCTGTG AAGACTATTG GAGCAAAACA	900
AGAGCCCGAT AACAGCGGTG GTGGTGGTGG TGGAAATGCTG AAATTAAAGT TATTCAGTAG	960
CAAAAACCCA TCTTCCTCAT CGAATAGCCC ACAACCTACG AGAAAGGCGG CGGCGGTGCC	1020
TCAACAACAA ACTTTGTCTGA AAATCGCTGC CCCAGTGAAA AGTGGCCTGA AGCCGCCGAC	1080
CAGTAAGCTG GGAAGTGCCA CGTCTATGTC GAAGCTTTGT ACGCCAAAAG TTTCTACCG	1140
TAAAACGGAC GCCCAATCA TATCTCAACA AGACTCGAAA CGATGCTCAA AGAGCAGTGA	1200
AGAAGAGTCC GGATACGCTG GATTCAACAG CACGTCGCCA ACGTCATCAT CGACGGAAGG	1260
TTCCCTAAGC ATGCATTCCA CATCTTCCAA GAGTTCAACG TCAGACGAAA AGTCTCCGTC	1320
ATCAGACGAT CTTACTCTTA ACGCCTCCAT CGTGACAGCT ATCAGACAGC CGATAGCCGC	1380
AACACCGGTT TCTCCAAATA TTATCAACAA GCCTGTTGAG GAAAAACCA CACTGGCAGT	1440

SUBSTITUTE SHEET (RULE 26)

FIG. 26 CONTINUED.

54/99

GAAAGGAGTG AAAAGCACAG CGAAAAAAGA TCCACCTCCA GCTGTTCCGC CACGTGACAC	1500
CCAGCCACA ATCGGAGTTG TTAGTCCAAT TATGGCACAT AAGAAGTTGA CAAATGACCC	1560
CGTGATATCT GAAAAACCAG AACCTGAAA GCTCCAATCA ATGAGCATCG ACACGACGGA	1620
CGTTCACCG CTTCACCTC TAAATCAGT TGTTCCACTT AAAATGACTT CAATCCGACA	1680
ACCACCAACG TACGATGTTT TTCTAAAACA AGGAAAAATC ACATCGCCTG TCAAGTCGTT	1740
TGGATATGAG CAGTCGTCCG CGTCTGAAGA CTCCATTGTG GCTCATGCGT CGGCTCAGGT	1800
GACTCCGCCG ACAAAAACCT CTGGTAATCA TTCGCTGGAG AGAAGGATGG GAAAGAATAA	1860
GACATCAGAA TCCAGCGGCT ACACCTCTGA CGCCGGTGTT GCGATGTGCG CCAAAATGAG	1920
GGAGAAGCTG AAAGAATACG ATGACATGAC TCGTCGAGCA CAGAACGGCT ATCCTGACAA	1980
CTTCGAAGAC AGTTCCTCCT TGTCGTCTGG AATATCCGAT AACACGAGC TCGACGACAT	2040
ATCCACGGAC GATTTGTCCG GAGTAGACAT GGCAACAGTC GCCTCCAAAC ATAGCGACTA	2100
TTCCCACTTT GTTCGCCATC CCACGTCTTC TTCTCAAAG CCCCAGTCC CCAGTCGGTC	2160
CTCCACATCA GTCGATTCTC GATCTCGAGC AGAACAGGAG AATGTGTACA AACTTCTGTC	2220
CCAGTGCCGA ACGAGCCAAC GTGGCGCCGC TGCCACCTCA ACCTTCGGAC AACATTGCGT	2280
AAGATCCCCG GGATACTCAT CCTATTCTCC ACACTTATCA GTGTCAGCTG ATAAGGACAC	2340
AATGTCTATG CACTCACAGA CTAGTCGAGC ACCTTCTTCA CAAAACCAA GCTATTCAGG	2400
CCAAATTCAT TCACTTGATC GTAAATGCCA CCTTCAAGAG TTCACATCCA CCGAGCACAG	2460
AATGGCGGCT CTCTTGAGCC CGAGACGGGT GCCGAACCTG ATGTCGAAAT ATGATTCTTC	2520
AGGATCCTAC TCGGCGCGTT CCCGAGGTGG AAGCTCTACT GGTATCTATG GAGAGACGTT	2580
CCAACTGCAC AGACTATCCG ATGAAAAATC CCCCGCACAT TCTGCCAAA GTGAGATGGG	2640
ATCCCAACTA TCACTGGCTA GCACGACAGC ATATGGATCT CTCAATGAGA AGTACGAACA	2700
TGCTATTTCG GACATGGCAC GTGACTTGA GTGTTACAAG AACACTGTCG ACTCACTAAC	2760
CAAGAAACAG GAGAACTATG GAGCATTGTT TGATCTTTTT GAGCAAAAGC TTAGAAAAC	2820
CACTCAACAC ATTGATCGAT CCAACTTGAA GCCTGAAGAG GCAATACGAT TCAGGCAGGA	2880
CATTGCTCAT TTGAGGGATA TTAGCAATCA TCTTGCATCC AACTCAGCTC ATGCTAACGA	2940
AGGCGCTGGT GAGCTTCTTC GTCAACCATC TCTGGAATCA GTTGCATCCC ATCGATCATC	3000
GATGTCATCG TCGTCGAAA GCAGCAAGCA GGAGAAGATC AGCTTGAGCT CGTTTGCAA	3060
GAACAAGAAG AGCTGGATCC GTCCTCACT CTCCAAGTTC ACCAAGAAGA AGAACAAGAA	3120
CTACGACGAA GCACATATGC CATCAATTTT CGGATCTCAA GGAACCTTTG ACAACATTGA	3180
TGTGATTGAG TTGAAGCAAG AGCTCAAAGA ACGCGATAGT GCACTTTACG AAGTCCGCCT	3240
TGACAATCTG GATCGTGCCC GCGAAGTTGA TGTCTGAGG GAGACAGTGA ACAAGTTGAA	3300
AACCGAGAAC AAGCAATTAA AGAAAGAAGT GGACAACTC ACCAACGGTC CAGCCACTCG	3360

SUBSTITUTE SHEET (RULE 26)

*FIG. 26 CONTINUED.**55/99*

TGCTTCTTCC CGCGCCTCAA TTCCAGTTAT CTACGACGAT GAGCATGTCT ATGATGCAGC	3420
GTGTAGCAGT ACATCAGCTA GTCAATCTTC GAAACGATCC TCTGGCTGCA ACTCAATCAA	3480
GGTTACTGTA AACGTGGACA TCGCTGGAGA AATCAGTTCG ATCGTTAACC CGGACAAAGA	3540
GATAATCGTA GGATATCTTG CCATGTCAAC CAGTCAGTCA TGCTGGAAAG ACATTGATGT	3600
TTCTATTCTA GGACTATTTG AAGTCTACCT ATCCAGAATT GATGTGGAGC ATCAACTTGG	3660
AATCGATGCT CGTGATTCTA TCCTTGGCTA TCAAATTGGT GAACTTCGAC GCGTCATTGG	3720
AGACTCCACA ACCATGATAA CCAGCCATCC AACTGACATT CTTACTTCCT CAACTACAAT	3780
CCGAATGTTT ATGCACGGTG CCGCACAGAG TCGCGTAGAC AGTCTGGTCC TTGATATGCT	3840
TCTTCCAAAG CAAATGATTC TCCAACCTCGT CAAGTCAATT TTGACAGAGA GACGTCTGGT	3900
GTTAGCTGGA GCAACTGGAA TTGGAAAGAG CAACTGGCG AAGACCCTGG CTGCTTATGT	3960
ATCTATTCTA ACAAATCAAT CCGAAGATAG TATTGTTAAT ATCAGCATTC CTGAAAACAA	4020
TAAAGAAGAA TTGCTTCAAG TGGAAACGACG CCTGGAAAAG ATCTTGAGAA GCAAAGAATC	4080
ATGCATCGTA ATTCTAGATA ATATCCCAAA GAATCGAATT GCATTTGTTG TATCCGTTTT	4140
TGCAAATGTC CCACTTCAAA ACAACGAAGG TCCATTTGTA GTATGCACAG TCAACCGATA	4200
TCAAATCCCT GAGCTTCAAA TTCACCACAA TTTCAAATG TCAGTAATGT CGAATCGTCT	4260
CGAAGGATTC ATCCTACGTT ACCTCCGACG ACGGGCGGTA GAGGATGAGT ATCGTCTAAC	4320
TGTACAGATG CCATCAGAGC TCTTCAAAAT CATTGACTTC TTCCCAATAG CTCTTCAGGC	4380
CGTCAATAAT TTTATTGAGA AAACGAATTC TGTGATGTG ACAGTTGGTC CAAGAGCATG	4440
CTTGAAGTGT CCTCTAACTG TCGATGGATC CCGTGAATGG TTCATTGATG TGTGGAATGA	4500
GAACTTCATT CCATATTTGG AACGTGTTGC TAGAGATGGC AAAAAAACCT TCGGTCGCTG	4560
CACTTCCTTC GAGGATCCCA CCGACATCGT CTCTAAAAAA TGGCCGTGGT TCGATGGTGA	4620
AAACCCGGAG AATGTGCTCA AACGTCTTCA ACTCCAAGAC CTCGTCCCGT CACCTGCCAA	4680
CTCATCCCGA CAACACTTCA ATCCCCTCGA GTCGTTGATC CAATTGCATG CTACCAAGCA	4740
TCAGACCATC GACAACATTT GAACAGAAGA CTCTAATCTT CTCTCGCCTC TCCCCCGCTT	4800
TCCTTATCTT CGTACCGGTA CCTGATGATT CCCCATTTTC CCCCTTTTCC CCCCAATTC	4860
CCAGAACCTC CTGTTCCCTT TGTTCCTAGT CCTCCCGGGT GCCGACGCCG AAGCGATTTA	4920
AAAACCTTTT TCTTTCCGAA ACATTTCCCA TTGCTCATT AATAGTCAAAT TGAATAAACA	4980
GTGTATGTAC TTAATAAAAA AAAAAAAAAA ACTCGAGGGG GGGCCCTATT CTATAGTGTC	5040
ACCTAAATGC TAGAGCTCGC TGATCAGCCT CGACTGTGCC TTCTAGTTGC CAGCCATCTG	5100
TTGTTTGCCC CTCCCCGTG CCTTCCTTGA CCCTGGAAGG TGCCACTCCC ACTGTCCTTT	5160
CCTAATAAAA TGAGGAAATT GCATCGCATT GTCTGAGTAG GTGTCATTCT ATTCTGGGGG	5220
GTGGGGTGGG GCAGGACAGC AAGGGGGAGG ATTGGGAAGA CAATAGCAGG CATGCTGGGG	5280

SUBSTITUTE SHEET (RULE 26)

56/99

FIG. 26 CONTINUED.

ATGCGGTGGG CTCTATGGCT TCTGAGGCGG AAAGAACCAG CTGGGGCTCT AGGGGGTATC	5340
CCCACGCGCC CTGTAGCGGC GCATTAAGCG CGGCGGGTGT GGTGGTTACG CGCAGCGTGA	5400
CCGCTACACT TGCCAGCGCC CTAGCGCCCG CTCCTTTCCG TTTCTTCCCT TCCTTTCTCG	5460
CCACGTTTCGC CGGCTTTCCC CGTCAAGCTC TAAATCGGG CATCCCTTTA GGGTTCCGAT	5520
TTAGTGCTTT ACGGCACCTC GACCCCAAAA AACTTGATTA GGGTGATGGT TCACGTAGTG	5580
GGCCATCGCC CTGATAGACG GTTTTTTCGCC CTTTGACGTT GGAGTCCACG TTCTTTAATA	5640
GTGGACTCTT GTTCCAACT GGAACAACAC TCAACCCTAT CTCGGTCTAT TCTTTTGATT	5700
TATAAGGGAT TTTGGGGATT TCGGCCTATT GGTAAAAA TGAGCTGATT TAACAAAAAT	5760
TTAACGCGAA TTAATTCTGT GGAATGTGTG TCAGTTAGGG TGTGGAAAGT CCCAGGCTC	5820
CCCAGGCAGG CAGAAGTAG CAAAGCATGC ATCTCAATTA GTCAGCAACC AGGTGTGGAA	5880
AGTCCCCAGG CTCCCCAGCA GGCAGAAGTA TGCAAAGCAT GCATCTCAAT TAGTCAGCAA	5940
CCATAGTCCC GCCCCTAACT CCGCCCATCC CGCCCCTAAC TCCGCCCAGT TCCGCCCAT	6000
CTCCGCCCCA TGGCTGACTA ATTTTTTTTA TTTATGCAGA GGCCGAGGCC GCCTCTGCCT	6060
CTGAGCTATT CCAGAAGTAG TGAGGAGGCT TTTTGGAGG CCTAGGCTTT TGCAAAAAGC	6120
TCCCGGGAGC TTGTATATCC ATTTTCGGAT CTGATCAAGA GACAGGATGA GGATCGTTTC	6180
GCATGATTGA ACAAGATGGA TTGCACGCAG GTTCTCCGGC CGCTTGGGTG GAGAGGCTAT	6240
TCGGCTATGA CTGGGCACAA CAGACAATCG GCTGCTCTGA TGCCGCCGTG TTCCGGCTGT	6300
CAGCGCAGGG GCGCCCGGTT CTTTTGTCA AGACCGACCT GTCCGGTGCC CTGAATGAAC	6360
TGCAGGACGA GGCAGCGCGG CTATCGTGGC TGGCCACGAC GGGCGTTCCT TGCGCAGCTG	6420
TGCTCGACGT TGTCACGAA GCGGGAAGGG ACTGGCTGCT ATTGGGCGAA GTGCCGGGGC	6480
AGGATCTCCT GTCATCTCAC CTTGCTCCTG CCGAGAAAGT ATCCATCATG GCTGATGCAA	6540
TGCGGCGGCT GCATACGCTT GATCCGGCTA CCTGCCCAT TCGACCACCA GCGAAACATC	6600
GCATCGAGCG AGCACGTA CTGATGGAAG CCGGTCTTGT CGATCAGGAT GATCTGGACG	6660
AAGAGCATCA GGGGCTCGCG CCAGCCGAAC TGTTCCGAG GCTCAAGGCG CGCATGCCCC	6720
ACGGCGAGGA TCTCGTCGTG ACCCATGGCG ATGCCTGCTT GCCGAATATC ATGGTGGAAA	6780
ATGGCCGCTT TTCTGGATTC ATCGACTGTG GCCGGCTGGG TGTGGCGGAC CGCTATCAGG	6840
ACATAGCGTT GGCTACCCGT GATATTGCTG AAGAGCTTGG CGGCGAATGG GCTGACCGCT	6900
TCCTCGTGCT TTACGGTATC GCCGCTCCCG ATTCCGACG CATCGCCTTC TATCGCCTTC	6960
TTGACGAGTT CTTCTGAGCG GGAATCTGGG GTTCGAAATG ACCGACCAAG CGACGCCCAA	7020
CCTGCCATCA CGAGATTTTC ATTCCACCGC CGCCTTCTAT GAAAGGTTGG GCTTCGGAAT	7080
CGTTTTCCGG GACGCCGGCT GGATGATCCT CCAGCGCGGG GATCTCATGC TGGAGTTCTT	7140
CGCCACCCC AACTTGTTTA TTGCAGCTTA TAATGGTTAC AAATAAAGCA ATAGCATCAC	7200

SUBSTITUTE SHEET (RULE 26)

57/99

FIG. 26 CONTINUED.

AAATTTACACA AATAAAGCAT TTTTTCCTACT GCATTCTAGT TGTGGTTTGT CCAAACATCAT	7260
CAATGTATCT TATCATGTCT GTATACCGTC GACCTCTAGC TAGAGCTTGG CGTAATCATG	7320
GTCATAGCTG TTTCCTGTGT GAAATTGTGA TCCGCTCACA ATTCCACACA ACATACGAGC	7380
CGGAAGCATA AAGTGTAAG CCTGGGGTGC CTAATGAGTG AGCTAACTCA CATTAAATTGC	7440
GTTGCGCTCA CTGCCCCTT TCCAGTCGGG AAACCTGTCTG TGCCAGCTGC ATTAATGAAT	7500
CGGCCAACGC GCGGGGAGAG GCGGTTTGC TATTGGGCGC TCTTCGCTT CCTCGCTCAC	7560
TGACTCGCTG CGCTCGGTCTG TTCGGCTGCG GCGAGCGGTA TCAGCTCACT CAAAGGCGGT	7620
AATACGGTTA TCCACAGAAT CAGGGGATAA CGCAGGAAAG AACATGTGAG CAAAAGGCCA	7680
GCAAAAGGCC AGGAACCGTA AAAAGGCCGC GTTGCTGGCG TTTTCCATA GGCTCCGCCC	7740
CCCTGACGAG CATCACAAA ATCGACGCTC AAGTCAGAGG TGGCGAAACC CGACAGGACT	7800
ATAAAGATAC CAGGCGTTTC CCCCTGGAAG CTCCTCTGTC CGCTCTCCTG TTCCGACCCT	7860
GCCGCTTACC GGATACCTGT CCGCCTTTCT CCCTTCGGGA AGCGTGGCGC TTTCTCAATG	7920
CTCAGCTGT AGGTATCTCA GTTCGGTGTA GGTGTTTCG TCCAAGCTGG GCTGTGTGCA	7980
CGAACCCCC GTTCAGCCCG ACCGCTGCGC CTTATCCGGT AACTATCGTC TTGAGTCCAA	8040
CCCGGTAAGA CACGACTTAT CGCCACTGGC AGCAGCCACT GGTAACAGGA TTAGCAGAGC	8100
GAGGTATGTA GCGGGTGCTA CAGAGTTCTT GAAGTGGTGG CCTAACTACG GCTACACTAG	8160
AAGGACAGTA TTTGGTATCT GCGCTCTGCT GAAGCCAGTT ACCTTCGGAA AAAGAGTTGG	8220
TAGCTCTTGA TCCGGCAAAC AAACCACCGC TGGTAGCGGT GGTTTTTTTG TTTGCAAGCA	8280
GCAGATTACG CGCAGAAAAA AAGGATCTCA AGAAGATCCT TTGATCTTT CTACGGGGTC	8340
TGACGCTCAG TGGAACGAAA ACTCACGTTA AGGGATTTTG GTCATGAGAT TATCAAAAAG	8400
GATCTTCACC TAGATCCTTT TAAATTAAAA ATGAAGTTT AAATCAATCT AAAGTATATA	8460
TGAGTAACT TGGTCTGACA GTTACCAATG CTTAATCAGT GAGGCACCTA TCTCAGCGAT	8520
CTGTCTATTT CGTTCATCCA TAGTTGCCTG ACTCCCCGTC GTGTAGATAA CTACGATACG	8580
GGAGGGCTTA CCATCTGGCC CCAGTGCTGC AATGATACCG CGAGACCCAC GCTCACCGGC	8640
TCCAGATTTA TCAGCAATAA ACCAGCCAGC CGGAAGGGCC GAGCGCAGAA GTGGTCCTGC	8700
AACTTTATCC GCCTCCATCC AGTCTATTAA TTGTTGCCGG GAAGCTAGAG TAAGTAGTTC	8760
GCCAGTTAAT AGTTTGCACA ACGTTGTTGC CATTGCTACA GGCATCGTGG TGTACGCTC	8820
GTCGTTTGGT ATGGCTTCAT TCAGCTCCGG TTCCCAACGA TCAAGGCGAG TTACATGATC	8880
CCCCATGTTG TGCAAAAAG CGGTTAGCTC CTTCCGTCCT CCGATCGTTG TCAGAAGTAA	8940
GTTGGCCGCA GTGTTATCAC TCATGGTTAT GGCAGCACTG CATAATTCTC TTACTGTCAT	9000
GCCATCCGTA AGATGCTTTT CTGTGACTGG TGAGTACTCA ACCAAGTCAT TCTGAGAATA	9060
GTGTATGCGG CGACCGAGTT GCTCTTGCCC GCGTCAATA CCGGATAATA CCGCGCCACA	9120

SUBSTITUTE SHEET (RULE 26)


58/99

FIG. 26 CONTINUED

TAGCAGAACT	TTAAAAGTGC	TCATCATTGG	AAAACGTTCT	TCGGGGCGAA	AACTCTCAAG	9180
GATCTTACCG	CTGTTGAGAT	CCAGTTCGAT	GTAACCCACT	CGTGCACCCA	ACTGATCTTC	9240
AGCATCTTTT	ACTTTCACCA	GCGTTTCTGG	GTGAGCAAAA	ACAGGAAGGC	AAAATGCCGC	9300
AAAAAAGGGA	ATAAGGGCGA	CACGGAAATG	TTGAATACTC	ATACTCTTCC	TTTTTCAATA	9360
TTATTGAAGC	ATTTATCAGG	GTTATTGTCT	CATGAGCGGA	TACATATTTG	AATGTATTTA	9420
GAAAAATAAA	CBAATAGGGG	TTCCGCGCAC	ATTTCCCCGA	AAAGTGCCAC	CTGACGTCGA	9480
CGGATCGGGA	GATCTCCCGA	TCCCCTATGG	TCGACTCTCA	GTACAATCTG	CTCTGATGCC	9540
GCATAGTTAA	GCCAGTATCT	GCTCCCTGCT	TGTGTGTTGG	AGGTCGCTGA	GTAGTGCGCG	9600
AGCAAAATTT	AAGCTACAAC	AAGGCAAGGC	TTGACCGACA	ATTGCATGAA	GAATCTGCTT	9660
AGGGTTAGGC	GTTTTGCGCT	GCTTCGCGAT	GTACGGGCCA	GATATACGCG	TTGACATTGA	9720
TTATTGACTA	GTTATTAATA	GTAATCAATT	ACGGGGTCAT	TAGTTCATAG	CCCATATATG	9780
GAGTTCCGCG	TTACATAACT	TACGGTAAAT	GGCCCGCCTG	GCTGACCGCC	CAACGACCCC	9840
CGCCCATTGA	CGTCAATAAT	GACGTATGTT	CCCATAGTAA	CGCCAATAGG	GACTTTCCAT	9900
TGACGTCAAT	GGGTGGACTA	TTTACGGTAA	ACTGCCCCACT	TGGCAGTACA	TCAAGTGTAT	9960
CATATGCCAA	GTACGCCCCC	TATTGACGTC	AATGACGGTA	AATGGCCCCG	CTGGCATTAT	10020
GCCCAGTACA	TGACCTTATG	GGACTTTCCT	ACTTGGCAGT	ACATCTACGT	ATTAGTCATC	10080
GCTATTACCA	TGGTGATGCG	GTTTTGGCAG	TACATCAATG	GGCGTGGATA	GCGGTTTGAC	10140
TCACGGGGAT	TTCCAAGTCT	CCACCCCAT	GACGTCAATG	GGAGTTTGT	TTGGCACCAA	10200
AATCAACGGG	ACTTTCCAAA	ATGTCGTAA	AACTCCGCC	CATTGACGCA	AATGGGCGGT	10260
AGGCGTGTAC	GGTGGGAGGT	CTATATAAGC	AGAGCTCTCT	GGCTAACTAG	AGAACCCACT	10320
GCTTACTGGC	TTATCGAAAT	TAATACGACT	CACTATAGGG	AGACCAAGC	TTGGTACCGA	10380
GCTCGGATCC	ACTAGTAACG	GCCGCCAGTG	TGCTGGAATT	CTGCAGATAT	CCATCACACT	10440
GGC						10443

59/99

FIG. 27.



SUBSTITUTE SHEET (RULE 26)

60/99

FIG. 28.

CTAAATTGTA AGCGTTAATA TTTTGTAAAA ATTGCGGTTA AATTTTTGTT AAATCAGCTC	60
ATTTTTTAAC CAATAGGCCG AAATCGGCAA AATCCCTTAT AAATCAAAAG AATAGACCGA	120
GATAGGGTTG AGTGTGTGTC CAGTTTGGAA CAAGAGTCCA CTATTAAAGA ACGTGGACTC	180
CAACGTCAAA GGGCGAAAAA CCGTCTATCA GGGCGATGGC CCACTACGTG AACCATCACC	240
CTAATCAAGT TTTTGGGGT CGAGGTGCCG TAAAGCACTA AATCGGAACC CTAAAGGGAG	300
CCCCGATTT AGAGCTTGAC GGGGAAAGCC GCGAACGTG GCGAGAAAGG AAGGGAAGAA	360
AGCGAAAGGA GCGGGCGCTA GGGCGCTGGC AAGTGTAGCG GTCACGCTGC GCGTAACCAC	420
CACACCCGCC GCGCTTAATG CGCCGCTACA GGGCGCGTCC CATTGCCCAT TCAGGCTGCG	480
CAACTGTTGG GAAGGGCGAT CGGTGCGGGC CTCTTCGCTA TTACGCCAGC TGGCGAAAGG	540
GGGATGTGCT GCAAGGCGAT TAAGTTGGGT AACGCCAGGG TTTTCCAGT CACGACGTTG	600
TAAAACGACG GCCAGTGAGC GCGCGTAATA CGACTACTA TAGGGCGAAT TGGAGCTCCA	660
CCGCGGTTTC TAAATTACCC TCGCCACGTG TCGCCACGTC AGCAACCGCT TCAGCAACTA	720
ACCCAAATTC CAACTTTCCA CAAATGTCAA CATCCAGGCT TCAGACTCCA CAGTCAAGAA	780
TATCGAAAAT TGATTCACTA AAGATTGGTA TCAAGCCAAA GACGTCTGGA CTTAAACCAC	840
CCTCATCATC AACCATTCA TCAAATAATA CAAATTCATT CCGTCCGTCG AGCCGTTCTGA	900
GTGGCAATAA TAATGTTGGC TCGACGATAT CCACATCTGC GAAGAGCTTA GAATCATCAT	960
CAACGTACAG CTCTATTTCTG AATCTAAACC GACCTACCTC CCAACTCCAA AAACCTTCTA	1020
GACCACAAAC CCAGCTAGTT CGTGTGCTA CAACTACAAA AATCGGAAGC TCAAAGCTAG	1080
CCGCTCCGAA AGCCGTGAGC ACCCCAAAAC TTGCTTCTGT GAAGACTATT GGAGCAAAAC	1140
AAGAGCCCGA TAACAGCGGT GGTGGTGGTG GTGGAATGCT GAAATTAAAG TTATTAGTA	1200
GCAAAAACCC ATCTTCCTCA TCGAATAGCC CACAACCTAC GAGAAAGGCG GCGGCGGTGC	1260
CTCAACAACA AACTTTGTCTG AAAATCGCTG CCCAGTGAA AAGTGGCCTG AAGCCGCCGA	1320
CCAGTAAGCT GGGAAAGTCC ACCTCTATGT CGAAGCTTTG TACGCCAAAA GTTTCCTACC	1380
GTAAACGGA CGCCCCAATC ATATCTCAAC AAGACTCGAA ACGATGCTCA AAGAGCAGTG	1440
AAGAAGAGTC CGGATACGCT GGATTCAACA GCACGTCGCC AACGTCATCA TCGACGGAAG	1500
GTTCCCTAAG CATGCATTCC ACATCTTCCA AGAGTTCAAC GTCAGACGAA AAGTCTCCGT	1560
CATCAGACGA TCTTACTCTT AACGCCTCCA TCGTGACAGC TATCAGACAG CCGATAGCCG	1620
CAACACCGGT TTCTCCAAAT ATTATCAACA AGCCTGTTGA GGAAAAACCA ACACTGGCAG	1680
TGAAAGGAGT GAAAAGCACA GCGAAAAAG ATCCACCTCC AGCTGTTCCG CCACGTGACA	1740
CCCAGCCAAC AATCGGAGTT GTTAGTCCAA TTATGGCACA TAAGAAGTTG ACAAATGACC	1800
CCGTGATATC TGA AAAACCA GAACCTGAAA AGCTCCAATC AATGAGCATC GACACGACGG	1860

SUBSTITUTE SHEET (RULE 26)

FIG. 28 CONTINUED.

6/1/99

ACGTTCCACC GCTTCCACCT CTAAATCAG TTGTTCCACT TAAATGACT TCAATCCGAC	1920
AACCACCAAC GTACGATGTT CTTCTAAAAC AAGGAAAAAT CACATCGCCT GTCAAGTCGT	1980
TTGGATATGA GCAGTCGTCC GCGTCTGAAG ACTCCATTGT GGCTCATGCG TCGGCTCAGG	2040
TGACTCCGCC GACAAAACT TCTGGTAATC ATTGCTGGA GAGAAGGATG GGAAAGAATA	2100
AGACATCAGA ATCCAGCGGC TACACCTCTG ACGCCGGTGT TGGATGTGC GCCAAATGA	2160
GGGAGAAGCT GAAAGAATAC GATGACATGA CTCGTCGAGC ACAGAACGGC TATCTGACA	2220
ACTTCGAAGA CAGTTCCTCC TTGTCGTCTG GAATATCCGA TAACAACGAG CTCGACGACA	2280
TATCCACGGA CGATTTGTCC GGAGTAGACA TGGCAACAGT CGCCTCCAAA CATAGCGACT	2340
ATTCCCACTT TGTTCGCCAT CCCACGTCTT CTTCTCAAA GCCCCGAGTC CCCAGTCGGT	2400
CCTCCACATC AGTCGATTCT CGATCTCGAG CAGAACAGGA GAATGTGTAC AAACCTTCTGT	2460
CCCAGTGCCG AACGAGCCAA CGTGGCGCCG CTGCCACCTC AACCTTCGGA CAACATTCGC	2520
TAAGATCCCC GGGATACTCA TCCTATTCTC CACACTTATC AGTGTGAGT GATAAGGACA	2580
CAATGTCTAT GCACTCACAG ACTAGTCGAC GACCTTCTC AAAAAACCA AGCTATTCAG	2640
GCCAATTTCA TTCACCTGAT CGTAAATGCC ACCTTCAAGA GTTCACATCC ACCGAGCACA	2700
GAATGGCGGC TCTCTTGAGC CCGAGACGGG TGCCGAACTC GATGTCGAAA TATGATTCTT	2760
CAGGATCCTA CTCGGCGCGT TCCCGAGGTG GAAGCTCTAC TGGTATCTAT GGAGAGACGT	2820
TCCAAC TGCA CAGACTATCC GATGAAAAAT CCCCCGACA TTCTGCCAAA AGTGAGATGG	2880
GATCCCAACT ATCACTGGCT AGCACGACAG CATATGGATC TCTCAATGAG AAGTACGAAC	2940
ATGCTATTCG GGACATGGCA CGTGACTTGG AGTGTTACAA GAACACTGTC GACTACTAA	3000
CCAAGAAACA GGAGAACTAT GGAGCATTGT TTGATCTTTT TGAGCAAAAG CTTAGAAAAC	3060
TCACTCAACA CATTGATCGA TCCAAC TTGA AGCCTGAAGA GGCAATACGA TTCAGGCAGG	3120
ACATTGCTCA TTTGAGGGAT ATTAGCAATC ATCTTGCATC CAACTCAGCT CATGCTAACG	3180
AAGGCGCTGG TGAGCTTCTT CGTCAACCAT CTCTGGAATC AGTTGCATCC CATCGATCAT	3240
CGATGTCATC GTCGTCGAAA AGCAGCAAGC AGGAGAAGAT CAGCTTGAGC TCGTTTGGCA	3300
AGAACAAGAA GAGCTGGATC CGCTCCTCAC TCTCCAAGTT CACCAAGAAG AAGAACAAGA	3360
ACTACGACGA AGCACATATG CCATCAATTT CCGGATCTCA AGGAACTCTT GACAACATTG	3420
ATGTGATTGA GTTGAAGCAA GAGCTCAAAG AACGCGATAG TGCACTTTAC GAAGTCCGCC	3480
TTGACAATCT GGATCGTGCC CGCGAAGTTG ATGTTCTGAG GGAGACAGTG AACAGTTGA	3540
AAACCGAGAA CAAGCAATTA AAGAAAGAAG TGGACAACT CACCAACGGT CCAGCCACTC	3600
GTGCTTCTTC CCGCGCCTCA ATTCCAGTTA TCTACGACGA TGAGCATGTC TATGATGCAG	3660
CGTGTAGCAG TACATCAGCT AGTCAATCTT CGAAACGATC CTCTGGCTGC AACTCAATCA	3720
AGGTTACTGT AAACGTGGAC ATCGCTGGAG AAATCAGTTC GATCGTTAAC CCGGACAAAG	3780

62/99

FIG. 28 CONTINUED.

AGATAATCGT AGGATATCTT GCCATGTCAA CCAGTCAGTC ATGCTGGAAA GACATTGATG	3840
TTTCTATTCT AGGACTATTT GAAGTCTACC TATCCAGAAT TGATGTGGAG CATCAACTTG	3900
GAATCGATGC TCGTGATTCT ATCCTTGGCT ATCAAATTGG TGAAGTTCGA CGCGTCATTG	3960
GAGACTCCAC AACCATGATA ACCAGCCATC CAACTGACAT TCTTACTTCC TCAACTACAA	4020
TCCGAATGTT CATGCACGGT GCCGCACAGA GTCGCGTAGA CAGTCTGGTC CTTGATATGC	4080
TTCTTCCAAA GCAATGATT CTCCAACCTCG TCAAGTCAAT TTTGACAGAG AGACGTCTGG	4140
TGTTAGCTGG AGCAACTGGA ATTGGAAAGA GCAAACTGGC GAAGACCCTG GCTGCTTATG	4200
TATCTATTCTG AACAAATCAA TCCGAAGATA GTATTGTAA TATCAGCATT CCTGAAAACA	4260
ATAAAGAAGA ATTGCTTCAA GTGGAACGAC GCCTGGAAAA GATCTTGAGA AGCAAAGAAT	4320
CATGCATCGT AATTCTAGAT AATATCCCAA AGAATCGAAT TGCATTTGTT GTATCCGTTT	4380
TTGCAATGT CCCACTTCAA AACAAACGAAG GTCCATTTGT AGTATGCACA GTCAACCGAT	4440
ATCAAATCCC TGAGCTTCAA ATTCACCACA ATTTCAAAAT GTCAGTAATG TCGAATCGTC	4500
TCGAAGGATT CATCCTACGT TACCTCCGAC GACGGGCGGT AGAGGATGAG TATCGTCTAA	4560
CTGTACAGAT GCCATCAGAG CTCTTCAAAA TCATTGACTT CTCCCCAATA GCTCTTCAGG	4620
CCGTCAATAA TTTTATTGAG AAAACGAATT CTGTTGATGT GACAGTTGGT CCAAGAGCAT	4680
GCTTGAAGTG TCCTCTAACT GTCGATGGAT CCCGTGAATG GTTCATTCTGA TTGTGGAATG	4740
AGAACTTCAT TCCATATTTG GAACGTGTTG CTAGAGATGG CAAAAAACC TTCGGTCGCT	4800
GCACTTCCTT CGAGGATCCC ACCGACATCG TCTCTAAAAA ATGGCCGTGG TTCGATGGTG	4860
AAAACCCGGA GAATGTGCTC AAACGTCTTC AACTCCAAGA CCTCGTCCCG TCACCTGCCA	4920
ACTCATCCCG ACAACACTTC AATCCCCTCG AGTCGTTGAT CCAATTGCAT GCTACCAAGC	4980
ATCAGACCAT CGACACATT TGAACAGAAG ACTCTAATCT TCTCTCGCCT CTCCCCGCT	5040
TTCTTATCT TCGTACCGGT ACCTGATGAT TCCCCATTTT CCCCCTTTTC CCCCCAATTT	5100
CCCAGAACCT CCGTTCCTT TTGTTCTAG TCCTCCCGGG TGCCGACGCC GAAGCGATTT	5160
AAAAACCTTT TTCTTTCCGA AACATTTCCC ATTGCTCATT AATAGTCAA TTGAATAAAC	5220
AGTGATGTA CTTAAAAAAA AAAAAAAAAA AACTCGAGGG GGGGCCCGGT ACCCAGCTTT	5280
TGTTCCCTTT AGTGAGGGTT AATTGCGCGC TTGGCGTAAT CATGGTCATA GCTGTTTCCT	5340
GTGTGAAATT GTTATCCGCT CACAATTCCA CACAACATAC GAGCCGGAAG CATAAAGTG	5400
AAAGCCTGGG GTGCCTAATG AGTGAGCTAA CTCACATTAA TTGCGTTGCG CTCACTGCCC	5460
GCTTTCCAGT CGGGAAACCT GTCGTGCCAG CTGCATTAAT GAATCGGCCA ACGCGCGGGG	5520
AGAGGCGGTT TGCGTATTGG GCGCTCTTCC GCTTCCTCGC TCACTGACTC GCTGCGCTCG	5580
GTCGTTCCGC TGCGGCGAGC GGTATCAGCT CACTCAAAGG CGGTAATACG GTTATCCACA	5640
GAATCAGGGG ATAACGCAGG AAAGAACATG TGAGCAAAG GCCAGCAAAA GGCCAGGAAC	5700

SUBSTITUTE SHEET (RULE 26)

FIG. 28 CONTINUED


63/99

CGTAAAAAGG	CCGCGTTGCT	GGCGTTTTTC	CATAGGCTCC	GCCCCCTGA	CGAGCATCAC	5760
AAAAATCGAC	GCTCAAGTCA	GAGGTGGCGA	AACCCGACAG	GACTATAAAG	ATACCAGGCG	5820
TTTCCCCCTG	GAAGCTCCCT	CGTGCGCTCT	CCTGTTCCGA	CCCTGCCGCT	TACCGGATAC	5880
CTGTCCGCCT	TTCTCCCTTC	GGGAAGCGTG	GCGCTTTCTC	ATAGCTCACG	CTGTAGGTAT	5940
CTCAGTTCGG	TGTAGGTCGT	TCGCTCCAAG	CTGGGCTGTG	TGCACGAACC	CCCCGTTTCA	6000
CCCGACCGCT	GCGCCTTATC	CGGTAACAT	CGTCTTGAGT	CCAACCCGGT	AAGACACGAC	6060
TTATCGCCAC	TGGCAGCAGC	CACTGGTAAC	AGGATTAGCA	GAGCGAGGTA	TGTAGGCGGT	6120
GCTACAGAGT	TCTTGAAGTG	GTGGCCTAAC	TACGGCTACA	CTAGAAGGAC	AGTATTTGGT	6180
ATCTGCGCTC	TGCTGAAGCC	AGTTACCTTC	GGAAAAAGAG	TTGGTAGCTC	TTGATCCGGC	6240
AAACAAACCA	CCGCTGGTAG	CGGTGGTTTT	TTTGTGTTGCA	AGCAGCAGAT	TACGCGCAGA	6300
AAAAAAGGAT	CTCAAGAAGA	TCCTTTGATC	TTTTCTACGG	GGTCTGACGC	TCAGTGGAAC	6360
GAAAACTCAC	GTTAAGGGAT	TTTGGTCATG	AGATTATCAA	AAAGGATCTT	CACCTAGATC	6420
CTTTTAAATT	AAAAATGAAG	TTTTAAATCA	ATCTAAAGTA	TATATGAGTA	AACTTGGTCT	6480
GACAGTTACC	AATGCTTAAT	CAGTGAGGCA	CCTATCTCAG	CGATCTGTCT	ATTTCTGTTCA	6540
TCCATAGTTG	CCTGACTCCC	CGTCGTGTAG	ATAACTACGA	TACGGGAGGG	CTTACCATCT	6600
GGCCCCAGTG	CTGCAATGAT	ACCGCGAGAC	CCACGCTCAC	CGGCTCCAGA	TTTATCAGCA	6660
ATAAACCAGC	CAGCCGGAAG	GGCCGAGCGC	AGAAGTGGTC	CTGCAACTTT	ATCCGCCTCC	6720
ATCCAGTCTA	TTAATTGTTG	CCGGGAAGCT	AGAGTAAGTA	GTTCCGCCAGT	TAATAGTTTG	6780
CGCAACGTTG	TTGCCATTGC	TACAGGCATC	GTGGTGTAC	GCTCGTCGTT	TGGTATGGCT	6840
TCATTGAGCT	CCGGTTCCCA	ACGATCAAGG	CGAGTTACAT	GATCCCCCAT	GTTGTGCAAA	6900
AAAGCGGTTA	GCTCCTTCGG	TCCTCCGATC	GTTGTGAGAA	GTAAGTTGGC	CGCAGTGTTA	6960
TCACTCATGG	TTATGGCAGC	ACTGCATAAT	TCTCTTACTG	TCATGCCATC	CGTAAGATGC	7020
TTTTCTGTGA	CTGGTGAGTA	CTCAACCAAG	TCATTCTGAG	AATAGTGTAT	GCGGCGACCG	7080
AGTTGCTCTT	GCCCCGCGTC	AATACGGGAT	AATACCGCGC	CACATAGCAG	AACTTTAAAA	7140
GTGCTCATCA	TTGGAAAACG	TTCTTCGGGG	CGAAACTCT	CAAGGATCTT	ACCGCTGTTG	7200
AGATCCAGTT	CGATGTAACC	CATCGTGCA	CCCAACTGAT	CTTCAGCATC	TTTTACTTTT	7260
ACCAGCGTTT	CTGGGTGAGC	AAAAACAGGA	AGGCAAAATG	CCGCAAAAAA	GGGAATAAGG	7320
GCGACACGGA	AATGTTGAAT	ACTCATACTC	TTCTTTTTC	AATATTATTG	AAGCATTTAT	7380
CAGGGTTATT	GTCTCATGAG	CGGATACATA	TTTGAATGTA	TTTAGAAAAA	TAAACAAATA	7440
GGGGTTCCGC	GCACATTTCC	CCGAAAAGTG	CCAC			7474

SUBSTITUTE SHEET (RULE 26)

64/99

FIG. 29.



65/99

FIG. 30.

TATGACGACG TCAAATGTAG AATTGATACC ATTCTACACG GATTGGGCCA ATCGGCACCT	60
TTCGAAGGGC AGCTTATCAA AGTCGATTAG GGATATTTCC AATGATTTTC GCGACTATCG	120
ACTGGTTTCT CAGCTTATTA ATGTGATCGT TCCGATCAAC GAATTCTCGC CTGCATTAC	180
GAAACGTTTG GCAAAAATCA CATCGAACCT GGATGGCCTC GAAACGTGTC TCGACTACCT	240
GAAAAATCTG GGTCTCGACT GCTCGAAACT CACCAAAACC GATATCGACA GCGGAAACTT	300
GGGTGCAGTT CTCCAGCTGC TCTTCCTGCT CTCCACCTAC AAGCAGAAGC TTCGGCAACT	360
GAAAAAGAT CAGAAGAAAT TGGAGCAACT ACCCACATCC ATTATGCCAC CCGCGGTTTC	420
TAAATTACCC TCGCCACGTG TCGCCACGTC AGCAACCGCT TCAGCAACTA ACCCAAATTC	480
CAACTTTCCA CAAATGTCAA CATCCAGGCT TCAGACTCCA CAGTCAAGAA TATCGAAAAT	540
TGATTCATCA AAGATTGGTA TCAAGCCAAA GACGCTGGA CTAAACCAC CCTCATCATC	600
AACCACTTCA TCAAATAATA CAAATTCATT CCGTCCGTCG AGCCGTTCGA GTGGCAATAA	660
TAATGTTGGC TCGACGATAT CCACATCTGC GAAGAGCTTA GAATCATCAT CAACGTACAG	720
CTCTATTTTCG AATCTAAACC GACCTACCTC CCAACTCCAA AAACCTTCTA GACCACAAAC	780
CCAGCTAGTT CGTGTGCTA CAACTACAAA AATCGGAAGC TCAAAGCTAG CCGCTCCGAA	840
AGCCGTGAGC ACCCCAAAAC TTGCTTCTGT GAAGACTATT GGAGCAAAAC AAGAGCCCGA	900
TAACAGCGGT GGTGGTGGTG GTGGAATGCT GAAATTAAAG TTATTCAGTA GCAAAAACCC	960
ATCTTCCTCA TCGAATAGCC CACAACCTAC GAGAAAGGCG GCGGCGGTGC CTCAACAACA	1020
AACTTTGTGCG AAAATCGCTG CCCAGTGAA AAGTGGCCTG AAGCCGCCGA CCAGTAAGCT	1080
GGGAAGTGCC ACGTCTATGT CGAAGCTTTG TACGCCAAAA GTTTCCTACC GTAAAACGGA	1140
CGCCCCAATC ATATCTCAAC AAGACTCGAA ACGATGCTCA AAGAGCAGTG AAGAAGAGTC	1200
CGGATACGCT GGATTCAACA GCACGTCGCC AACGTCATCA TCGACGGAAG GTTCCCTAAG	1260

FIG. 30 CONTINUED. *66/99*

CATGCATTCC ACATCTTCCA AGAGTTCAAC GTCAGACGAA AAGTCTCCGT CATCAGACGA	1320
TCTTACTCTT AACGCCTCCA TCGTGACAGC TATCAGACAG CCGATAGCCG CAACACCGGT	1380
TTCTCCAAAT ATTATCAACA AGCCTGTTGA GGAAAAACCA AACTGGCAG TGAAAGGAGT	1440
GAAAAGCACA GCGAAAAAAG ATCCACCTCC AGCTGTTCCG CCACGTGACA CCCAGCCAAC	1500
AATCGGAGTT GTTAGTCCAA TTATGGCACA TAAGAAGTTG ACAAATGACC CCGTGATATC	1560
TGAAAAACCA GAACCTGAAA AGCTCCAATC AATGAGCATC GACACGACGG ACGTTCCACC	1620
GCTTCCACCT CTAAATCAG TTGTTCCACT TAAATGACT TCAATCCGAC AACCACCAAC	1680
GTACGATGTT CTTCTAAAAC AAGGAAAAAT CACATCGCCT GTCAAGTCGT TTGGATATGA	1740
GCACTCGTCC GCGTCTGAAG ACTCCATTGT GGCTCATGCG TCGGCTCAGG TGAATCCGCC	1800
GACAAAAACT TCTGGTAATC ATTCGCTGGA GAGAAGGATG GGAAAGAATA AGACATCAGA	1860
ATCCAGCGGC TACACCTCTG ACGCCGGTGT TGCGATGTGC GCCAAAATGA GGGAGAAGCT	1920
GAAAGAATAC GATGACATGA CTCGTGAGC ACAGAACGGC TATCCTGACA ACTTCGAAGA	1980
CAGTTCCTCC TTGTCGTCTG GAATATCCGA TAACAACGAG CTCGACGACA TATCCACGGA	2040
CGATTTGTCC GGAGTAGACA TGGCAACAGT CGCCTCCAAA CATAGCGACT ATTCCCACTT	2100
TGTTGCGCAT CCCACGTCTT CTCCTCAAA GCCCCGAGTC CCCAGTCGGT CCTCCACATC	2160
AGTCGATTCT CGATCTCGAG CAGAACAGGA GAATGTGTAC AAACCTTCTGT CCCAGTGCCG	2220
AACGAGCCAA CGTGGCGCCG CTGCCACCTC AACCTTCGGA CAACATTGCG TAAGATCCCC	2280
GGGATACTCA TCCTATTCTC CACACTTATC AGTGTGAGCT GATAAGGACA CAATGTCTAT	2340
GCACTCACAG ACTAGTCGAC GACCTTCTTC ACAAACCA AGCTATTGAG GCCAATTTCA	2400
TTCACTTGAT CGTAAATGCC ACCTTCAAGA GTTCACATCC ACCGAGCACA GAATGGCGGC	2460
TCTCTTGAGC CCGAGACGGG TGCCGAATC GATGTGAAA TATGATTCTT CAGGATCCTA	2520
CTCGGCGCGT TCCCGAGGTG GAAGCTCTAC TGGTATCTAT GGAGAGACGT TCCAACTGCA	2580
CAGACTATCC GATGAAAAAT CCCCCGACA TTCTGCCAAA AGTGAGATGG GATCCCACT	2640
ATCACTGGCT AGCACGACAG CATATGGATC TCTCAATGAG AAGTACGAAC ATGCTATTG	2700
GGACATGGCA CGTGACTTGG AGTGTTACAA GAACACTGTC GACTCACTAA CCAAGAAACA	2760
GGAGAACTAT GGAGCATTGT TTGATCTTTT TGAGCAAAG CTTAGAAAAC TCACTCAACA	2820
CATTGATCGA TCCAACCTGA AGCCTGAAGA GGCAATACGA TTCAGGCAGG ACATTGCTCA	2880
TTTGAGGGAT ATTAGCAATC ATCTGTCATC CAACTCAGCT CATGCTAACG AAGGCGCTGG	2940
TGAGCTTCTT CGTCAACCAT CTCTGGAATC AGTTGCATCC CATCGATCAT CGATGTCATC	3000
GTCGTCGAAA AGCAGCAAGC AGGAGAAGAT CAGCTTGAGC TCGTTTGGCA AGAACAAGAA	3060
GAGCTGGATC CGCTCCTCAC TCTCCAAGTT CACCAAGAAG AAGAACAAGA ACTACGACGA	3120
AGCACATATG CCATCAATTT CCGGATCTCA AGGAACTCTT GACAACATTG ATGTGATTGA	3180

SUBSTITUTE SHEET (RULE 26)

FIG. 30 CONTINUED.

67/99

GTTGAAGCAA GAGCTCAAAG AACGCGATAG TGCACTTTAC GAAGTCCGCC TTGACAATCT	3240
GGATCGTGCC CGCGAAGTTG ATGTTCTGAG GGAGACAGTG AACAAAGTTGA AAACCGAGAA	3300
CAAGCAATTA AAGAAAGAAG TGGACAACT CACCAACGGT CCAGCCACTC GTGCTTCTTC	3360
CCGCGCCTCA ATTCCAGTTA TCTACGACGA TGAGCATGTC TATGATGCAG CGTGTAGCAG	3420
TACATCAGCT AGTCAATCTT CGAAACGATC CTCTGGCTGC AACTCAATCA AGGTTACTGT	3480
AAACGTGGAC ATCGCTGGAG AAATCAGTTC GATCGTTAAC CCGGACAAAG AGATAATCGT	3540
AGGATATCTT GCCATGTCAA CCAGTCAGTC ATGCTGGAAA GACATTGATG TTTCTATTCT	3600
AGGACTATTT GAAGTCTACC TATCCAGAAT TGATGTGGAG CATCAACTTG GAATCGATGC	3660
TCGTGATTCT ATCCTTGGCT ATCAAATTGG TGAACCTCGA CGCGTCATTG GAGACTCCAC	3720
AACCATGATA ACCAGCCATC CAACTGACAT TCTTACTTCC TCAACTACAA TCCGAATGTT	3780
CATGCACGGT GCCGCACAGA GTCGCGTAGA CAGTCTGGTC CTTGATATGC TTCTTCCAAA	3840
GCAAATGATT CTCCAACGCG TCAAGTCAAT TTGACAGAG AGACGTCTGG TGTTAGCTGG	3900
AGCAACTGGA ATTGGAAGA GCAAACGGC GAAGACCCTG GCTGCTTATG TATCTATTCTG	3960
AACAAATCAA TCCGAAGATA GTATTGTTAA TATCAGCATT CCTGAAAACA ATAAAGAAGA	4020
ATTGCTTCAA GTGGAACGAC GCCTGGAAAA GATCTTGAGA AGCAAAGAAT CATGCATCGT	4080
AATTCTAGAT AATATCCCAA AGAATCGAAT TGCATTTGTT GTATCCGTTT TTGCAAATGT	4140
CCCCTTCAA AACAAACGAAG GTCCATTTGT AGTATGCACA GTCAACCGAT ATCAAATCCC	4200
TGAGCTTCAA ATTCACCACA ATTTCAAAT GTCAGTAATG TCGAATCGTC TCGAAGGATT	4260
CATCCTACGT TACCTCCGAC GACGGGCGGT AGAGGATGAG TATCGTCTAA CTGTACAGAT	4320
GCCATCAGAG CTCTTCAAAA TCATTGACTT CTTCCCAATA GCTCTTCAGG CCGTCAATAA	4380
TTTTATTGAG AAAACGAATT CTGTTGATGT GACAGTTGGT CCAAGAGCAT GCTTGAACGT	4440
TCCTCTAACT GTCGATGGAT CCCGTGAATG GTTCATTGCA TTGTGGAATG AGAACTTCAT	4500
TCCATATTG GAACGTGTTG CTAGAGATGG CAAAAAACC TTCGGTCGCT GCACTTCCTT	4560
CGAGGATCCC ACCGACATCG TCTCTAAAAA ATGGCCGTGG TTCGATGGTG AAAACCCGGA	4620
GAATGTGCTC AAACGTCTTC AACTCCAAGA CCTCGTCCCG TCACCTGCCA ACTCATCCCG	4680
ACAACACTTC AATCCCCTCG AGTCGTTGAT CCAATTGCAT GCTACCAAGC ATCAGACCAT	4740
CGACAACATT TGAACAGAAG ACTCTAATCT TCTCTCGCCT CTCCCCGCT TTCCTTATCT	4800
TCGTACCGGT ACCTGATGAT TCCCCATTTT CCCCCTTTTC CCCCCAATT CCCAGAACCT	4860
CCTGTTCCCT TTGTTCTTAG TCCTCCCGGG TGCCGACGCC GAAGCGATT AAAAACCTTT	4920
TTCTTTCCGA AACATTTCCC ATTGCTCATT AATAGTCAA TTGAATAAAC AGTGTATGTA	4980
CTTAAAAAAA AAAAAAAAAA AAAAAAAAAA GGCCTATGCG GCCGGGCCAT GGAGGCCGAA	5040
TTCCCGGGGA TCCGTCGACC TGACGCCAAG CTAATTCGG GCGAATTTCT TATGATTTAT	5100

FIG. 30 CONTINUED. *68/99*

GATTTTTATT ATTAAATAAG TTATAAAAAA AATAAGTGTA TACAAATTTT AAAGTGACTC	5160
TTAGGTTTTTA AAACGAAAAT TCTTGTTCTT GAGTAACTCT TTCCTGTAGG TCAGGTTGCT	5220
TTCTCAGGTA TAGCATGAGG TCGCTCTTAT TGACCACACC TCTACCGGCA TGCAAGCTTG	5280
GCGTAATCAT GGTCATAGCT GTTTCCTGTG TGAAATTGTT ATCCGCTCAC AATTCCACAC	5340
AACATACGAG CCGGAAGCAT AAAGTGTAAG GCCTGGGGTG CCTAATGAGT GAGGTAAGTC	5400
ACATTAATTG CGTTGCGCTC ACTGCCCCGCT TTCCAGTCGG GAAACCTGTC GTGCCAGCTG	5460
GATTAATGAA TCGGCCAACG CGCGGGGAGA GCGGGTTTGC GTATTGGGCG CTCTTCCGCT	5520
TCCTCGCTCA CTGACTCGCT GCGCTCGGTC GTTCGGCTGC GCGGAGCGGT ATCAGCTCAC	5580
TCAAAGGCGG TAATACGGTT ATCCACAGAA TCAGGGGATA ACGCAGGAAA GAACATGTGA	5640
GCAAAAGGCC AGCAAAAGGC CAGGAACCGT AAAAAGGCCG CGTTGCTGGC GTTTTCCAT	5700
AGGCTCCGCC CCCCTGACGA GCATCACAAA AATCGACGCT CAAGTCAGAG GTGGCGAAAC	5760
CCGACAGGAC TATAAAGATA CCAGGCGTTT CCCCCTGGAA GCTCCCTCGT GCGCTCTCCT	5820
GTTCCGACCC TGCCGCTTAC CGGATACCTG TCCGCCTTTC TCCCTTCGGG AAGCGTGGCG	5880
CTTTCTCATA GCTCACGCTG TAGGTATCTC AGTTCGGTGT AGGTCGTTTC CTCCAAGCTG	5940
GGCTGTGTGC ACGAACCCCC CGTTCAGCCC GACCGCTGCG CTTATCCGG TAACTATCGT	6000
CTTGAGTCCA ACCCGGTAAG ACACGACTTA TCGCCACTGG CAGCAGCCAC TGGAACAGG	6060
ATTAGCAGAG CGAGGTATGT AGGCGGTGCT ACAGAGTTCT TGAAGTGGTG GCCTAACTAC	6120
GGCTACACTA GAAGGACAGT ATTTGGTATC TGCGCTCTGC TGAAGCCAGT TACCTTCGGA	6180
AAAAGAGTTG GTAGCTCTTG ATCCGGCAAA CAAACCACCG CTGGTAGCGG TGTTTTTTTT	6240
GTTTGCAAGC AGCAGATTAC GCGCAGAAAA AAAGGATCTC AAGAAGATCC TTTGATCTTT	6300
TCTACGGGGT CTGACGCTCA GTGGAACGAA AACTCACGTT AAGGGATTTT GGTTCATGAGA	6360
TTATCAAAAA GGATCTTCAC CTAGATCCTT TTAAATTAAA AATGAAGTTT TAAATCAATC	6420
TAAAGTATAT ATGAGTAAAC TTGGTCTGAC AGTTACCAAT GCTTAATCAG TGAGGCACCT	6480
ATCTCAGCGA TCTGTCTATT TCGTTCATCC ATAGTTGCCT GACTCCCCGT CGTGTAGATA	6540
ACTACGATAC GGGAGGGCTT ACCATCTGGC CCCAGTGCTG CAATGATACC GCGAGACCCA	6600
CGCTCACCGG CTCCAGATTT ATCAGCAATA AACCAGCCAG CCGGAAGGGC CGAGCGCAGA	6660
AGTGGTCTCG CAACTTTATC CGCCTCCATC CAGTCTATTA ATTGTTGCCG GGAAGCTAGA	6720
GTAAGTAGTT CGCCAGTTAA TAGTTTGCGC AACGTTGTTG CCATTGCTAC AGGCATCGTG	6780
GTGTCACGCT CGTCGTTTGG TATGGCTTCA TTCAGCTCCG GTTCCCAACG ATCAAGGCGA	6840
GTTACATGAT CCCCCATGTT GTGCAAAAAA GCGGTTAGCT CCTTCGGTCC TCCGATCGTT	6900
GTCAGAAGTA AGTTGGCCGC AGTGTTATCA CTCATGGTTA TGGCAGCACT GCATAATTCT	6960
CTTACTGTCA TGCCATCCGT AAGATGCTTT TCTGTGACTG GTGAGTACTC AACCAAGTCA	7020

SUBSTITUTE SHEET (RULE 26)

FIG. 30 CONTINUED.

69/99

TTCTGAGAAT AGTGTATGCG GCGACCGAGT TGCTCTTGCC CGGCGTCAAT ACGGGATAAT	7080
ACCGCGCCAC ATAGCAGAAC TTTAAAAGTG CTCATCATTG GAAAACGTTT TCCGGGGCGA	7140
AAACTCTCAA GGATCTTACC GCTGTTGAGA TCCAGTTCGA TGTAAACCCAC TCGTGCACCC	7200
AACTGATCTT CAGCATCTTT TACTTTTACC AGCGTTTCTG GGTGAGCAAA AACAGGAAGG	7260
CAAAATGCCG CAAAAAAGGG AATAAGGGCG ACACGGAAAT GTTGAATACT CATACTCTTC	7320
CTTTTTCAAT ATTATTGAAG CATTATCAG GGTATTGTC TCATGAGCGG ATACATATTT	7380
GAATGTATTT AGAAAAATAA ACAAATAGGG GTTCCGCGCA CATTTCCCG AAAAGTGCCA	7440
CCTGAACGAA GCATCTGTGC TTCATTTTGT AGAACAAAA TGCAACGCGA GAGCGCTAAT	7500
TTTTCAAACA AAGAATCTGA GCTGCATTTT TACAGAACAG AAATGCAACG CGAAAGCGCT	7560
ATTTTACCAA CGAAGAATCT GTGCTTCATT TTTGTAAAC AAAATGCAA CGCGAGAGCG	7620
CTAATTTTTT AAACAAAGAA TCTGAGCTGC ATTTTACAG AACAGAAATG CAACGCGAGA	7680
GCGCTATTTT ACCAACAAAG AATCTATACT TCTTTTTTGT TCTACAAAA TGCAATCCCGA	7740
GAGCGCTATT TTTCTAACAA AGCATCTTAG ATTACTTTT TTCTCCTTG TCGCTCTAT	7800
AATGCACTCT CTTGATAACT TTTTGCCTG TAGGTCCGT AAGGTTAGAA GAAGGCTACT	7860
TTGGTGTCTA TTTTCTCTC CATAAAAAA GCCTGACTCC ACTTCCCGCG TTTACTGATT	7920
ACTAGCGAAG CTGCGGGTGC ATTTTTTCAA GATAAAGGCA TCCCGGATTA TATTCTATAC	7980
CGATGTGGAT TGCGCATACT TTGTGAACAG AAAGTGATAG CGTTGATGAT TCTTCATTGG	8040
TCAGAAAATT ATGAACGGT TCTTCTATTT TGTCTCTATA TACTACGTAT AGGAAATGTT	8100
TACATTTTCG TATTGTTTC GATTCACTCT ATGAATAGTT CTTACTACAA TTTTTTGTG	8160
TAAAGAGTAA TACTAGAGAT AAACATAAAA AATGTAGAGG TCGAGTTTAG ATGCAAGTTC	8220
AAGGAGCGAA AGGTGGATGG GTAGGTTATA TAGGGATATA GCACAGAGAT ATATAGCAAA	8280
GAGATACTTT TGAGCAATGT TTGTGGAAGC GGTATTCGCA ATATTTTAGT AGCTCGTTAC	8340
AGTCCGGTGC GTTTTTGGTT TTTTGAAAGT GCGTCTTCAG AGCGCTTTTG GTTTTCAAAA	8400
GCGCTCTGAA GTTCTATAC TTTCTAGAGA ATAGGAACTT CGGAATAGGA ACTTCAAAGC	8460
GTTCGCGAAA ACGAGCGCTT CCGAAAATGC AACGCGAGCT GCGCACATAC AGCTCACTGT	8520
TCACGTCGCA CCTATATCTG CGTGTTCCT GTATATATAT ATACATGAGA AGAACGGCAT	8580
AGTGCGTGT TATGCTTAAA TGCGTACTTA TATGCGTCTA TTTATGTAGG ATGAAAGGTA	8640
GTCTAGTACC TCCTGTGATA TTATCCCAT CCATGCGGGG TATCGTATGC TTCCTTCAGC	8700
ACTACCCTTT AGCTGTTCTA TATGCTGCCA CTCCTCAATT GGATTAGTCT CATCCTTCAA	8760
TGCTATCATT TCCTTTGATA TTGGATCATA TTAAGAAACC ATTATTATCA TGACATTAA	8820
CTATAAAAT AGGCGTATCA CGAGGCCCTT TCGTCTCGCG CGTTTCGGTG ATGACGGTGA	8880
AAACCTCTGA CACATGCAGC TCCCGGAGAC GGTACAGCT TGTCTGTAAG CGGATGCCGG	8940

SUBSTITUTE SHEET (RULE 26)

*FIG. 30 CONTINUED**70/99*

GAGCAGACAA GCCCGTCAGG GCGCGTCAGC GGGTGTGGC GGGTGTGGG GCTGGCTTAA	9000
CTATGCGGCA TCAGAGCAGA TTGTACTGAG AGTGCACCAT AGATCAACGA CATTACTATA	9060
TATATAATAT AGGAAGCATT TAATAGACAG CATCGTAATA TATGTGTACT TTGCAGTTAT	9120
GACGCCAGAT GGCAGTAGTG GAAGATATTC TTTATTGAAA AATAGCTTGT CACCTTACGT	9180
ACAATCTTGA TCCGGAGCTT TTCTTTTTTT GCCGATTAAG AATTAATTCG GTCGAAAAA	9240
GAAAAGGAGA GGGCCAAGAG GGAGGGCATT GGTGACTATT GAGCACGTGA GTATACGTGA	9300
TTAAGCACAC AAAGGCAGCT TGGAGTATGT CTGTTATTAA TTTCACAGGT AGTTCTGGTC	9360
CATTGGTGAA AGTTTGCGGC TTGCAGAGCA CAGAGGCCGC AGAATGTGCT CTAGATTCCG	9420
ATGCTGACTT GCTGGGTATT ATATGTGTGC CCAATAGAAA GAGAACAATT GACCCGGTTA	9480
TTGCAAGGAA AATTTCAAGT CTTGTAAAAG CATATAAAAA TAGTTCAGGC ACTCCGAAAT	9540
ACTTGGTTGG CGTGTTCGT AATCAACCTA AGGAGGATGT TTTGGCTCTG GTCAATGATT	9600
ACGGCATTGA TATCGTCCAA CTGCATGGAG ATGAGTCGTG GCAAGAATAC CAAGAGTTCC	9660
TCGGTTTGCC AGTTATTAAA AGACTCGTAT TTCCAAAAGA CTGCAACATA CTA CTACTCAGTG	9720
CAGCTTCACA GAAACCTCAT TCGTTTATTC CCTTGTTTGA TTCAGAAGCA GGTGGGACAG	9780
GTGAACTTTT GGATTGGAAC TCGATTTCTG ACTGGGTGG AAGGCAAGAG AGCCCCGAAA	9840
GCTTACATTT TATGTTAGCT GGTGGACTGA CGCCAGAAAA TGTTGGTGAT GCGCTTAGAT	9900
TAAATGGCGT TATTGGTGT GATGTAAGCG GAGGTGTGGA GACAAATGGT GTAAAAGACT	9960
CTAACAAAT AGCAAATTC GTCAAAAATG CTAAGAAATA GGTTATTACT GAGTAGTATT	10020
TATTTAAGTA TTGTTGTGC ACTTGCCGAT CTATGCGGTG TGAATACCG CACAGATGCG	10080
TAAGGAGAAA ATACCGCATC AGGAAATTGT AAACGTTAAT ATTTTGTAA AATTCGCGTT	10140
AAATTTTGT TAAATCAGCT CATTTTTTAA CCAATAGGCC GAAATCGGCA AAATCCCTTA	10200
TAAATCAAAA GAATAGACCG AGATAGGGTT GAGTGTGTG CAGTTTGGA ACAAGAGTCC	10260
ACTATTAAAG AACGTGGACT CCAACGTCAA AGGGCGAAAA ACCGTCTATC AGGGCGATGG	10320
CCCACTACGT GAACCATCAC CCTAATCAAG TTTTTTGGG TCGAGGTGCC GTAAAGCACT	10380
AAATCGGAAC CCTAAAGGA GCCCCCGATT TAGAGCTTGA CGGGGAAAGC CGGCGAACGT	10440
GGCGAGAAAAG GAAGGGAAGA AAGCGAAAGG AGCGGGCGCT AGGGCGCTGG CAAGTGTAGC	10500
GGTCACGCTG CGCGTAACCA CCACACCCGC CGCGCTTAAT GCGCCGCTAC AGGGCGCGTC	10560
GCGCCATTTC CCATTCAGGC TCGCCAACTG TTGGGAAGGG CGATCGGTGC GGGCCTCTTC	10620
GCTATTACGC CAGCTGGCGA AAGGGGGATG TGCTGCAAGG CGATTAAAGT GGGTAACGCC	10680
AGGGTTTTCC CAGTCACGAC GTTGTAAAAC GACGGCCAGT CGTCCAAGCT TTCGCGAGCT	10740
CGAGATCCCG AGCTTTGCAA ATTAAAGCCT TCGAGCGTCC CAAAACCTTC TCAAGCAAGG	10800
TTTTCAGTAT AATGTTACAT GCGTACACGC GTCTGTACAG AAAAAAAGA AAAATTTGAA	10860

SUBSTITUTE SHEET (RULE 26)

*FIG. 30 CONTINUED.**71/99*

ATATAAATAA	CGTTCTTAAT	ACTAACATAA	CTATAAAAAA	ATAAATAGGG	ACCTAGACTT	10920
CAGGTTGTCT	AACTCCTTCC	TTTTCGGTTA	GAGCGGATGT	GGGGGGAGGG	CGTGAATGTA	10980
AGCGTGACAT	AACTAATTAC	ATGATATCGA	CAAAGGAAAA	GGGGCCTGTT	TACTCACAGG	11040
CTTTTTTCAA	GTAGGTAATT	AAGTCGTTTC	TGTCTTTTTT	CTTCTTCAAC	CCACCAAAGG	11100
CCATCTTGGT	ACTTTTTTTT	TTTTTTTTTT	TTTTTTTTTT	TTTTTTTTTT	TTTTTTTTTT	11160
TTTTTTTTTT	TTTTTTTTTT	TTTTTTTTTT	TTTTTTTTTT	TTTTTTCATA	GAAATAATAC	11220
AGAAGTAGAT	GTTGAATTAG	ATTAAACTGA	AGATATATAA	TTTATTGGAA	AATACATAGA	11280
GCTTTTTGTT	GATGCGCTTA	AGCGATCAAT	TCAACAACAC	CACCAGCAGC	TCTGATTTTT	11340
TCTTCAGCCA	ACTTGGAGAC	GAATCTAGCT	TTGACGATAA	CTGGAACATT	TGGGATTCTA	11400
CCCTTACCCA	AGATCTTACC	GTAACCGGCT	GCCAAAGTGT	CAATAACTGG	AGCAGTTTCC	11460
TTAGAAGCAG	ATTTCAAGTA	TTGGTCTCTC	TTGTCTTCTG	GGATCAATGT	CCACAATTTG	11520
TCCAAGTTCA	AGACTGGCTT	CCAGAAATGA	GCTTGTTGCT	TGTGGAAGTA	TCTCATACCA	11580
ANCCTTACCG	AAATAACCTG	GATGGTATTT	ATCCATGTTA	ATTCTGTGGT	GATGTTGACC	11640
ACCGGCCATA	CCTCTACCAC	CGGGGTGCTT	TCTGTGCTTA	CCGATACGAC	CTTTACCGGC	11700
TGAGACGTGA	CCTCTGTGCT	TTCTAGTCTT	AGTGAATCTG	GAAGGCATTG	TTGATTAGTT	11760
GGATGATTGT	TCTGGGATTT	AATGCAAAAA	AATCACTAAG	AAGGAAAAAA	ATCAACGGAG	11820
AAAGCAAACG	CCATCTTAAA	TATACGGGAT	ACAGATGAAA	GGTTTGAACC	TATCTGGGAA	11880
AATACGCATT	AAACAAGCGA	AAAACCTGCGA	GGAAAATTGT	TTGCGTCTCT	GCGGGCTATT	11940
CACGCGCCAG	AGGAAAATAG	GAAAAATAAC	AGGGCATTAG	AAAAATAATT	TTGATTTTGG	12000
TAATGTGTGG	GTCCCTGGTG	TACAGATGTT	ACATTGGTTA	CAGTACTCTT	GTTTTTGCTG	12060
TGTTTTTCGA	TGAATCTCCA	AAATGGTTGT	TAGCACATGG	AAGAGTCACC	GATGCTAAGT	12120
TATCTCTATG	TAAGCTACGT	GGCGTGACTT	TTGATGAAGC	CGCACAAGAG	ATACAGGATT	12180
GGCAACTGCA	AATAGAATCT	GGGGATCTAG	ATATCCTTTT	GTTGTTTCCG	GGTGATACAAT	12240
ATGGACTTCC	TCTTTTCTGG	CAACCAAACC	CATACATCGG	GATTCCTATA	ATACCTTCGT	12300
TGGTCTCCCT	AACATGTAGG	TGGCGGAGGG	GAGATATACA	ATAGAACAGA	TACCAGACAA	12360
GACATAATGG	GCTAAACAAG	ACTACACCAA	TTACACTGCC	TCATTGATGG	TGGTACATAA	12420
CGAACTAATA	CTGTAGCCCT	AGACTTGATA	GCCATCATCA	TATCGAAGTT	TCACTACCCT	12480
TTTTCATT	GCCATCTATT	GAAGTAATAA	TAGGCGCATG	CAACTTCTTT	TCTTTTTTTT	12540
TCTTTTCTCT	CTCCCCGTT	GTTGTCTCAC	CATATCCGCA	ATGACAAAAA	AAATGATGGA	12600
AGACACTAAA	GGAAAAAATT	AACGACAAAG	ACAGCACCAA	CAGATGTCGT	TGTTCCAGAG	12660
CTGATGAGGG	GTATCTTCGA	ACACACGAAA	CTTTTTCCTT	CCTTCATTCA	CGCACACTAC	12720
TCTCTAATGA	GCAACGGTAT	ACGGCCTTCC	TTCCAGTTAC	TTGAATTTGA	AATAAAAAAA	12780


72/99

FIG. 30 CONTINUED.

GTTTGCCGCT	TTGCTATCAA	GTATAAATAG	ACCTGCAATT	ATTAATCTTT	TGTTTCCTCG	12840
TCATTGTTCT	CGTTCCCTTT	CTTCCTTGTT	TCTTTTCTG	CACAATATTT	CAAGCTATAC	12900
CAAGCATACA	ATCAACTCCA	AGCTTGAAGC	AAGCCTCCTG	AAAGATGAAG	CTACTGTCTT	12960
CTATCGAACA	AGCATGCGAT	ATTTGCCGAC	TTAAAAAGCT	CAAGTGCTCC	AAAGAAAAAC	13020
CGAAGTGCGC	CAAGTGCTG	AAGAACAACT	GGGAGTGTG	CTACTCTCCC	AAACCAAAA	13080
GGTCTCCGCT	GACTAGGGCA	CATCTGACAG	AAGTGAATC	AAGGCTAGAA	AGACTGGAAC	13140
AGCTATTTCT	ACTGATTTT	CCTCGAGAAG	ACCTTGACAT	GATTTTGAAA	ATGGATTCTT	13200
TACAGGATAT	AAAAGCATTG	TTAACAGGAT	TATTTGTACA	AGATAATGTG	AATAAAGATG	13260
CCGTCACAGA	TAGATTGGCT	TCAGTGGAGA	CTGATATGCC	TCTAACATTG	AGACAGCATA	13320
GAATAAGTGC	GACATCATCA	TCGGAAGAGA	GTAGTAACAA	AGGTCAAAGA	CAGTTGACTG	13380
TATCGCCGGA	ATTGCAATAC	CCAGCTTTGA	CTCA			13414

73/99

FIG. 31.



74/99

FIG. 32.

TATGCCATCA	ATTTCCGGAT	CTCAAGGAAC	TCTTGACAAC	ATTGATGTGA	TTGAGTTGAA	60
GCAAGAGCTC	AAAGAACGCG	ATAGTGCACT	TTACGAAGTC	CGCCTTGACA	ATCTGGATCG	120
TGCCCCGCGAA	GTTGATGTTC	TGAGGGAGAC	AGTGAACAAG	TTGAAAACCG	AGAACAAGCA	180
ATTAAAGAAA	GAAGTGGACA	AACTCACCAA	CGGTCCAGCC	ACTCGTGCTT	CTTCCC GCCG	240
CTCAATTCCA	GTTATCTACG	ACGATGAGCA	TGTCTATGAT	GCAGCGTGTA	GCAGTACATC	300
AGCTAGTCAA	TCTTCGAAAC	GATCCTCTGG	CTGCAACTCA	ATCAAGGTTA	CTGTAAACGT	360
GGACATCGCT	GGAGAAATCA	GTTGATCGT	TAACCCGGAC	AAAGAGATAA	TCGTAGGATA	420
TCTTGCCATG	TCAACCAGTC	AGTCATGCTG	GAAAGACATT	GATGTTTCTA	TTCTAGGACT	480
ATTTGAAGTC	TACCTATCCA	GAATTGATGT	GGAGCATCAA	CTTGGAATCG	ATGCTCGTGA	540

*FIG. 32 CONTINUED.**75/99*

TTCTATCCTT GGCTATCAAA TTGGTGAAGT TCGACGCGTC ATTGGAGACT CCACAACCAT	600
GATAACCAGC CATCCAAGT ACATTCTTAC TTCCTCAACT ACAATCCGAA TGTTTCATGCA	660
CGGTGCCGCA CAGAGTCGCG TAGACAGTCT GGTCCCTGAT ATGCTTCTTC CAAAGCAAAT	720
GATTCTCCAA CTCGTCAAGT CAATTTTGAC AGAGAGACGT CTGGTGTTAG CTGGAGCAAC	780
TGGAATTGGA AAGAGCAAAC TGGCGAAGAC CCTGGCTGCT TATGTATCTA TTCGAACAAA	840
TCAATCCGAA GATAGTATTG TTAATATCAG CATTCTGAA AACAATAAAG AAGAATTGCT	900
TCAAGTGGA CGACGCCTGG AAAAGATCTT GAGAAGCAAA GAATCATGCA TCGTAATTCT	960
AGATAATATC CCAAGAATC GAATTGCATT TGTTGTATCC GTTTTTCGAA ATGTCCCACT	1020
TCAAAACAAC GAAGGTCCAT TTGTAGTATG CACAGTCAAC CGATATCAAA TCCCTGAGCT	1080
TCAAATTCAC CACAATTTCA AAATGTCAGT AATGTCGAAT CGTCTCGAAG GATTTCATCCT	1140
ACGTTACCTC CGACGACGGG CGGTAGAGGA TGAGTATCGT CTAAGTGTAC AGATGCCATC	1200
AGAGCTCTTC AAAATCATTG ACTTCTTCCC AATAGCTCTT CAGGCCGTCA ATAATTTTAT	1260
TGAGAAAACG AATTCTGTTG ATGTGACAGT TGGTCCAAGA GCATGCTTGA ACTGTCCTCT	1320
AACTGTGAT GATCCCGTG AATGGTTCAT TCGATTGTGG AATGAGAAGT TCATTCCATA	1380
TTTGGAACGT GTTGCTAGAG ATGGCAAAAA AACCTTCGGT CGCTGCACTT CCTTCGAGGA	1440
TCCCACCGAC ATCGTCTCTA AAAAATGGCC GTGGTTCGAT GGTGAAAACC CGGAGAATGT	1500
GCTCAAACGT CTTCAACTCC AAGACCTCGT CCCGTACCT GCCAACTCAT CCCGACAACA	1560
CTTCAATCCC CTCGAGTCGT TGATCCAATT GCATGCTACC AAGCATCAGA CCATCGACAA	1620
CATTGAACA GAAGACTCTA ATCTTCTCTC GCCTCTCCCC CGCTTTCCTT ATCTTCGTAC	1680
CGGTACCTGA TGATTCCCCA TTTTCCCCCT TTTCCCCCA ATTCCCAGA ACCTCCTGTT	1740
CCCTTTGTTT CTAGTCCTCC CGGGTGCCGA CGCCGAAGCG ATTTAAAAAC CTTTTCTTT	1800
CCGAAACATT TCCCATTGCT CATTAAATAGT CAAATTGAAT AAACAGTGTA TGACTTAAA	1860
AAAAAAAAAA AAAAAAAAAA AAAAGGCTTA TGCGGCCGGG CCATGGAGGC CGAATTCCTG	1920
GGGATCCGTC GACCTGCAGC CAAGCTAATT CCGGGCGAAT TTCTTATGAT TTATGATTTT	1980
TATTATTAAA TAAGTTATAA AAAAAATAAG TGTATACAAA TTTTAAAGTG ACTCTTAGGT	2040
TTTAAACGA AAATCTTGT TCTTGAGTAA CTCTTTCCTG TAGGTCAGGT TGCTTTCTCA	2100
GGTATAGCAT GAGGTCGCTC TTATTGACCA CACCTCTACC GGCATGCAAG CTTGGCGTAA	2160
TCATGGTCAT AGCTGTTTCC TGTGTGAAAT TGTTATCCGC TCACAATTCC ACACAACATA	2220
CGAGCCGGAA GCATAAAGTG TAAAGCCTGG GGTGCCTAAT GAGTGAGGTA ACTCACATTA	2280
ATTGCGTTGC GCTCACTGCC CGCTTTCCAG TCGGGAAACC TGTCGTGCCA GCTGGATTAA	2340
TGAATCGGCC AACGCGCGGG GAGAGGCGGT TTGCGTATTG GGCCTCTTC CGCTTCCTCG	2400
CTCACTGACT CGCTGCGCTC GGTGTTCCG CTGCGCGAG CGGTATCAGC TCACTCAAAG	2460

*FIG. 32 CONTINUED.**76/99*

GCGGTAATAC GGTATCCAC AGAATCAGGG GATAACGCAG GAAAGAACAT GTGAGCAAAA	2520
GGCCAGCAAA AGGCCAGGAA CCGTAAAAAG GCCGCGTTGC TGGCGTTTTT CCATAGGCTC	2580
CGCCCCCTG ACGAGCATCA CAAAAATCGA CGCTCAAGTC AGAGGTGGCG AAACCCGACA	2640
GGACTATAAA GATACCAGGC GTTCCCCCT GGAAGCTCCC TCGTGCCTC TCCTGTTCCG	2700
ACCCTGCCGC TTACCGGATA CCTGTCCGCC TTTCTCCCTT CGGGAAGCGT GCGCCTTTCT	2760
CATAGCTCAC GCTGTAGGTA TCTCAGTTCG GTGTAGGTCG TTCGCTCCAA GCTGGGCTGT	2820
GTGCACGAAC CCCCCGTTCA GCCCGACCGC TCGCCTTAT CCGGTAAC TAAGTCTTGAG	2880
TCCAACCCGG TAAGACACGA CTTATCGCCA CTGGCAGCAG CCACTGGTAA CAGGATTAGC	2940
AGAGCGAGGT ATGTAGGCGG TGCTACAGAG TTCTGAAGT GGTGGCCTAA CTACGGCTAC	3000
ACTAGAAGGA CAGTATTTGG TATCTGCGCT CTGCTGAAGC CAGTTACCTT CGGAAAAAGA	3060
GTTGGTAGCT CTTGATCCGG CAAACAAACC ACCGCTGGTA GCGGTGGTTT TTTGTTTGC	3120
AAGCAGCAGA TTACGCGCAG AAAAAAGGA TCTCAAGAAG ATCCTTTGAT CTTTCTACG	3180
GGGTCTGACG CTCAGTGGAA CGAAACTCA CGTTAAGGGA TTTTGGTCAT GAGATTATCA	3240
AAAAGGATCT TCACCTAGAT CCTTTTAAAT TAAAAATGAA GTTTTAAATC AATCTAAAGT	3300
ATATATGAGT AAACCTGGTC TGACAGTTAC CAATGCTTAA TCAGTGAGGC ACCTATCTCA	3360
GCGATCTGTC TATTTCTGTC ATCCATAGTT GCCTGACTCC CCGTCGTGTA GATAACTACG	3420
ATACGGGAGG GCTTACCATC TGGCCCCAGT GCTGCAATGA TACCGCGAGA CCCACGCTCA	3480
CCGGCTCCAG ATTTATCAGC AATAAACAG CCAGCCGGAA GGGCCGAGCG CAGAAGTGGT	3540
CCTGCAACTT TATCCGCTC CATCCAGTCT ATTAATTGTT GCCGGGAAGC TAGAGTAAGT	3600
AGTTCGCCAG TTAATAGTTT GCGCAACGTT GTTGCCATTG CTACAGGCAT CGTGGTGTC	3660
CGCTCGTCGT TTGGTATGGC TTCATTGAGC TCCGGTCCC AACGATCAAG GCGAGTTACA	3720
TGATCCCCCA TGTTGTGCAA AAAAGCGGTT AGCTCCTTCG GTCCTCCGAT CGTTGTCAGA	3780
AGTAAGTTGG CCGCAGTGTT ATCACTCATG GTTATGGCAG CACTGCATAA TTCTCTTACT	3840
GTCATGCCAT CCGTAAGATG CTTTCTGTG ACTGGTGAGT ACTCAACCAA GTCATTCTGA	3900
GAATAGTGTA TGCGGCGACC GAGTTGCTCT TGCCCGGCGT CAATACGGGA TAATACCGCG	3960
CCACATAGCA GAACTTTAAA AGTGCTCATC ATTGGAAAAC GTTCTTCGGG GCGAAAACCTC	4020
TCAAGGATCT TACCGCTGTT GAGATCCAGT TCGATGTAAC CCACTCGTGC ACCCAACTGA	4080
TCTTCAGCAT CTTTACTTT CACCAGCGTT TCTGGGTGAG CAAAAACAGG AAGGCAAAAT	4140
GCCGCAAAAA AGGGAATAAG GCGACACGG AAATGTTGAA TACTCATACT CTTCTTTTTT	4200
CAATATTATT GAAGCATTTA TCAGGGTTAT TGTCTCATGA GCGGATACAT ATTTGAATGT	4260
ATTTAGAAAA ATAAACAAAT AGGGGTTCCG CGCACATTTT CCCGAAAAGT GCCACCTGAA	4320
CGAAGCATCT GTGCTTCATT TTGTAGAACA AAAATGCAAC GCGAGAGCGC TAATTTTTCA	4380

SUBSTITUTE SHEET (RULE 26)

*FIG. 32 CONTINUED.**77/99*

AACAAAGAAT CTGAGCTGCA TTTTACAGA ACAGAAATGC AACGCGAAAG CGCTATTTTA	4440
CCAACGAAGA ATCTGTGCTT CATTTTTGTA AAACAAAAT GCAACGCGAG AGCGCTAATT	4500
TTTCAACAA AGAATCTGAG CTGCATTTT ACAGAACAGA AATGCAACGC GAGAGCGCTA	4560
TTTTACCAAC AAAGAATCTA TACTTCTTTT TTGTTCTACA AAAATGCATC CCGAGAGCGC	4620
TATTTTCTA ACAAAGCATC TTAGATTACT TTTTCTCC TTTGTGCGCT CTATAATGCA	4680
GTCTCTTGAT AACTTTTTGC ACTGTAGGTC CGTTAAGGTT AGAAGAAGGC TACTTTGGTG	4740
TCTATTTTCT CTTCCATAAA AAAAGCCTGA CTCCACTTCC CGCGTTTACT GATTACTAGC	4800
GAAGCTGCGG GTGCATTTT TCAAGATAAA GGCATCCCCG ATTATATTCT ATACCGATGT	4860
GGATTGCGCA TACTTTGTGA ACAGAAAGTG ATAGCGTTGA TGATTCTTCA TTGGTCAGAA	4920
AATTATGAAC GGTTCCTTCT ATTTTGTCTC TATATACTAC GTATAGGAAA TGTTTACATT	4980
TTCGTATTGT TTTCGATTCA CTCTATGAAT AGTTCTTACT ACAATTTTTT TGTCTAAAGA	5040
GTAATACTAG AGATAAACAT AAAAATGTA GAGGTCGAGT TTAGATGCAA GTTCAAGGAG	5100
CGAAAGGTGG ATGGGTAGGT TATATAGGGA TATAGCACAG AGATATATAG CAAAGAGATA	5160
CTTTGAGCA ATGTTTGTGG AAGCGGTATT CGCAATATTT TAGTAGCTCG TTACAGTCCG	5220
GTGCGTTTTT GGTTTTTTGA AAGTGCCTCT TCAGAGCGCT TTTGGTTTTC AAAAGCGCTC	5280
TGAAGTTCCT ATACTTTCTA GAGAATAGGA ACTTCGGAAT AGGAACTTCA AAGCGTTTCC	5340
GAAACGAGC GCTTCCGAA ATGCAACGCG AGCTGCGCAC ATACAGCTCA CTGTTACGT	5400
CGCACCTATA TCTGCGTGT GCCTGTATAT ATATATACAT GAGAAGAAGC GCATAGTGCG	5460
TGTTTATGCT TAAATGCGTA CTTATATGCG TCTATTTATG TAGGATGAAA GGTAGTCTAG	5520
TACCTCCTGT GATATTATCC CATTCATGC GGGGTATCGT ATGCTTCCTT CAGCACTACC	5580
CTTTAGCTGT TCTATATGCT GCCACTCCTC AATTGGATTA GTCTCATCCT TCAATGCTAT	5640
CATTTCTTT GATATTGGAT CATATTAAGA AACCATTATT ATCATGACAT TAACCTATAA	5700
AAATAGGCGT ATCACGAGGC CCTTTCGTCT CGCGCGTTTC GGTGATGACG GTGAAAACCT	5760
CTGACACATG CAGCTCCCGG AGACGGTCAC AGCTTGCTG TAAGCGGATG CCGGGAGCAG	5820
ACAAGCCCGT CAGGGCGCGT CAGCGGGTGT TGGCGGGTGT CGGGGCTGGC TTAACATATGC	5880
GGCATCAGAG CAGATTGTAC TGAGAGTGCA CCATAGATCA ACGACATTAC TATATATATA	5940
ATATAGGAAG CATTTAATAG ACAGCATCGT AATATATGTG TACTTTGCAG TTATGACGCC	6000
AGATGGCAGT AGTGGGAAGAT ATTCTTTATT GAAAAATAGC TTGTCACCTT ACGTACAATC	6060
TTGATCCGGA GCTTTTCTTT TTTTGCCGAT TAAGAATTAA TTCGGTCGAA AAAAGAAAAG	6120
GAGAGGGCCA AGAGGGAGGG CATTGGTGAC TATTGAGCAC GTGAGTATAC GTGATTAAGC	6180
ACACAAAGGC AGCTTGAGT ATGTCTGTTA TTAATTCAC AGGTAGTTCT GGTCCATTGG	6240
TGAAAGTTTG CGGCTTGACAG AGCACAGAGG CCGCAGAATG TGCTCTAGAT TCCGATGCTG	6300

SUBSTITUTE SHEET (RULE 26)

*FIG. 32 CONTINUED.**78/99*

ACTTGCTGGG TATTATATGT GTGCCCAATA GAAAGAGAAC AATTGACCCG GTTATTGCAA	6360
GGAAAATTTC AAGTCTTGTA AAAGCATATA AAAATAGTTC AGGCACTCCG AAATACTTGG	6420
TTGGCGTGTT TCGTAATCAA CCTAAGGAGG ATGTTTGGC TCTGGTCAAT GATTACGGCA	6480
TTGATATCGT CCAACTGCAAT GGAGATGAGT CGTGGCAAGA ATACCAAGAG TTCCTCGGTT	6540
TGCCAGTTAT TAAAAGACTC GTATTTCCAA AAGACTGCAA CATACTACTC AGTGCAGCTT	6600
CACAGAAACC TCATTCTGTT ATTCCCTTGT TTGATTGAGA AGCAGGTGGG ACAGGTGAAC	6660
TTTTGGATTG GAACTCGATT TCTGACTGGG TTGGAAGGCA AGAGAGCCCC GAAAGCTTAC	6720
ATTTTATGTT AGCTGGTGGA CTGACGCCAG AAAATGTTGG TGATGCGCTT AGATTAAATG	6780
GCGTTATTGG TGTGATGTA AGCGGAGGTG TGGAGACAAA TGGTGTAAAA GACTCTAACA	6840
AAATAGCAAA TTTCGTCAA AATGCTAAGA AATAGGTTAT TACTGAGTAG TATTTATTTA	6900
AGTATTGTTT GTGCACTTGC CGATCTATGC GGTGTGAAAT ACCGCACAGA TGCCTAAGGA	6960
GAAATACCG CATCAGGAAA TTGTAAACGT TAATATTTTG TTAAAATTCG CGTTAAATTT	7020
TTGTTAAATC AGCTCATTTT TTAACCAATA GGCCGAAATC GGCAAAATCC CTTATAAATC	7080
AAAAGAATAG ACCGAGATAG GGTGAGTGT TGTTCCAGTT TGGAACAAGA GTCCACTATT	7140
AAAGAACGTG GACTCCAACG TCAAAGGGCG AAAAACCGTC TATCAGGGCG ATGGCCCACT	7200
ACGTGAACCA TCACCCTAAT CAAGTTTTTT GGGGTCGAGG TGCCGTAAAG CACTAAATCG	7260
GAACCCTAAA GGGAGCCCC GATTTAGAGC TTGACGGGGA AAGCCGGCGA ACGTGGCGAG	7320
AAAGGAAGGG AAGAAAGCGA AAGGAGCGGG CGCTAGGGCG CTGGCAAGTG TAGCGGTCAC	7380
GCTGCGCGTA ACCACCACAC CCGCCGCGCT TAATGCGCGC CTACAGGGCG CGTCGCGCCA	7440
TTCGCCATTC AGGCTGCGCA ACTGTTGGGA AGGGCGATCG GTGCGGGCCT CTTGCTATT	7500
ACGCCAGCTG GCGAAAGGGG GATGTGCTGC AAGGCGATTA AGTTGGGTAA CGCCAGGGTT	7560
TTCCAGTCA CGACGTTGTA AAACGACGGC CAGTCGTCCA AGCTTTCGCG AGCTCGAGAT	7620
CCCGAGCTTT GCAAATTAAA GCCTTCGAGC GTCCCAAAC CTTCTCAAGC AAGGTTTTCA	7680
GTATAATGTT ACATGCGTAC ACGCGTCTGT ACAGAAAAAA AAGAAAAATT TGAAATATAA	7740
ATAACGTTCT TAATACTAAC ATAATAATA AAAAATAAAT AGGGACCTAG ACTTCAGGTT	7800
GTCTAACTCC TTCCTTTTCG GTTAGAGCGG ATGTGGGGGG AGGGCGTGAA TGTAAGCGTG	7860
ACATAACTAA TTACATGATA TCGACAAAGG AAAAGGGGCC TGTTTACTCA CAGGCTTTTT	7920
TCAAGTAGGT AATTAAGTCG TTTCTGTCTT TTTCTTCTT CAACCCACCA AAGGCCATCT	7980
TGGTACTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT	8040
TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT CATAGAAATA ATACAGAAGT	8100
AGATGTTGAA TTAGATTAAA CTGAAGATAT ATAATTATT GGAAATACA TAGAGCTTTT	8160
TGTTGATGCG CTTAAGCGAT CAATTCAACA ACACCACCAG CAGCTCTGAT TTTTCTTCA	8220

SUBSTITUTE SHEET (RULE 26)

FIG. 32 CONTINUED.

79/99


GCCAACTTGG AGACGAATCT AGCTTTGACG ATAAGTGGAA CATTTGGGAT TCTACCCTTA	8280
CCCAAGATCT TACCGTAACC GGCTGCCAAA GTGTCAATAA CTGGAGCAGT TTCCTTAGAA	8340
GCAGATTTCA AGTATTGGTC TCTCTTGTCT TCTGGGATCA ATGTCCACAA TTTGTCCAAG	8400
TTCAAGACTG GCTTCCAGAA ATGAGCTTGT TGCTTGTGGA AGTATCTCAT ACCAANCCTT	8460
ACCGAAATAA CCTGGATGGT ATTTATCCAT GTTAATTCTG TGGTGATGTT GACCACCGGC	8520
CATACCTCTA CCACCGGGT GCTTTCTGTG CTTACCGATA CGACCTTAC CGGCTGAGAC	8580
GTGACCTCTG TGCTTTCTAG TCTTAGTGAA TCTGGAAGGC ATTCTTGATT AGTTGGATGA	8640
TTGTTCTGGG ATTTAATGCA AAAAAATCAC TAAGAAGGAA AAAAAATCAAC GGAGAAAGCA	8700
AACGCCATCT TAAATATACG GGATACAGAT GAAAGGTTTG AACCTATCTG GGAAAATACG	8760
CATTAAACAA GCGAAAACT GCGAGGAAAA TTGTTTGCCT CTCTGCGGGC TATTCACGCG	8820
CCAGAGGAAA ATAGGAAAAA TAACAGGGCA TTAGAAAAAT AATTTTGATT TTGGTAATGT	8880
GTGGGTCCCT GGTGTACAGA TGTTACATTG GTTACAGTAC TCTTGTTTTT GCTGTGTTTT	8940
TCGATGAATC TCCAAAATGG TTGTTAGCAC ATGGAAGAGT CACCGATGCT AAGTTATCTC	9000
TATGTAAGCT ACGTGGCGTG ACTTTTGATG AAGCCGCACA AGAGATACAG GATTGGCAAC	9060
TGCAATAGA ATCTGGGGAT CTAGATATCC TTTTGTTGTT TCCGGGTGTA CAATATGGAC	9120
TTCTCTTTT CTGGCAACCA AACCATACA TCGGGATTCC TATAATACCT TCGTTGGTCT	9180
CCCTAACATG TAGGTGGCGG AGGGGAGATA TACAATAGAA CAGATACCAG ACAAGACATA	9240
ATGGGCTAAA CAAGACTACA CCAATTACAC TGCCTCATTG ATGGTGGTAC ATAACGAACT	9300
AATACTGTAG CCCTAGACTT GATAGCCATC ATCATATCGA AGTTTCACTA CCCTTTTTC	9360
ATTTGCCATC TATTGAAGTA ATAATAGGCG CATGCAACTT CTTTCTTTT TTTTCTTTT	9420
CTCTCTCCCC CGTTGTTGTC TCACCATATC CGCAATGACA AAAAAATGA TGGAGACAC	9480
TAAAGGAAAA AATTAACGAC AAAGACAGCA CCAACAGATG TCGTTGTTCC AGAGCTGATG	9540
AGGGGTATCT TCGAACACAC GAACTTTTT CCTTCCTTCA TTCACGCACA CTAATCTCTA	9600
ATGAGCAACG GTATACGGCC TTCCTTCCAG TTAATTTGAAT TTGAAATAA AAAAGTTTGC	9660
CGCTTTGCTA TCAAGTATAA ATAGACCTGC AATTATTAAT CTTTGTTC CTCGTCATTG	9720
TTCTCGTTCC CTTTCTTCCT TGTTTCTTTT TCTGCACAAT ATTTCAAGCT ATACCAAGCA	9780
TACAATCAAC TCCAAGCTTG AAGCAAGCCT CCTGAAAGAT GAAGCTACTG TCTTCTATCG	9840
AACAAGCATG CGATATTTGC CGACTTAAAA AGCTCAAGTG CTCCAAAGAA AAACCGAAGT	9900
GCGCCAAGTG TCTGAAGAAC AACTGGGAGT GTCGCTACTC TCCCAAACC AAAAGGTCTC	9960
CGCTGACTAG GGCACATCTG ACAGAAGTGG AATCAAGGCT AGAAAGACTG GAACAGCTAT	10020
TTCTACTGAT TTTTCCTCGA GAAGACCTTG ACATGATTTT GAAAATGGAT TCTTTACAGG	10080
ATATAAAGC ATTGTTAACA GGATTATTTG TACAAGATAA TGTGAATAA GATGCCGTCA	10140

*80/99**FIG. 32 CONTINUED.*

CAGATAGATT GGCTTCAGTG GAGACTGATA TGCCTCTAAC ATTGAGACAG CATAGAATAA	10200
GTGCGACATC ATCATCGGAA GAGAGTAGTA ACAAAGGTCA AAGACAGTTG ACTGTATCGC	10260
CGGAATTGCA ATACCCAGCT TTGACTCA	10288

81/99

FIG. 33



82/99

FIG. 34.

GCTTGCATGC AACTTCTTTT CTTTTTTTTT CTTTCTCTC TCCCCCGTTG TTGTCTCACC	60
ATATCCGCAA TGACAAAAA AATGATGGAA GACACTAAAG GAAAAAATTA ACGACAAAGA	120
CAGCACCAAC AGATGTCGTT GTTCCAGAGC TGATGAGGGG TATCTTCGAA CACACGAAAC	180
TTTTTCCTTC CTTCAATCAC GCACACTACT CTCTAATGAG CAACGGTATA CGGCCTTCCT	240
TCCAGTTACT TGAATTTGAA ATAAAAAAG TTTGCCGCTT TGCTATCAAG TATAAATAGA	300
CCTGCAATTA TTAATCTTTT GTTTCCTCGT CATGTGTTCTC GTTCCCTTTC TTCCTTGTTT	360
CTTTTCTGCG ACAATATTTT AAGCTATACC AAGCATACAA TCAACTCCAA GCTTTGCAAA	420
GATGGATAAA GCGGAATTAA TTCCCGAGCC TCCAAAAAG AAGAGAAAGG TCGAATTGGG	480
TACCGCCGCC AATTTTAATC AAAGTGGGAA TATGCTGAT AGCTCATTGT CCTTCACTTT	540
CACTAACAGT AGCAACGGTC CGAACCTCAT AACAACTCAA ACAAATTCTC AAGCGCTTTC	600
ACAACCAATT GCCTCCTCTA ACGTTCATGA TAACTTCATG AATAATGAAA TCACGGCTAG	660
TAAAATTGAT GATGGTAATA ATTCAAAACC ACTGTCACCT GGTGGACGG ACCAAACTGC	720
GTATAACGCG TTTGGAATCA CTACAGGGAT GTTAATACC ACTACAATGG ATGATGTATA	780
TAACTATCTA TTCGATGATG AAGATACCCC ACCAAACCCA AAAAAAGAGA TCGAATTCCC	840
GGGGATCCGC TCCTCACTCT CCAAGTTCAC CAAGAAGAAG AACAGAAGT ACGACGAAGC	900
ACATATGCCA TCAATTTCCG GATCTCAAGG AACTCTTGAC AACATTGATG TGATTGAGTT	960
GAAGCAAGAG CTCAAGAAGC GCGATAGTGC ACTTTACGAA GTCCGCCTTG ACAATCTGGA	1020
TCGTGCCCCG GAAGTTGATG TTCTGAGGGA GACAGTGAAC AAGTTGAAAA CCGAGAACAA	1080
GCAATTAAAG AAAGAAGTGG ACAAACTCAC CAACGGTCCA GCCACTCGTG CTTCTTCCCG	1140
CGCCTCAATT CCAGTTATCT ACGACGATGA GCATGTCTAT GATGCAGCGT GTAGCAGTAC	1200

*FIG. 34 CONTINUED.**83/99*

ATCAGCTAGT CAATCTTCGA AACGATCCTC TGGCTGCAAC TCAATCAAGG TTA CTGTAAA	1260
CGTGGACATC GCTGGAGAAA TCAGTTCGAT CGTTAACCCG GACAAAGAGA TAATCGTAGG	1320
ATATCTTGCC ATGTCAACCA GTCAGTCATG CTGGAAAGAC ATTGATGTTT CTATTCTAGG	1380
ACTATTTGAA GTCTACCTAT CCAGAATTGA TGTGGAGCAT CAACTTGGA TCGATGCTCG	1440
TGATTCTATC CTTGGCTATC AAATTGGTGA ACTTCGACGC GTCATTGGAG ACTCCACAAC	1500
CATGATAACC AGCCATCCAA CTGACATTCT TACTTCCTCA ACTACAATCC GAATGTTTAT	1560
GCACGGTGCC GCACAGAGTC GCGTAGACAG TCTGGTCCTT GATATGCTTC TTCCAAAGCA	1620
AATGATTCTC CAACTCGTCA AGTCAATTTT GACAGAGAGA CGTCTGGTGT TAGCTGGAGC	1680
AACTGGAATT GGAAAGAGCA AACTGGCGAA GACCCTGGCT GCTTATGTAT CTATTCGAAC	1740
AAATCAATCC GAAGATAGTA TTGTTAATAT CAGCATTCCT GAAAACAATA AAGAAGAATT	1800
GCTTCAAGTG GAACGACGCC TGGAAAAGAT CTATGAATCG TAGATACTGA AAAACCCCGC	1860
AAGTTCACCT CAACTGTGCA TCGTGCACCA TCTCAATTC TTTCAATTTAT ACATCGTTTT	1920
GCCTTCTTTT ATGTAATAT ACTCCTCTAA GTTTCATCT TGGCCATGTA ACCTCTGATC	1980
TATAGAATTT TTTAAATGAC TAGAATTAAT GCCCATCTTT TTTTGGACC TAAATCTTC	2040
ATGAAATAT ATTACGAGGG CTTATTCAGA AGCTTTGGAC TTCTTCGCCA GAGGTTTGGT	2100
CAAGTCTCCA ATCAAGGTTG TCGGCTTGTC TACCTTGCCA GAAATTTACG AAAAGATGGA	2160
AAAGGGTCAA ATCGTTGGTA GATACGTTGT TGACACTTCT AAATAAGCGA ATTTCTTATG	2220
ATTTATGATT TTTATTATTA AATAAGTTAT AAAAAAATA AGTGATACA AATTTTAAAG	2280
TGACTCTTAG GTTTTAAAC GAAATTCCT GTTCTTGAGT AACTCTTCC TGTAGGTCAG	2340
GTTGCTTTCT CAGGTATAGC ATGAGGTCGC TCTTATTGAC CACACCTCTA CCGGCATGCC	2400
CGAAATTCCT CTACCCTATG AACATATTCC ATTTTGTAAT TTCGTGTCGT TTCTATTATG	2460
AATTTCAATT ATAAAGTTTA TGTACAAATA TCATAAAAA AGAGAATCTT TTTAAGCAAG	2520
GATTTTCTTA ACTTCTTCGG CGACAGCATC ACCGACTTCG GTGGTACTGT TGGAACCACC	2580
TAAATCACCA GTTCTGATAC CTGCATCCAA AACCTTTTTA ACTGCATCTT CAATGGCCTT	2640
ACCTTCTTCA GGCAAGTTCA ATGACAATTT CAACATCATT GCAGCAGACA AGATAGTGGC	2700
GATAGGGTCA ACCTTATTCT TTGGCAAATC TGGAGCAGAA CCGTGGCATG GTTCGTACAA	2760
ACCAAATGCG GTGTTCTTGT CTGGCAAAGA GGCCAAGGAC GCAGATGGCA ACAAACCCAA	2820
GGAACCTGGG ATAACGGAGG CTTCATCGGA GATGATATCA CCAACATGT TGCTGGTGAT	2880
TATAATACCA TTTAGGTGGG TTGGGTTCTT AACTAGGATC ATGGCGGCAG AATCAATCAA	2940
TTGATGTTGA ACCTTCAATG TAGGAAATTC GTTCTTGATG GTTTCCTCCA CAGTTTTTCT	3000
CCATAATCTT GAAGAGGCCA AAACATTAGC TTTATCCAAG GACCAAATAG GCAATGGTGG	3060
CTCATGTTGT AGGGCCATGA AAGCGGCCAT TCTTGTGATT CTTTGCACTT CTGGAACGGT	3120

*FIG. 34 CONTINUED.**84/99*

GTATTGTTCA CTATCCCAAG CGACACCATC ACCATCGTCT TCCTTTCTCT TACCAAAGTA	3180
AATACCTCCC ACTAATTCTC TGACAACAAC GAAGTCAGTA CCTTTAGCAA ATTGTGGCTT	3240
GATTGGAGAT AAGTCTAAAA GAGAGTCGGA TGCAAAGTTA CATGGTCTTA AGTTGGCGTA	3300
CAATTGAAGT TCTTTACGGA TTTTGTAGTA ACCTTGTTCA GGTCTAACAC TACCTGTACC	3360
CCATTTAGGA CCACCCACAG CACCTAACAA AACGGCATCA ACCTTCTTGG AGGCTTCCAG	3420
CGCCTCATCT GGAAGTGGGA CACCTGTAGC ATCGATAGCA GCACCACCA TTAATGATT	3480
TTCGAAATCG AACTTGACAT TGGAACGAAC ATCAGAAATA GCTTTAAGAA CCTTAATGGC	3540
TTCGGCTGTG ATTTCTTGAC CAACGTGGTC ACCTGGCAAA ACGACGATCT TCTTAGGGGC	3600
AGACATTAGA ATGGTATATC CTTGAAATAT ATATATATAT TGCTGAAATG TAAAAGGTAA	3660
GAAAAGTTAG AAAGTAAGAC GATTGCTAAC CACCTATTGG AAAAAACAAT AGGTCCTTAA	3720
ATAATATTGT CAACTTCAAG TATTGTGATG CAAGCATTTA GTCATGAACG CTTCTCTATT	3780
CTATATGAAA AGCCGGTTCC GGCCTCTCAC CTTTCCTTTT TCTCCCAATT TTTCAGTTGA	3840
AAAAGGTATA TGCCTCAGGC GACCTCTGAA ATTAACAAAA AATTTCCAGT CATCGAATTT	3900
GATTCTGTGC GATAGCGCCC CTGTGTGTTT TCGTTATGTT GAGGAAAAAA ATAATGGTTG	3960
CTAAGAGATT CGAACTCTTG CATCTTACGA TACCTGAGTA TTCCACAGT TGGGGATCTC	4020
GACTCTAGCT AGAGGATCAA TTCGTAATCA TGGTCATAGC TGTTTCCTGT GTGAAATTGT	4080
TATCCGCTCA CAATTCCACA CAACATACGA GCCGGAAGCA TAAAGTGTA AGCCTGGGGT	4140
GCCTAATGAG TGAGGTAACT CACATTAATT GCGTTGCGCT CACTGCCCCG TTTCCAGTCG	4200
GGAAACCTGT CGTGCCAGCT GGATTAATGA ATCGGCCAAC GCGCGGGGAG AGGCGGTTTG	4260
CGTATTGGGC GCTCTTCCGC TTCCTCGCTC ACTGACTCGC TGCCTCGGT CGTTCCGCTG	4320
CGGCGAGCGG TATCAGCTCA CTCAAAGGCG GTAATACGGT TATCCACAGA ATCAGGGGAT	4380
AACGCAGGAA AGAACATGTG AGCAAAAGGC CAGCAAAAGG CCAGGAACCG TAAAAAGGCC	4440
GCGTTGCTGG CGTTTTTCCA TAGGCTCCGC CCCCCTGACG AGCATCACAA AAATCGACGC	4500
TCAAGTCAGA GGTGGCGAAA CCCGACAGGA CTATAAAGAT ACCAGGCGTT TCCCCCTGGA	4560
AGCTCCCTCG TCGCTCTCC TGTTCCGACC CTGCCGCTTA CCGGATACCT GTCCGCCTTT	4620
CTCCCTTCGG GAAGCGTGGC GCTTTCTCAT AGCTCACGCT GTAGGTATCT CAGTTCGGTG	4680
TAGGTCGTTT GCTCCAAGCT GGGCTGTGTG CACGAACCCC CCGTTCAGCC CGACCCTGTC	4740
GCCTTATCCG GTAACATATG TCTTGAGTCC AACCCGGTAA GACACGACTT ATCGCCACTG	4800
GCAGCAGCCA CTGGTAACAG GATTAGCAGA GCGAGGTATG TAGGCGGTGC TACAGAGTTC	4860
TTGAAGTGGT GGCCTAACTA CGGCTACACT AGAAGGACAG TATTTGGTAT CTGCGCTCTG	4920
CTGAAGCCAG TTACCTTCGG AAAAAGAGTT GGTAGCTCTT GATCCGGCAA ACAAACCACC	4980
GCTGGTAGCG GTGGTTTTTT TGTGTGCAAG CAGCAGATTA CGCGCAGAAA AAAAGGATCT	5040

*FIG. 34 CONTINUED.**85/99*

CAAGAAGATC CTTTGATCTT TTCTACGGGG TCTGACGCTC AGTGGAACGA AACTCAGCT	5100
TAAGGGATTT TGGTCATGAG ATTATCAAAA AGGATCTTCA CCTAGATCCT TTAAATTAA	5160
AAATGAAGTT TTAATCAAT CTAAAGTATA TATGAGTAAA CTTGGTCTGA CAGTTACCAA	5220
TGCTTAATCA GTGAGGCACC TATCTCAGCG ATCTGTCTAT TTCGTTTCATC CATAGTTGCC	5280
TGACTCCCCG TCGTGTAGAT AACTACGATA CGGGAGGGCT TACCATCTGG CCCAGTGCT	5340
GCAATGATAC CGCGAGACCC ACGCTCACCG GCTCCAGATT TATCAGCAAT AAACCAGCCA	5400
GCCGGAAGGG CCGAGCGCAG AAGTGGTCCT GCAACTTTAT CCGCTCCAT CCAGTCTATT	5460
AATTGTTGCC GGAAGCTAG AGTAAGTAGT TCGCCAGTTA ATAGTTTGC CAACGTTGTT	5520
GCCATTGCTA CAGGCATCGT GGTGTCACGC TCGTCGTTG GTATGGCTTC ATTCAGCTCC	5580
GGTTCCCAAC GATCAAGGCG AGTTACATGA TCCCCATGT TGTGCAAAA AGCGGTTAGC	5640
TCCTTCGGTC CTCCGATCGT TGTCAGAACT AAGTTGGCCG CAGTGTATC ACTCATGGTT	5700
ATGGCAGCAC TGCATAATTC TCTTACTGTC ATGCCATCCG TAAGATGCTT TTCTGTGACT	5760
GGTGAGTACT CAACCAAGTC ATTCTGAGAA TAGTGTATGC GCGACCGAG TTGCTCTTGC	5820
CCGGCGTCAA TACGGGATAA TACCGCGCCA CATAGCAGAA CTTTAAAAGT GCTCATCATT	5880
GGAAAACGTT CTTGCGGGCG AAAACTCTCA AGGATCTTAC CGCTGTTGAG ATCCAGTTCCG	5940
ATGTAACCCA CTCGTGCACC CAACTGATCT TCAGCATCTT TTACTTTCAC CAGCGTTTCT	6000
GGGTGAGCAA AAACAGGAAG GCAAAATGCC GCAAAAAGG GAATAAGGGC GACACGGAAA	6060
TGTTGAATAC TCATACTCTT CCTTTTTCAA TATTATTGAA GCATTTATCA GGGTTATTGT	6120
CTCATGAGCG GATACATATT TGAATGTATT TAGAAAAATA AACAAATAGG GGTTCGCGC	6180
ACATTTCCCC GAAAAGTGCC ACCTGACGTC TAAGAAACCA TTATTATCAT GACATTAACC	6240
TATAAAAATA GCGGTATCAC GAGGCCCTTT CGTCTCGCGC GTTTCGGTGA TGACGGTGAA	6300
AACCTCTGAC ACATGCAGCT CCCGGAGACG GTCACAGCTT GTCTGTAAGC GGATGCCGGG	6360
AGCAGACAAG CCCGTAGGG CGCGTCAGCG GGTGTTGGCG GGTGTCGGGG CTGGCTTAAC	6420
TATGCGGCAT CAGAGCAGAT TGTACTGAGA GTGCACCATA ACGCATTTAA GCATAAACAC	6480
GCACTATGCC GTTCTTCTCA TGTATATATA TATACAGGCA ACACGCAGAT ATAGGTGCGA	6540
CGTGAACAGT GAGCTGTATG TGCGCAGCTC GCGTTGCATT TTCGGAAGCG CTCGTTTTCG	6600
GAAACGCTTT GAAGTTCCTA TTCCGAAGTT CCTATTCTCT AGCTAGAAAG TATAGGAAGT	6660
TCAGAGCGCT TTTGAAAACC AAAAGCGCTC TGAAGACGCA CTTTCAAAA ACCAAAACG	6720
CACCGGACTG TAACGAGCTA CTAAATATT GCGAATACCG CTTCCACAAA CATTGCTCAA	6780
AAGTATCTCT TTGCTATATA TCTCTGTGCT ATATCCCTAT ATAACCTACC CATCCACCTT	6840
TCGCTCCTTG AACTTGCATC TAACTCGAC CTCTACATTT TTTATGTTTA TCTCTAGTAT	6900
TACTCTTTAG ACAAAAAAAT TGTAGTAAGA ACTATTCATA GAGTGAATCG AAAACAATAC	6960

86/99

FIG. 34 CONTINUED.

GAAATGTAA ACATTTCTTA TACGTAGTAT ATAGAGACAA AATAGAAGAA ACCGTTTCATA	7020
ATTTTCTGAC CAATGAAGAA TCATCAACGC TATCACTTTC TGTTACAAA GTATGCGCAA	7080
TCCACATCGG TATAGAATAT AATCGGGGAT GCCTTTATCT TGAAAAATG CACCCGCAGC	7140
TTGCTAGTA ATCAGTAAAC GCGGGAAGTG GAGTCAGGCT TTTTTATGG AAGAGAAAAT	7200
AGACACCAA GTAGCCTTCT TCTAACCTTA ACGGACCTAC AGTGCAAAA GTTATCAAGA	7260
GACTGCATTA TAGAGCGCAC AAAGGAGAAA AAAAGTAATC TAAGATGCTT TGTTAGAAA	7320
ATAGCGCTCT CGGGATGCAT TTTGTAGAA CAAAAAGAA GTATAGATTC TTTGTTGGTA	7380
AAATAGCGCT CTCGCGTTGC ATTTCTGTTT TGTAATAATG CAGCTCAGAT TCTTTGTTTG	7440
AAAAATTAGC GCTCTCGCGT TGCATTTTTG TTTTACAAA ATGAAGCACA GATTCTTCGT	7500
TGGTAAAATA GCGCTTTCGC GTTGCAATTC TGTCTGTAA AAATGCAGCT CAGATTCITT	7560
GTTTGAAAAA TTAGCGCTCT CGCGTTGCAT TTTGTTCTA CAAATGAAG CACAGATGCT	7620
TCGTT	7625





FIG. 35.

SUBSTITUTE SHEET (RULE 26)


88/99

FIG. 36.



SUBSTITUTE SHEET (RULE 26)


89/99

FIG. 36 (CONTD.)

SUBSTITUTE SHEET (RULE 26)

90/99


FIG. 37.



SUBSTITUTE SHEET (RULE 26)

91/99

FIG. 38.



SUBSTITUTE SHEET (RULE 26)

*92/99**FIG. 39.*

ATGACCATGA TTACGCCAAG CTTGTCTTCT TCTAAATTCC CATAAAATCC CGAAACTCCT	60
TCCCTCTATC TTCTTTTTCT TCTCGTTTTC AAATGTTTCT CTCTATCCCA TTCTCTCATC	120
AATTGAGTGG GATGAGGCTA TCTCTGCCTC TCTTCTGAAT CTCTGAACCA TCTTACATTA	180
CACTGTGGAT GACGAGCCCC ACAGGCTCCC TTGCATCAGA TACTGCCATT GGGGATGGCA	240
AAGAAGAGAG AAGGTATTGT GAGGATATAT TTTTCTAAGA AAAACGTTT GAAGAAAAGA	300
AGATGAAGAA GATCTGCTTG ATTCATTGCA CAAGTTAGAA GTAACAGGGG TCTATATTTC	360
GAAGAACTTA AAGGGAATGC AACTGAACAT AAAATTAAAC AAAGGGATTG AATCCTGCAG	420
TGAGTATTTT CGGTTTTTCA CTGGTTCTCT GTAAAAAGAG TAATGCAAAG GGCAAGTTAA	480
CTTAGGTCGT AAATGTATTG AATTGCTTA AAATCTGAAG ATCTAGTGGT GAACCGTGGA	540
AGATTATCAA GAGGAGGCTG AAGATCTGTT TAAGAACCAT TAATCAAACCT GGTATTCTAT	600
TTTCACTGGT TGTATGTAAA CATTCTATCT TATTCCTTTT ATCACTGTTC TGCACTTTCC	660

*FIG. 39 CONTINUED.**93/99*

TATAAAAAA	GTTGACCGAC	CGTACTCTCT	GAATTCATTT	TTCCCGATCT	TACCAACTCC	720
CGATCTATCT	CTATCCCTGG	TTTTTCTTC	GTGCTCCAAT	GGAATTCCTG	AGACTTCCAC	780
TATCTTCTCT	GGCACCCCTCC	ACTACGCGTA	GGCGTCTCTC	GCTTCGTGTA	TTCCCGGGAA	840
GCCGGTTCCC	GTCTCTCCCG	CCGCTGCCGC	TGCCGCACAC	AGCTTTACAC	CTCGTAGAAT	900
CCCCAAAGAG	GGGCGTGGCT	TGCGGGTGCC	AACATCCTCC	TGCCGAGGAA	GAAGCAGGCA	960
CTCATCACTC	GCATCATCAA	CCTCGGGATT	GGCCAAAGGA	CCCAAAGGTA	TGTTTCGAAT	1020
GATACTAACA	TAACATAGAA	CATTTTCAGG	AGGACCCTTG	GCTAGAACTA	GTGGATCCGA	1080
GCTCTCCCAT	ATGACGACGT	CAAATGTAGA	ATTGATACCA	ATCTACACGG	ATTGGGCCAA	1140
TCGGCACCTT	TCGAAGGGCA	GCTTATCAAA	GTGATTAGG	GATATTTCCA	ATGATTTTCG	1200
CGACTATCGA	CTGGTTTCTC	AGCTTATTAA	TGTGATCGTT	CCGATCAACG	AATTCTCGCC	1260
TGCATTACAG	AAACGTTTGG	CAAAAATCAC	ATCGAACCTG	GATGGCCTCG	AAACGTGTCT	1320
CGACTACCTG	AAAAATCTGG	GTCTCGACTG	CTCGAAACTC	ACCAAACCG	ATATCGACAG	1380
CGGAAACTTG	GGTGCACTT	TCCAGCTGCT	CTTCTGCTC	TCCACCTACA	AGCAGAAGCT	1440
TCGGCAACTG	AAAAAGATC	AGAAGAAATT	GGAGCAACTA	CCCACATCCA	TTATGCCACC	1500
CGCGGTTTCT	AAATTACCTT	CGCCACGTGT	CGCCACGTCA	GCAACCGCTT	CAGCAACTAA	1560
CCCAAATTCC	AACTTTCCAC	AAATGTCAAC	ATCCAGGCTT	CAGACTCCAC	AGTCAAGAAT	1620
ATCGAAAATT	GATTCATCAA	AGATTGGTAT	CAAGCCAAAG	ACGTCTGGAC	TTAAACCACC	1680
CTCATCATCA	ACCACTTCAT	CAAATAATAC	AAATTCATT	CGTCCGTCGA	GCCGTTTCGAG	1740
TGGCAATAAT	AATGTTGGCT	CGACGATATC	CACATCTGCG	AAGAGCTTAG	AATCATCATC	1800
AACGTACAGC	TCTATTTCTGA	ATCTAAACCG	ACCTACCTCC	CAACTCCAAA	AACCTTCTAG	1860
ACCACAAACC	CAGCTAGTTC	GTGTTGCTAC	AACTACAAAA	ATCGGAAGCT	CAAAGCTAGC	1920
CGCTCCGAAA	GCCGTGAGCA	CCCCAAAAC	TGCTTCTGTG	AAGACTATTG	GAGCAAAACA	1980
AGAGCCCGAT	AACAGCGGTG	GTGGTGGTGG	TGGAATGCTG	AAATTAAAGT	TATTCAGTAG	2040
CAAAAACCCA	TCTTCTCAT	CGAATAGCCC	ACAACCTACG	AGAAAGGCGG	CGGCGGTGCC	2100
TCAACAACAA	ACTTTGTCGA	AAATCGCTGC	CCCAGTGAAA	AGTGGCCTGA	AGCCGCCGAC	2160
CAGTAAGCTG	GGAAGTGCCA	CGTCTATGTC	GAAGCTTTGT	ACGCCAAAAG	TTTCTTACCG	2220
TAAAACGGAC	GCCCCAATCA	TATCTCAACA	AGACTCGAAA	CGATGCTCAA	AGAGCAGTGA	2280
AGAAGAGTCC	GGATACGCTG	GATTCAACAG	CACGTCGCCA	ACGTCATCAT	CGACGGAAGG	2340
TTCCCTAAGC	ATGCATTCCA	CATCTTCCAA	GAGTTCAACG	TCAGACGAAA	AGTCTCCGTC	2400
ATCAGACGAT	CTTACTCTTA	ACGCCTCCAT	CGTGACAGCT	ATCAGACAGC	CGATAGCCGC	2460
AACACCGGTT	TCTCCAAATA	TTATCAACAA	GCCTGTTGAG	GAAAAACCAA	CACTGGCAGT	2520
GAAAGGAGTG	AAAAGCACAG	CGAAAAAAGA	TCCACCTCCA	GCTGTTCCGC	CACGTGACAC	2580

SUBSTITUTE SHEET (RULE 26)

*FIG. 39 CONTINUED.**94/99*

CCAGCCAACA ATCGGAGTTG TTAGTCCAAT TATGGCACAT AAGAAGTTGA CAAATGACCC	2640
CGTGATATCT GAAAAACCAG AACCTGAAAA GCTCCAATCA ATGAGCATCG ACACGACGGA	2700
CGTTCCACCG CTTCCACCTC TAAATCAGT TGTTCACCTT AAAATGACTT CAATCCGACA	2760
ACCACCAACG TACGATGTTT TTCTAAAACA AGGAAAAATC ACATCGCCTG TCAAGTCGTT	2820
TGGATATGAG CAGTCGTCCG CGTCTGAAGA CTCCATTGTG GTCATGCGT CGGCTCAGGT	2880
GACTCCGCCG AAAAAAATT CTGGTAATCA TTCGCTGGAG AGAAGGATGG GAAAGAATAA	2940
GACATCAGAA TCCAGCGGCT ACACCTCTGA CGCCGGTGTG GCGATGTGCG CCAAAATGAG	3000
GGAGAAGCTG AAAGAATACG ATGACATGAC TCGTCGAGCA CAGAACGGCT ATCCTGACAA	3060
CTTCGAAGAC AGTTCCTCCT TGTCGTCTGG AATATCCGAT AACAACGAGC TCGACGACAT	3120
ATCCACGGAC GATTTGTCCG GAGTAGACAT GGCAACAGTC GCCTCCAAAC ATAGCGACTA	3180
TTCCCACTTT GTTCGCCATC CCACGTCTTC TTCCTCAAAG CCCCAGTCC CAGTCGGTC	3240
CTCCACATCA GTCGATTCTC GATCTCGAGC AGAACAGGAG AATGTGTACA AACTTCTGTC	3300
CCAGTGCCGA ACGAGCCAAC GTGGCGCCGC TGCCACCTCA ACCTTCGGAC AACATTGCT	3360
AAGATCCCCG GGATACTCAT CCTATTCTCC ACACCTATCA GTGTCAGCTG ATAAGGACAC	3420
AATGTCTATG CACTCACAGA CTAGTCGACG ACCTTCTTCA CAAAAACCAA GCTATTGAGG	3480
CCAATTTTAT TCACTTGATC GTAAATGCCA CCTTCAAGAG TTCACATCCA CCGAGCACAG	3540
AATGGCGGCT CTCTTGAGCC CGAGACGGGT GCCGAACCTG ATGTCGAAAT ATGATTCTTC	3600
AGGATCCTAC TCGGCGCGTT CCCGAGGTGG AAGCTCTACT GGTATCTATG GAGAGACGTT	3660
CCAATGCAC AACTATCCG ATGAAAAATC CCCCACACAT TCTGCCAAA GTGAGATGGG	3720
ATCCCAACTA TCACTGGCTA GCACGACAGC ATATGGATCT CTCAATGAGA AGTACGAACA	3780
TGCTATTCGG GACATGGCAC GTGACTTGGA GTGTTACAAG AACACTGTG ACTCACTAAC	3840
CAAGAAACAG GAGAACTATG GAGCATTGTT TGATCTTTTT GAGCAAAAGC TTAGAAAAT	3900
CACTCAACAC ATTGATCGAT CCAACTTGAA GCCTGAAGAG GCAATACGAT TCAGGCAGGA	3960
CATTGCTCAT TTGAGGGATA TTAGCAATCA TCTTGCATCC AACTCAGCTC ATGCTAACGA	4020
AGGCGCTGGT GAGCTTCTTC GTCAACCATC TCTGGAATCA GTTGCATCCC ATCGATCATC	4080
GATGTCATCG TCGTCGAAAA GCAGCAAGCA GGAGAAGATC AGCTTGAGCT CGTTTGCCAA	4140
GAACAAGAAG AGCTGGATCC GCTCCTCACT CTCCAAGTTC ACCAAGAAGA AGAACAAGAA	4200
CTACGACGAA GCACATATGC CATCAATTTT CGGATCTCAA GGAACCTTG ACAACATTGA	4260
TGTGATTGAG TTGAAGCAAG AGCTCAAAGA ACGCGATAGT GCACTTTACG AAGTCCGCCT	4320
TGACAATCTG GATCGTGCCC GCGAAGTTGA TGTCTGAGG GAGACAGTGA ACAAGTTGAA	4380
AACCGAGAAC AAGCAATTAA AGAAAGAAGT GGACAAACTC ACCAACGGTC CAGCCACTCG	4440
TGCTTCTTCC CGCGCTCAA TTCCAGTTAT CTACGACGAT GAGCATGTCT ATGATGCAGC	4500

SUBSTITUTE SHEET (RULE 26)

FIG. 39 CONTINUED. 95/99

GTGTAGCAGT	ACATCAGCTA	GTCAATCTTC	GAAACGATCC	TCTGGCTGCA	ACTCAATCAA	4560
GGTTACTGTA	AACGTGGACA	TCGCTGGAGA	AATCAGTTCG	ATCGTTAACC	CGGACAAAGA	4620
GATAATCGTA	GGATATCTTG	CCATGTCAAC	CAGTCAGTCA	TGCTGGAAAG	ACATTGATGT	4680
TTCTATTCTA	GGACTATTTG	AAGTCTACCT	ATCCAGAATT	GATGTGGAGC	ATCAACTTGG	4740
AATCGATGCT	CGTGATTCTA	TCCTTGGCTA	TCAAATTGGT	GAAGTTCGAC	GCGTCATTGG	4800
AGACTCCACA	ACCATGATAA	CCAGCCATCC	AAGTACATT	CTTACTTCCT	CAACTACAAT	4860
CCGAATGTTT	ATGCACGGTG	CCGCACAGAG	TCGCGTAGAC	AGTCTGGTCC	TTGATATGCT	4920
TCTTCCAAAG	CAAAATGATC	TCCAACTCGT	CAAGTCAATT	TTGACAGAGA	GACGTCTGGT	4980
GTTAGCTGGA	GCAACTGGAA	TTGGAAAGAG	CAAACTGGCG	AAGACCCTGG	CTGCTTATGT	5040
ATCTATTCTA	ACAAATCAAT	CCGAAGATAG	TATTGTTAAT	ATCAGCATTC	CTGAAAACAA	5100
TAAAGAAGAA	TTGCTTCAAG	TGGAACGACG	CCTGGAAAAG	ATCTTGAGAA	GCAAAGAATC	5160
ATGCATCGTA	ATTCTAGATA	ATATCCCAA	GAATCGAATT	GCATTGTGTG	TATCCGTTTT	5220
TGCAATGTC	CCACTTCAA	ACAACGAAGG	TCCATTGTGA	GTATGCACAG	TCAACCGATA	5280
TCAAATCCCT	GAGCTTCAA	TTCACCACAA	TTTCAAATG	TCAGTAATGT	CGAATCGTCT	5340
CGAAGGATTC	ATCCTACGTT	ACCTCCGACG	ACGGGCGGTA	GAGGATGAGT	ATCGTCTAAC	5400
TGTACAGATG	CCATCAGAGC	TCTTCAAAAT	CATTGACTTC	TTCCCAATAG	CTCTTCAGGC	5460
CGTCAATAAT	TTTATTGAGA	AAACGAATTC	TGTTGATGTG	ACAGTTGGTC	CAAGAGCATG	5520
CTTGAAGTGT	CCTCTAACTG	TCGATGGATC	CCGTGAATGG	TTCAATCGAT	TGTGGAATGA	5580
GAAGTTCATT	CCATATTTGG	AACGTGTTGC	TAGAGATGGC	AAAAAAACCT	TCGGTCGCTG	5640
CACTTCCTTC	GAGGATCCCA	CCGACATCGT	CTCTAAAAAA	TGGCCGTGGT	TCGATGGTGA	5700
AAACCCGGAG	AATGTGCTCA	AACGTCTTCA	ACTCCAAGAC	CTCGTCCCGT	CACCTGCCAA	5760
CTCATCCCGA	CAACACTTCA	ATCCCTCGA	GTCGTTGATC	CAATTGCATG	CTACCAAGCA	5820
TCAGACCATC	GACAACATTT	GAACAGAAGA	CTCTAATCTT	CTCTCGCCTC	TCCCCCGCTT	5880
TCCTTATCTT	CGTACCGGTA	CCATGGTATT	GATATCTGAG	CTCCGCATCG	GCCGCTGTCA	5940
TCAGATCGCC	ATCTCGCGCC	CGTGCCTCTG	ACTTCTAAGT	CCAATTACTC	TTCAACATCC	6000
CTACATGCTC	TTTCTCCCTG	TGCTCCCAAC	CCCTATTTTT	GTTATTATCA	AAAAAACTTC	6060
TTCTTAATTT	CTTTGTTTTT	TAGCTTCTTT	TAAGTCACCT	CTAACAATGA	AATTGTGTAG	6120
ATTCAAAAAT	AGAATTAATT	CGTAATAAAA	AGTCGAAAAA	AATTGTGCTC	CCTCCCCCA	6180
TTAATAATAA	TTCTATCCCA	AAATCTACAC	AATGTTCTGT	GTACACTTCT	TATGTTTTTT	6240
TTACTTCTGA	TAAATTTTTT	TTGAAACATC	ATAGAAAAAA	CCGCACACAA	AATACCTTAT	6300
CATATGTTAC	GTTTCAGTTT	ATGACCGCAA	TTTTTATTTT	TTGCGACGTC	TGGGCCTCTC	6360
ATGACGTCAA	ATCATGCTCA	TCGTGAAAAA	GTTTTGGAGT	ATTTTTGGAA	TTTTTCAATC	6420

SUBSTITUTE SHEET (RULE 26)

*FIG. 39 CONTINUED.**96/99*

AAGTGAAAGT TTATGAAATT AATTTTCCTG CTTTTCCTTT TTGGGGGTTT CCCCTATTGT	6480
TTGTCAAGAG TTTCGAGGAC GGCGTTTTTC TTGCTAAAAT CACAAGTATT GATGAGCACG	6540
ATGCAAGAAA GATCGGAAGA AGGTTTGGGT TTGAGGCTCA GTGGAAGGTG AGTAGAAGTT	6600
GATAATTTGA AAGTGGAGTA GTGTCTATGG GGTTTTTGCC TTAAATGACA GAATACATTC	6660
CCAATATACC AAACATAACT GTTTAAAATT AAACATTTTT CTAAATTTTA TATGATTTCT	6720
TTTAAATTTG CAAAATTAC TTAAATTTGA ATTCCCGCGC AAATGAGTGA CTTCAATTTTC	6780
TGCATTATTG TGTTTTCCGG CTATATTAAT AGGTATTTGT TTGTGTTTTT CTTATTTTAA	6840
TGATTCGAAC TCCAATTTGT AAATTTTCGA ACATATTTCC CTAAAGAAAA AATATGATTA	6900
ATCTGGAAAA ATTGGAAAAT TATTTTTCAA ATAAAAACA AAGAAAAAA TGAAGAAAA	6960
CCTATTAGTT TGGCCATAAA ACGCAAAAAT GTCGAAAATG ACGTCACTCA TCTGCGCGGG	7020
AAATCAAGAA TAATTCGGCC TTTTTATTT TTTTGGAAA TCGTAAAACA TTAGAAAAA	7080
TTTTTTAATA GTTATAGTGG GACTGTATTC TGTCATTTAG GGCAAAAGCC AGAGACGCTA	7140
CTCCACCGTT GGGGGATCCA CTAGTCGGCC GTACGGGCCC TTTCGTCTCG CGCGTTTCGG	7200
TGATGACGGT GAAACCTCT GACACATGCA GCTCCCGGAG ACGGTCACAG CTTGTCTGTA	7260
AGCGGATGCC GGGAGCAGAC AAGCCCGTCA GGGCGCGTCA GCGGGTGTTG GCGGGTGTCG	7320
GGGCTGGCTT AACTATGCGG CATCAGAGCA GATTGTACTG AGAGTGCACC ATATGCGGTG	7380
TGAAATACCG CACAGATGCG TAAGGAGAAA ATACCGCATC AGGCGGCCTT AAGGGCCTCG	7440
TGATACGCCT ATTTTATAG GTTAATGTCA TGATAATAAT GGTTTCTTAG ACGTCAGGTG	7500
GCACTTTTCG GGGAAATGTG CGCGGAACCC CTATTTGTTT ATTTTCTAA ATACATTCAA	7560
ATATGTATCC GTCATGAGA CAATAACCCT GATAAATGCT TCAATAATAT TGAAAAAGGA	7620
AGAGTATGAG TATTCAACAT TTCCGTGTCG CCCTTATTCC CTTTTTGCG GCATTTTGCC	7680
TTCTGTGTTT TGCTACCCA GAAACGCTGG TGAAAGTAAA AGATGCTGAA GATCAGTTGG	7740
GTGCACGAGT GGGTTACATC GAACTGGATC TCAACAGCGG TAAGATCCTT GAGAGTTTTC	7800
GCCCCGAAGA ACGTTTCCA ATGATGAGCA CTTTTAAAGT TCTGCTATGT GGCGCGGTAT	7860
TATCCCGTAT TGACGCCGGG CAAGAGCAAC TCGGTGCGCG CATACTAT TCTCAGAATG	7920
ACTTGGTTGA GTACTACCA GTCACAGAAA AGCATCTTAC GGATGGCATG ACAGTAAGAG	7980
AATTATGCAG TGCTGCCATA ACCATGAGTG ATAACACTGC GGCCAACTTA CTTCTGACAA	8040
CGATCGGAGG ACCGAAGGAG CTAAACCGCTT TTTTGACAA CATGGGGGAT CATGTAATC	8100
GCCTTGATCG TTGGGAACCG GAGCTGAATG AAGCCATACC AAACGACGAG CGTGACACCA	8160
CGATGCCTGT AGCAATGGCA ACAACGTTGC GCAAACTATT AACTGGCGAA CTAATTACTC	8220
TAGCTTCCCG GCAACAATTA ATAGACTGGA TGGAGGCGGA TAAAGTTGCA GGACCACTTC	8280
TGCGCTCGGC CCTTCCGGCT GGCTGGTTTA TTGCTGATAA ATCTGGAGCC GGTGAGCGTG	8340


SUBSTITUTE SHEET (RULE 26)

97/99

FIG. 39 CONTINUED.


GGTCTCGCGG TATCATTGCA GCACTGGGGC CAGATGGTAA GCCCTCCCGT ATCGTAGTTA	8400
TCTACACGAC GGGGAGTCAG GCAACTATGG ATGAACGAAA TAGACAGATC GCTGAGATAG	8460
GTGCCTCACT GATTAAGCAT TGGTAACTGT CAGACCAAGT TTACTCATAT ATACTTTAGA	8520
TTGATTTAAA ACTTCATTTT TAATTTAAAA GGATCTAGGT GAAGATCCTT TTTGATAATC	8580
TCATGACCAA AATCCCTTAA CGTGAGTTTT CGTTCCACTG AGCGTCAGAC CCCGTAGAAA	8640
AGATCAAAGG ATCTTCTTGA GATCCTTTTT TTCTGCGCGT AATCTGCTGC TTGCAAACAA	8700
AAAAACCACC GCTACCAGCG GTGGTTTGTT TGCCGGATCA AGAGCTACCA ACTCTTTTTTC	8760
CGAAGGTAAC TGGCTTCAGC AGAGCGCAGA TACCAAATAC TGTCTTCTA GTGTAGCCGT	8820
AGTTAGGCCA CCACTTCAAG AACTCTGTAG CACCGCCTAC ATACCTCGCT CTGCTAATCC	8880
TGTTACCACT GGCTGCTGCC AGTGGCGATA AGTCGTGTCT TACCGGGTTG GACTCAAGAC	8940
GATAGTTACC GGATAAGGCG CAGCGGTCGG GCTGAACGGG GGGTTCGTGC ACACAGCCCA	9000
GCTTGAGCG AACGACCTAC ACCGAACTGA GATACCTACA GCGTGAGCAT TGAGAAAGCG	9060
CCACGCTTCC CGAAGGGAGA AAGGCGGACA GGTATCCGGT AAGCGGCAGG GTCGGAACAG	9120
GAGAGCGCAC GAGGGAGCTT CCAGGGGGAA ACGCCTGGTA TCTTTATAGT CCTGTGCGGT	9180
TTGCCCACCT CTGACTTGAG CGTCGATTTT TGTGATGCTC GTCAGGGGGG CGGAGCCTAT	9240
GGAAAAACGC CAGCAACGCG GCCTTTTTAC GGTTCCTGGC CTTTGTCTGG CCTTTTGCTC	9300
ACATGTTCTT TCCTGCGTTA TCCCCTGATT CTGTGGATAA CCGTATTACC GCCTTTGAGT	9360
GAGCTGATAC CGCTCGCCGC AGCCGAACGA CCGAGCGCAG CGAGTCAGTG AGCGAGGAAG	9420
CGGAAGAGCG CCCAATACGC AAACCGCCTC TCCC CGCGCG TTGGCCGATT CATTAATGCA	9480
GCTGGCACGA CAGGTTTCCC GACTGGAAAG CGGGCAGTGA GCGCAACGCA ATTAATGTGA	9540
GTTAGCTCAC TCATTAGGCA CCCAGGCTT TACACTTTAT GCTTCCGGCT CGTATGTTGT	9600
GTGGAATTGT GAGCGGATAA CAATTCACA CAGGAAACAG CT	9642

FIG. 40. 98/99



99/99

FIG. 41.



SUBSTITUTE SHEET (RULE 26)

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/12, C07K 14/435, C12N 5/10, A01K 67/027, 67/033, A61K 38/17, A01H 5/00, C07K 16/18, C12N 5/26	A3	(11) International Publication Number: WO 96/38555 (43) International Publication Date: 5 December 1996 (05.12.96)
(21) International Application Number: PCT/EP96/02311 (22) International Filing Date: 31 May 1996 (31.05.96) (30) Priority Data: 9510944.3 31 May 1995 (31.05.95) GB (71)(72) Applicants and Inventors: BOGAERT, Thierry [BE/BE]; Voorstraat 36 bus 11, B-8500 Kortrijk (BE). STRINGHAM, Eve [CA/CA]; 9326-133 A Street, Surrey, British Columbia V3V 5R5 (CA). VANDEKERCKHOVE, Joel [BE/BE]; Rode Beukendreef 27, B-Loppem (BE). (74) Agent: BALDOCK, Sharon, Claire; Boulton Wade Tennant, 27 Furnival Street, London EC4A 1PQ (GB).		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 30 January 1997 (30.01.97)
(54) Title: UNC-53 FROM C. ELEGANS AND ITS USES IN TESTING COMPOUNDS INVOLVED IN THE CONTROL OF CELL BEHAVIOUR AND PHARMACEUTICAL COMPOSITIONS (57) Abstract UNC-53 protein of <i>C. elegans</i> or its functional equivalent is identified as a signal transducer/integrator involved in controlling the rate and directionality of cell migration and/or cell shape. Nucleic acid sequences encoding UNC-53 protein or its functional equivalent, such as genomic or cDNA are used to transfect <i>C. elegans</i> or mammalian cell lines useful for identifying inhibitors or enhancers of the UNC-53 protein. Any of the inhibitors or enhancers identified or the UNC-53 protein itself or sequences encoding UNC-53 protein can be used in the preparation of medicament for treatment of neurological conditions such as Alzheimer's or Huntington's disease, peripheral neuropathies for inhibition of metastasis.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

INTERNATIONAL SEARCH REPORT

Int. Appl. No.
PCT/EP 96/02311

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/12 C07K14/435 C12N5/10 A01K67/027 A01K67/033
A01H5/00 A61K38/17 C07K16/18 C12N5/26

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K C12N A01K A61K A01H

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X A	EMBL Database Entry CEF45E10 Accession number Z47810; 26 January 1995 XP002019188 & NATURE, vol. 368, no. 6466, 3 April 1994, LONDON GB, pages 32-38, R. WILSON ET AL.: "2.2 Mb of contiguous nucleotide sequence from chromosome III of C. elegans" see the whole document --- -/--	1-10

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

4 December 1996

Date of mailing of the international search report

13. 12. 96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

Montero Lopez, B

INTERNATIONAL SEARCH REPORT

Int. Patent Application No.
PCT/EP 96/02311

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JOURNAL OF NEUROSCIENCE 13 (10). 1993. 4254-4271. ISSN: 0270-6474, XP000612286 HEKIMI S ET AL: "Axonal guidance defects in a Caenorhabditis elegans mutant reveal cell-extrinsic determinants of neuronal morphology."	19,43
A	see abstract see page 4255, left-hand column, paragraph 2 - paragraph 3 see page 4267, right-hand column, paragraph 2 - page 4271, left-hand column, paragraph 3 -----	1-18, 20-42, 44-88